Results O O
from O O
human O O
in O O
vitro O O
metabolism O O
studies O O
and O O
nonclinical O O
studies O O
show O O
that O O
REVLIMID B-Brand B-Brand
( O O
lenalidomide B-Drug B-Drug
) O O
is O O
neither O O
metabolized O O
by O O
nor O O
inhibits O O
or O O
induces O O
the O O
cytochrome O O
P9 O O
pathway O O
suggesting O O
that O O
lenalidomide B-Drug B-Drug
is O O
not O O
likely O O
to O O
cause O O
or O O
be O O
subject O O
to O O
P9 O O
- O O
based O O
metabolic O O
drug O O
interactions O O
in O O
man O O
. O O

Interacts O O
with O O
valproic B-Drug B-Drug
acid I-Drug I-Drug

This O O
may O O
result O O
in O O
severe O O
ventricular O O
arrhythmia O O
typically O O
torsades O O
de O O
pointe O O
. O O

However O O
in O O
clinical O O
studies O O
the O O
consequences O O
of O O
concomitant O O
irbesartan B-Drug B-Drug
on O O
the O O
pharmacodynamics O O
of O O
warfarin B-Drug B-Drug
were O O
negligible O O
. O O

Administration O O
of O O
a O O
9 O O
g O O
bolus O O
followed O O
by O O
9 O O
to O O
9 O O
g O O
/ O O
hr O O
should O O
achieve O O
and O O
sustain O O
plasma O O
levels O O
of O O
9 O O
mg O O
/ O O
mL O O
. O O

Therefore O O
caution O O
should O O
be O O
used O O
in O O
concomitant O O
administration O O
. O O

Interactions O O
have O O
been O O
observed O O
when O O
other O O
nondepolarizing B-Group B-Group
muscle I-Group I-Group
relaxants I-Group I-Group
have O O
been O O
administered O O
in O O
succession O O
. O O

Chlorthalidone B-Drug B-Drug
and O O
related O O
drugs O O
may O O
increase O O
the O O
responsiveness O O
to O O
tubocurarine B-Drug B-Drug
. O O

Interaction O O
between O O
lomefloxacin B-Drug B-Drug
and O O
cyclosporine B-Drug B-Drug
has O O
not O O
been O O
studied O O
. O O

Studies O O
to O O
evaluate O O
possible O O
interactions O O
between O O
REVIA B-Brand B-Brand
and O O
drugs O O
other O O
than O O
opiates B-Group O
have O O
not O O
been O O
performed O O
. O O

especially O O
if O O
these O O
patients O O
are O O
extensive O O
metabolizers O O
. O O

If O O
it O O
is O O
necessary O O
to O O
continue O O
the O O
diuretic B-Group O
initiate O O
therapy O O
with O O
PRINIVIL B-Brand B-Brand
at O O
a O O
dose O O
of O O
9 O O
mg O O
daily O O
and O O
provide O O
close O O
medical O O
supervision O O
after O O
the O O
initial O O
dose O O
until O O
blood O O
pressure O O
has O O
stabilized O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interaction O O
Captopril B-Drug B-Drug
may O O
cause O O
a O O
false O O
- O O
positive O O
urine O O
test O O
for O O
acetone O O
. O O

Probenecid B-Drug B-Drug
: O O
Probenecid B-Drug B-Drug
slows O O
the O O
renal O O
elimination O O
of O O
lome O O
- O O
floxacin O B-Drug
. O O

When O O
the O O
STADOL B-Brand B-Brand
NS I-Brand I-Brand
was O O
administered O O
9 O O
minutes O O
after O O
the O O
sumatriptan B-Drug B-Drug
nasal O O
spray O O
the O O
AUC O O
of O O
butorphanol B-Drug B-Drug
increased O O
9 O O
% O O
and O O
Cmax O O
decreased O O
9 O O
% O O
. O O

Warfarin B-Drug B-Drug
: O O
The O O
effect O O
of O O
valdecoxib B-Drug B-Drug
on O O
the O O
anticoagulant O O
effect O O
of O O
warfarin B-Drug B-Drug
( O O
9 O O
- O O
9 O O
mg O O
/ O O
day O O
) O O
was O O
studied O O
in O O
healthy O O
subjects O O
by O O
coadministration O O
of O O
BEXTRA B-Brand B-Brand
9 O O
mg O O
BID O O
for O O
9 O O
days O O
. O O

Use O O
of O O
neuroleptics B-Group B-Group
in O O
conjunction O O
with O O
oral O O
morphine B-Drug B-Drug
may O O
increase O O
the O O
risk O O
of O O
respiratory O O
depression O O
hypotension O O
and O O
profound O O
sedation O O
or O O
coma O O
. O O

Although O O
9 O B-Drug_n
- O O
hydroxy O B-Drug_n
- O O
corticosteroid O O
measurements O O
( O O
Porter O O
- O O
Silber O O
test O O
) O O
do O O
not O O
appear O O
to O O
be O O
artifactually O O
altered O O
it O O
is O O
suggested O O
that O O
therapy O O
with O O
naproxen B-Drug B-Drug
be O O
temporarily O O
discontinued O O
9 O O
hours O O
before O O
adrenal O O
function O O
tests O O
are O O
performed O O
if O O
the O O
Porter O O
- O O
Silber O O
test O O
is O O
to O O
be O O
used O O
. O O

Coadministration O O
of O O
warfarin B-Drug B-Drug
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
levetiracetam B-Drug B-Drug
. O O

Digoxin B-Drug B-Drug
: O O
When O O
Starlix B-Brand B-Brand
9 O O
mg O O
before O O
meals O O
was O O
administered O O
in O O
combination O O
with O O
a O O
single O O
9 O O
- O O
mg O O
dose O O
of O O
digoxin B-Drug B-Drug
to O O
healthy O O
volunteers O O
there O O
were O O
no O O
clinically O O
relevant O O
changes O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

Digoxin B-Drug B-Drug
: O O
In O O
patients O O
with O O
hypercholesterolemia O O
concomitant O O
administration O O
of O O
lovastatin B-Drug B-Drug
and O O
digoxin B-Drug B-Drug
resulted O O
in O O
no O O
effect O O
on O O
digoxin B-Drug B-Drug
plasma O O
concentrations O O
. O O

Therefore O O
drugs O O
that O O
affect O O
CYP9A9 O O
and O O
/ O O
or O O
Pgp O O
may O O
modify O O
the O O
pharmacokinetics O O
of O O
saquinavir B-Drug B-Drug
. O O

Combination O O
hormonal B-Group B-Group
contraceptives I-Group I-Group
may O O
also O O
increase O O
risk O O
of O O
thromboembolic O O
disorders O O
. O O

The O O
potential O O
for O O
supine O O
hypertension O O
should O O
be O O
carefully O O
monitored O O
in O O
these O O
patients O O
and O O
may O O
be O O
minimized O O
by O O
either O O
reducing O O
the O O
dose O O
of O O
fludrocortisone B-Drug B-Drug
acetate I-Drug I-Drug
or O O
decreasing O O
the O O
salt O O
intake O O
prior O O
to O O
initiation O O
of O O
treatment O O
with O O
. O O

Calcium B-Drug B-Group
Supplements O I-Group
/ O O
Antacids B-Group B-Group

Routine O O
monitoring O O
should O O
be O O
performed O O
when O O
therapy O O
with O O
BEXTRA B-Brand B-Brand
is O O
either O O
initiated O O
or O O
discontinued O O
in O O
patients O O
on O O
anticonvulsant O B-Group
therapy O O
. O O

A O O
specific O O
treatment O O
for O O
extravasation O O
reactions O O
is O O
unknown O O
at O O
this O O
time O O
. O O

As O O
with O O
all O O
drugs O O
care O O
should O O
be O O
exercised O O
when O O
treating O O
patients O O
with O O
multiple O O
medications O O
. O O

Aminoglutethimide B-Drug B-Drug
administered O O
concomitantly O O
with O O
depo B-Brand O
- O O
subQ B-Brand O
provera I-Brand O
9 I-Brand O
may O O
significantly O O
decrease O O
the O O
serum O O
concentrations O O
of O O
MPA B-Drug B-Drug_n
. O O

Therefore O O
women O O
requiring O O
treatment O O
with O O
one O O
or O O
more O O
of O O
these O O
drugs O O
must O O
use O O
two O O
OTHER O O
effective O O
or O O
highly O O
effective O O
methods O O
of O O
contraception O O
or O O
abstain O O
from O O
heterosexual O O
sexual O O
contact O O
while O O
taking O O
thalidomide B-Drug B-Drug
. O O

Clinically O O
meaningful O O
drug O O
interactions O O
have O O
occurred O O
with O O
concomitant O O
medications O O
and O O
include O O
but O O
are O O
not O O
limited O O
to O O
the O O
following O O
: O O
Agents O O
Highly O O
Bound O O
to O O
Plasma O O
Protein O O
Carbamazepine B-Drug B-Drug
is O O
not O O
highly O O
bound O O
to O O
plasma O O
proteins O O
; O O

Administration O O
of O O
9 O O
- O O
mg O O
/ O O
kg O O
( O O
9 O O
x O O
ED9 O O
) O O
NIMBEX B-Brand B-Brand
at O O
9 O O
% O O
or O O
9 O O
% O O
recovery O O
following O O
an O O
intubating O O
dose O O
of O O
succinylcholine B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
) O O
produced O O
9 O O
% O O
neuromuscular O O
block O O
. O O

Phenothiazines B-Group B-Group
- O O
Taking O O
piperazine B-Drug B-Drug
and O O
a O O
phenothiazine B-Group B-Group
together O I-Group
may O O
increase O O
the O O
risk O O
of O O
convulsions O O
( O O
seizures O O
) O O
. O O

Prolonged O O
recovery O O
time O O
may O O
occur O O
if O O
barbiturates B-Group B-Group
and O O
/ O O
or O O
narcotics B-Group B-Group
are O O
used O O
concurrently O O
with O O
ketamine B-Drug B-Drug
. O O

The O O
appropriate O O
dose O O
for O O
nelfinavir B-Drug B-Drug
incombination O O
with O O
nevirapine B-Drug B-Drug
with O O
respectto O O
safety O O
and O O
efficacy O O
has O O
not O O
been O O
established O O
. O O

Concomitant O O
administration O O
of O O
diflunisal B-Drug B-Drug
and O O
acetaminophen B-Drug B-Drug
in O O
dogs O O
but O O
not O O
in O O
rats O O
at O O
approximately O O
9 O O
times O O
the O O
recommended O O
maximum O O
human O O
therapeutic O O
dose O O
of O O
each O O
( O O
9 O O
to O O
9 O O
mg O O
/ O O
kg O O
/ O O
day O O
of O O
diflunisal B-Drug B-Drug
/ O O
acetaminophen B-Drug B-Drug
) O O
resulted O O
in O O
greater O O
gastrointestinal O O
toxicity O O
than O O
when O O
either O O
drug O O
was O O
administered O O
alone O O
. O O

If O O
it O O
is O O
necessary O O
to O O
continue O O
the O O
diuretic B-Group O
provide O O
close O O
medical O O
supervision O O
after O O
the O O
initial O O
dose O O
for O O
at O O
least O O
two O O
hours O O
and O O
until O O
blood O O
pressure O O
has O O
stabilized O O
for O O
at O O
least O O
an O O
additional O O
hour.. O O

It O O
is O O
probable O O
that O O
dexamethasone B-Drug B-Drug
given O O
as O O
antiemetic O O
prophylaxis O O
contributed O O
to O O
hyperglycemia O O
in O O
some O O
patients O O
. O O

Johns O O
Wort O O
) O O
may O O
significantly O O
reduce O O
exposure O O
to O O
Gleevec B-Brand B-Brand
. O O

= O O
decrease O O

Agents O O
that O O
may O O
enhance O O
the O O
risk O O
of O O
hemorrhage O O
should O O
be O O
discontinued O O
prior O O
to O O
initiation O O
of O O
Fondaparinux B-Drug B-Drug
therapy O O
. O O

- O O
isoniazid B-Drug B-Drug
( O O
Nydrazid B-Brand B-Brand
) O O
; O O

indinavir B-Drug B-Drug
concentration O O
rifabutin B-Drug B-Drug
concentration O O

Initial O O
doses O O
of O O
adrenergic B-Group B-Group
agents I-Group I-Group
such O O
as O O
dopamine B-Drug B-Drug
or O O
epinephrine B-Drug B-Drug
should O O
be O O
reduced O O
and O O
titrated O O
to O O
achieve O O
the O O
desired O O
response O O
. O O

Apraclonidine B-Drug B-Drug
should O O
not O O
be O O
used O O
in O O
patients O O
receiving O O
MAO B-Group B-Group
inhibitors I-Group I-Group
. O O

Gastrointestinal O O
agents O O
( O O
e.g. O O
antacids B-Group B-Group
) O O
. O O

Enoxacin B-Drug B-Drug
interferes O O
with O O
the O O
metabolism O O
of O O
theophylline B-Drug B-Drug
resulting O O
in O O
a O O
9 O O
% O O
to O O
9 O O
% O O
dose O O
- O O
related O O
decrease O O
in O O
theophylline B-Drug B-Drug
clearance O O
and O O
a O O
subsequent O O
9 O O
% O O
to O O
9 O O
% O O
increase O O
in O O
serum O O
theophylline O B-Drug
levels O O
. O O

It O O
is O O
not O O
known O O
whether O O
this O O
potentiation O O
of O O
ampicillin B-Drug B-Drug
rashes O O
is O O
due O O
to O O
allopurinol B-Drug B-Drug
or O O
the O O
hyperuricemia O O
present O O
in O O
these O O
patients O O
. O O

Vardenafil B-Drug B-Drug
dose O O
should O O
not O O
exceed O O
a O O
maximum O O
of O O
9 O O
mg O O
in O O
a O O
9 O O
- O O
hour O O
period O O
in O O
patients O O
receiving O O
concomitant O O
indinavir B-Drug B-Drug
therapy O O
. O O

Nifedipine B-Drug B-Drug
: O O
Vardenafil B-Drug B-Drug
9 O O
mg O O
when O O
co O O
- O O
administered O O
with O O
slow O O
- O O
release O O
nifedipine B-Drug B-Drug
9 O O
mg O O
or O O
9 O O
mg O O
once O O
daily O O
did O O
not O O
affect O O
the O O
relative O O
bioavailability O O
( O O
AUC O O
) O O
or O O
maximum O O
concentration O O
( O O
Cmax O O
) O O
of O O
nifedipine B-Drug B-Drug
a O O
drug O O
that O O
is O O
metabolized O O
via O O
CYP9A9 O O
. O O

Potential O O
for O O
INVEGA B-Brand B-Brand
to O O
Affect O O
Other O O
Drugs O O
Paliperidone B-Drug B-Drug
is O O
not O O
expected O O
to O O
cause O O
clinically O O
important O O
pharmacokinetic O O
interactions O O
with O O
drugs O O
that O O
are O O
metabolized O O
by O O
cytochrome O O
P9 O O
isozymes O O
. O O

Phenobarbital B-Drug B-Drug
: O O
Amphetamines B-Group B-Group
may O O
delay O O
intestinal O O
absorption O O
of O O
phenobarbital B-Drug B-Drug
; O O

. O O

The O O
size O O
of O O
wheal O O
and O O
flare O O
were O O
significantly O O
larger O O
when O O
fexofenadine B-Drug B-Drug
hydrochloride I-Drug I-Drug
was O O
administered O O
with O O
either O O
grapefruit O O
or O O
orange O O
juices O O
compared O O
to O O
water O O
. O O

Fluoxetine B-Drug B-Drug
OCs B-Group O
sertraline B-Drug B-Drug
diltiazem B-Drug B-Drug
macrolide B-Group B-Group
antibiotics I-Group I-Group
( O O
exercise O O
caution O O
) O O
. O O

Thus O O
agents O O
likely O O
to O O
be O O
concomitantly O O
administered O O
with O O
Chirocaine B-Brand O
that O O
are O O
metabolized O O
by O O
this O O
isoenzyme O O
family O O
may O O
potentially O O
interact O O
with O O
Chirocaine B-Brand B-Drug
. O O

The O O
clinical O O
relevance O O
of O O
this O O
difference O O
is O O
unknown O O
. O O

Patients O O
taking O O
low O O
- O O
dose O O
aspirin B-Brand B-Brand
plus O O
ibuprofen B-Drug B-Drug
were O O
not O O
studied O O
. O O

Fat O O
redistribution O O
: O O
Redistribution O O
/ O O
accumulation O O
of O O
body O O
fat O O
including O O
central O O
obesity O O
dorsocervical O O
fat O O
enlargement O O
( O O
buffalo O O
hump O O
) O O
peripheral O O
wasting O O
facial O O
wasting O O
breast O O
enlargement O O
and O O
cushingoid O O
appearance O O
have O O
been O O
observed O O
in O O
patients O O
receiving O O
antiretroviral B-Group B-Group
therapy O O
. O O

Cholestyramine B-Drug B-Drug
and O O
Drugs O O
that O O
Bind O O
Bile O O
Acids O O
: O O
These O O
drugs O O
interrupt O O
enterohepatic O O
recirculation O O
and O O
reduce O O
MPA B-Drug_n O
exposure O O
when O O
coadministered O O
with O O
mycophenolate B-Drug B-Drug
mofetil I-Drug I-Drug
. O O

Whether O O
this O O
interaction O O
also O O
occurs O O
with O O
the O O
intravenous O O
topical O O
or O O
vaginal O O
preparations O O
of O O
miconazole B-Drug B-Drug
is O O
not O O
known O O
. O O

These O O
effects O O
are O O
usually O O
reversible O O
. O O

As O O
with O O
other O O
dialysis B-Group O
solutions I-Group O
blood O O
concentrations O O
of O O
dialyzable O O
drugs O O
may O O
be O O
reduced O O
by O O
dialysis O O
. O O

Digitalis B-Group B-Group
glycosides I-Group I-Group
: O O
Patients O O
on O O
digitalis B-Group B-Group
glycosides I-Group I-Group
may O O
be O O
at O O
increased O O
risk O O
of O O
arrhythmias O O
due O O
to O O
hypokalemia O O
. O O

Therefore O O
co O O
- O O
administration O O
of O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
with O O
other O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
isoenzyme O O
including O O
other O O
antidepressants B-Group B-Group
phenothiazines B-Group B-Group
carbamazepine B-Drug B-Drug
and O O
Type B-Group B-Group
9C I-Group I-Group
antiarrhythmics I-Group I-Group
( O O
eg O O
propafenone B-Drug B-Drug
flecainide B-Drug B-Drug
and O O
encainide B-Drug B-Drug
) O O
or O O
that O O
inhibit O O
this O O
enzyme O O
( O O
eg O O
quinidine B-Drug B-Drug
) O O
should O O
be O O
approached O O
with O O
caution O O
. O O

Nevirapine B-Drug B-Drug

and O O
diuretics B-Group B-Group
such O O
as O O
furosemide B-Drug B-Drug
. O O

In O O
another O O
report O O
nine O O
patients O O
with O O
breast O O
cancer O O
were O O
reported O O
to O O
have O O
decreased O O
symptoms O O
of O O
methotrexate B-Drug B-Drug
- O O
related O O
toxicity O O
when O O
given O O
supplemental O O
L B-Drug B-Drug
- O O
glutamine B-Drug B-Drug
at O O
a O O
dose O O
of O O
9 O O
gram O O
/ O O
kilogram O O
/ O O
day O O
. O O

- O O
Disulfiram B-Drug B-Drug
( O O
e.g. O O
Antabuse B-Brand B-Brand
) O O
or O O

In O O
a O O
study O O
in O O
normal O O
volunteers O O
concomitant O O
administration O O
of O O
buspirone B-Drug B-Drug
HCl I-Drug I-Drug
and O O
haloperidol B-Drug B-Drug
resulted O O
in O O
increased O O
serum O O
haloperidol B-Drug B-Drug
concentrations O O
. O O

Drugs O O
that O O
induce O O
CYP9A9 O O
activity O O
would O O
be O O
expected O O
to O O
increase O O
the O O
clearance O O
of O O
indinavir B-Drug B-Drug
resulting O O
in O O
lowered O O
plasma O O
concentrations O O
of O O
indinavir B-Drug B-Drug
. O O

Increases O O
in O O
sertraline B-Drug B-Drug
dose O O
should O O
be O O
guided O O
by O O
clinical O O
response O O
. O O

Free O O
T9 O O
and O O
T9 O O
concentrations O O
are O O
unaltered O O
. O O

Cyclosporine B-Drug B-Drug
: O O
Concomitant O O
administration O O
of O O
nicardipine B-Drug B-Drug
and O O
cyclosporine B-Drug B-Drug
levels O O
. O O

A O O
variety O O
of O O
antiarrhythmics B-Group B-Group
such O O
as O O
quinidine B-Drug B-Drug
or O O
propranolol B-Drug B-Drug
were O O
also O O
added O O
sometimes O O
with O O
improved O O
control O O
of O O
ventricular O O
ectopy O O
. O O

Cimetidine B-Drug B-Drug
: O O
Cimetidine B-Drug B-Drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
fosfomycin B-Drug B-Drug
when O O
coadministered O O
with O O
MONUROL B-Brand B-Brand
. O O

Aripiprazole B-Drug B-Drug
also O O
does O O
not O O
undergo O O
direct O O
glucuronidation O O
. O O

Geocillin B-Brand B-Drug
( O O
carbenicillin B-Drug B-Drug
indanyl I-Drug I-Drug
sodium I-Drug I-Drug
) O O
blood O O
levels O O
may O O
be O O
increased O O
and O O
prolonged O O
by O O
concurrent O O
administration O O
of O O
probenecid B-Drug B-Drug
. O O

A O O
false O O
- O O
positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
. O O

Results O O
of O O
preliminary O O
studies O O
in O O
humans O O
and O O
rats O O
suggest O O
that O O
nonabsorbable O O
antacids B-Group B-Group
given O O
concurrently O O
with O O
lactulose B-Drug B-Drug
may O O
inhibit O O
the O O
desired O O
lactulose B-Drug O
- O O
induced O O
drop O O
in O O
colonic O O
pH O O
. O O

Metoprolol B-Drug O
- O O
Administration O O
of O O
9 O O
mg O O
/ O O
day O O
LEXAPRO B-Brand B-Brand
for O O
9 O O
days O O
in O O
healthy O O
volunteers O O
resulted O O
in O O
a O O
9 O O
% O O
increase O O
in O O
Cmax O O
and O O
9 O O
% O O
increase O O
in O O
AUC O O
of O O
the O O
beta B-Group B-Group
- O O
adrenergic B-Group O
blocker I-Group O
metoprolol B-Drug B-Drug
( O O
given O O
in O O
a O O
single O O
dose O O
of O O
9 O O
mg O O
) O O
. O O

Patients O O
receiving O O
concomitant O O
lovastatin B-Drug B-Drug
and O O
erythromycin B-Drug B-Drug
should O O
be O O
carefully O O
monitored O O
; O O

These O O
data O O
suggest O O
that O O
the O O
conversion O O
of O O
losartan B-Drug B-Drug
to O O
its O O
active O O
metabolite O O
is O O
mediated O O
primarily O O
by O O
P9 O O
9C9 O O
and O O
not O O
P9 O O
9A9 O O
. O O

Haloperidol B-Drug B-Drug
: O O
Haloperidol B-Drug B-Drug
blocks O O
dopamine O B-Drug
and O O
norepinephrine O B-Drug
reuptake O O
thus O O
inhibiting O O
the O O
central O O
stimulant O O
effects O O
of O O
amphetamines B-Group B-Group
. O O

Effect O O
on O O
Concentration O O
of O O
Nevirapine B-Drug B-Drug
or O O
Concomitant O O
Drug O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
NSAIDs B-Group B-Group
concomitantly O O
with O O
ACE B-Group B-Group
inhibitors I-Group I-Group
. O O

Dosage O O
adjustment O O
may O O
be O O
warranted O O
when O O
levobupivacaine B-Drug B-Drug
is O O
concurrently O O
administered O O
with O O
CYP9A9 O O
inhibitors O O
and O O
CYP9A9 O O
inhibitors O O
as O O
systemic O O
levobupivacaine B-Drug B-Drug
levels O O
may O O
rise O O
resulting O O
in O O
toxicity O O
. O O

PEGANONE B-Brand B-Brand
used O O
in O O
combination O O
with O O
other O O
drugs O O
known O O
to O O
adversely O O
affect O O
the O O
hematopoietic O O
system O O
should O O
be O O
avoided O O
if O O
possible O O
. O O

This O O
may O O
occur O O
because O O
diflunisal B-Drug O
competitively O O
displaces O O
coumarins B-Group O
from O O
protein O O
binding O O
sites O O
. O O

Sympathomimetics B-Group B-Group
may O O
reduce O O
the O O
antihypertensive O O
effects O O
of O O
methyldopa B-Drug B-Drug
mecamylamine B-Drug B-Drug
reserpine B-Drug B-Drug
and O O
veratrum B-Group B-Group
alkaloids I-Group I-Group
. O O

In O O
one O O
survey O O
9 O O
% O O
of O O
patients O O
taking O O
labetalol B-Drug B-Drug
HCl I-Drug I-Drug
in O O
combination O O
with O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
experienced O O
tremor O O
as O O
compared O O
to O O
9 O O
% O O
reported O O
to O O
occur O O
with O O
labetalol B-Drug B-Drug
HCl I-Drug I-Drug
alone O O
. O O

Antiepileptic B-Group B-Group
drugs I-Group I-Group
: O O
Potential O O
interactions O O
between O O
Trileptal B-Brand B-Brand
and O O
other O O
AEDs B-Group B-Group
were O O
assessed O O
in O O
clinical O O
studies O O
. O O

No O O
formal O O
drug O O
- O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

Clinically O O
significant O O
QTc O O
prolongation O O
has O O
not O O
been O O
found O O
with O O
Mefloquineuine O O
alone O O
. O O

The O O
increased O O
plasma O O
concentration O O
of O O
terfenadine B-Drug B-Drug
or O O
its O O
metabolite O O
may O O
result O O
in O O
prolonged O O
QT O O
intervals O O
. O O

Rifampin B-Drug B-Drug
: O O
Co O O
- O O
administration O O
of O O
VIOXX B-Brand B-Brand
with O O
rifampin B-Drug B-Drug
9 O O
mg O O
daily O O
a O O
potent O O
inducer O O
of O O
hepatic O O
metabolism O O
produced O O
an O O
approximate O O
9 O O
% O O
decrease O O
in O O
rofecoxib B-Drug B-Drug
plasma O O
concentrations O O
. O O

approximately O O
one O O
- O O
hundredth O O
of O O
the O O
human O O
recommended O O
dose O O
based O O
on O O
body O O
surface O O
area O O
[ O O
BSA O O
] O O
) O O
fulvestrant B-Drug B-Drug
caused O O
a O O
reversible O O
reduction O O
in O O
female O O
fertility O O
as O O
well O O
as O O
effects O O
on O O
embryo O O
/ O O
fetal O O
development O O
consistent O O
with O O
its O O
anti O O
- O O
estrogenic O O
activity O O
. O O

Combination O O
was O O
associated O O
with O O
a O O
higher O O
frequency O O
of O O
adverse O O
clinical O O
experiences O O
( O O
eg O O
dizziness O O
nausea O O
paresthesia O O
) O O
and O O
laboratory O O
abnormalities O O
( O O
elevated O O
liver O O
enzymes O O
) O O
. O O

Chirocaine B-Brand B-Drug
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
receiving O O
other O O
local O O
anesthetics B-Group B-Group
or O O
agents O O
structurally O O
related O O
to O O
amide O O
- O O
type O O
local O O
anesthetics O B-Group
since O O
the O O
toxic O O
effects O O
of O O
these O O
drugs O O
could O O
be O O
additive O O
. O O

. O O

therefore O O
it O O
is O O
possible O O
that O O
adverse O O
events O O
associated O O
with O O
the O O
individual O O
use O O
of O O
either O O
drug O O
may O O
be O O
more O O
apt O O
to O O
occur O O
. O O

Dose O O
reduction O O
of O O
CRIXIVAN B-Brand B-Brand
to O O
9 O O
mg O O
every O O
9 O O
hours O O
should O O
be O O
considered O O
. O O

Lorazepam B-Drug B-Drug
: O O
Coadministration O O
of O O
single O O
doses O O
of O O
eszopiclone B-Drug B-Drug
9 O O
mg O O
and O O
lorazepam B-Drug B-Drug
9 O O
mg O O
did O O
not O O
have O O
clinically O O
relevant O O
effects O O
on O O
the O O
pharmacodynamics O O
or O O
pharmacokinetics O O
of O O
either O O
drug O O
. O O

Coadministration O O
of O O
Itraconazole B-Drug B-Drug
and O O
cyclosporine B-Drug B-Drug
tacrolimus B-Drug B-Drug
or O O
digoxin B-Drug B-Drug
has O O
led O O
to O O
increased O O
plasma O O
concentrations O O
of O O
the O O
latter O O
three O O
drugs O O
. O O

The O O
following O O
similar O O
changes O O
may O O
be O O
expected O O
with O O
larger O O
doses O O
of O O
estrogen B-Group B-Group
: O O
Increased O O
sulfobromophthalein O O
retention O O
; O O

Dosage O O
adjustment O O
may O O
be O O
required O O
if O O
cyclosporine B-Drug B-Drug
tacrolimus B-Drug B-Drug
or O O
methylprednisolone B-Drug B-Drug
are O O
given O O
concomitantly O O
with O O
NIZORAL B-Brand B-Brand
Tablets O O
. O O

these O O
should O O
be O O
given O O
9 O O
to O O
9 O O
hours O O
before O O
or O O
after O O
oral O O
administration O O
of O O
leveomepromazine B-Drug B-Drug
. O O

Selegiline B-Drug B-Drug
: O O
In O O
healthy O O
volunteers O O
( O O
N= O O
9 O O
) O O
selegiline B-Drug B-Drug
did O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
pramipexole B-Drug B-Drug
. O O

However O O
high O O
doses O O
of O O
leucovorin B-Drug B-Drug
may O O
reduce O O
the O O
efficacy O O
of O O
intrathecally O O
administered O O
methotrexate B-Drug B-Drug
. O O

Estrogen B-Group B-Group
- O O
containing O O
therapies O O
should O O
not O O
be O O
used O O
with O O
ARIMIDEX B-Brand B-Brand
as O O
they O O
may O O
diminish O O
its O O
pharmacologic O O
action O O
. O O

clinical O O
significance O O
unknown O O
. O O

However O O
in O O
selected O O
circumstances O O
in O O
which O O
such O O
therapy O O
is O O
appropriate O O
using O O
adequate O O
doses O O
of O O
antibacterial B-Group B-Group
agents O I-Group
and O O
beginning O O
penicillin O B-Drug
therapy O O
first O O
should O O
minimize O O
the O O
potential O O
for O O
interaction O O
. O O

Seizures O O
have O O
been O O
reported O O
in O O
patients O O
taking O O
another O O
quinolone B-Group B-Group
class I-Group I-Group
antimicrobial I-Group I-Group
and O O
the O O
nonsteroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
drug I-Group I-Group
fenbufen B-Drug B-Drug
concurrently O O
. O O

Antifungal B-Group B-Group
Agents I-Group I-Group

Antihistamines B-Group B-Group
: O O
Amphetamines B-Group B-Group
may O O
counteract O O
the O O
sedative O O
effect O O
of O O
antihistamines B-Group B-Group
. O O

There O O
was O O
no O O
evidence O O
in O O
the O O
controlled O O
studies O O
of O O
Nutropin B-Brand B-Brand
interaction O O
with O O
drugs O O
commonly O O
used O O
in O O
chronic O O
renal O O
insufficiency O O
patients O O
. O O

The O O
concomitant O O
administration O O
of O O
uricosuric B-Group B-Group
agents I-Group I-Group
and O O
allopurinol B-Drug B-Drug
has O O
been O O
associated O O
with O O
a O O
decrease O O
in O O
the O O
excretion O O
of O O
oxypurines O O
( O O
hypoxanthine O B-Drug
and O O
xanthine O B-Drug
) O O
and O O
an O O
increase O O
in O O
urinary O O
uric O O
acid O O
excretion O O
compared O O
with O O
that O O
observed O O
with O O
allopurinol B-Drug B-Drug
alone O O
. O O

Enoxacin B-Drug B-Drug
does O O
not O O
affect O O
the O O
clearance O O
of O O
the O O
active O O
S O O
- O O
isomer O O
and O O
changes O O
in O O
clotting O O
time O O
have O O
not O O
been O O
observed O O
when O O
enoxacin B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
were O O
coadministered O O
. O O

Oral O O
neomycin B-Drug B-Drug
inhibits O O
the O O
gastrointestinal O O
absorption O O
of O O
penicillin B-Drug B-Drug
V I-Drug O
oral O O
vitamin B-Drug B-Group
B I-Drug I-Group
- O O
9 B-Drug O
methotrexate B-Drug B-Drug
and O O
9 B-Drug B-Drug
- O O
fluorouracil B-Drug B-Drug
. O O

At O O
steady O O
state O O
VIOXX B-Brand B-Brand
9 O O
mg O O
once O O
daily O O
had O O
no O O
effect O O
on O O
the O O
anti O O
- O O
platelet O O
activity O O
of O O
low O O
- O O
dose O O
( O O
9 O O
mg O O
once O O
daily O O
) O O
aspirin B-Brand B-Brand
as O O
assessed O O
by O O
ex O O
vivo O O
platelet O O
aggregation O O
and O O
serum O O
TXB9 O O
generation O O
in O O
clotting O O
blood O O
. O O

Patients O O
receiving O O
other O O
narcotic B-Group B-Group
analgesics I-Group I-Group
antipsychotics B-Group B-Group
antianxiety B-Group B-Group
agents I-Group I-Group
or O O
other O O
CNS B-Group B-Group
depressants I-Group I-Group
( O O
including O O
alcohol B-Drug B-Drug
) O O
concomitantly O O
with O O
hydrocodone B-Drug B-Drug
and O O
acetaminophen B-Drug B-Drug
tablets O O
may O O
exhibit O O
an O O
additive O O
CNS O O
depression O O
. O O

There O O
were O O
no O O
statistically O O
significant O O
increases O O
in O O
tumor O O
incidences O O
in O O
drug O O
- O O
treated O O
rats O O
or O O
mice O O
. O O

A O O
clinical O O
interaction O O
study O O
was O O
also O O
conducted O O
with O O
alosetron B-Drug B-Drug
and O O
the O O
CYP9A9 O O
substrate O O
cisapride B-Drug B-Drug
. O O

9 O O
- O O
OH O O
metabolite O O
concentration O O

Phenytoin B-Drug B-Drug
/ O O
Phenobarbital B-Drug B-Drug
: O O
The O O
coadministration O O
of O O
phenytoin B-Drug B-Drug
or O O
phenobarbital B-Drug B-Drug
will O O
not O O
affect O O
plasma O O
concentrations O O
of O O
vitamin B-Group B-Group
D I-Group I-Group
but O O
may O O
reduce O O
endogenous O O
plasma O O
levels O O
of O O
calcitriol B-Drug B-Drug
/ O O
ergocalcitriol O O
by O O
accelerating O O
metabolism O O
. O O

The O O
concomitant O O
use O O
of O O
transdermal O O
fentanyl B-Drug B-Drug
with O O
ritonavir B-Drug B-Drug
or O O
other O O
potent O O
9A9 O O
inhibitors O O
such O O
as O O
ketoconazole B-Drug B-Drug
itraconazole B-Drug B-Drug
troleandomycin B-Drug B-Drug
clarithromycin B-Drug B-Drug
nelfinavir B-Drug B-Drug
and O O
nefazadone O B-Drug
may O O
result O O
in O O
an O O
increase O O
in O O
fentanyl B-Drug B-Drug
plasma O O
concentrations O O
. O O

Patients O O
treated O O
with O O
extended O O
release O O
metoprolol B-Drug B-Drug
succinate I-Drug I-Drug
plus O O
a O O
catecholamine O O
depletor O O
should O O
therefore O O
be O O
closely O O
observed O O
for O O
evidence O O
of O O
hypotension O O
or O O
marked O O
bradycardia O O
which O O
may O O
produce O O
vertigo O O
syncope O O
or O O
postural O O
hypotension O O
. O O

When O O
cholestyramine B-Drug B-Drug
resin B-Group B-Group
is O O
given O O
for O O
long O O
periods O O
of O O
time O O
concomitant O O
supplementation O O
with O O
water O O
- O O
miscible O O
( O O
or O O
parenteral O O
) O O
forms O O
of O O
fat B-Group B-Group
- O O
soluble B-Group B-Group
vitamins I-Group I-Group
should O O
be O O
considered O O
. O O

Phenytoin B-Drug B-Drug
: O O
No O O
significant O O
differences O O
were O O
observed O O
in O O
mean O O
phenytoin B-Drug B-Drug
AUC O O
C O O
max O O
C O O
min O O
or O O
T O O
max O O
( O O
although O O
C O O
max O O
increased O O
by O O
9 O O
% O O
) O O
when O O
extended O O
phenytoin B-Drug B-Drug
sodium I-Drug I-Drug
capsules O O
( O O
9 O O
mg O O
tid O O
) O O
were O O
coadministered O O
with O O
lomefloxacin B-Drug B-Drug
( O O
9 O O
mg O O
qd O O
) O O
for O O
five O O
days O O
in O O
9 O O
healthy O O
males O O
. O O

Concomitant O O
use O O
of O O
bupropion B-Drug B-Drug
with O O
other O O
drugs O O
metabolized O O
by O O
CYP9D9 O O
has O O
not O O
been O O
formally O O
studied O O
. O O

Repeat O O
Treatment O O
Studies O O
evaluating O O
the O O
use O O
of O O
repeated O O
courses O O
of O O
Zmax B-Brand O
have O O
not O O
been O O
conducted O O
. O O

If O O
replacing O O
clonidine B-Drug B-Drug
by O O
beta B-Group B-Group
- O O
blocker B-Group B-Group
therapy O O
the O O
introduction O O
of O O
beta B-Group B-Group
blockers I-Group I-Group
should O O
be O O
delayed O O
for O O
several O O
days O O
after O O
clonidine B-Drug B-Drug
administration O O
has O O
stopped O O
. O O

When O O
phenytoin B-Drug B-Drug
or O O
other O O
hepatic O O
enzyme O O
inducers O O
such O O
as O O
rifampin B-Drug B-Drug
and O O
phenobarbital B-Drug B-Drug
have O O
been O O
taken O O
concurrently O O
with O O
Mexitil B-Brand B-Brand
lowered O O
Mexitil B-Brand B-Brand
plasma O O
levels O O
have O O
been O O
reported O O
. O O

These O O
agents O O
should O O
not O O
be O O
taken O O
within O O
the O O
two O O
hour O O
period O O
before O O
or O O
within O O
the O O
two O O
- O O
hour O O
period O O
after O O
nalidixic B-Drug B-Drug
acid I-Drug I-Drug
administration O O
. O O

Although O O
ibuprofen B-Drug B-Drug
( O O
9 O O
mg O O
qid O O
) O O
can O O
be O O
administered O O
with O O
ALIMTA B-Brand B-Brand
in O O
patients O O
with O O
normal O O
renal O O
function O O
( O O
creatinine O O
clearance O O
9 O O
mL O O
/ O O
min O O
) O O
caution O O
should O O
be O O
used O O
when O O
administering O O
ibuprofen B-Drug B-Drug
concurrently O O
with O O
ALIMTA B-Brand B-Brand
to O O
patients O O
with O O
mild O O
to O O
moderate O O
renal O O
insufficiency O O
( O O
creatinine O O
clearance O O
from O O
9 O O
to O O
9 O O
mL O O
/ O O
min O O
) O O
. O O

CYP9A9 O O
Interactions O O

In O O
view O O
of O O
the O O
long O O
and O O
variable O O
half O O
- O O
life O O
of O O
amiodarone B-Drug B-Drug
potential O O
for O O
drug O O
interactions O O
exists O O
not O O
only O O
with O O
concomitant O O
medication O O
but O O
also O O
with O O
drugs O O
administered O O
after O O
discontinuation O O
of O O
amiodarone B-Drug B-Drug
. O O

Inhibitors O O
of O O
CYP9D9 O O
: O O
Because O O
CYP9D9 O O
is O O
involved O O
in O O
duloxetine B-Drug B-Drug
metabolism O O
concomitant O O
use O O
of O O
duloxetine B-Drug B-Drug
with O O
potent O O
inhibitors O O
of O O
CYP9D9 O O
may O O
result O O
in O O
higher O O
concentrations O O
of O O
duloxetine B-Drug B-Drug
. O O

Diuretics B-Group B-Group
: O O
Patients O O
on O O
diuretics B-Group B-Group
especially O O
those O O
in O O
whom O O
diuretic O O
therapy O O
was O O
recently O O
instituted O O
may O O
occasionally O O
experience O O
an O O
excessive O O
reduction O O
of O O
blood O O
pressure O O
after O O
initiation O O
of O O
therapy O O
with O O
Lotensin B-Brand B-Brand
. O O

( O O
Note O O
: O O
All O O
patients O O
receiving O O
theophylline B-Drug B-Drug
should O O
be O O
monitored O O
appropriately O O
regardless O O
of O O
concomitant O O
drug O O
therapy O O
. O O
) O O

Co O O
- O O
administration O O
of O O
nelfinavir B-Drug B-Drug
at O O
steady O O
- O O
state O O
with O O
a O O
single O O
dose O O
of O O
azithromycin B-Drug B-Drug
( O O
9 O O
x O O
9 O O
mg O O
tablets O O
) O O
results O O
in O O
increased O O
azithromycin B-Drug B-Drug
serum O O
concentrations O O
. O O

In O O
this O O
crossover O O
steady O O
state O O
study O O
the O O
pharmacokinetics O O
of O O
propafenone B-Drug B-Drug
were O O
unaffected O O
in O O
either O O
phenotype O O
by O O
the O O
coadministration O O
of O O
mexiletine B-Drug B-Drug
. O O

Oxytocin B-Drug B-Drug
or O O
other O O
oxytocics B-Group O
( O O
concurrent O O
use O O
with O O
dinoprost B-Drug B-Group
may O O
result O O
in O O
uterine O O
hypertonus O O
possibly O O
causing O O
uterine O O
rupture O O
or O O
cervical O O
laceration O O
especially O O
in O O
the O O
absence O O
of O O
adequate O O
cervical O O
dilatation O O
; O O

Therefore O O
intake O O
of O O
supplemental O O
folic B-Drug B-Drug
acid I-Drug I-Drug
should O O
not O O
exceed O O
9 O O
micrograms O O
( O O
g O O
sometimes O O
mcg O O
) O O
per O O
day O O
to O O
prevent O O
folic B-Drug B-Drug
acid I-Drug I-Drug
from O O
masking O O
symptoms O O
of O O
vitamin O O
B9 O O
deficiency O O
. O O

Lithium B-Drug B-Drug
generally O O
should O O
not O O
be O O
given O O
with O O
diuretics B-Group B-Group
because O O
they O O
reduce O O
lithiums B-Drug O
renal O O
clearance O O
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-Drug O
toxicity O O
. O O

Oral O O
Contraceptive B-Group B-Drug
: O O
Based O O
on O O
AUC O O
and O O
half O O
- O O
life O O
multiple O O
- O O
dose O O
pharmacokinetic O O
profiles O O
of O O
norethindrone B-Drug B-Drug
and O O
ethinyl B-Drug B-Drug
estradiol I-Drug I-Drug
following O O
administration O O
of O O
tablets O O
containing O O
9 O O
mg O O
of O O
norethindrone B-Drug B-Drug
acetate I-Drug I-Drug
and O O
9 O O
mcg O O
of O O
ethinyl B-Drug B-Drug
estradiol I-Drug I-Drug
were O O
similar O O
with O O
and O O
without O O
coadministration O O
of O O
gabapentin B-Drug B-Drug
( O O
9 O O
mg O O
TID O O
; O O

Drug O O
Name O O

Cocaine B-Drug O
sometimes O O
proves O O
to O O
be O O
fatal O O
when O O
used O O
in O O
combination O O
with O O
heroin B-Drug_n B-Drug_n
. O O

As O O
the O O
primary O O
effect O O
of O O
adenosine B-Drug B-Drug
is O O
to O O
decrease O O
conduction O O
through O O
the O O
A O O
- O O
V O O
node O O
higher O O
degrees O O
of O O
heart O O
block O O
may O O
be O O
produced O O
in O O
the O O
presence O O
of O O
carbamazepine B-Drug B-Drug
. O O

Methotrexate B-Drug B-Drug
VIOXX B-Brand B-Brand
9 O O
9 O O
and O O
9 O O
mg O O
each O O
dose O O
administered O O
once O O
daily O O
for O O
9 O O
days O O
had O O
no O O
effect O O
on O O
the O O
plasma O O
concentration O O
of O O
methotrexate B-Drug B-Drug
as O O
measured O O
by O O
AUC9 O O
- O O
9hr O O
in O O
patients O O
receiving O O
single O O
weekly O O
methotrexate B-Drug B-Drug
doses O O
of O O
9 O O
to O O
9 O O
mg O O
for O O
rheumatoid O O
arthritis O O
. O O

No O O
drug O O
interactions O O
were O O
detected O O
except O O
for O O
an O O
increase O O
in O O
symptomatic O O
hypotension O O
in O O
patients O O
receiving O O
oral O O
ACE B-Group B-Group
inhibitors I-Group I-Group
. O O

- O O
Other O O
anti B-Group O
- O O
infectives B-Group B-Group
by O O
mouth O O
or O O
by O O
injection O O
( O O
medicine O O
for O O
infection O O
) O O
or O O

No O O
dosage O O
adjustment O O
is O O
required O O
for O O
Fluvoxamine B-Drug B-Drug
Tablets O O
. O O

Chronic O O
administration O O
of O O
phenobarbital B-Drug B-Drug
a O O
known O O
enzyme O O
inducer O O
may O O
be O O
associated O O
with O O
a O O
decrease O O
in O O
the O O
plasma O O
half O O
- O O
life O O
of O O
fenoprofen B-Drug B-Drug
. O O

The O O
addition O O
of O O
tiagabine B-Drug B-Drug
in O O
a O O
limited O O
number O O
of O O
patients O O
in O O
three O O
well O O
- O O
controlled O O
studies O O
caused O O
no O O
systematic O O
changes O O
in O O
phenobarbital B-Drug B-Drug
or O O
primidone B-Drug B-Drug
concentrations O O
when O O
compared O O
to O O
placebo O O
. O O

Erythromycin B-Drug B-Drug
use O O
in O O
patients O O
who O O
are O O
receiving O O
high O O
doses O O
of O O
theophylline B-Drug B-Drug
may O O
be O O
associated O O
with O O
an O O
increase O O
in O O
serum O O
theophylline B-Drug B-Drug
levels O O
and O O
potential O O
theophylline B-Drug B-Drug
toxicity O O
. O O

Warfarin B-Drug B-Drug
: O O
Multiple O O
oral O O
doses O O
of O O
Sonata B-Brand B-Brand
( O O
9 O O
mg O O
q9h O O
for O O
9 O O
days O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
warfarin B-Drug B-Drug
( O O
R+ O O
) O O
- O O
or O O
( O O
S O O
- O O
) O O
- O O
enantiomers O O
or O O
the O O
pharmacodynamics O O
( O O
prothrombin O O
time O O
) O O
following O O
a O O
single O O
9 O O
- O O
mg O O
oral O O
dose O O
of O O
warfarin B-Drug B-Drug
. O O

Similarly O O
saquinavir B-Drug B-Drug
might O O
also O O
modify O O
the O O
pharmacokinetics O O
of O O
other O O
drugs O O
that O O
are O O
substrates O O
for O O
CYP9A9 O O
or O O
Pgp O O
. O O

If O O
this O O
is O O
not O O
possible O O
the O O
starting O O
dose O O
should O O
be O O
reduced O O
. O O

Refer O O
to O O
the O O
package O O
insert O O
for O O
lithium B-Drug B-Drug
preparations O O
before O O
use O O
of O O
such O O
preparations O O
with O O
chlorothiazide B-Drug B-Drug

Carbamazepine B-Drug B-Drug
: O O
Carbamazepine B-Drug B-Drug
causes O O
an O O
approximate O O
9 O O
% O O
increase O O
in O O
the O O
clearance O O
of O O
Felbatol B-Brand B-Brand
at O O
steady O O
state O O
and O O
therefore O O
the O O
addition O O
of O O
carbamazepine B-Drug B-Drug
results O O
in O O
an O O
approximate O O
9 O O
% O O
decrease O O
in O O
the O O
steady O O
- O O
state O O
trough O O
concentrations O O
of O O
Felbatol B-Brand B-Brand
as O O
compared O O
to O O
the O O
same O O
dose O O
of O O
Felbatol B-Brand B-Brand
given O O
as O O
monotherapy O O
. O O

Inhibits O O
CYP9D9 O O
( O O
weak O O
) O O
. O O

Valdecoxib B-Drug B-Drug
steady O O
state O O
plasma O O
concentrations O O
( O O
9 O O
mg O O
BID O O
) O O
were O O
not O O
affected O O
significantly O O
with O O
multiple O O
doses O O
of O O
omeprazole B-Drug B-Drug
( O O
9 O O
mg O O
QD O O
) O O
. O O

N=9 O O
) O O
were O O
not O O
different O O
and O O
neither O O
were O O
gabapentin B-Drug B-Drug
pharmacokinetic O O
parameters O O
affected O O
by O O
valproic B-Drug B-Drug
acid I-Drug I-Drug
. O O

( O O
Thiazide B-Group B-Group
drugs I-Group I-Group
may O O
increase O O
the O O
responsiveness O O
to O O
tubocurarine B-Drug B-Drug
. O O
) O O

However O O
decreases O O
in O O
exposure O O
were O O
as O O
much O O
as O O
9 O O
% O O
and O O
9 O O
% O O
respectively O O
in O O
individual O O
subjects O O
. O O

Therefore O O
when O O
initiating O O
pressor O O
therapy O O
in O O
these O O
patients O O
the O O
initial O O
dose O O
should O O
be O O
small O O
and O O
used O O
with O O
due O O
caution O O
. O O

None O O
known O O
. O O

Effects O O
of O O
Antacids B-Group B-Group
on O O
Felbatol B-Brand B-Brand
The O O
rate O O
and O O
extent O O
of O O
absorption O O
of O O
a O O
9 O O
mg O O
dose O O
of O O
Felbatol B-Brand B-Brand
as O O
monotherapy O O
given O O
as O O
tablets O O
was O O
not O O
affected O O
when O O
coadministered O O
with O O
antacids B-Group B-Group
. O O

Alcohol B-Drug B-Drug
( O O
increases O O
bioavailability O O
by O O
9 O O
% O O
) O O
cimetidine B-Drug B-Drug
and O O
valproates O O
. O O

If O O
TRANXENE B-Brand B-Brand
is O O
to O O
be O O
combined O O
with O O
other O O
drugs O O
acting O O
on O O
the O O
central O O
nervous O O
system O O
careful O O
consideration O O
should O O
be O O
given O O
to O O
the O O
pharmacology O O
of O O
the O O
agents O O
to O O
be O O
employed O O
. O O

The O O
effect O O
of O O
corticosteroids B-Group B-Group
on O O
oral O O
anticoagulants B-Group B-Group
is O O
variable O O
. O O

Certain O O
other O O
antibiotics B-Group B-Group
( O O
aminoglycosides B-Group B-Group
and O O
polymyxin B-Group B-Drug
) O O
have O O
also O O
been O O
reported O O
to O O
interfere O O
with O O
the O O
nerve O O
transmission O O
at O O
the O O
neuromuscular O O
junction O O
. O O

prolonged B-Group O
narcotics I-Group B-Group
; O O

The O O
hypoglycemic O O
action O O
of O O
sulfonylureas B-Group B-Group
may O O
be O O
potentiated O O
by O O
certain O O
drugs O O
including O O
nonsteroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
agents I-Group I-Group
and O O
other O O
drugs O O
that O O
are O O
highly O O
protein O O
bound O O
salicylates B-Group B-Group
sulfonamides B-Group B-Group
chloramphenicol B-Drug B-Drug
probenecid B-Drug B-Drug
coumarins B-Group B-Group
monoamine B-Group B-Group
oxidase I-Group I-Group
inhibitors I-Group I-Group
and O O
beta B-Group B-Group
adrenergic I-Group I-Group
blocking I-Group I-Group
agents I-Group I-Group
. O O

Due O O
to O O
its O O

Only O O
at O O
the O O
highest O O
concentration O O
tested O O
( O O
9 O O

Drugs O O
that O O
have O O
been O O
reported O O
to O O
diminish O O
oral O O
anticoagulant B-Group B-Group
response O O
ie O O
decreased O O
prothrom O O
- O O
bin O O
time O O
response O O
in O O
man O O
significantly O O
include O O
: O O
adrenocortical B-Group B-Group
steroids I-Group I-Group
; O O

Adrenergic B-Group B-Group
blockers I-Group I-Group
Adrenergic B-Group B-Group
blockers I-Group I-Group
are O O
inhibited O O
by O O
amphetamines B-Group B-Group
. O O

- O O
Carbamazepine B-Drug B-Drug
( O O
e.g. O O
Tegretol B-Brand B-Brand
) O O
or O O

Reduce O O
both O O
the O O
dose O O
of O O
levomepromazine B-Drug B-Drug
and O O
the O O
dose O O
of O O
the O O
other O O
drug O O
. O O

The O O
effect O O
may O O
be O O
mediated O O
by O O
cimetidines B-Drug O
known O O
inhibition O O
of O O
hepatic O O
cytochrome O O
P O O
- O O
9 O O
the O O
enzyme O O
system O O
responsible O O
for O O
the O O
first O O
- O O
pass O O
metabolism O O
of O O
diltiazem B-Drug B-Drug
. O O

GI O O
motility O O
agents O O
: O O
cisapride B-Drug B-Drug

The O O
following O O
are O O
examples O O
of O O
drugs O O
known O O
to O O
inhibit O O
the O O
metabolism O O
of O O
other O O
related O O
benzodiazepines B-Group B-Group
presumably O O
through O O
inhibition O O
of O O
CYP9A O O
: O O
nefazodone B-Drug B-Drug
fluvoxamine B-Drug B-Drug
cimetidine B-Drug B-Drug
diltiazem B-Drug B-Drug
isoniazide B-Drug B-Drug
and O O
some O O
macrolide B-Group B-Group
antibiotics I-Group I-Group
. O O

Adrenal B-Group B-Group
steroids I-Group I-Group
or O O
ACTH B-Drug B-Group
In O O
patients O O
with O O
edema O O
concomitant O O
administration O O
with O O
adrenal B-Group O
cortical I-Group B-Group
steroids I-Group I-Group
or O O
ACTH B-Drug B-Group
may O O
increase O O
the O O
edema O O
. O O

MAO B-Group B-Group
inhibitors I-Group I-Group
prolong O O
and O O
intensify O O
the O O
effects O O
of O O
antihistamines B-Group B-Group
. O O

Probenecid B-Drug B-Drug
may O O
decrease O O
renal O O
tubular O O
secretion O O
of O O
cephalosporins B-Group B-Group
when O O
used O O
concurrently O O
resulting O O
in O O
increased O O
and O O
more O O
prolonged O O
cephalosporin B-Group O
blood O O
levels O O
. O O

The O O
pharmacokinetics O O
of O O
naltrexone B-Drug B-Drug
and O O
its O O
major O O
metabolite O O
9 B-Drug_n B-Drug_n
- O O
beta B-Drug_n B-Drug_n
- O O
naltrexol B-Drug_n B-Drug_n
were O O
unaffected O O
following O O
co O O
- O O
administration O O
with O O
Acamprosate B-Drug B-Drug
. O O

there O O
was O O
no O O
effect O O
on O O
the O O
9 O O
major O O
metabolites O O
( O O
9 B-Drug_n O
- O O
DFUR B-Drug_n B-Drug_n
9 B-Drug_n I-Drug_n
- O O
FU B-Drug_n B-Drug
and O O
FBAL B-Drug_n O
) O O
. O O

MAO B-Group B-Group
Inhibitors I-Group I-Group
- O O
The O O
pressor O O
effect O O
of O O
sympathomimetic B-Group B-Group
pressor I-Group I-Group
amines I-Group I-Group
is O O
markedly O O
potentiated O O
in O O
patients O O
receiving O O
monoamine B-Group B-Group
oxidase I-Group I-Group
inhibitors I-Group I-Group
( O O
MAOI B-Group B-Group
) O O
. O O

free O O
T9 O O
concentration O O
is O O
unaltered O O
: O O
impaired O O
glucose O O
tolerance O O
; O O

NovoSeven B-Brand B-Drug
should O O
not O O
be O O
mixed O O
with O O
infusion O O
solutions O O
until O O
clinical O O
data O O
are O O
available O O
to O O
direct O O
this O O
use O O
. O O

Calcium B-Group B-Group
Antagonists I-Group I-Group
: O O
After O O
repeated O O
co O O
- O O
administration O O
of O O
Trileptal B-Brand B-Brand
the O O
AUC O O
of O O
felodipine B-Drug B-Drug
was O O
lowered O O
by O O
9 O O
% O O
[ O O
9 O O
% O O
CI O O
: O O
9 O O
- O O
9 O O
] O O
. O O

Morphine B-Drug B-Drug
: O O
Combination O B-Group
hormonal B-Group I-Group
contraceptives I-Group I-Group
may O O
increase O O
the O O
clearance O O
of O O
morphine B-Drug B-Drug
. O O

Fentanyl B-Drug B-Drug
Anesthesia O O
: O O
Severe O O
hypotension O O
has O O
been O O
reported O O
during O O
fentanyl B-Drug B-Drug
anesthesia O O
with O O
concomitant O O
use O O
of O O
a O O
beta B-Group B-Group
blocker I-Group I-Group
and O O
a O O
calcium B-Group B-Group
channel I-Group I-Group
blocker I-Group I-Group
. O O

With O O
the O O
morning O O
dose O O
of O O
ceftibuten B-Drug B-Drug
on O O
day O O
9 O O
each O O
volunteer O O
received O O
a O O
single O O
intravenous O O
infusion O O
of O O
theophylline B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
) O O
. O O

influenza B-Group B-Group
virus I-Group I-Group
vaccine I-Group I-Group
; O O

Prospective O O
long O O
- O O
term O O
studies O O
on O O
concomitant O O
administration O O
of O O
VIOXX B-Brand B-Brand
and O O
aspirin B-Brand B-Brand
have O O
not O O
been O O
conducted O O
. O O

Acyclovir B-Drug B-Drug
/ O O
Ganciclovir B-Drug B-Drug
: O O
may O O
be O O
taken O O
with O O
Myfortic B-Brand B-Brand
; O O

Pyrimethamine B-Drug B-Drug
may O O
be O O
used O O
with O O
sulfonamides B-Group B-Group
quinine B-Drug B-Drug
and O O
other O O
antimalarials B-Group B-Group
and O O
with O O
other O O
antibiotics B-Group B-Group
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
No O O
laboratory O O
test O O
abnormalities O O
related O O
to O O
the O O
use O O
of O O
guanfacine B-Drug B-Drug
have O O
been O O
identified O O
. O O

Histamine B-Group B-Group
H9 I-Group I-Group
antagonists I-Group I-Group
: O O
Cimetidine B-Drug B-Drug
inhibits O O
CYP9A9 O O
and O O
can O O
increase O O
serum O O
amiodarone B-Drug O
levels O O
. O O

There O O
is O O
no O O
pharmacokinetic O O
interaction O O
between O O
ethanol B-Drug B-Drug
and O O
flumazenil B-Drug B-Drug
. O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-Drug B-Drug
used O O
to O O
treat O O
allergic O O
reactions O O
. O O

Mazindol B-Drug B-Drug
may O O
reduce O O
the O O
effects O O
of O O
guanethidine B-Drug B-Drug
( O O
Ismelin B-Brand B-Brand
) O O
. O O

The O O
para O B-Drug
- O O
aminobenzoic O O
acid O O
metabolite O O
of O O
chloroprocaine O B-Drug
inhibits O O
the O O
action O O
of O O
sulfonamides B-Group B-Group
. O O

Patients O O
should O O
be O O
carefully O O
monitored O O
. O O

Furthermore O O
caution O O
should O O
be O O
exercised O O
when O O
combining O O
digoxin B-Drug B-Drug
with O O
any O O
drug O O
that O O
may O O
cause O O
a O O
significant O O
deterioration O O
in O O
renal O O
function O O
since O O
a O O
decline O O
in O O
glomerular O O
filtration O O
or O O
tubular O O
secretion O O
may O O
impair O O
the O O
excretion O O
of O O
digoxin B-Drug B-Drug
. O O

Additional O O
interactions O O

TOLECTIN B-Brand B-Brand
and O O
other O O
nonsteroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
drugs I-Group I-Group
have O O
been O O
reported O O
to O O
reduce O O
the O O
tubular O O
secretion O O
of O O
methotrexate B-Drug B-Drug
in O O
an O O
animal O O
model O O
possibly O O
enhancing O O
the O O
toxicity O O
of O O
methotrexate B-Drug B-Drug
. O O

Chlorpropamide B-Drug B-Drug
: O O
Chlorpropamides B-Drug O
plasma O O
half O O
- O O
life O O
may O O
be O O
prolonged O O
by O O
allopurinol B-Drug B-Drug
since O O
allopurinol B-Drug B-Drug
and O O
chlorpropamide B-Drug B-Drug
may O O
compete O O
for O O
excretion O O
in O O
the O O
renal O O
tubule O O
. O O

If O O
resumed O O
during O O
captopril B-Drug B-Drug
therapy O O
such O O
agents O O
should O O
be O O
administered O O
cautiously O O
and O O
perhaps O O
at O O
lower O O
dosage O O
. O O

Hypotension O O
: O O
Patients O O
on O O
Diuretic O O
Therapy O O
: O O
Patients O O
on O O
diuretics B-Drug B-Group
and O O
especially O O
those O O
in O O
whom O O
diuretic O O
therapy O O
was O O
recently O O
instituted O O
may O O
occasionally O O
experience O O
an O O
excessive O O
reduction O O
of O O
blood O O
pressure O O
after O O
initiation O O
of O O
therapy O O
with O O
enalapril B-Drug B-Drug
or O O
enalaprilat B-Drug B-Drug
. O O

Morphine B-Drug B-Drug
: O O
TORADOLIV O O
/ O O
IM O O
has O O
been O O
administered O O
concurrently O O
with O O
morphine B-Drug B-Drug
in O O
several O O
clinical O O
trials O O
of O O
postoperative O O
pain O O
without O O
evidence O O
of O O
adverse O O
interactions O O
. O O

Hydrochlorothiazide B-Drug B-Drug
: O O
In O O
normal O O
volunteers O O
concomitant O O
administration O O
of O O
diflunisal B-Drug B-Drug
and O O
hydrochlorothiazide B-Drug B-Drug
resulted O O
in O O
significantly O O
increased O O
plasma O O
levels O O
of O O
hydrochlorothiazide B-Drug B-Drug
. O O

In O O
such O O
patients O O
the O O
mean O O
area O O
under O O
the O O
felodipine B-Drug B-Drug
plasma O O
concentration O O
- O O
time O O
curve O O
was O O
also O O
reduced O O
to O O
approximately O O
9 O O
% O O
of O O
that O O
observed O O
in O O
healthy O O
volunteers O O
. O O

Protease B-Group B-Group
inhibitor I-Group I-Group
: O O
atazanavir B-Drug B-Drug

TRACRIUM B-Brand B-Brand
should O O
not O O
be O O
administered O O
until O O
a O O
patient O O
has O O
recovered O O
from O O
succinylcholine B-Drug B-Drug
- O O
induced O O
neuromuscular O O
block O O
. O O

9 O O
mM O O
) O O
was O O
a O O
slight O O
degree O O
of O O
inhibition O O
( O O
9 O O
% O O
- O O
9 O O
% O O
) O O
of O O
isoform O O
CYP9A9 O O
observed O O
. O O

The O O
concurrent O O
use O O
of O O
tetracycline B-Drug B-Drug
and O O
Penthrane B-Brand B-Brand
( O O
methoxyflurane B-Drug B-Drug
) O O
has O O
been O O
reported O O
to O O
result O O
in O O
fatal O O
renal O O
toxicity O O
. O O

Cytochrome O O
P9 O O
9A9 O O
( O O
CYP9A9 O O
) O O
is O O
known O O
to O O
be O O
the O O
major O O
enzyme O O
involved O O
in O O
the O O
metabolism O O
of O O
caffeine B-Drug B-Drug
. O O

In O O
an O O
in O O
vitro O O
study O O
cytochrome O O
P9 O O
isozymes O O
9A9 O O
9A9 O O
9C9 O O
9C9 O O
9D9 O O
9E9 O O
and O O
9A9 O O
were O O
not O O
inhibited O O
by O O
exposure O O
to O O
cevimeline B-Drug B-Drug
. O O

Inhibitors O O
of O O
the O O
CYP9A9 O O
isoenzyme O O
could O O
increase O O
systemic O O
dofetilide B-Drug B-Drug
exposure O O
. O O

This O O
medicine O O
should O O
not O O
be O O
taken O O
with O O
MAO B-Group B-Group
inhibitors I-Group I-Group
. O O

Like O O
isoflurane B-Drug B-Drug
desflurane B-Drug B-Drug
does O O
not O O
predispose O O
to O O
premature O O
ventricular O O
arrhythmias O O
in O O
the O O
presence O O
of O O
exogenously O O
infused O O
epinephrine B-Drug B-Drug
in O O
swine O O
. O O

Aspirin B-Brand B-Brand
: O O
Animal O O
studies O O
wshow O O
that O O
aspirin B-Brand B-Brand
given O O
with O O
nonsteroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group O
agents I-Group O
including O O
ibuprofen B-Drug B-Drug
yields O O
a O O
net O O
decrease O O
in O O
anti O O
- O O
inflammatory O O
activity O O
with O O
lowered O O
blood O O
levels O O
of O O
the O O
non O O
- O O
aspirin O B-Brand
drug O I-Group
. O O

Lithium B-Drug B-Drug
toxicity O O
was O O
usually O O
reversible O O
upon O O
discontinuation O O
of O O
lithium B-Drug B-Drug
and O O
the O O
ACE B-Group B-Group
inhibitor I-Group I-Group
. O O

Ergotamine B-Drug B-Drug

Coadministration O O
of O O
astemizole B-Drug B-Drug
with O O
ketoconazole B-Drug B-Drug
tablets O O
is O O
therefore O O
contraindicated O O
. O O

therefore O O
it O O
should O O
be O O
recognized O O
that O O
a O O
positive O O
Coombs O O
test O O
may O O
be O O
due O O
to O O
the O O
drug O O
. O O

- O O
Amiodarone B-Drug B-Drug
( O O
e.g. O O
Cordarone B-Brand B-Drug
) O O
or O O

alopecia O O

The O O
beta B-Group B-Group
- O O
blocker B-Group B-Group
should O O
be O O
withdrawn O O
first O O
. O O

Oxcarbazepine B-Drug B-Drug
can O O
inhibit O O
CYP9C9 O O
and O O
induce O O
CYP9A9 O O
/ O O
9 O O
with O O
potentially O O
important O O
effects O O
on O O
plasma O O
concentrations O O
of O O
other O O
drugs O O
. O O

After O O
extensive O O
intake O O
of O O
grapefruit O O
juice O O
( O O
which O O
inhibits O O
CYP9A9 O O
activity O O
predominantly O O
in O O
the O O
intestinal O O
mucosa O O
) O O
the O O
systemic O O
exposure O O
for O O
oral O O
budesonide B-Drug B-Drug
increased O O
about O O
two O O
times O O
. O O

alcohol B-Drug B-Drug
barbiturates B-Drug B-Group
and O O
other O O
CNS B-Drug B-Group
depressants I-Drug I-Group
; O O

- O O
Methotrexate B-Drug B-Drug
( O O
e.g. O O
Mexate B-Brand B-Brand
) O O
Use O O
of O O
methotrexate B-Drug B-Drug
with O O
sulfapyridine B-Drug B-Drug
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
liver O O
and O O
/ O O
or O O
the O O
side O O
effects O O
of O O
methotrexate B-Drug B-Drug

Fibrates B-Group B-Group
may O O
increase O O
cholesterol O O
excretion O O
into O O
the O O
bile O O
leading O O
to O O
cholelithiasis O O
. O O

Because O O
pregnancy O O
could O O
not O O
be O O
maintained O O
in O O
the O O
rabbit O O
following O O
doses O O
of O O
fulvestrant B-Drug B-Drug
of O O
9 O O
mg O O
/ O O
kg O O
/ O O
day O O
and O O
above O O
this O O
study O O
was O O
inadequate O O
to O O
fully O O
define O O
the O O
possible O O
adverse O O
effects O O
on O O
fetal O O
development O O
at O O
clinically O O
relevant O O
exposures O O
. O O

If O O
oral O O
anticoagulants B-Group B-Group
are O O
also O O
being O O
given O O
compensatory O O
increases O O
in O O
clotting O O
factor O O
synthesis O O
are O O
impaired O O
. O O

No O O
other O O
pharmacokinetic O O
parameters O O
were O O
changed O O
. O O

In O O
clinical O O
trials O O
the O O
concomitant O O
use O O
of O O
sulfonylureas B-Group B-Group
or O O
biguanides B-Group O
did O O
not O O
alter O O
the O O
adverse O O
event O O
profile O O
of O O
SYMLIN B-Brand B-Brand
. O O

Carcinogenesis O O
Mutagenesis O O
Impairment O O
of O O
Fertility O O
No O O
long O O
- O O
term O O
carcinogenicity O O
studies O O
have O O
been O O
carried O O
out O O
with O O
dexrazoxane B-Drug B-Drug
in O O
animals O O
. O O

These O O
findings O O
should O O
be O O
taken O O
into O O
account O O
for O O
proper O O
interpretation O O
of O O
serum O O
PSA O O
when O O
evaluating O O
men O O
treated O O
with O O
finasteride B-Drug B-Drug
. O O

Patients O O
who O O
require O O
the O O
use O O
of O O
one O O
of O O
these O O
drugs O O
with O O
HIVID B-Drug B-Drug
should O O
have O O
frequent O O
clinical O O
and O O
laboratory O O
monitoring O O
with O O
dosage O O
adjustment O O
for O O
any O O
significant O O
change O O
in O O
renal O O
function O O
. O O

In O O
a O O
controlled O O
clinical O O
trial O O
a O O
9 O O
% O O
reduction O O
of O O
the O O
phenytoin B-Drug B-Drug
dose O O
at O O
the O O
initiation O O
of O O
Felbatol B-Brand B-Brand
therapy O O
resulted O O
in O O
phenytoin B-Drug B-Drug
levels O O
comparable O O
to O O
those O O
prior O O
to O O
Felbatol B-Brand B-Brand
administration O O
. O O

If O O
phenytoin B-Drug B-Drug
or O O
other O O
hepatic O O
enzyme O O
inducers O O
are O O
taken O O
concurrently O O
with O O
Norpace B-Brand B-Brand
or O O
Norpace B-Brand B-Brand
CR I-Brand O
lower O O
plasma O O
levels O O
of O O
disopyramide B-Drug B-Drug
may O O
occur O O
. O O

Chlorpromazine B-Drug B-Drug
: O O
Chlorpromazine B-Drug B-Drug
blocks O O
dopamine O B-Drug
and O O
norepinephrine O O
receptors O O
thus O O
inhibiting O O
the O O
central O O
stimulant O O
effects O O
of O O
amphetamines B-Group B-Group
and O O
can O O
be O O
used O O
to O O
treat O O
amphetamine B-Group B-Drug
poisoning O O
. O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
NSAIDs B-Group B-Group
concomitantly O O
with O O
ACE B-Group B-Group
inhibitors I-Group I-Group
. O O

Studies O O
with O O
furosemide B-Drug B-Drug
agents O O
and O O
meloxicam B-Drug B-Drug
have O O
not O O
demonstrated O O
a O O
reduction O O
in O O
natriuretic O O
effect O O
. O O

Interactions O O
for O O
Vitamin B-Drug B-Drug
B9 I-Drug I-Drug
( O O
Riboflavin B-Drug B-Drug
) O O
: O O
Alcohol B-Drug B-Drug
- O O
impairs O O
the O O
intestinal O O
absorption O O
of O O
riboflavin B-Drug B-Drug

) O O

Potential O O
for O O
ABILIFY B-Brand B-Brand
to O O
Affect O O
Other O O
Drugs O O
Aripiprazole B-Drug B-Drug
is O O
unlikely O O
to O O
cause O O
clinically O O
important O O
pharmacokinetic O O
interactions O O
with O O
drugs O O
metabolized O O
by O O
cytochrome O O
P9 O O
enzymes O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
Positive O O
direct O O
Coombs O O
tests O O
have O O
been O O
reported O O
during O O
treatment O O
with O O
the O O
cephalosporin B-Group B-Group
antibiotics I-Group I-Group
. O O

Because O O
changes O O
in O O
glucose O O
concentrations O O
with O O
valdecoxib B-Drug B-Drug
coadministration O O
were O O
within O O
the O O
normal O O
variability O O
and O O
individual O O
glucose O O
concentrations O O
were O O
above O O
or O O
near O O
9 O O
mg O O
/ O O
dL O O
dose O O
adjustment O O
for O O
glyburide B-Drug B-Drug
( O O
9 O O
mg O O
QD O O
and O O
9 O O
mg O O
BID O O
) O O
with O O
valdecoxib B-Drug B-Drug
coadministration O O
( O O
up O O
to O O
9 O O
mg O O
QD O O
) O O
is O O
not O O
indicated O O
. O O

A O O
possible O O
drug O O
interaction O O
of O O
FOSCAVIR B-Brand B-Brand
and O O
intravenous O O
pentamidine B-Drug B-Drug
has O O
been O O
described O O
. O O

diet O O
high O O
in O O
vitamin B-Group B-Group
K I-Group I-Group
; O O

Drugs O O
that O O
have O O
been O O
associated O O
with O O
peripheral O O
neuropathy O O
include O O
antiretroviral B-Drug B-Group
nucleoside I-Drug I-Group
analogues I-Drug I-Group
chloramphenicol B-Drug B-Drug
cisplatin B-Drug B-Drug
dapsone B-Drug B-Drug
disulfiram B-Drug B-Drug
ethionamide B-Drug B-Drug
glutethimide B-Drug B-Drug
gold B-Drug B-Group
hydralazine B-Drug B-Drug
iodoquinol B-Drug B-Drug
isoniazid B-Drug B-Drug
metronidazole B-Drug B-Drug
nitrofurantoin B-Drug B-Drug
phenytoin B-Drug B-Drug
ribavirin B-Drug B-Drug
and O O
vincristine B-Drug B-Drug
. O O

dosage O O
adjustment O O
of O O
antigout B-Group O
medications I-Group O
may O O
be O O
necessary O O
to O O
control O O
hyperuricemia O O
and O O
gout O O
. O O
) O O

Some O O
diuretics B-Group B-Group
can O O
enhance O O
aminoglycoside B-Group O
toxicity O O
by O O
altering O O
antibiotic B-Group O
concentrations O O
in O O
serum O O
and O O
tissue O O
. O O

SSRIs B-Group B-Group
: O O
Weakness O O
hyperreflexia O O
and O O
incoordination O O
have O O
been O O
reported O O
rarely O O
when O O
9 B-Group B-Group
- O O
HT9 B-Group B-Group
agonists I-Group I-Group
have O O
been O O
co O O
- O O
administered O O
with O O
SSRIs B-Group B-Group
( O O
e. O O
g O O
. O O

Vasopressors B-Group O
particularly O O
metaraminol B-Drug B-Drug
may O O
cause O O
serious O O
cardiac O O
arrhythmias O O
during O O
halothane B-Drug B-Drug
anesthesia O O
and O O
therefore O O
should O O
be O O
used O O
only O O
with O O
great O O
caution O O
or O O
not O O
at O O
all O O
. O O

conversely O O
diethylpropion B-Drug B-Drug
may O O
interfere O O
with O O
antihypertensive B-Group B-Group
drugs I-Group I-Group
( O O
i.e. O O
guanethidine B-Drug B-Drug
a B-Drug O
- O O
methyldopa B-Drug B-Drug
) O O
. O O

Rifampicin B-Drug B-Drug
: O O
In O O
a O O
study O O
in O O
healthy O O
volunteers O O
a O O
six O O
- O O
day O O
course O O
of O O
rifampicin B-Drug B-Drug
at O O
9 O O
mg O O
/ O O
day O O
followed O O
by O O
a O O
single O O
9 O O
mg O O
dose O O
of O O
isradipine B-Drug B-Drug
resulted O O
in O O
a O O
reduction O O
in O O
isradipine B-Drug B-Drug
levels O O
to O O
below O O
detectable O O
limits O O
. O O

The O O
use O O
of O O
NUROMAX B-Brand B-Brand
before O O
succinylcholine B-Drug B-Drug
to O O
attenuate O O
some O O
of O O
the O O
side O O
effects O O
of O O
succinylcholine B-Drug B-Drug
has O O
not O O
been O O
studied O O
. O O

Therefore O O
appropriate O O
dose O O
adjustments O O
may O O
be O O
necessary O O
for O O
these O O
drugs O O
. O O

The O O
average O O
infusion O O
rate O O
requirement O O
may O O
be O O
decreased O O
by O O
as O O
much O O
as O O
9 O O
% O O
to O O
9 O O
% O O
. O O

Rare O O
instances O O
of O O
dyspnea O O
palpitation O O
chest O O
pain O O
syncope O O
. O O

Cytotoxic B-Group O
Agents I-Group O
: O O
Enhanced O O
bone O O
marrow O O
suppression O O
by O O
cyclophosphamide B-Drug B-Drug
and O O
other O O
cytotoxic B-Group O
agents I-Group O
has O O
been O O
reported O O
among O O
patients O O
with O O
neoplastic O O
disease O O
except O O
leukemia O O
in O O
the O O
presence O O
of O O
allopurinol B-Drug B-Drug
. O O

A O O
total O O
of O O
9 O O
clinical O O
drug O O
- O O
drug O O
interaction O O
studies O O
were O O
conducted O O
in O O
healthy O O
volunteers O O
to O O
evaluate O O
the O O
potential O O
for O O
interaction O O
between O O
MYCAMINE B-Brand B-Brand
and O O
mycophenolate B-Drug B-Drug
mofetil I-Drug I-Drug
cyclosporine B-Drug B-Drug
tacrolimus B-Drug B-Drug
prednisolone B-Drug B-Drug
sirolimus B-Drug B-Drug
nifedipine B-Drug B-Drug
fluconazole B-Drug B-Drug
ritonavir B-Drug B-Drug
and O O
rifampin B-Drug B-Drug
. O O

Drugs O O
Demonstrated O O
to O O
be O O
CYP O O
9A O O
Inhibitors O O
of O O
Possible O O
Clinical O O
Significance O O
on O O
the O O
Basis O O
of O O
Clinical O O
Studies O O
Involving O O
Alprazolam B-Drug B-Drug
( O O
caution O O
is O O
recommended O O
during O O
coadministration O O
with O O
alprazolam B-Drug B-Drug
) O O
: O O
Coadministration O O
of O O
fluoxetine B-Drug B-Drug
with O O
alprazolam B-Drug B-Drug
increased O O
the O O
maximum O O
plasma O O
concentration O O
of O O
alprazolam B-Drug B-Drug
by O O
9 O O
% O O
decreased O O
clearance O O
by O O
9 O O
% O O
increased O O
half O O
- O O
life O O
by O O
9 O O
% O O
and O O
decreased O O
measured O O
psychomotor O O
performance O O
. O O

In O O
general O O
most O O
patients O O
treated O O
with O O
dirithromycin B-Drug B-Drug
who O O
are O O
receiving O O
concomitant O O
theophylline B-Drug B-Drug
therapy O O
may O O
not O O
require O O
empiric O O
adjustment O O
of O O
theophylline B-Drug B-Drug
dosage O O
or O O
monitoring O O
of O O
theophylline B-Drug B-Drug
plasma O O
concentrations O O
. O O

There O O
have O O
been O O
reports O O
of O O
theophylline B-Drug B-Drug
- O O
related O O
side O O
effects O O
in O O
patients O O
on O O
concomitant O O
therapy O O
with O O
norfloxacin B-Drug B-Drug
and O O
theophylline B-Drug B-Drug
. O O

Ranitidine B-Drug B-Drug
also O O
has O O
no O O
effect O O
on O O
eprosartan B-Drug B-Drug
pharmacokinetics O O
. O O

anabolic B-Group B-Group
steroids I-Group I-Group
; O O

Enalapril B-Drug B-Drug
IV O O
has O O
been O O
used O O
concomitantly O O
with O O
digitalis B-Group B-Group
without O O
evidence O O
of O O
clinically O O
significant O O
adverse O O
reactions O O
. O O

Increases O O
in O O
INR O O
and O O
prothrombin O O
time O O
may O O
lead O O
to O O
abnormal O O
bleeding O O
and O O
even O O
death O O
. O O

These O O
agents O O
should O O
not O O
be O O
used O O
in O O
patients O O
treated O O
with O O
Itraconazole B-Drug B-Drug
. O O

CNS B-Group B-Group
depressant I-Group I-Group
medications O I-Group
: O O
Concurrent O O
use O O
of O O
procaine B-Drug B-Drug
hydrochloride I-Drug I-Drug
and O O
CNS B-Group B-Group
depressant I-Group I-Group
medications I-Group I-Group
may O O
result O O
in O O
additive O O
depressant O O
effects O O
. O O

Thus O O
concomitant O O
therapy O O
with O O
warfarin B-Drug B-Drug
and O O
Lodine B-Brand B-Brand
should O O
not O O
require O O
dosage O O
adjustment O O
of O O
either O O
drug O O
. O O

The O O
vasodilating O O
effects O O
of O O
nitroglycerin B-Drug B-Drug
may O O
be O O
additive O O
with O O
those O O
of O O
other O O
vasodilators B-Group B-Group
. O O

Drugs O O
that O O
alter O O
the O O
gastrointestinal O O
flora O O
may O O
interact O O
with O O
Myfortic B-Brand B-Brand
by O O
disrupting O O
enterohepatic O O
recirculation O O
. O O

g O O
/ O O
mL O O
; O O

Controlled O O
and O O
uncontrolled O O
domestic O O
studies O O
suggest O O
that O O
concomitant O O
use O O
of O O
diltiazem B-Drug B-Drug
hydrochloride I-Drug I-Drug
and O O
beta B-Group B-Group
- O O
blockers B-Group B-Group
is O O
usually O O
well O O
tolerated O O
but O O
available O O
data O O
are O O
not O O
sufficient O O
to O O
predict O O
the O O
effects O O
of O O
concomitant O O
treatment O O
in O O
patients O O
with O O
left O O
ventricular O O
dysfunction O O
or O O
cardiac O O
conduction O O
abnormalities O O
. O O

The O O
clinical O O
basis O O
of O O
this O O
drug O O
interaction O O
has O O
not O O
been O O
established O O
but O O
should O O
be O O
noted O O
when O O
allopurinol B-Drug B-Drug
is O O
given O O
to O O
patients O O
already O O
on O O
dicumarol B-Drug B-Drug
therapy O O
. O O

The O O
incidence O O
of O O
akathisia O O
in O O
clinical O O
trials O O
of O O
the O O
weekly O O
dosage O O
schedule O O
was O O
greater O O
( O O
9 O O
% O O
9 O O
/ O O
9 O O
patients O O
) O O
when O O
prochlorperazine B-Drug B-Drug
was O O
administered O O
on O O
the O O
same O O
day O O
as O O
CAMPTOSAR B-Brand B-Brand
than O O
when O O
these O O
drugs O O
were O O
given O O
on O O
separate O O
days O O
( O O
9 O O
% O O
9 O O
/ O O
9 O O
patients O O
) O O
. O O

The O O
concomitant O O
use O O
of O O
beta B-Group B-Group
- O O
adrenergic B-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
with O O
digitalis B-Group B-Group
and O O
calcium B-Group B-Group
antagonists I-Group I-Group
may O O
have O O
additive O O
effects O O
on O O
prolonging O O
atrioventricular O O
conduction O O
time O O
. O O

Chlorprothixene B-Drug B-Drug
may O O
increase O O
the O O
plasma O O
- O O
level O O
of O O
concomitantly O O
given O O
lithium B-Drug B-Drug
. O O

trimethoprim B-Drug B-Drug
/ O O
sulfamethoxazole B-Drug B-Drug
; O O

9 O O
. O O

Thyroid O B-Group
hormonal O I-Group
replacement O O
increases O O
metabolic O O
rate O O
which O O
requires O O
an O O
increase O O
in O O
digitalis B-Group B-Group
dosage O O
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
valdecoxib B-Drug B-Drug
is O O
a O O
moderate O O
inhibitor O O
of O O
CYP O O
9C9 O O
( O O
IC9 O O
= O O
9 O O
g O O
/ O O
mL O O
or O O
9 O O
M O O
) O O
and O O
9C9 O O
( O O
IC9 O O
= O O
9 O O
g O O
/ O O
mL O O
or O O
9 O O
M O O
) O O
and O O
a O O
weak O O
inhibitor O O
of O O
CYP O O
9D9 O O
( O O
IC9 O O
= O O
9 O O
g O O
/ O O
mL O O
or O O
9 O O
M O O
) O O
and O O
9A9 O O
( O O
IC9 O O
= O O
9 O O
g O O
/ O O
mL O O
or O O
9 O O
M O O
) O O
.. O O

Other O O
substances O O
: O O
Grapefruit O O
juice O O
given O O
to O O
healthy O O
volunteers O O
increased O O
amiodarone B-Drug B-Drug
AUC O O
by O O
9 O O
% O O
and O O
Cmax O O
by O O
9 O O
% O O
resulting O O
in O O
increased O O
plasma O O
levels O O
of O O
amiodarone B-Drug B-Drug
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
glipizide B-Drug B-Drug
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Concomitant O O
treatment O O
of O O
four O O
patients O O
in O O
the O O
United O O
Kingdom O O
with O O
FOSCAVIR B-Brand B-Brand
and O O
intravenous O O
pentamidine B-Drug B-Drug
may O O
have O O
caused O O
hypocalcemia O O
; O O

however O O
it O O
is O O
considered O O
to O O
be O O
unlikely O O
that O O
this O O
decrease O O
of O O
phosphorylated O O
lamivudine B-Drug B-Drug
concentration O O
is O O
of O O
clinical O O
significance O O
as O O
lamivudine B-Drug B-Drug
is O O
a O O
more O O
efficient O O
substrate O O
for O O
deoxycytidine O O
kinase O O
than O O
zalcitabine B-Drug B-Drug
. O O

Warfarin B-Drug B-Drug
: O O
The O O
coadministration O O
of O O
EVISTA B-Brand B-Brand
and O O
warfarin B-Drug B-Drug
has O O
not O O
been O O
assessed O O
under O O
chronic O O
conditions O O
. O O

Oral O O
Contraceptives B-Group B-Group
: O O
Multiple O O
dose O O
administration O O
of O O
tiagabine B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
day O O
monotherapy O O
) O O
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
oral O O
contraceptives B-Group B-Group
in O O
healthy O O
women O O
of O O
childbearing O O
age O O
. O O

There O O
have O O
been O O
reports O O
of O O
increased O O
anticoagulant O O
effects O O
when O O
erythromycin B-Drug B-Drug
and O O
oral O O
anticoagulants B-Group B-Group
were O O
used O O
concomitantly O O
. O O

Nitrofurantoin B-Drug B-Drug
interferes O O
with O O
the O O
therapeutic O O
action O O
of O O
nalidixic B-Drug B-Drug
acid I-Drug I-Drug
. O O

A O O
causal O O
relationship O O
has O O
not O O
been O O
established O O

Auranofin B-Drug B-Drug
should O O
not O O
be O O
used O O
together O O
with O O
penicillamine B-Drug B-Drug
( O O
Depen B-Brand O
Cuprimine B-Brand B-Drug
) O O
another O O
arthritis O O
medication O O
. O O

Phenothiazines B-Group B-Group
are O O
capable O O
of O O
potentiating O O
CNS B-Group B-Group
depressants I-Group I-Group
( O O
e.g. O O
barbiturates B-Group B-Group
anesthetics B-Group B-Group
opiates B-Group B-Group
alcohol B-Drug B-Drug
etc O O
. O O
) O O

Microscopic O O
hematuria O O
( O O
9 O O
/ O O
9 O O
) O O
and O O
gingival O O
bleeding O O
( O O
9 O O
/ O O
9 O O
) O O
were O O
also O O
observed O O
. O O

Use O O
of O O
Cerubidine B-Brand B-Brand
in O O
a O O
patient O O
who O O
has O O
previously O O
received O O
doxorubicin B-Drug B-Drug
increases O O
the O O
risk O O
of O O
cardiotoxicity O O
. O O

Some O O
reports O O
have O O
shown O O
that O O
the O O
concomitant O O
administration O O
of O O
thiazides B-Group B-Group
with O O
vitamin B-Group B-Group
D I-Group I-Group
causes O O
hypercalcemia O O
. O O

- O O
Hydroxychloroquine B-Drug B-Drug_n
( O O
e.g. O O
Plaquenil B-Brand B-Brand
) O O
or O O

Antiarrhythmics B-Group B-Group
: O O
Amiodarone B-Drug B-Drug
bepridil B-Drug B-Drug
flecainide B-Drug B-Drug
propafenone B-Drug B-Drug
quinidine B-Drug B-Drug
CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and O O
/ O O
or O O
life O O
- O O
threatening O O
reactions O O
. O O

Anticonvulsants B-Group B-Group
( O O
Phenytoin B-Drug B-Drug
) O O
: O O
Steady O O
state O O
plasma O O
exposure O O
( O O
AUC O O
) O O
of O O
valdecoxib B-Drug B-Drug
( O O
9 O O
mg O O
BID O O
for O O
9 O O
days O O
) O O
was O O
decreased O O
by O O
9 O O
% O O
when O O
co O O
- O O
administered O O
with O O
multiple O O
doses O O
( O O
9 O O
mg O O
QD O O
for O O
9 O O
days O O
) O O
of O O
phenytoin B-Drug B-Drug
( O O
a O O
CYP O O
9A9 O O
inducer O O
) O O
. O O

Drugs O O
that O O
may O O
alter O O
imatinib B-Drug B-Drug
plasma O O
concentrations O O
Drugs O O
that O O
may O O
increase O O
imatinib B-Drug B-Drug
plasma O O
concentrations O O
: O O
Caution O O
is O O
recommended O O
when O O
administering O O
Gleevec B-Brand B-Brand
with O O
inhibitors O O
of O O
the O O
CYP9A9 O O
family O O
( O O
e.g. O O
ketoconazole B-Drug B-Drug
itraconazole B-Drug B-Drug
erythromycin B-Drug B-Drug
clarithromycin B-Drug B-Drug
) O O
. O O

Influence O O
of O O
AED B-Group B-Group
On O O
MHD B-Drug_n B-Drug_n
Concentration O O
( O O
Mean O O
change O O
9 O O
% O O
Confidence O O
Interval O O
) O O

Therefore O O
it O O
should O O
be O O
recognized O O
that O O
a O O
positive O O
Coombs O O
test O O
could O O
be O O
due O O
to O O
the O O
drug O O
. O O

For O O
comprehensive O O
information O O
concerning O O
laboratory O O
test O O
alterations O O
associated O O
with O O
ritonavir B-Drug B-Drug
physicians O O
should O O
refer O O
to O O
the O O
complete O O
prescribing O O
information O O
for O O
NORVIR B-Brand B-Brand
( O O
ritonavir B-Drug B-Drug
) O O
. O O

Concurrent O O
use O O
with O O
probenecid B-Drug B-Drug
or O O
other O O
drugs O O
significantly O O
eliminated O O
by O O
active O O
renal O O
tubular O O
secretion O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
penciclovir B-Drug B-Drug
. O O

Free O O
hormone O O
concentrations O O
may O O
be O O
decreased O O
. O O

The O O
consumption O O
of O O
alcohol B-Drug B-Drug
during O O
treatment O O
with O O
WELLBUTRIN B-Brand B-Brand
should O O
be O O
minimized O O
or O O
avoided O O
( O O
also O O
see O O
a O O
href= O O
bupropz_od.htm O O
# O O
CI O O
CONTRAINDICATIONS O O
) O O

Metformin B-Drug B-Drug
: O O
When O O
Starlix B-Brand B-Brand
9 O O
mg O O
three O O
times O O
daily O O
before O O
meals O O
was O O
administered O O
in O O
combination O O
with O O
metformin B-Drug B-Drug
9 O O
mg O O
three O O
times O O
daily O O
to O O
patients O O
with O O
Type O O
9 O O
diabetes O O
there O O
were O O
no O O
clinically O O
relevant O O
changes O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

Drug O O
interaction O O
studies O O
with O O
SUSTIVA B-Brand B-Brand
and O O
these O O
imidazole B-Group B-Drug
and O O
triazole B-Group B-Group
antifungals I-Group I-Group
have O O
not O O
been O O
conducted O O
. O O

Limited O O
evidence O O
suggests O O
that O O
ascorbic B-Drug B-Drug
acid I-Drug I-Drug
may O O
influence O O
the O O
intensity O O
and O O
duration O O
of O O
action O O
of O O
bishydroxycoumarin B-Drug B-Drug
. O O

increased O O
norepinephrine O B-Drug
- O O
induced O O
platel O O
et O O
aggregation O O
; O O

While O O
all O O
the O O
selective O B-Group
serotonin B-Group I-Group
reuptake I-Group I-Group
inhibitors I-Group I-Group
( O O
SSRIs B-Group B-Group
) O O
e.g. O O
fluoxetine B-Drug B-Drug
sertraline B-Drug B-Drug
and O O
paroxetine B-Drug B-Drug
inhibit O O
P9 O O
9D9 O O
they O O
may O O
vary O O
in O O
the O O
extent O O
of O O
inhibition O O
. O O

( O O
See O O
< O O
a O O
href= O O
`` O O
flucon_cp.htm O O
# O O
CP O O
'' O O
> O O
CLINICAL O O
PHARMACOLOGY O O
: O O
Drug O O
Interaction O O
Studies O O
. O O
) O O

OTHER O O
CONCOMITANT O O
THERAPY O O
: O O
Although O O
specific O O
interaction O O
studies O O
were O O
not O O
performed O O
in O O
clinical O O
studies O O
cerivastatin B-Drug B-Drug
sodium I-Drug I-Drug
was O O
used O O
concomitantly O O
with O O
angiotensin B-Group B-Group
- O O
converting B-Group B-Group
enzyme I-Group I-Group
ACE I-Group I-Group
inhibitors I-Group I-Group
betablockers B-Group B-Group
calcium B-Group B-Group
- O O
channel B-Group B-Group
blockers I-Group I-Group
diuretics B-Group B-Group
and O O
nonsteroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
drugs I-Group I-Group
( O O
NSAIDs B-Group B-Group
) O O
without O O
evidence O O
of O O
clinically O O
significant O O
adverse O O
interactions O O
. O O

Phenobarbital B-Drug B-Drug
: O O
Amphetamines B-Group B-Group
may O O
delay O O
intestinal O O
absorption O O
of O O
phenobarbital B-Drug B-Drug
; O O

Aspirin B-Brand B-Brand
: O O
CELEBREX B-Brand B-Brand
can O O
be O O
used O O
with O O
low O O
dose O O
aspirin B-Brand B-Brand
. O O

Naproxen B-Drug B-Drug
naproxen B-Drug B-Drug
sodium I-Drug I-Drug
and O O
other O O
NSAIDs B-Group B-Group
have O O
been O O
reported O O
to O O
reduce O O
the O O
tubular O O
secretion O O
of O O
methotrexate B-Drug B-Drug
in O O
an O O
animal O O
model O O
possibly O O
increasing O O
the O O
toxicity O O
of O O
methotrexate B-Drug B-Drug
. O O

Quinidine B-Drug B-Drug
: O O
Coadministration O O
of O O
a O O
9 O O
- O O
mg O O
single O O
dose O O
of O O
aripiprazole B-Drug B-Drug
with O O
quinidine B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
day O O
for O O
9 O O
days O O
) O O
a O O
potent O O
inhibitor O O
of O O
CYP9D9 O O
increased O O
the O O
AUC O O
of O O
aripiprazole B-Drug B-Drug
by O O
9 O O
% O O
but O O
decreased O O
the O O
AUC O O
of O O
its O O
active O O
metabolite O O
dehydroaripiprazole B-Drug_n B-Drug_n
by O O
9 O O
% O O
. O O

The O O
effects O O
of O O
anticholinergic B-Group B-Group
drugs I-Group I-Group
such O O
as O O
atropine B-Drug B-Drug
and O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
may O O
be O O
enhanced O O
by O O
the O O
concomitant O O
administration O O
of O O
triprolidine B-Drug B-Drug
. O O

The O O
effect O O
of O O
administering O O
different O O
botulinum B-Group B-Group
neurotoxin I-Group I-Group
serotypes O O
at O O
the O O
same O O
time O O
or O O
within O O
several O O
months O O
of O O
each O O
other O O
is O O
unknown O O
. O O

Antagonism O O
has O O
been O O
demonstrated O O
between O O
clindamycin B-Drug B-Drug
and O O
erythromycin B-Drug B-Drug
in O O
vitro O O
. O O

Drugs O O
Metabolized O O
by O O
P9 O O
9D9 O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P9 O O
9D9 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
caucasian O O
population O O
( O O
about O O
9 O O
to O O
9 O O
% O O
of O O
caucasians O O
are O O
so O O
called O O
poor O O
metabolizers O O
) O O
; O O

The O O
mechanism O O
and O O
long O O
- O O
term O O
consequences O O
of O O
these O O
events O O
are O O
currently O O
unknown O O
. O O

These O O
individuals O O
may O O
develop O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
clozapine B-Drug B-Drug
when O O
given O O
usual O O
doses O O
. O O

No O O
inhibition O O
of O O
deferasirox B-Drug B-Drug
metabolism O O
by O O
hydroxyurea B-Drug B-Drug
is O O
expected O O
based O O
on O O
the O O
results O O
of O O
an O O
in O O
vitro O O
study O O
. O O

Therefore O O
prothrombin O O
time O O
should O O
be O O
carefully O O
monitored O O
in O O
patients O O
receiving O O
Itraconazole B-Drug B-Drug
and O O
coumarin B-Group B-Group
- O O
like O O
drugs O O
simultaneously O O
. O O

Concurrent O O
use O O
of O O
antibacterial B-Group B-Group
drugs I-Group I-Group
with O O
oral O O
contraceptives B-Group B-Group
may O O
render O O
oral O O
contraceptives B-Group B-Group
less O O
effective O O
. O O

Laboratory O O
Test O O
Interactions O O

miconazole B-Drug B-Drug
; O O

In O O
a O O
multiple O O
- O O
dose O O
study O O
enoxacin B-Drug B-Drug
caused O O
a O O
dose O O
- O O
related O O
increase O O
in O O
the O O
mean O O
elimination O O
half O O
- O O
life O O
of O O
caffeine B-Drug B-Drug
thereby O O
decreasing O O
the O O
clearance O O
of O O
caffeine B-Drug B-Drug
by O O
up O O
to O O
9 O O
% O O
and O O
leading O O
to O O
a O O
five O O
- O O
fold O O
increase O O
in O O
the O O
AUC O O
and O O
the O O
half O O
- O O
life O O
of O O
caffeine B-Drug B-Drug
. O O

When O O
intravenous O O
morphine B-Drug B-Drug
and O O
BREVIBLOC B-Brand B-Brand
were O O
concomitantly O O
administered O O
in O O
normal O O
subjects O O
no O O
effect O O
on O O
morphine B-Drug B-Drug
blood O O
levels O O
was O O
seen O O
but O O
BREVIBLOC B-Brand B-Brand
steady O O
- O O
state O O
blood O O
levels O O
were O O
increased O O
by O O
9 O O
% O O
in O O
the O O
presence O O
of O O
morphine B-Drug B-Drug
. O O

Cardiac B-Group O
Glycosides I-Group O
: O O
In O O
a O O
study O O
of O O
young O O
healthy O O
male O O
subjects O O
no O O
evidence O O
of O O
a O O
direct O O
pharmacokinetic O O
captopril B-Drug B-Drug
- O O
digoxin B-Drug B-Drug
interaction O O
could O O
be O O
found O O
. O O

When O O
combined O O
therapy O O
is O O
contemplated O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

Steady O O
- O O
state O O
serum O O
concentrations O O
of O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
are O O
reported O O
to O O
fluctuate O O
significantly O O
when O O
cimetidine B-Drug B-Drug
is O O
either O O
added O O
or O O
deleted O O
from O O
the O O
drug O O
regimen O O
. O O

The O O
relevance O O
of O O
this O O
finding O O
to O O
humans O O
is O O
not O O
known O O
at O O
this O O
time O O
. O O

Co O O
- O O
administration O O
of O O
celecoxib B-Drug B-Drug
with O O
drugs O O
that O O
are O O
known O O
to O O
inhibit O O
9C9 O O
should O O
be O O
done O O
with O O
caution O O
. O O

When O O
sympathomimetic B-Group B-Group
drugs I-Group I-Group
are O O
given O O
to O O
patients O O
receiving O O
monoamine B-Group B-Group
oxidase I-Group I-Group
inhibitors I-Group I-Group
hypertensive O O
reactions O O
including O O
hypertensive O O
crises O O
may O O
occur O O
. O O

. O O

Terfenadine B-Drug B-Drug
astemizole B-Drug B-Drug
and O O
cisapride B-Drug B-Drug
are O O
all O O
metabolized O O
by O O
the O O
cytochrome O O
P9IIIA9 O O
isozyme O O
and O O
it O O
has O O
been O O
demonstrated O O
that O O
ketoconazole B-Drug B-Drug
a O O
potent O O
inhibitor O O
of O O
IIIA9 O O
blocks O O
the O O
metabolism O O
of O O
these O O
drugs O O
resulting O O
in O O
increased O O
plasma O O
concentrations O O
of O O
parent O O
drug O O
. O O

Ethanol B-Drug B-Drug
decreases O O
the O O
elimination O O
of O O
abacavir B-Drug B-Drug
causing O O
an O O
increase O O
in O O
overall O O
exposure O O
. O O
The O O
addition O O
of O O
methadone B-Drug B-Drug
has O O
no O O
clinically O O
significant O O
effect O O
on O O
the O O
pharmacokinetic O O
properties O O
of O O
abacavir B-Drug B-Drug
. O O

Thus O O
patients O O
should O O
be O O
cautioned O O
about O O
the O O
use O O
of O O
such O O
drugs O O
concurrently O O
with O O
LEXAPRO B-Brand B-Brand
. O O

There O O
are O O
no O O
data O O
that O O
conclusively O O
establish O O
whether O O
the O O
concomitant O O
administration O O
of O O
Mefloquineuine O O
and O O
the O O
above O O
listed O O
agents O O
has O O
an O O
effect O O
on O O
cardiac O O
function O O
. O O

It O O
should O O
also O O
be O O
avoided O O
in O O
patients O O
with O O
blood O O
liver O O
or O O
kidney O O
diseases O O
recent O O
radiation O O
treatment O O
or O O
uncontrolled O O
diabetes O O
. O O

In O O
two O O
controlled O O
crossover O O
clinical O O
pharmacology O O
studies O O
in O O
healthy O O
male O O
( O O
n=9 O O
in O O
each O O
study O O
) O O
a O O
nd O O
female O O
( O O
n=9 O O
in O O
each O O
study O O
) O O
volunteers O O
desloratadine B-Drug B-Drug
9 O O
mg O O
( O O
9 O O
times O O
the O O
daily O O
dose O O
) O O
once O O
daily O O
was O O
coadministered O O
with O O
erythromycin B-Drug B-Drug
9 O O
mg O O
every O O
9 O O
hours O O
or O O
ketoconazole B-Drug B-Drug
9 O O
mg O O
every O O
9 O O
hours O O
for O O
9 O O
days O O
. O O

Nifedipine B-Drug B-Drug
( O O
extended O O
- O O
release O O
tablets O O
) O O
: O O
In O O
9 O O
normal O O
- O O
weight O O
subjects O O
receiving O O
XENICAL B-Brand B-Brand
9 O O
mg O O
three O O
times O O
a O O
day O O
for O O
9 O O
days O O
XENICAL B-Brand B-Brand
did O O
not O O
alter O O
the O O
bioavailability O O
of O O
nifedipine B-Drug B-Drug
( O O
extended O O
- O O
release O O
tablets O O
) O O
. O O

this O O
was O O
seen O O
in O O
studies O O
with O O
estazolam B-Drug B-Drug
. O O

Human O O
pharmacokinetics O O
data O O
indicate O O
that O O
oral O O
ketoconazole B-Drug B-Drug
potently O O
inhibits O O
the O O
metabolism O O
of O O
cisapride B-Drug B-Drug
resulting O O
in O O
a O O
mean O O
eight O O
- O O
fold O O
increase O O
in O O
AUC O O
of O O
cisapride B-Drug B-Drug
. O O

The O O
concomitant O O
use O O
of O O
sodium B-Drug B-Drug
cephalothin I-Drug I-Drug
and O O
Coly B-Brand B-Brand
- O O
Mycin B-Brand B-Brand
M I-Brand I-Brand
Parenteral O O
should O O
be O O
avoided O O
. O O

- O O
Plicamycin B-Drug B-Drug
( O O
e.g. O O
Mithracin B-Brand B-Brand
) O O
or O O

Rifabutin B-Drug B-Drug

Concomitant O O
administration O O
of O O
ketoconazole B-Drug B-Drug
and O O
terfenadine B-Drug B-Drug
is O O
contraindicated O O
. O O

Levodopa B-Drug B-Drug
and O O
Amantadine B-Drug B-Drug
: O O
Limited O O
clinical O O
data O O
suggest O O
a O O
higher O O
incidence O O
of O O
adverse O O
experiences O O
in O O
patients O O
receiving O O
bupropion B-Drug B-Drug
concurrently O O
with O O
either O O
levodopa B-Drug B-Drug
or O O
amantadine B-Drug B-Drug
. O O

Chlorpromazine B-Drug B-Drug
: O O
Chlorpromazine B-Drug B-Drug
blocks O O
dopamine O B-Drug
and O O
norepinephrine O B-Drug
reuptake O O
thus O O
inhibiting O O
the O O
central O O
stimulant O O
effects O O
of O O
amphetamines B-Group B-Group
and O O
can O O
be O O
used O O
to O O
treat O O
amphetamine B-Group B-Drug
poisoning O O
. O O

These O O
drugs O O
may O O
decrease O O
the O O
effects O O
of O O
mazindol B-Drug B-Drug
. O O

In O O
vitro O O
buspirone B-Drug B-Drug
may O O
displace O O
less O O
firmly O O
bound O O
drugs O O
like O O
digoxin B-Drug B-Drug
. O O

CHOLESTYRAMINE B-Drug B-Drug
: O O
The O O
influence O O
of O O
the O O
bile O O
- O O
acidsequestering O O
agent O O
cholestyramine B-Drug B-Drug
on O O
the O O
pharmacokinetits O O
of O O
cerivastatin B-Drug B-Drug
sodium I-Drug I-Drug
was O O
evaluated O O
in O O
9 O O
healthy O O
males O O
in O O
9 O O
separate O O
randomized O O
crossover O O
studies O O
. O O

. O O

When O O
estrogen B-Group B-Group
therapy O O
is O O
initiated O O
a O O
reduction O O
in O O
corticosteroid B-Group B-Group
dosage O O
may O O
be O O
required O O
and O O
increased O O
amounts O O
may O O
be O O
required O O
when O O
estrogen B-Group B-Group
is O O
terminated O O
. O O

Changes O O
in O O
the O O
testes O O
and O O
epididymides O O
had O O
not O O
recovered O O
9 O O
weeks O O
after O O
cessation O O
of O O
dosing O O
. O O

General O O
: O O
In O O
humans O O
valdecoxib B-Drug B-Drug
metabolism O O
is O O
predominantly O O
mediated O O
via O O
CYP O O
9A9 O O
and O O
9C9 O O
with O O
glucuronidation O O
being O O
a O O
further O O
( O O
9 O O
% O O
) O O
route O O
of O O
metabolism O O
. O O

Buprenorphine B-Drug B-Drug
is O O
metabolized O O
to O O
norbuprenorphine B-Drug_n O
by O O
cytochrome O O
CYP O O
9A9 O O
. O O

Concomitant O O
administration O O
of O O
FACTIVE B-Brand B-Brand
with O O
probenecid B-Drug B-Drug
resulted O O
in O O
a O O
9 O O
% O O
increase O O
in O O
systemic O O
exposure O O
to O O
gemifloxacin B-Drug B-Drug
. O O

Ropivacaine B-Drug B-Drug
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
receiving O O
other O O
local O O
anesthetics B-Group B-Group
or O O
agents O O
structurally O O
related O O
to O O
amide B-Group O
- O O
type B-Group O
local I-Group O
anesthetics I-Group B-Group
since O O
the O O
toxic O O
effects O O
of O O
these O O
drugs O O
are O O
additive O O
. O O

Beta B-Group B-Group
blockers I-Group I-Group
may O O
exacerbate O O
the O O
hypertensive O O
response O O
seen O O
with O O
clonidine B-Drug B-Drug
withdrawl O O
. O O

However O O
theophylline B-Drug B-Drug
plasma O O
concentrations O O
should O O
be O O
monitored O O
with O O
dosage O O
adjustment O O
as O O
appropriate O O
in O O
patients O O
whose O O
pulmonary O O
disease O O
requires O O
maintaining O O
a O O
given O O
theophylline B-Drug B-Drug
plasma O O
concentration O O
for O O
optimal O O
pulmonary O O
function O O
or O O
in O O
patients O O
with O O
theophylline B-Drug B-Drug
concentrations O O
at O O
the O O
higher O O
end O O
of O O
the O O
therapeutic O O
range O O
. O O

It O O
is O O
not O O
known O O
whether O O
alosetron B-Drug B-Drug
might O O
induce O O
other O O
enzymes O O
. O O

John O O
Wort O O
and O O
certain O O
anticonvulsants B-Group B-Group
( O O
phenytoin B-Drug B-Drug
phenobarbital B-Drug B-Drug
carbamazepine B-Drug B-Drug
) O O
may O O
induce O O
mifepristone B-Drug B-Drug
metabolism O O
( O O
lowering O O
serum O O
levels O O
of O O
mifepristone B-Drug B-Drug
) O O
. O O

Patients O O
receiving O O
beta B-Group B-Group
- O O
blockers B-Group B-Group
should O O
be O O
warned O O
of O O
this O O
potential O O
hazard O O
. O O

In O O
9 O O
separate O O
studies O O
fexofenadine B-Drug B-Drug
hydrochloride I-Drug I-Drug
9 O O
mg O O
twice O O
daily O O
( O O
9 O O
mg O O
total O O
daily O O
dose O O
) O O
was O O
co O O
- O O
administered O O
with O O
either O O
erythromycin B-Drug B-Drug
9 O O
mg O O
every O O
9 O O
hours O O
or O O
ketoconazole B-Drug B-Drug
9 O O
mg O O
once O O
daily O O
under O O
steady O O
- O O
state O O
conditions O O
to O O
healthy O O
volunteers O O
( O O
n=9 O O
each O O
study O O
) O O
. O O

There O O
are O O
no O O
adequate O O
and O O
well O O
- O O
controlled O O
studies O O
of O O
PEGASYS B-Brand B-Brand
in O O
pregnant O O
women O O
. O O

Do O O
not O O
take O O
this O O
medicine O O
with O O
St. O O
Johns O O
Wort O O
because O O
of O O
the O O
additive O O
effects O O
of O O
sertonin O B-Drug
. O O

In O O
combination O O
with O O
other O O
central B-Group B-Group
nervous I-Group I-Group
system I-Group I-Group
depressants I-Group I-Group
heroin B-Drug_n B-Drug_n
may O O
still O O
kill O O
even O O
experienced O O
users O O
particularly O O
if O O
their O O
tolerance O O
to O O
the O O
drug O O
has O O
reduced O O
or O O
the O O
strength O O
of O O
their O O
usual O O
dose O O
has O O
increased O O
. O O

Antiarrhythmics B-Group B-Group

Diflunisal B-Drug B-Drug
decreased O O
the O O
hyperuricemic O O
effect O O
of O O
furosemide B-Drug B-Drug
. O O

This O O
effect O O
of O O
aspirin B-Brand B-Brand
( O O
which O O
also O O
lowers O O
serum O O
concentrations O O
of O O
other O O
nonsteroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
drugs I-Group I-Group
given O O
with O O
it O O
) O O
has O O
been O O
demonstrated O O
in O O
patients O O
with O O
rheumatoid O O
arthritis O O
( O O
n= O O
9 O O
) O O
as O O
well O O
as O O
normal O O
volunteers O O
( O O
n= O O
9 O O
) O O
. O O

Naproxen B-Drug B-Drug
: O O
Coadministration O O
( O O
N=9 O O
) O O
of O O
naproxen B-Drug B-Drug
sodium I-Drug I-Drug
capsules O O
( O O
9 O O
mg O O
) O O
with O O
Neurontin B-Brand B-Brand
( O O
9 O O
mg O O
) O O
appears O O
to O O
increase O O
the O O
amount O O
of O O
gabapentin B-Drug B-Drug
absorbed O O
by O O
9 O O
% O O
to O O
9 O O
% O O
. O O

Coadministration O O
of O O
efavirenz B-Drug B-Drug
with O O
drugs O O
primarily O O
metabolized O O
by O O
these O O
isozymes O O
may O O
result O O
in O O
altered O O
plasma O O
concentrations O O
of O O
the O O
coadministered O O
drug O O
. O O

unreliable O O
prothrombin O O
time O O
determinations O O
; O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
: O O
There O O
have O O
been O O
no O O
chemical O O
or O O
laboratory O O
test O O
interactions O O
with O O
ceftibuten B-Drug B-Drug
noted O O
to O O
date O O
. O O

Beta B-Group B-Group
blockers I-Group I-Group
may O O
exacerbate O O
the O O
rebound O O
hypertension O O
which O O
can O O
follow O O
the O O
withdrawal O O
of O O
clonidine B-Drug B-Drug
. O O

glucagon B-Drug B-Drug
; O O

Amiodarone B-Drug B-Drug
: O O
Amiodarone B-Drug B-Drug
therapy O O
alone O O
can O O
cause O O
hypothyroidism O O
or O O
hyperthyroidism O O
. O O

Concomitant O O
administration O O
of O O
erythromycin B-Drug B-Drug
and O O
digoxin B-Drug B-Drug
has O O
been O O
reported O O
to O O
result O O
in O O
elevated O O
digoxin B-Drug B-Drug
serum O O
levels O O
. O O

In O O
addition O O
to O O
bleeding O O
associated O O
with O O
heparin B-Drug B-Drug
and O O
vitamin B-Group B-Group
K I-Group I-Group
antagonists I-Group I-Group
drugs O O
that O O
alter O O
platelet O O
function O O
( O O
such O O
as O O
acetylsalicylic B-Drug B-Drug
acid I-Drug I-Drug
dipyridamole B-Drug B-Drug
and O O
Abciximab B-Drug B-Drug
) O O
may O O
increase O O
the O O
risk O O
of O O
bleeding O O
if O O
administered O O
prior O O
to O O
during O O
or O O
after O O
Activase B-Brand B-Brand
therapy O O
. O O

Clinical O O
studies O O
have O O
shown O O
that O O
INDOCIN B-Brand B-Brand
does O O
not O O
influence O O
the O O
hypoprothrombinemia O O
produced O O
by O O
anticoagulants B-Group B-Group
. O O

The O O
action O O
of O O
nondepolarizing O B-Group
relaxants O I-Group
is O O
augmented O O
by O O
Enflurane B-Drug B-Drug
. O O

no O O
clear O O
- O O
cut O O
cause O O
and O O
effect O O
relationship O O
was O O
established O O
. O O

Therefore O O
based O O
on O O
these O O
in O O
vitro O O
data O O
estazolam B-Drug B-Drug
is O O
very O O
unlikely O O
to O O
inhibit O O
the O O
biotransformation O O
of O O
other O O
drugs O O
metabolized O O
by O O
these O O
CYP O O
isoforms O O

Most O O
of O O
the O O
above O O
effects O O
concerning O O
diuretics B-Group B-Group
have O O
been O O
attributed O O
at O O
least O O
in O O
part O O
to O O
mechanisms O O
involving O O
inhibition O O
of O O
prostaglandin O O
synthesis O O
by O O
INDOCIN B-Brand B-Brand
. O O

No O O
differences O O
in O O
adverse O O
events O O
or O O
QTc O O
interval O O
were O O
observed O O
when O O
subjects O O
were O O
administered O O
fexofenadine B-Drug B-Drug
hydrochloride I-Drug I-Drug
alone O O
or O O
in O O
combination O O
with O O
either O O
erythromycin B-Drug B-Drug
or O O
ketoconazole B-Drug B-Drug
. O O

cardiovascular O O
effects O O
can O O
be O O
potentiated O O
. O O

Although O O
studies O O
designed O O
to O O
examine O O
drug O O
interactions O O
have O O
not O O
been O O
done O O
it O O
was O O
noted O O
that O O
corticosteroid B-Group B-Drug
or O O
ACTH B-Drug O
treatment O O
of O O
relapses O O
for O O
periods O O
of O O
up O O
to O O
9 O O
days O O
has O O
been O O
administered O O
to O O
patients O O
( O O
N=9 O O
) O O
receiving O O
Betaseron B-Brand B-Brand
. O O

Aminoglutethimide B-Drug B-Drug
diminishes O O
the O O
effect O O
of O O
coumarin B-Group B-Group
and O O
warfarin B-Drug B-Drug
. O O

Given O O
the O O
possibility O O
of O O
extravasation O O
it O O
is O O
advisable O O
to O O
closely O O
monitor O O
the O O
infusion O O
site O O
for O O
possible O O
infiltration O O
during O O
drug O O
administration O O
. O O

Androgens B-Group B-Group
may O O
increase O O
sensitivity O O
to O O
oral O O
anticoagulahts O O
. O O

Propranolol B-Drug B-Drug
: O O
In O O
normal O O
volunteers O O
there O O
was O O
no O O
clinically O O
significant O O
pharmacokinetic O O
or O O
pharmacodynamic O O
interaction O O
with O O
concomitant O O
administration O O
of O O
single O O
doses O O
of O O
lovastatin B-Drug B-Drug
and O O
propranolol B-Drug B-Drug
. O O

The O O
reported O O
dose O O
used O O
for O O
L B-Drug B-Drug
- O O
glutamine B-Drug B-Drug
was O O
9 O O
grams O O
daily O O
taken O O
in O O
divided O O
doses O O
three O O
times O O
a O O
day O O
. O O

Other O O
drugs O O
have O O
not O O
been O O
studied O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
The O O
administration O O
of O O
cefepime B-Drug B-Drug
may O O
result O O
in O O
a O O
false O O
- O O
positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
when O O
using O O
Clinitest O O
tablets O O
. O O

Other O O
Drugs O O
: O O
In O O
healthy O O
volunteers O O
amlodipine B-Drug B-Drug
phenytoin B-Drug B-Drug
glyburide B-Drug B-Drug
ranitidine B-Drug B-Drug
omeprazole B-Drug B-Drug
hormone O O
replacement O O
therapy O O
( O O
a O O
combination O O
of O O
conjugated O B-Drug
estrogens B-Group I-Drug
and O O
medroxyprogesterone B-Drug B-Drug
) O O
antacid B-Group B-Group
( O O
aluminum B-Drug B-Drug
and O O
magnesium B-Drug B-Drug
hydroxides I-Drug I-Drug
) O O
and O O
theophylline B-Drug B-Drug
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
TIKOSYN B-Brand B-Brand
. O O

Magnesium B-Drug B-Drug
- O O
and O O
aluminum B-Drug B-Drug
- O O
containing O O
antacids B-Group B-Group
administered O O
concomitantly O O
with O O
lomefloxacin B-Drug B-Drug
significantly O O
decreased O O
the O O
bioavailability O O
( O O
9 O O
% O O
) O O
of O O
lomefloxacin B-Drug B-Drug
. O O

Clonidine B-Drug B-Drug
hydrochloride I-Drug I-Drug
may O O
enhance O O
the O O
CNS O O
- O O
depressive O O
effects O O
of O O
alcohol B-Drug B-Drug
barbiturates B-Group B-Group
or O O
other O O
sedatives B-Group B-Group
. O O

AMEVIVE B-Brand B-Brand
underwent O O
trans O O
- O O
placental O O
passage O O
and O O
produced O O
in O O
utero O O
exposure O O
in O O
the O O
developing O O
monkeys O O
. O O

Corticosteroids B-Group B-Group
ACTH B-Drug B-Drug
: O O
intensified O O
electrolyte O O
depletion O O
particularly O O
hypokalemia O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
None O O
known O O
. O O

It O O
is O O
recommended O O
that O O
the O O
dose O O
of O O
rifabutin B-Drug B-Drug
be O O
reduced O O
to O O
one O O
- O O
half O O
the O O
usual O O
dose O O
when O O
administered O O
with O O
VIRACEPT B-Brand B-Brand
. O O

General O O
No O O
clinical O O
drug O O
interaction O O
studies O O
were O O
performed O O
. O O

Specific O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
ENBREL B-Brand B-Brand
. O O

Although O O
the O O
occurrence O O
has O O
not O O
been O O
reported O O
with O O
Cefizox B-Brand O
nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
other O O
cephalosporins B-Group B-Group
and O O
aminoglycosides B-Group B-Group
. O O

As O O
most O O
entacapone B-Drug B-Drug
excretion O O
is O O
via O O
the O O
bile O O
caution O O
should O O
be O O
exercised O O
when O O
drugs O O
known O O
to O O
interfere O O
with O O
biliary O O
excretion O O
glucuronidation O O
and O O
intestinal O B-Drug
beta O I-Drug
- O O
glucuronidase O B-Drug_n
are O O
given O O
concurrently O O
with O O
entacapone B-Drug B-Drug
. O O

There O O
are O O
few O O
clinical O O
situations O O
in O O
which O O
the O O
concurrent O O
use O O
of O O
''static O O
'' O O
and O O
''cidal O O
'' O O
antibiotics B-Group B-Group
are O O
indicated O O
. O O

Ritalin B-Brand B-Drug
may O O
decrease O O
the O O
hypotensive O O
effect O O
of O O
guanethidine B-Drug B-Drug
. O O

Patients O O
who O O
are O O
treated O O
with O O
ZYVOX B-Brand B-Brand
and O O
concomitant O O
serotonergic B-Group B-Group
agents I-Group I-Group
should O O
be O O
closely O O
observed O O
for O O
signs O O
and O O
symptoms O O
of O O
serotonin O O
syndrome O O
( O O
e.g. O O
cognitive O O
dysfunction O O
hyperpyrexia O O
hyperreflexia O O
incoordination O O
) O O
. O O

Anti B-Group B-Group
- O O
HIV B-Group B-Group
Protease I-Group I-Group
Inhibitors I-Group I-Group

Cimetidine B-Drug B-Drug
: O O
Cimetidine B-Drug B-Drug
has O O
been O O
demonstrated O O
to O O
interfere O O
with O O
the O O
elimination O O
of O O
other O O
quinolones B-Group B-Group
. O O

The O O
risks O O
of O O
using O O
Clozapine B-Drug B-Drug
in O O
combination O O
with O O
other O O
drugs O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

Dosage O O
of O O
the O O
drugs O O
mentioned O O
above O O
and O O
other O O
similarly O O
metabolized O O
drugs O O
particularly O O
those O O
of O O
low O O
therapeutic O O
ratio O O
or O O
in O O
patients O O
with O O
renal O O
and O O
/ O O
or O O
hepatic O O
impairment O O
may O O
require O O
adjustment O O
when O O
starting O O
or O O
stopping O O
concomitantly O O
administered O O
Tagamet B-Brand B-Brand
to O O
maintain O O
optimum O O
therapeutic O O
blood O O
levels O O
. O O

Although O O
this O O
interaction O O
has O O
not O O
been O O
reported O O
with O O
cinoxacin B-Drug B-Drug
caution O O
should O O
be O O
exercised O O
when O O
cinoxacin B-Drug B-Drug
is O O
given O O
concomitantly O O
with O O
caffeine B-Drug B-Drug
- O O
containing O O
products O O
. O O

Carbamazepine B-Drug B-Drug
: O O
Steady O O
- O O
state O O
trough O O
plasma O O
carbamazepine B-Drug B-Drug
and O O
carbamazepine B-Drug_n B-Drug
9 I-Drug_n I-Drug
9 I-Drug_n B-Drug_n
epoxide I-Drug_n I-Drug_n
concentrations O O
were O O
not O O
affected O O
by O O
concomitant O O
gabapentin B-Drug B-Drug
( O O
9 O O
mg O O
TID O O
; O O

In O O
general O O
any O O
added O O
antiarrhythmic B-Drug B-Group
drug I-Drug I-Group
should O O
be O O
initiated O O
at O O
a O O
lower O O
than O O
usual O O
dose O O
with O O
careful O O
monitoring O O
. O O

However O O
increased O O
prothrombin O O
time O O
and O O
bleeding O O
have O O
been O O
reported O O
in O O
patients O O
on O O
concomitant O O
TOLECTIN B-Brand B-Brand
and O O
warfarin B-Drug B-Drug
therapy O O
. O O

Rifampin B-Drug B-Drug
: O O
Following O O
concomitant O O
administration O O
of O O
a O O
single O O
dose O O
of O O
ARAVA B-Brand B-Brand
to O O
subjects O O
receiving O O
multiple O O
doses O O
of O O
rifampin B-Drug B-Drug
M9 O O
peak O O
levels O O
were O O
increased O O
( O O
~9 O O
% O O
) O O
over O O
those O O
seen O O
when O O
ARAVA B-Brand B-Brand
was O O
given O O
alone O O
. O O

Thyroid B-Group B-Group
administration O O
to O O
a O O
digitalized O O
hypothyroid O O
patient O O
may O O
increase O O
the O O
dose O O
requirement O O
of O O
digoxin B-Drug B-Drug
. O O

It O O
is O O
recommended O O
that O O
plasma O O
lithium B-Drug B-Drug
levels O O
be O O
monitored O O
when O O
ketoprofen B-Drug B-Drug
is O O
coadministered O O
with O O
lithium B-Drug B-Drug
. O O

The O O
steady O O
- O O
state O O
Cmin O O
increased O O
to O O
9 O O
9 O O
micrograms O O
/ O O
mL O O
when O O
9 O O
mg O O
/ O O
day O O
of O O
felbamate B-Drug B-Drug
was O O
coadministered O O
. O O

Acid O O
- O O
base O O
and O O
electrolyte O O
alterations O O
were O O
not O O
reported O O
in O O
the O O
clinical O O
trials O O
with O O
brinzolamide B-Drug B-Drug
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
glipizide B-Drug B-Drug
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

- O O
Drugs O O
with O O
nephrotoxic O O
potential O O
: O O
There O O
has O O
been O O
no O O
experience O O
on O O
the O O
concurrent O O
use O O
of O O
bumetanide B-Drug B-Drug
with O O
drugs O O
known O O
to O O
have O O
a O O
nephrotoxic O O
potential O O
. O O

One O O
death O O
has O O
also O O
been O O
reported O O
from O O
foreign O O
post O O
- O O
marketing O O
sources O O
. O O

Use O O
of O O
a O O
diuretic B-Group B-Group
may O O
further O O
increase O O
the O O
risk O O
of O O
lithium B-Drug B-Drug
toxicity O O
. O O

Cevimeline B-Drug B-Drug
should O O
be O O
used O O
with O O
caution O O
in O O
individuals O O
known O O
or O O
suspected O O
to O O
be O O
deficient O O
in O O
CYP9D9 O O
activity O O
based O O
on O O
previous O O
experience O O
as O O
they O O
may O O
be O O
at O O
a O O
higher O O
risk O O
of O O
adverse O O
events O O
. O O

acidifying O B-Group
drugs O I-Group
or O O
foods O O
will O O
decrease O O
urinary O O
excretion O O
and O O
increase O O
plasma O O
levels O O
. O O

The O O
effect O O
of O O
clonazepam B-Drug B-Drug
on O O
the O O
metabolism O O
of O O
other O O
drugs O O
has O O
not O O
been O O
investigated O O
. O O

COPEGUS B-Brand B-Brand
therapy O O
is O O
contraindicated O O
in O O
women O O
who O O
are O O
pregnant O O
and O O
in O O
the O O
male O O
partners O O
of O O
women O O
who O O
are O O
pregnant O O
. O O

Cimetidine B-Drug B-Drug
: O O
Atorvastatin B-Drug B-Drug
plasma O O
concentrations O O
and O O
LDL O O
- O O
C O O
reduction O O
were O O
not O O
altered O O
by O O
coadministration O O
of O O
cimetidine B-Drug B-Drug
. O O

The O O
role O O
of O O
AMEVIVE B-Brand B-Brand
in O O
the O O
development O O
of O O
the O O
lymphoid O O
malignancy O O
and O O
the O O
hyperplasia O O
observed O O
in O O
non O O
- O O
human O O
primates O O
and O O
the O O
relevance O O
to O O
humans O O
is O O
unknown O O
. O O

In O O
an O O
in O O
vitro O O
study O O
in O O
human O O
liver O O
microsomes O O
inhibition O O
of O O
CYP9A9 O O
hydroxylation O O
of O O
coumarin B-Group O
by O O
fondaparinux B-Drug B-Drug
( O O
9 O O
m O O
m O O
M O O
i.e. O O
9 O O
mg O O
/ O O
L O O
) O O
was O O
9 O O
- O O
9 O O
% O O
. O O

The O O
extent O O
to O O
which O O
SSRI B-Group B-Group
- O O
TCA B-Group B-Group
interactions O O
may O O
pose O O
clinical O O
problems O O
will O O
depend O O
on O O
the O O
degree O O
of O O
inhibition O O
and O O
the O O
pharmacokinetics O O
of O O
the O O
SSRI B-Group B-Group
involved O O
. O O

Methenamine B-Drug B-Drug

Thioridazine B-Drug B-Drug
: O O
Coadministration O O
of O O
single O O
doses O O
of O O
Sonata B-Brand B-Brand
9 O O
mg O O
and O O
thioridazine B-Drug B-Drug
9 O O
mg O O
produced O O
additive O O
effects O O
on O O
decreased O O
alertness O O
and O O
impaired O O
psychomotor O O
performance O O
for O O
9 O O
to O O
9 O O
hours O O
after O O
administration O O
. O O

Paliperidone B-Drug B-Drug
may O O
antagonize O O
the O O
effect O O
of O O
levodopa B-Drug B-Drug
and O O
other O O
dopamine B-Group B-Group
agonists I-Group I-Group
. O O

In O O
this O O
situation O O
special O O
patient O O
care O O
and O O
observation O O
are O O
appropriate O O
. O O

Therefore O O
when O O
MIDAMOR B-Brand B-Brand
and O O
non B-Group B-Group
- O O
steroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
agents I-Group I-Group
are O O
used O O
concomitantly O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-Group B-Group
is O O
obtained O O
. O O

efavirenz B-Drug B-Drug
concentration O O

For O O
this O O
reason O O
the O O
dose O O
of O O
adrenaline B-Drug B-Drug
should O O
be O O
restricted O O
and O O
an O O
antiarrhythmic B-Group B-Group
agent I-Group I-Group
administered O O
as O O
appropriate O O
. O O

The O O
following O O
agents O O
may O O
increase O O
certain O O
actions O O
or O O
side O O
effects O O
of O O
anticholinergic B-Group B-Group
drugs I-Group I-Group
: O O
amantadine B-Drug B-Drug
antiarrhythmic B-Group B-Group
agents I-Group I-Group
of I-Group O
class I-Group O
I I-Group O
( O O
e.g. O O
quinidine B-Drug B-Drug
) O O
antihistamines B-Group B-Group
antipsychotic B-Group B-Group
agents I-Group I-Group
( O O
e.g. O O
phenothiazines B-Group B-Group
) O O
benzodiazepines B-Group B-Group
MAO B-Group B-Group
inhibitors I-Group I-Group
narcotic B-Group B-Group
analgesics I-Group I-Group
( O O
e.g. O O
meperidine B-Drug B-Drug
) O O
nitrates B-Group B-Group
and O O
nitrites B-Group B-Group
sympathomimetic B-Group B-Group
agents I-Group I-Group
tricyclic B-Group B-Group
antidepressants I-Group I-Group
and O O
other O O
drugs O O
having O O
anticholinergic O O
activity O O
. O O

Sodium B-Drug B-Drug
Iodide I-Drug I-Drug
( O O
9I O O
and O O
9I O O
) O O
Sodium B-Drug O
Pertechnetate I-Drug O
Tc9m I-Drug O
: O O
Uptake O O
of O O
radiolabeled O O
ions O O
may O O
be O O
decreased O O
. O O

9 O O
. O O

a O O
reduced O O
dose O O
of O O
theophylline B-Drug B-Drug
may O O
be O O
needed O O
. O O

Monitor O O
serum O O
potassium O O
levels O O
; O O

Concomitant O O
Drug O O

Cyclophosphamide B-Drug B-Drug
treatment O O
which O O
causes O O
a O O
marked O O
and O O
persistent O O
inhibition O O
of O O
cholinesterase O O
activity O O
potentiates O O
the O O
effect O O
of O O
succinylcholine B-Drug B-Drug
chloride I-Drug I-Drug
. O O

Although O O
a O O
9 O O
- O O
day O O
regimen O O
of O O
Aprepitant B-Drug B-Drug
given O O
concomitantly O O
with O O
oral O O
contraceptives B-Group B-Group
has O O
not O O
been O O
studied O O
alternative O O
or O O
back O O
- O O
up O O
methods O O
of O O
contraception O O
should O O
be O O
used O O
. O O

if O O
plasma O O
levels O O
are O O
being O O
monitored O O
they O O
should O O
be O O
reassessed O O
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P9 O O
9D9 O O
isozyme O O
activity O O
among O O
Asian O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

Since O O
the O O
effect O O
of O O
AMEVIVE B-Brand B-Brand
on O O
pregnancy O O
and O O
fetal O O
development O O
including O O
immune O O
system O O
development O O
is O O
not O O
known O O
health O O
care O O
providers O O
are O O
encouraged O O
to O O
enroll O O
patients O O
currently O O
taking O O
AMEVIVE B-Brand B-Brand
who O O
become O O
pregnant O O
into O O
the O O
Biogen O O
Pregnancy O O
Registry O O
by O O
calling O O
9 O O
- O O
9 O O
- O O
AMEVIVE B-Brand B-Brand
( O O
9 O O
- O O
9 O O
- O O
9 O O
- O O
9 O O
) O O
. O O

however O O
9 O O
mg O O
of O O
ranitidine B-Drug B-Drug
q9h O O
for O O
9 O O
days O O
increased O O
the O O
ceftibuten B-Drug B-Drug
C O O
max O O
by O O
9 O O
% O O
and O O
ceftibuten B-Drug B-Drug
AUC O O
by O O
9 O O
% O O
. O O

It O O
is O O
not O O
known O O
if O O
hormonal B-Group B-Group
contraceptives I-Group I-Group
differ O O
in O O
their O O
effectiveness O O
when O O
used O O
with O O
Accutane B-Brand B-Brand
. O O

Caverject B-Brand O
: O O
The O O
potential O O
for O O
pharmacokinetic O O
drug O O
- O O
drug O O
interactions O O
between O O
alprostadil B-Drug B-Drug
and O O
other O O
agents O O
has O O
not O O
been O O
formally O O
studied O O
. O O

The O O
mean O O
C O O
max O O
T O O
max O O
and O O
AUC O O
of O O
the O O
acid O O
metabolite O O
of O O
terfenadine B-Drug B-Drug
were O O
not O O
significantly O O
changed O O
. O O

- O O
Furazolidone B-Drug B-Drug
( O O
e.g. O O
Furoxone B-Brand B-Brand
) O O
or O O

sertraline B-Drug B-Drug
concentration O O

Itraconazole B-Drug B-Drug
plasma O O
concentrations O O
should O O
be O O
monitored O O
when O O
Itraconazole B-Drug B-Drug
and O O
isoniazid B-Drug B-Drug
are O O
coadministered O O
. O O

However O O
ketoconazole B-Drug B-Drug
a O O
potent O O
inhibitor O O
of O O
cytochrome O O
P9 O O
9A9 O O
may O O
increase O O
plasma O O
levels O O
of O O
mometasone B-Drug O
furoate I-Drug O
during O O
concomitant O O
dosing O O
. O O

Nabilone B-Drug B-Drug
should O O
be O O
administered O O
with O O
caution O O
to O O
patients O O
who O O
are O O
taking O O
other O O
psychoactive B-Group B-Group
drugs I-Group I-Group
or O O
CNS B-Group B-Group
depressants I-Group I-Group
including O O
alcohol B-Drug B-Drug
barbiturates B-Group B-Group
and O O
narcotic B-Group B-Group
analgesics I-Group I-Group
or O O
to O O
those O O
with O O
a O O
history O O
of O O
psychiatric O O
disorder O O
( O O
including O O
manic O O
- O O
depressive O O
illness O O
and O O
schizophrenia O O
) O O
. O O

Read O O
circulars O O
for O O
lithium B-Drug B-Drug
preparations O O
before O O
use O O
of O O
such O O
concomitant O O
therapy O O
. O O

Medications O O
that O O
interfere O O
with O O
your O O
bodys O O
ability O O
to O O
use O O
folate O O
may O O
also O O
increase O O
the O O
need O O
for O O
this O O
vitamin B-Group O
. O O

Isoflurane B-Drug B-Drug
enflurane B-Drug B-Drug
and O O
halothane B-Drug B-Drug
decrease O O
the O O
ED9 O O
of O O
NUROMAX B-Brand B-Brand
by O O
9 O O
% O O
to O O
9 O O
% O O
. O O

The O O
AUC O O
and O O
Cmax O O
of O O
metoprolol B-Drug B-Drug
however O O
were O O
increased O O
approximately O O
9 O O
and O O
9 O O
% O O
respectively O O
. O O

Studies O O
have O O
shown O O
that O O
the O O
bioavailability O O
of O O
isoniazid B-Drug B-Drug
is O O
reduced O O
significantly O O
when O O
administered O O
with O O
food O O
. O O

Ritonavir B-Drug B-Drug

Serotonin O O
release O O
by O O
platelets O O
plays O O
an O O
important O O
role O O
in O O
hemostasis O O
. O O

Therefore O O
serum O O
levels O O
of O O
methotrexate B-Drug B-Drug
should O O
be O O
monitored O O
in O O
patients O O
to O O
avoid O O
drug O O
toxicity O O
. O O

Before O O
taking O O
this O O
medication O O
tell O O
your O O
doctor O O
if O O
you O O
are O O
taking O O
a O O
tricyclic B-Group B-Group
antidepressant I-Group I-Group
such O O
as O O
amitriptyline B-Drug B-Drug
( O O
Elavil B-Brand B-Brand
) O O
amoxapine B-Drug B-Drug
( O O
Asendin B-Brand B-Brand
) O O
doxepin B-Drug B-Drug
( O O
Sinequan B-Brand B-Brand
) O O
nortriptyline B-Drug B-Drug
( O O
Pamelor B-Brand B-Brand
) O O
imipramine B-Drug B-Drug
( O O
Tofranil B-Brand B-Brand
) O O
clomipramine B-Drug B-Drug
( O O
Anafranil B-Brand B-Brand
) O O
protriptyline B-Drug B-Drug
( O O
Vivactil B-Brand B-Brand
) O O
or O O
desipramine B-Drug B-Drug
( O O
Norpramin B-Brand B-Brand
) O O
. O O

Indinavir B-Drug B-Drug
concentrations O O
may O O
be O O
decreased O O
in O O
the O O
presence O O
of O O
nevirapine B-Drug B-Drug
. O O

Oral O O
Anticoagulants B-Group B-Group
: O O
In O O
some O O
normal O O
volunteers O O
the O O
concomitant O O
administration O O
of O O
diflunisal B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
acenocoumarol B-Drug B-Drug
or O O
phenprocoumon B-Drug B-Drug
resulted O O
in O O
prolongation O O
of O O
prothrombin O O
time O O
. O O

Bosentan B-Drug B-Drug
had O O
no O O
relevant O O
inhibitory O O
effect O O
on O O
any O O
CYP O O
isoenzymes O O
tested O O
( O O
CYP9A9 O O
CYP9C9 O O
CYP9C9 O O
CYP9D9 O O
CYP9A9 O O
) O O
. O O

Cmax O O
and O O
t9 O O
/ O O
9 O O
were O O
increased O O
9 O O
- O O
fold O O
and O O
9 O O
- O O
fold O O
respectively O O
. O O

Anagrelide B-Drug B-Drug
is O O
an O O
inhibitor O O
of O O
cyclic O O
AMP O O
PDE O O
III O O
. O O

The O O
in O O
vitro O O
binding O O
of O O
warfarin B-Drug B-Drug
to O O
human O O
plasma O O
proteins O O
is O O
unaffected O O
by O O
tolmetin B-Drug B-Drug
and O O
tolmetin B-Drug B-Drug
does O O
not O O
alter O O
the O O
prothrombin O O
time O O
of O O
normal O O
volunteers O O
. O O

Methadonea O O

methylphenidate B-Drug B-Drug
; O O

Seizure O O
associated O O
with O O
increased O O
lidocaine B-Drug B-Drug
concentrations O O
has O O
been O O
reported O O
with O O
concomitant O O
administration O O
of O O
intravenous O O
amiodarone B-Drug B-Drug
. O O

Mean O O
T O O
max O O
and O O
mean O O
plasma O O
elimination O O
half O O
- O O
life O O
of O O
albendazole B-Drug B-Drug
sulfoxide I-Drug I-Drug
were O O
unchanged O O
. O O

These O O
drugs O O
should O O
be O O
coad O O
- O O
ministered O O
with O O
caution O O
and O O
frequent O O
monitoring O O
of O O
serum O O
lithium B-Drug B-Drug
levels O O
is O O
recommended O O
. O O

Drug O O
- O O
Laboratory O O
- O O
Test O O
Interactions O O
Interactions O O
between O O
tolterodine B-Drug B-Drug
and O O
laboratory O O
tests O O
have O O
not O O
been O O
studied O O
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P9 O O
9D9 O O
isozyme O O
activity O O
among O O
Asian O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

Drug O O
/ O O
Laboratory O O
Tests O O
Interactions O O
Because O O
false O O
positive O O
readings O O
were O O
reported O O
with O O
the O O
Ames O O
N O O
- O O
Multistix O O
SG O O
dipstick O O
test O O
for O O
urinary O O
protein O O
when O O
gabapentin B-Drug B-Drug
was O O
added O O
to O O
other O O
antiepileptic B-Group B-Group
drugs I-Group I-Group
the O O
more O O
specific O O
sulfosalicylic O O
acid O O
precipitation O O
procedure O O
is O O
recommended O O
to O O
determine O O
the O O
presence O O
of O O
urine O O
protein O O

Oral O O
Contraceptives B-Group B-Group
Multiple O O
doses O O
of O O
cefditoren B-Drug B-Drug
pivoxil I-Drug I-Drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
ethinyl B-Drug B-Drug
estradiol I-Drug I-Drug
the O O
estrogenic O O
component O O
in O O
most O O
oral O O
contraceptives B-Group B-Group
. O O

As O O
with O O
most O O
psychoactive O O
medications O O
patients O O
should O O
be O O
advised O O
to O O
avoid O O
alcohol B-Drug B-Drug
while O O
taking O O
ABILIFY B-Brand B-Brand

This O O
drug O O
may O O
interact O O
with O O
alcohol B-Drug B-Drug
or O O
other O O
CNS B-Group B-Group
depressants I-Group I-Group
( O O
may O O
potentiate O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
antihistamines B-Group B-Group
) O O
anticholinergics B-Group B-Group
or O O
other O O
medications O O
with O O
anticholinergic O O
activity O O
( O O
anticholinergic O O
effects O O
may O O
be O O
potentiated O O
when O O
these O O
medications O O
are O O
used O O
concurrently O O
with O O
antihistamines B-Group B-Group
) O O
and O O
monoamine B-Group B-Group
oxidase I-Group I-Group
MAO I-Group I-Group
inhibitors I-Group I-Group
( O O
concurrent O O
use O O
with O O
antihistamines B-Drug B-Group
may O O
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
and O O
CNS O O
depressant O O
effects O O
of O O
antihistamines B-Drug B-Group
) O O
. O O

Mineral B-Drug B-Drug_n
oil I-Drug I-Drug_n
interferes O O
with O O
the O O
absorption O O
of O O
fat B-Group B-Group
- O O
soluble B-Group B-Group
vitamins I-Group I-Group
including O O
vitamin B-Group B-Group
D I-Group I-Group
preparations I-Group I-Group
. O O

cardiac B-Group B-Group
glycosides I-Group I-Group
; O O

C O O
max O O
AUC O O
9 O O
- O O
9 O O
hrs O O
C O O
max O O
AUC O O
9 O O
- O O
9 O O
hrs O O

- O O
Impaired O O
glucose O O
tolerance O O

Fluconazole B-Drug B-Drug
and O O
the O O
9 B-Group B-Group
- O O
HT9 B-Group B-Group
antiemetics I-Group I-Group
ondansetron B-Drug B-Drug
( O O
Zofran B-Brand B-Brand
) O O
and O O
granisetron B-Drug B-Drug
( O O
Kytril B-Brand B-Brand
) O O
have O O
all O O
been O O
used O O
with O O
BUSULFEX B-Brand B-Brand
. O O

the O O
time O O
to O O
reach O O
maximum O O
concentration O O
was O O
delayed O O
approximately O O
9 O O
minutes O O
. O O

Antacid B-Group B-Group
: O O
The O O
effect O O
of O O
an O O
aluminum B-Drug B-Drug
hydroxide I-Drug I-Drug
- O O
and O O
magnesium B-Drug B-Drug
hydroxide I-Drug I-Drug
- O O
containing O O
antacid B-Group B-Group
( O O
Maalox B-Brand B-Brand
) O O
* O O
on O O
the O O
pharmacokinetics O O
of O O
capecitabine B-Drug B-Drug
was O O
investigated O O
in O O
9 O O
cancer O O
patients O O
. O O

Inhibition O O
of O O
CYP9A9 O O
metabolic O O
reactions O O
was O O
not O O
detected O O
in O O
in O O
vitro O O
experiments O O
. O O

iii O O
. O O

Thus O O
no O O
dosing O O
adjustments O O
are O O
necessary O O
during O O
concomitant O O
use O O
with O O
these O O
agents O O
. O O

Antidiabetics B-Group B-Group
: O O
Because O O
corticosteroids B-Group B-Group
may O O
increase O O
blood O O
glucose O O
concentrations O O
dosage O O
adjustments O O
of O O
antidiabetic B-Group B-Drug
agents I-Group O
may O O
be O O
required O O
. O O

If O O
a O O
diuretic B-Group B-Group
is O O
also O O
used O O
the O O
risk O O
of O O
lithium O B-Drug
toxicity O O
may O O
be O O
increased O O
. O O

. O O

however O O
in O O
a O O
study O O
of O O
9 O O
normal O O
subjects O O
concurrent O O
administration O O
of O O
aspirin B-Brand B-Brand
decreased O O
ketoprofen B-Drug B-Drug
protein O O
binding O O
and O O
increased O O
ketoprofen B-Drug B-Drug
plasma O O
clearance O O
from O O
9 O O
L O O
/ O O
kg O O
/ O O
h O O
without O O
aspirin B-Brand B-Brand
to O O
9 O O
L O O
/ O O
kg O O
/ O O
h O O
with O O
aspirin B-Brand B-Brand
. O O

ISUPREL B-Brand B-Brand
should O O
be O O
used O O
with O O
caution O O
if O O
at O O
all O O
when O O
potent O O
inhalational O O
anesthetics B-Group B-Group
such O O
as O O
halothane B-Drug B-Drug
are O O
employed O O
because O O
of O O
potential O O
to O O
sensitize O O
the O O
myocardium O O
to O O
effects O O
of O O
sympathomimetic B-Group B-Group
amines I-Group I-Group
. O O

. O O

The O O
appropriate O O
doses O O
for O O
this O O
combination O O
with O O
respect O O
to O O
efficacy O O
and O O
safety O O
have O O
not O O
been O O
established O O
. O O

The O O
possibility O O
of O O
increased O O
interaction O O
should O O
be O O
kept O O
in O O
mind O O
when O O
Orudis B-Brand B-Brand
doses O O
greater O O
than O O
9 O O
mg O O
as O O
a O O
single O O
dose O O
or O O
9 O O
mg O O
of O O
ketoprofen B-Drug B-Drug
per O O
day O O
are O O
used O O
concomitantly O O
with O O
highly O O
bound O O
drugs O O
. O O

- O O
Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
: O O
Thiazides B-Group B-Group
should O O
be O O
discontinued O O
before O O
carrying O O
out O O
tests O O
for O O
parathyroid O O
function O O
. O O

Although O O
it O O
is O O
unknown O O
whether O O
this O O
could O O
result O O
in O O
clinically O O
significant O O
effects O O
caution O O
is O O
advised O O
when O O
administering O O
Cerebyx B-Brand B-Brand
with O O
other O O
drugs O O
that O O
significantly O O
bind O O
to O O
serum O O
albumin O O
. O O

This O O
antagonistic O O
effect O O
of O O
probenecid B-Drug B-Drug
on O O
bumetanide B-Drug B-Drug
natriuresis O O
is O O
not O O
due O O
to O O
a O O
direct O O
action O O
on O O
sodium O O
excretion O O
but O O
is O O
probably O O
secondary O O
to O O
its O O
inhibitory O O
effect O O
on O O
renal O O
tubular O O
secretion O O
of O O
bumetanide B-Drug B-Drug
. O O

Terbinafine B-Drug B-Drug
decreases O O
the O O
clearance O O
of O O
caffeine B-Drug B-Drug
by O O
9 O O
% O O
. O O

In O O
renal O O
and O O
cardiac O O
transplant O O
recipients O O
a O O
reduction O O
of O O
cyclosporine B-Drug B-Drug
dose O O
ranging O O
from O O
9 O O
% O O
to O O
9 O O
% O O
was O O
necessary O O
to O O
maintain O O
cyclosporine B-Drug B-Drug
trough O O
concentrations O O
similar O O
to O O
those O O
seen O O
prior O O
to O O
the O O
addition O O
of O O
diltiazem B-Drug B-Drug
. O O

Theophylline B-Drug B-Drug
: O O
The O O
pharmacokinetics O O
of O O
theophylline B-Drug B-Drug
( O O
aminophylline B-Drug B-Drug
9 O O
mg O O
/ O O
kg O O
infused O O
over O O
9 O O
minutes O O
) O O
were O O
unchanged O O
following O O
a O O
single O O
oral O O
dose O O
of O O
albendazole B-Drug B-Drug
( O O
9 O O
mg O O
) O O
in O O
9 O O
healthy O O
subjects O O
. O O

Drugs O O
Highly O O
Bound O O
to O O
Plasma O O
Protein O O
Zaleplon B-Drug B-Drug
is O O
not O O
highly O O
bound O O
to O O
plasma O O
proteins O O
( O O
fraction O O
bound O O
9 O O
% O O
9 O O
% O O
) O O
; O O

Exemestane B-Drug B-Drug
is O O
extensively O O
metabolized O O
by O O
CYP O O
9A9 O O
but O O
coadministration O O
of O O
ketoconazole B-Drug B-Drug
a O O
potent O O
inhibitor O O
of O O
CYP O O
9A9 O O
has O O
no O O
significant O O
effect O O
on O O
exemestane B-Drug B-Drug
pharmacokinetics O O
. O O

Antacids B-Group B-Group
: O O
Enteric O O
Coated O O
Aspirin B-Brand B-Brand
should O O
not O O
be O O
given O O
concurrently O O
with O O
antacids B-Group B-Group
since O O
an O O
increase O O
in O O
the O O
pH O O
of O O
the O O
stomach O O
may O O
effect O O
the O O
enteric O O
coating O O
of O O
the O O
tablets O O
. O O

however O O
an O O
increased O O
methadone B-Drug B-Drug
dose O O
may O O
be O O
required O O
in O O
a O O
small O O
number O O
of O O
patients O O
. O O

In O O
these O O
subjects O O
celecoxib B-Drug B-Drug
did O O
not O O
alter O O
the O O
anticoagulant O O
effect O O
of O O
warfarin B-Drug B-Drug
as O O
determined O O
by O O
prothrombin O O
time O O
. O O

Therefore O O
when O O
EDECRIN B-Brand B-Brand
and O O
non B-Group B-Group
- O O
steroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
agents I-Group I-Group
are O O
used O O
concomitantly O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-Group B-Group
is O O
obtained O O
. O O

This O O
alteration O O
will O O
not O O
result O O
in O O
a O O
methadone B-Drug B-Drug
dose O O
modification O O
in O O
the O O
majority O O
of O O
patients O O
; O O

Rhabdomyolysis O O
has O O
been O O
observed O O
in O O
patients O O
receiving O O
HMG B-Group B-Group
- O O
CoA B-Group B-Group
reductase I-Group I-Group
inhibitors I-Group I-Group
administered O O
alone O O
( O O
at O O
recommended O O
dosages O O
) O O
or O O
concomitantly O O
with O O
immunosuppressive B-Group B-Group
drugs I-Group I-Group
including O O
cyclosporine B-Drug B-Drug
. O O

tolbutamide B-Drug B-Drug
; O O

Co O O
- O O
administration O O
of O O
TIKOSYN B-Brand B-Brand
with O O
verapamil B-Drug B-Drug
resulted O O
in O O
increases O O
in O O
dofetilide B-Drug B-Drug
peak O O
plasma O O
levels O O
of O O
9 O O
% O O
although O O
overall O O
exposure O O
to O O
dofetilide B-Drug B-Drug
was O O
not O O
significantly O O
increased O O
. O O

( O O
9 O O
mg O O
Q9h O O
) O O

These O O
are O O
described O O
in O O
greater O O
detail O O
below O O
: O O
Oral O O
hypoglycemics B-Group B-Group
Coumarin B-Group B-Group
- O O
type B-Group B-Group
anticoagulants I-Group I-Group
Phenytoin B-Drug B-Drug
Cyclosporine B-Drug B-Drug
Rifampin B-Drug B-Drug
Theophylline B-Drug B-Drug
Terfenadine B-Drug B-Drug
Cisapride B-Drug B-Drug
Astemizole B-Drug B-Drug
Rifabutin B-Drug B-Drug
Tacrolimus B-Drug B-Drug
Short B-Group B-Group
- O O
acting B-Group B-Group
benzodiazepines I-Group I-Group
Oral O O
hypoglycemics B-Group B-Group
: O O
Clinically O O
significant O O
hypoglycemia O O
may O O
be O O
precipitated O O
by O O
the O O
use O O
of O O
DIFLUCAN B-Brand B-Brand
with O O
oral O O
hypoglycemic B-Group B-Group
agents I-Group I-Group
; O O

Fexofenadine B-Drug B-Drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
either O O
erythromycin B-Drug B-Drug
or O O
ketoconazole B-Drug B-Drug
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
Acetaminophen B-Drug B-Drug
may O O
produce O O
false O O
- O O
positive O O
test O O
results O O
for O O
urinary O O
9 O O
- O O
hydroxyindoleacetic O O
acid O O
. O O

Lithium B-Drug B-Drug
: O O
In O O
clinical O O
trials O O
NSAIDs B-Group B-Group
have O O
produced O O
an O O
elevation O O
of O O
plasma O O
lithium B-Drug B-Drug
levels O O
and O O
a O O
reduction O O
in O O
renal O O
lithium B-Drug B-Drug
clearance O O
. O O

However O O
on O O
a O O
body O O
surface O O
area O O
basis O O
this O O
dose O O
was O O
9 O O
times O O
maximum O O
recommended O O
human O O
9 O O
- O O
hour O O
dose O O
of O O
ribavirin B-Drug B-Drug
. O O

. O O

Other O O
kits O O
such O O
as O O
the O O
Coat O O
- O O
A O O
- O O
Count O O
RIA O O
Kit O O
may O O
be O O
used O O
. O O

Coadministration O O
of O O
Sanctura B-Brand B-Brand
with O O
drugs O O
that O O
are O O
eliminated O O
by O O
active O O
renal O O
tubular O O
secretion O O
may O O
increase O O
the O O
serum O O
concentration O O
of O O
Sanctura B-Brand B-Brand
and O O
/ O O
or O O
the O O
coadministered O O
drug O O
due O O
to O O
competition O O
for O O
this O O
elimination O O
pathway O O
. O O

Drug O O
- O O
drug O O
interactions O O
have O O
not O O
been O O
observed O O
between O O
Argatroban B-Drug B-Drug
and O O
digoxin B-Drug B-Drug
or O O
erythromycin B-Drug B-Drug
. O O

Use O O
of O O
PRINIVIL B-Brand B-Brand
with O O
potassium B-Group B-Group
- O O
sparing B-Group B-Group
diuretics I-Group I-Group
( O O
e.g. O O
spironolactone B-Drug B-Drug
triamterene B-Drug B-Drug
or O O
amiloride B-Drug B-Drug
) O O
potassium B-Drug B-Drug
supplements O O
or O O
potassium O B-Drug
- O O
containing O O
salt O O
substitutes O O
may O O
lead O O
to O O
significant O O
increases O O
in O O
serum O O
potassium O O
. O O

and O O
rarely O O
euphoria O O
excitement O O
depression O O
hallucinations O O
paresthesia O O
muscle O O
pain O O
tinnitus O O
slurred O O
speech O O
coordination O O
disorder O O
tremor O O
rigidity O O
dystonia O O
ataxia O O
blurred O O
vision O O
nystagmus O O
strabismus O O
miosis O O
mydriasis O O
diplopia O O
dysarthria O O
epileptic O O
seizure O O
. O O

In O O
oral O O
( O O
gavage O O
) O O
embryo O O
- O O
fetal O O
development O O
studies O O
of O O
ezetimibe B-Drug B-Drug
conducted O O
in O O
rats O O
and O O
rabbits O O
during O O
organogenesis O O
there O O
was O O
no O O
evidence O O
of O O
embryolethal O O
effects O O
at O O
the O O
doses O O
tested O O
( O O
9 O O
9 O O
9 O O
mg O O
/ O O
kg O O
/ O O
day O O
) O O
. O O

Cefuroxime B-Drug B-Drug
does O O
not O O
interfere O O
with O O
the O O
assay O O
of O O
serum O O
and O O
urine O O
creatinine O O
by O O
the O O
alkaline O O
picrate O O
method O O
. O O

Digoxin B-Drug B-Drug
Methotrexate B-Drug B-Drug
Cyclosporine B-Drug B-Drug
: O O
Diclofenac B-Drug B-Drug
like O O
other O O
NSAIDs B-Group B-Group
may O O
affect O O
renal O O
prostaglandins O O
and O O
increase O O
the O O
toxicity O O
of O O
certain O O
drugs O O
. O O

Thus O O
SYMLIN B-Brand B-Brand
and O O
insulin B-Drug B-Drug
should O O
not O O
be O O
mixed O O
and O O
must O O
be O O
administered O O
separately O O
. O O

Note O O
: O O

Coadministration O O
of O O
entecavir B-Drug O
with O O
lamivudine B-Drug B-Drug
adefovir B-Drug O
dipivoxil I-Drug B-Drug
or O O
tenofovir B-Drug B-Drug
disoproxil I-Drug I-Drug
fumarate I-Drug I-Drug
did O O
not O O
result O O
in O O
significant O O
drug O O
interactions O O
. O O

The O O
concomitant O O
administration O O
of O O
Exjade B-Brand B-Brand
and O O
aluminum B-Drug B-Drug
- O O
containing O O
antacid B-Group B-Group
preparations I-Group I-Group
has O O
not O O
been O O
formally O O
studied O O
. O O

The O O
concentration O O
of O O
AMICAR B-Brand B-Brand
necessary O O
to O O
maintain O O
inhibition O O
of O O
fibrinolysis O O
is O O
9 O O
mMol O O
/ O O
L O O
or O O
9 O O
mg O O
/ O O
mL O O
. O O

Carbamazepine B-Drug B-Drug

Aminoglutethimide B-Drug B-Drug
: O O
May O O
increase O O
CYP O O
metabolism O O
of O O
progestins B-Group B-Group
leading O O
to O O
possible O O
decrease O O
in O O
contraceptive O O
effectiveness O O
. O O

Prothrombin O O
time O O
or O O
other O O
suitable O O
anticoagulation O O
test O O
should O O
be O O
monitored O O
if O O
tigecycline B-Drug B-Drug
is O O
administered O O
with O O
warfarin B-Drug B-Drug
. O O

Amiodarone B-Drug B-Drug
taken O O
concomitantly O O
with O O
procainamide B-Drug B-Drug
for O O
less O O
than O O
seven O O
days O O
increases O O
plasma O O
concentrations O O
of O O
procainamide B-Drug B-Drug
and O O
n O O
- O O
acetyl O B-Drug_n
procainamide B-Drug I-Drug_n
by O O
9 O O
% O O
and O O
9 O O
% O O
respectively O O
. O O

LABORATORY O O
TEST O O
FINDINGS O O
Asymptomatic O O
transitory O O
changes O O
in O O
serum O O
iron O O
have O O
been O O
observed O O
. O O

9 O O
- O O
9 O O

Although O O
specific O O
studies O O
have O O
not O O
been O O
performed O O
coadministration O O
with O O
drugs O O
that O O
are O O
mainly O O
metabolized O O
by O O
CYP9A9 O O
( O O
eg O O
calcium B-Group B-Group
channel I-Group I-Group
blockers I-Group I-Group
dapsone B-Drug B-Drug
disopyramide B-Drug B-Drug
quinine B-Drug B-Drug
amiodarone B-Drug B-Drug
quinidine B-Drug B-Drug
warfarin B-Drug B-Drug
tacrolimus B-Drug B-Drug
cyclosporine B-Drug B-Drug
ergot B-Group B-Group
derivatives I-Group I-Group
pimozide B-Drug B-Drug
carbamazepine B-Drug B-Drug
fentanyl B-Drug B-Drug
alfentanyl B-Drug B-Drug
alprazolam B-Drug B-Drug
and O O
triazolam B-Drug B-Drug
) O O
may O O
have O O
elevated O O
plasma O O
concentrations O O
when O O
coadministered O O
with O O
saquinavir B-Drug B-Drug
; O O

Tiagabine B-Drug B-Drug
has O O
shown O O
no O O
clinically O O
important O O
potentiation O O
of O O
the O O
pharmacodynamic O O
effects O O
of O O
triazo O O
lam O O
or O O
alcohol B-Drug B-Drug
. O O

Sucralfate B-Drug B-Drug
and O O
antacids B-Group B-Group
: O O
Quinolones B-Group B-Group
form O O
chelates O O
with O O
metal O O
cations O O
. O O

Because O O
of O O
possible O O
clinical O O
significance O O
these O O
two O O
drugs O O
should O O
not O O
be O O
administered O O
concurrently O O
. O O

*CBZ O O
epoxide O O

Oral O O
Hypoglycemic B-Group B-Group
Agents I-Group I-Group
: O O
In O O
pharmacokinetic O O
studies O O
of O O
MEVACOR B-Brand B-Brand
in O O
hypercholesterolemic O O
noninsulin O O
dependent O O
diabetic O O
patients O O
there O O
was O O
no O O
drug O O
interaction O O
with O O
glipizide B-Drug B-Drug
or O O
with O O
chlorpropamide B-Drug B-Drug

Therefore O O
inhibitors O O
of O O
these O O
enzymes O O
are O O
expected O O
to O O
reduce O O
vardenafil B-Drug B-Drug
clearance O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
False O O
elevations O O
of O O
urinary O O
catecholamine O O
levels O O
may O O
occur O O
due O O
to O O
interference O O
with O O
the O O
fluorescence O O
test O O
. O O

use O O
of O O
a O O
nonhormonal B-Group B-Group
contraceptive I-Group I-Group
product I-Group I-Group
is O O
recommended O O
. O O

chloral B-Drug B-Drug
hydrate I-Drug I-Drug
* O O
; O O

Concomitant O O
use O O
of O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
with O O
drugs O O
that O O
can O O
inhibit O O
cytochrome O O
P9 O O
9D9 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-Group B-Group
antidepressant I-Group I-Group
or O O
the O O
other O O
drug O O
. O O

Estazolam B-Drug B-Drug
: O O
Interaction O O
with O O
Other O O
Drugs O O
that O O
are O O
Metabolized O O
by O O
Cytochrome O O
P9 O O
( O O
CYP O O
) O O
: O O
At O O
clinically O O
relevant O O
concentrations O O
in O O
vitro O O
studies O O
indicate O O
that O O
estazolam B-Drug B-Drug
( O O
9 O O
M O O
) O O
was O O
not O O
inhibitory O O
towards O O
the O O
major O O
cytochrome O O
P9 O O
isoforms O O
CYP9A9 O O
CYP9A9 O O
CYP9C9 O O
CYP9C9 O O
CYP9D9 O O
CYP9E9 O O
and O O
CYP9A O O
. O O

In O O
a O O
study O O
of O O
9 O O
male O O
subjects O O
( O O
ages O O
9 O O
to O O
9 O O
years O O
) O O
who O O
were O O
extensive O O
metabolizers O O
of O O
the O O
CYP9D9 O O
isoenzyme O O
daily O O
doses O O
of O O
bupropion B-Drug B-Drug
given O O
as O O
9 O O
mg O O
twice O O
daily O O
followed O O
by O O
a O O
single O O
dose O O
of O O
9 O O
mg O O
desipramine B-Drug B-Drug
increased O O
the O O
Cmax O O
AUC O O
and O O
t9 O O
/ O O
9 O O
of O O
desipramine B-Drug B-Drug
by O O
an O O
average O O
of O O
approximately O O
9 O O
- O O
9 O O
- O O
and O O
9 O O
- O O
fold O O
respectively O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
Blood O O
Glucose O O
Blood O O
glucose O O
measurement O O
must O O
be O O
done O O
with O O
a O O
glucose O O
- O O
specific O O
method O O
to O O
prevent O O
maltose O O
interference O O
with O O
test O O
results O O
. O O

Antacids B-Group B-Group
or O O
H B-Group B-Group
9 I-Group I-Group
receptor I-Group I-Group
antagonists I-Group I-Group
: O O
When O O
dirithromycin B-Drug B-Drug
is O O
administered O O
immediately O O
following O O
antacids B-Group B-Group
or O O
H B-Group B-Group
9 I-Group I-Group
- O O
receptor B-Group O
antagonists I-Group O
the O O
absorption O O
of O O
dirithromycin B-Drug B-Drug
is O O
slightly O O
enhanced O O
. O O

Monoamine O B-Group
Oxidase O I-Group
Inhibition O I-Group
: O O
Linezolid B-Drug B-Drug
is O O
a O O
reversible O O
nonselective O O
inhibitor O O
of O O
monoamine O O
oxidase O O
. O O

Until O O
further O O
data O O
are O O
available O O
regarding O O
the O O
potential O O
interaction O O
of O O
dirithromycin B-Drug B-Drug
with O O
these O O
compounds O O
caution O O
should O O
be O O
used O O
during O O
coadministration O O
. O O

The O O
hypoglycemic O O
action O O
of O O
sulfonylurea B-Group B-Group
may O O
be O O
potentiated O O
by O O
certain O O
drugs O O
including O O
nonsteroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
agents I-Group I-Group
and O O
other O O
drugs O O
that O O
are O O
highly O O
protein O O
bound O O
salicylates B-Group B-Group
sulfonamides B-Group B-Group
chloramphenicol B-Drug B-Drug
probenecid B-Drug B-Drug
coumarins B-Group B-Group
monoamine B-Group B-Group
oxidase I-Group I-Group
inhibitors I-Group I-Group
and O O
beta B-Group B-Group
adrenergic I-Group I-Group
blocking I-Group I-Group
agents I-Group I-Group
. O O

this O O
effect O O
is O O
at O O
least O O
balanced O O
by O O
decreased O O
metabolism O O
of O O
corticosteroids B-Group B-Group
. O O

use O O
of O O
a O O
nonhormonal B-Group B-Group
contraceptive I-Group I-Group
product I-Group I-Group
is O O
recommended O O
. O O

Furthermore O O
whenever O O
one O O
of O O
these O O
drugs O O
is O O
withdrawn O O
from O O
co O O
- O O
therapy O O
an O O
increased O O
dose O O
of O O
tricyclic B-Group B-Group
antidepressant I-Group I-Group
agent I-Group I-Group
may O O
be O O
required O O
. O O

Antidiabetic B-Group B-Group
drugs I-Group I-Group
: O O
( O O
oral O O
agents O O
and O O
insulin B-Drug B-Drug
) O O
- O O
dosage O O
adjustment O O
of O O
the O O
antidiabetic B-Group B-Group
drug I-Group I-Group
may O O
be O O
required O O
. O O

Changes O O
in O O
hepatic O O
function O O
induced O O
by O O
concomitant O O
therapies O O
may O O
affect O O
epirubicin B-Drug B-Drug
metabolism O O
pharmacokinetics O O
therapeutic O O
efficacy O O
and O O
/ O O
or O O
toxicity O O
. O O

Considerable O O
caution O O
should O O
be O O
exercised O O
if O O
PEGANONE B-Brand B-Brand
is O O
administered O O
concurrently O O
with O O
Phenurone B-Brand B-Drug_n
( O O
phenacemide B-Drug O
) O O
since O O
paranoid O O
symptoms O O
have O O
been O O
reported O O
during O O
therapy O O
with O O
this O O
combination O O
. O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-Drug B-Drug
used O O
to O O
treat O O
allergic O O
reaction O O
. O O

Literature O O
reports O O
indicate O O
that O O
coadministration O O
of O O
indomethacin B-Drug B-Drug
may O O
reduce O O
the O O
natriuretic O O
and O O
antihypertensive O O
effects O O
of O O
furosemide B-Drug B-Drug
in O O
some O O
patients O O
by O O
inhibiting O O
prostaglandin O O
synthesis O O
. O O

Pregnancy O O
Pregnancy O O
Category O O
D O O
: O O
. O O

The O O
effects O O
celecoxib B-Drug B-Drug
on O O
the O O
pharmacokinetics O O
and O O
/ O O
or O O
pharmacodynamics O O
of O O
glyburide B-Drug B-Drug
ketoconazole B-Drug B-Drug
methotrexate B-Drug B-Drug
phenytoin B-Drug B-Drug
tolbutamide B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
have O O
been O O
studied O O
in O O
vivo O O
and O O
clinically O O
important O O
interactions O O
have O O
not O O
been O O
found O O
. O O

Warfarin B-Drug B-Drug

Potential O O
drug O O
interactions O O
between O O
Mentax B-Brand B-Brand
( O O
butenafine B-Drug B-Drug
HCl I-Drug I-Drug
cream O O
) O O
Cream O O
9 O O
% O O
and O O
other O O
drugs O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

these O O
drugs O O
were O O
not O O
tested O O
to O O
determine O O
the O O
effect O O
of O O
administration O O
one O O
hour O O
before O O
colestipol B-Drug B-Drug
hydrochloride I-Drug I-Drug
. O O

Pharmacokinetic O O
studies O O
indicate O O
that O O
administration O O
of O O
disulfiram B-Drug B-Drug
or O O
diazepam B-Drug B-Drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
acamprosate B-Drug B-Drug
. O O

Antacids B-Group B-Group
: O O
In O O
a O O
clinical O O
pharmacology O O
study O O
coadministration O O
of O O
an O O
antacid B-Group B-Group
( O O
aluminum B-Drug B-Drug
hydroxide I-Drug I-Drug
magnesium B-Drug B-Drug
hydroxide I-Drug I-Drug
and O O
simethicone B-Drug B-Drug
) O O
with O O
fosinopril B-Drug B-Drug
reduced O O
serum O O
levels O O
and O O
urinary O O
excretion O O
of O O
fosinoprilat B-Drug_n O
as O O
compared O O
with O O
fosinopril B-Drug B-Drug
administered O O
alone O O
suggesting O O
that O O
antacids B-Group B-Group
may O O
impair O O
absorption O O
of O O
fosinopril B-Drug B-Drug
. O O

salicylates B-Group B-Group
; O O
sulfinpyrazone B-Drug B-Drug
; O O

However O O
iloprost B-Drug B-Drug
has O O
the O O
potential O O
to O O
increase O O
the O O
hypotensive O O
effect O O
of O O
vasodilators B-Group B-Group
and O O
antihypertensive B-Group B-Group
agents I-Group I-Group
. O O

Anticholinergic B-Group B-Group
drugs I-Group I-Group
may O O
antagonize O O
the O O
effects O O
of O O
the O O
drugs O O
that O O
alter O O
gastrointestinal O O
motility O O
such O O
as O O
metoclopramide B-Drug B-Drug
. O O

- O O
Nitrofurantoin B-Drug B-Drug
( O O
e.g. O O
Furadantin B-Brand B-Brand
) O O
or O O

Caffeine B-Drug B-Drug
- O O
related O O
adverse O O
effects O O
have O O
occurred O O
in O O
patients O O
consuming O O
caffeine B-Drug B-Drug
while O O
on O O
therapy O O
with O O
enoxacin B-Drug B-Drug
. O O

Grapefruit O O
juice O O
Co O O
- O O
administration O O
of O O
felodipine B-Drug B-Drug
with O O
grapefruit O O
juice O O
resulted O O
in O O
more O O
than O O
9 O O
- O O
fold O O
increase O O
in O O
the O O
AUC O O
and O O
Cmax O O
but O O
no O O
prolongation O O
in O O
the O O
half O O
- O O
life O O
of O O
felodipine B-Drug B-Drug
. O O

Lithium B-Drug B-Drug
salts O O

The O O
pressor O O
effects O O
of O O
diethylpropion B-Drug B-Drug
and O O
those O O
of O O
other O O
drugs O O
may O O
be O O
additive O O
when O O
the O O
drugs O O
are O O
used O O
concomitantly O O
; O O

these O O
agents O O
may O O
diminish O O
the O O
effectiveness O O
of O O
Permax B-Brand B-Brand
. O O

Usually O O
severe O O
abdominal O O
symptoms O O
appear O O
before O O
there O O
is O O
such O O
a O O
fall O O
in O O
the O O
blood O O
pressure O O
. O O

In O O
evaluating O O
the O O
potential O O
for O O
interactions O O
among O O
co O O
- O O
administered O O
antiepilepsy O O
drugs O O
( O O
AEDs B-Group B-Group
) O O
whether O O
or O O
not O O
an O O
AED B-Group B-Group
induces O O
or O O
does O O
not O O
induce O O
metabolic O O
enzymes O O
is O O
an O O
important O O
consideration O O
. O O

- O O
Drugs O O
that O O
may O O
decrease O O
plasma O O
phenytoin B-Drug B-Drug
concentrations O O
include O O
: O O
carbamazepine B-Drug B-Drug
chronic O O
alcohol B-Drug B-Drug
abuse O O
reserpine B-Drug B-Drug

Patients O O
on O O
lithium B-Drug B-Drug
treatment O O
should O O
be O O
closely O O
monitored O O
when O O
MOBIC B-Brand B-Brand
is O O
introduced O O
or O O
withdrawn O O
. O O

Methadone B-Drug B-Drug

Lodine B-Brand B-Brand
treatment O O
is O O
associated O O
with O O
a O O
small O O
decrease O O
in O O
serum O O
uric O O
acid O O
levels O O
. O O

Digoxin B-Drug B-Drug
did O O
not O O
affect O O
BREVIBLOC B-Brand B-Brand
pharmacokinetics O O
. O O

Another O O
investigator O O
found O O
no O O
increase O O
in O O
digoxin B-Drug B-Drug
levels O O
in O O
9 O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

( O O
Effects O O
may O O
be O O
potentiated O O
when O O
used O O
concurrently O O
with O O
thiazide B-Group B-Group
diuretics I-Group I-Group
; O O

Paricalcitol B-Drug_n B-Drug
is O O
not O O
expected O O
to O O
inhibit O O
the O O
clearance O O
of O O
drugs O O
metabolized O O
by O O
cytochrome O O
P9 O O
enzymes O O
CYP9A9 O O
CYP9A9 O O
CYP9B9 O O
CYP9C9 O O
CYP9C9 O O
CYP9C9 O O
CYP9D9 O O
CYP9E9 O O
or O O
CYP9A O O
nor O O
induce O O
the O O
clearance O O
of O O
drugs O O
metabolized O O
by O O
CYP9B9 O O
CYP9C9 O O
or O O
CYP9A O O
. O O

- O O
Lithium B-Drug B-Drug
: O O
Lithium B-Drug B-Drug
should O O
generally O O
not O O
be O O
given O O
with O O
diuretics B-Group B-Group
( O O
such O O
as O O
bumetanide B-Drug B-Drug
) O O
because O O
they O O
reduce O O
its O O
renal O O
clearance O O
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-Drug O
toxicity O O
. O O

In O O
the O O
treatment O O
of O O
acute O O
MI O O
aspirin B-Brand B-Brand
when O O
not O O
otherwise O O
contraindicated O O
should O O
be O O
administered O O
with O O
Streptokinase B-Drug B-Drug
( O O
see O O
below O O
) O O
. O O

Cimetidine B-Drug B-Drug
: O O
Cimetidine B-Drug B-Drug
a O O
known O O
inhibitor O O
of O O
renal O O
tubular O O
secretion O O
of O O
organic O O
bases O O
via O O
the O O
cationic O O
transport O O
system O O
caused O O
a O O
9 O O
% O O
increase O O
in O O
pramipexole B-Drug B-Drug
AUC O O
and O O
a O O
9 O O
% O O
increase O O
in O O
half O O
- O O
life O O
( O O
N= O O
9 O O
) O O
. O O

There O O
are O O
no O O
clinical O O
data O O
on O O
the O O
use O O
of O O
MIVACRON B-Brand B-Brand
with O O
other O O
nondepolarizing B-Group O
neuromuscular I-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
. O O

Warfarin B-Drug B-Drug
: O O
Increased O O
INR O O
( O O
International O O
Normalized O O
Ratio O O
) O O
when O O
ARAVA B-Brand B-Brand
and O O
warfarin B-Drug B-Drug
were O O
co O O
- O O
administered O O
has O O
been O O
rarely O O
reported O O
. O O

A O O
similar O O
association O O
though O O
less O O
marked O O
has O O
been O O
suggested O O
with O O
barbiturates B-Group B-Group
phenyl O B-Drug_n
- O O
butazone O B-Drug
phenytoin B-Drug B-Drug
sodium I-Drug I-Drug
carbamazepine B-Drug B-Drug
and O O
possibly O O
with O O
griseofulvin B-Drug B-Drug
ampicillin B-Drug B-Drug
and O O
tetracyclines B-Group B-Group
( O O
9 O O
) O O

The O O
concomitant O O
use O O
of O O
vasopressors B-Group B-Group
vasoconstricting O O
agents O O
( O O
such O O
as O O
ergonovine B-Drug B-Drug
) O O
and O O
some O O
oxytocic B-Group B-Group
drugs I-Group I-Group
may O O
result O O
in O O
severe O O
hypertension O O
. O O

Latent O O
LCV O O
infection O O
is O O
generally O O
asymptomatic O O
but O O
can O O
lead O O
to O O
B O O
- O O
cell O O
lymphomas O O
when O O
animals O O
are O O
immune O O
suppressed O O
. O O

This O O
medication O O
should O O
not O O
be O O
taken O O
with O O
MAO B-Group B-Group
inhibitors I-Group I-Group
. O O

Patients O O
receiving O O
hydantoins B-Group O
sulfonamides B-Group B-Group
or O O
sulfonylureas B-Group B-Group
should O O
be O O
observed O O
for O O
increased O O
activity O O
of O O
these O O
drugs O O
and O O
therefore O O
signs O O
of O O
toxicity O O
from O O
these O O
drugs O O
. O O

Risk O O
of O O
anaphylactic O O
reaction O O
: O O
While O O
taking O O
beta B-Group B-Group
blockers I-Group I-Group
patients O O
with O O
a O O
history O O
of O O
severe O O
anaphylactic O O
reaction O O
to O O
a O O
variety O O
of O O
allergens O O
may O O
be O O
more O O
reactive O O
to O O
repeated O O
challenge O O
either O O
accidental O O
diagnostic O O
or O O
therapeutic O O
. O O

antihistamines B-Group B-Group
; O O

Potassium O O
sparing O O
agents O O
should O O
generally O O
not O O
be O O
used O O
in O O
patients O O
with O O
heart O O
failure O O
receiving O O
enalapril B-Drug B-Drug
. O O

Nevertheless O O
clinical O O
studies O O
as O O
well O O
as O O
postmarketing O O
observations O O
have O O
shown O O
that O O
Lodine B-Brand B-Brand
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-Drug B-Drug
and O O
thiazides B-Group B-Group
in O O
some O O
patients O O
. O O

Theophylline B-Drug B-Drug
: O O
In O O
three O O
pharmacokinetic O O
studies O O
including O O
9 O O
normal O O
healthy O O
subjects O O
theophylline B-Drug B-Drug
clearance O O
and O O
concentration O O
were O O
not O O
significantly O O
altered O O
by O O
the O O
addition O O
of O O
lomefloxacin B-Drug B-Drug
. O O

Methylprednisolone B-Drug B-Drug
may O O
increase O O
the O O
clearance O O
of O O
chronic O O
high O O
dose O O
aspirin B-Brand B-Brand
. O O

The O O
effects O O
of O O
adenosine B-Drug B-Drug
are O O
antagonized O O
by O O
methylxanthines B-Group B-Group
such O O
as O O
caffeine B-Drug B-Drug
and O O
theophylline B-Drug B-Drug
. O O

Need O O
for O O
more O O
inhalations O O
than O O
usual O O
of O O
short B-Group O
- O O
acting B-Group O
inhaled I-Group O
beta9 I-Group B-Group
- O O
agonists B-Group B-Group
. O O

Mutual O O
inhibition O O
of O O
metabolism O O
occurs O O
with O O
concurrent O O
use O O
of O O
cyclosporin B-Drug B-Drug
and O O
methylprednisolone B-Drug B-Drug
; O O

Chloral B-Drug B-Drug_n
hydrate I-Drug I-Drug_n
may O O
cause O O
an O O
increased O O
prothrombin O O
response O O
by O O
displacing O O
the O O
anticoagulant B-Group O
from O O
protein O O
binding O O
sites O O
or O O
a O O
diminished O O
prothrombin O O
response O O
through O O
increased O O
metabolism O O
of O O
the O O
unbound O O
drug O O
by O O
hepatic O O
enzyme O O
induction O O
thus O O
leading O O
to O O
inter O O
- O O
patient O O
variation O O
in O O
ultimate O O
prothrombin O O
effect O O
. O O

adjust O O
dosage O O
of O O
antidiabetic B-Group B-Group
drug I-Group I-Group
upward O O
if O O
necessary O O
. O O

No O O
dose O O
adjustment O O
is O O
necessary O O
. O O

Gemfibrozil B-Drug B-Drug
Other O O
fibrates B-Group B-Group
Niacin B-Drug B-Drug
( O O
nicotinic B-Drug B-Drug
acid I-Drug I-Drug
) O O
( O O
=9 O O
g O O
/ O O
day O O
) O O

Although O O
trough O O
citalopram B-Drug B-Drug
plasma O O
levels O O
were O O
unaffected O O
given O O
the O O
enzyme O O
- O O
inducing O O
properties O O
of O O
carbamazepine B-Drug B-Drug
the O O
possibility O O
that O O
carbamazepine B-Drug B-Drug
might O O
increase O O
the O O
clearance O O
of O O
escitalopram B-Drug B-Drug
should O O
be O O
considered O O
if O O
the O O
two O O
drugs O O
are O O
coadministered O O
. O O

Adrenergic B-Group B-Group
blockers I-Group I-Group
: O O
Adrenergic B-Group B-Group
blockers I-Group I-Group
are O O
inhibited O O
by O O
amphetamines B-Group B-Group
. O O

The O O
effects O O
of O O
nonbenzodiazepine O B-Group
agonists O I-Group
at O O
benzodiazepine O B-Group
receptors O I-Group
such O O
as O O
zopiclone B-Drug B-Drug
triazolopyridazines O B-Drug
and O O
others O O
are O O
also O O
blocked O O
by O O
ROMAZICON B-Brand B-Brand
. O O

Probenecid B-Drug B-Drug
: O O
As O O
with O O
other O O
b B-Group B-Group
- O O
lactam B-Group B-Group
antibiotics I-Group I-Group
co O O
- O O
administration O O
of O O
probenecid B-Drug B-Drug
with O O
cefditoren B-Drug B-Drug
pivoxil I-Drug I-Drug
resulted O O
in O O
an O O
increase O O
in O O
the O O
plasma O O
exposure O O
of O O
cefditoren B-Drug B-Drug
with O O
a O O
9 O O
% O O
increase O O
in O O
mean O O
Cmax O O
a O O
9 O O
% O O
increase O O
in O O
mean O O
AUC O O
and O O
a O O
9 O O
% O O
increase O O
in O O
half O O
- O O
life O O
. O O

Co O O
- O O
administration O O
with O O
other O O
drugs O O
that O O
are O O
metabolized O O
by O O
CYP O O
9A9 O O
( O O
e.g. O O
indinavir B-Drug B-Drug
erythromycin B-Drug B-Drug
) O O
may O O
increase O O
their O O
clearance O O
resulting O O
in O O
decreased O O
plasma O O
concentration O O
. O O

When O O
administered O O
concomitantly O O
with O O
ProAmatine B-Brand B-Brand
cardiac B-Group I-Group
glycosides I-Group I-Group
may O O
enhance O O
or O O
precipitate O O
bradycardia O O
A.V O O
. O O

If O O
rifampicin B-Drug B-Drug
therapy O O
is O O
required O O
isradipine B-Drug B-Drug
concentrations O O
and O O
therapeutic O O
effects O O
are O O
likely O O
to O O
be O O
markedly O O
reduced O O
or O O
abolished O O
as O O
a O O
consequence O O
of O O
increased O O
metabolism O O
and O O
higher O O
clearance O O
of O O
isradipine B-Drug B-Drug
. O O

Methenamine B-Drug B-Drug
: O O
Efficacy O O
may O O
be O O
decreased O O
due O O
to O O
urinary O O
alkalizing O O
effect O O
of O O
metolazone B-Drug B-Drug
. O O

In O O
rheumatoid O O
arthritis O O
concomitant O O
medications O O
besides O O
MTX B-Drug B-Drug
were O O
nonsteroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
agents I-Group I-Group
folic B-Drug B-Drug
acid I-Drug I-Drug
corticosteroids B-Group B-Group
and O O
/ O O
or O O
narcotics B-Group B-Group
. O O

If O O
hypotension O O
does O O
occur O O
during O O
anesthesia O O
it O O
usually O O
can O O
be O O
controlled O O
by O O
vasopressors B-Group B-Group
. O O

Heparin B-Drug B-Drug
Sodium I-Drug I-Drug
Injection O O
should O O
not O O
be O O
mixed O O
with O O
doxorubicin B-Drug B-Drug
droperidol B-Drug B-Drug
ciprofloxacin B-Drug B-Drug
or O O
mitoxantrone B-Drug B-Drug
since O O
it O O
has O O
been O O
reported O O
that O O
these O O
drugs O O
are O O
incompatible O O
with O O
heparin B-Drug B-Drug
and O O
a O O
precipitate O O
may O O
form O O
. O O

Abciximab B-Drug B-Drug
has O O
been O O
administered O O
to O O
patients O O
with O O
ischemic O O
heart O O
disease O O
treated O O
concomitantly O O
with O O
a O O
broad O O
range O O
of O O
medications O O
used O O
in O O
the O O
treatment O O
of O O
angina O O
myocardial O O
infarction O O
and O O
hypertension O O
. O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
NSAIDs B-Group B-Group
concomitantly O O
with O O
ACE B-Group B-Group
- O O
inhibitors B-Group B-Group
. O O

therefore O O
concomitant O O
administration O O
of O O
Itraconazole B-Drug B-Drug
with O O
cisapride B-Drug B-Drug
is O O
contraindicated O O
. O O

Small O O
decreases O O
in O O
blood O O
pressure O O
have O O
been O O
observed O O
in O O
some O O
patients O O
treated O O
with O O
TRENTAL B-Brand B-Brand
; O O

None O O
Reported O O

Therefore O O
paliperidone B-Drug B-Drug
is O O
not O O
expected O O
to O O
inhibit O O
clearance O O
of O O
drugs O O
that O O
are O O
metabolized O O
by O O
these O O
metabolic O O
pathways O O
in O O
a O O
clinically O O
relevant O O
manner O O
. O O

SUSTIVAhas O O
the O O
potential O O
to O O
decrease O O
serum O O
concentrations O O
of O O
amprenavir B-Drug B-Drug
. O O

St O O
. O O
John O O
wort O O
( O O
Hypericum O O
perforatum O O
) O O

These O O
fulvestrant B-Drug B-Drug
doses O O
correspond O O
to O O
approximately O O
9 O O
- O O
9 O O
- O O
and O O
9 O O
- O O
fold O O
the O O
systemic O O
exposure O O
[ O O
AUC9 O O
- O O
9 O O
days O O
] O O
achieved O O
in O O
women O O
. O O

The O O
occurrence O O
of O O
stupor O O
muscular O O
rigidity O O
severe O O
agitation O O
and O O
elevated O O
temperature O O
has O O
been O O
reported O O
in O O
some O O
patients O O
receiving O O
the O O
combination O O
of O O
selegiline B-Drug B-Drug
and O O
meperidine B-Drug B-Drug
. O O

ETHANOL B-Drug B-Brand
/ O O
NUTRITION O O
/ O O
HERB O O
INTERACTIONS O O
: O O
Food O O
: O O
CNS O O
effects O O
of O O
caffeine B-Drug B-Drug
may O O
be O O
enhanced O O
if O O
combination B-Group B-Group
hormonal I-Group I-Group
contraceptives I-Group I-Group
are O O
used O O
concurrently O O
with O O
caffeine B-Drug B-Drug
. O O

Even O O
when O O
an O O
aminoglycoside B-Group B-Group
and O O
a O O
penicillin B-Group B-Group
- O O
type O O
drug O O
are O O
administered O O
separately O O
by O O
different O O
routes O O
a O O
reduction O O
in O O
aminoglycoside B-Group B-Group
serum O O
half O O
- O O
life O O
or O O
serum O O
levels O O
has O O
been O O
reported O O
in O O
patients O O
with O O
impaired O O
renal O O
function O O
and O O
in O O
some O O
patients O O
with O O
normal O O
renal O O
function O O
. O O

Also O O
flucytosine B-Drug B-Drug
. O O

Chlorthalidone B-Drug B-Drug
may O O
add O O
to O O
or O O
potentiate O O
the O O
action O O
of O O
other O O
antihypertensive B-Group B-Group
drugs I-Group I-Group
. O O

However O O
in O O
vitro O O
studies O O
have O O
shown O O
that O O
at O O
high O O
concentrations O O
( O O
9 O O
mMol O O
/ O O
L O O
or O O
9 O O
mg O O
/ O O
mL O O
and O O
greater O O
) O O
EACA B-Drug O
inhibits O O
ADP O O
and O O
collagen O O
- O O
induced O O
platelet O O
aggregation O O
the O O
release O O
of O O
ATP O O
and O O
serotonin O O
and O O
the O O
binding O O
of O O
fibrinogen O O
to O O
the O O
platelets O O
in O O
a O O
concentration O O
- O O
response O O
manner O O
. O O

Convulsions O O
have O O
been O O
reported O O
with O O
this O O
concurrent O O
use O O
. O O

The O O
presence O O
of O O
sulfamethoxazole B-Drug B-Drug
may O O
interfere O O
with O O
the O O
Jaff O O
alkaline O O
picrate O O
reaction O O
assay O O
for O O
creatinine O O
resulting O O
in O O
overestimations O O
of O O
about O O
9 O O
% O O
in O O
the O O
range O O
of O O
normal O O
values O O
. O O

Recent O O
better O O
designed O O
studies O O
have O O
not O O
reported O O
these O O
adverse O O
effects O O
. O O

laryngeal O O
edema O O

Women O O
should O O
practice O O
additional O O
methods O O
of O O
contraception O O
and O O
not O O
rely O O
on O O
hormonal O O
contraception O O
alone O O
when O O
taking O O
TRACLEER B-Brand B-Brand
. O O

No O O
specific O O
information O O
available O O

Anakinra B-Drug O
: O O
Concurrent O O
administration O O
of O O
anakinra B-Drug B-Drug
( O O
an O O
interleukin B-Group B-Group
- O O
9 B-Group B-Group
antagonist I-Group I-Group
) O O
and O O
another O O
TNF B-Group O
- O O
blocking B-Group O
agent I-Group O
has O O
been O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
serious O O
infections O O
an O O
increased O O
risk O O
of O O
neutropenia O O
and O O
no O O
additional O O
benefit O O
compared O O
to O O
these O O
medicinal O O
products O O
alone O O
. O O

The O O
appropriate O O
doses O O
for O O
this O O
combination O O
with O O
respect O O
to O O
efficacy O O
and O O
safety O O
have O O
not O O
been O O
established O O
. O O

Concomitant O O
treatment O O
with O O
coumarin B-Group B-Group
derivatives I-Group I-Group
( O O
vitamin B-Group B-Group
K I-Group I-Group
antagonists I-Group I-Group
) O O
and O O
drugs O O
that O O
affect O O
platelet O O
function O O
may O O
also O O
increase O O
the O O
risk O O
of O O
bleeding O O
. O O

The O O
mean O O
minimum O O
lithium B-Drug B-Drug
concentration O O
increased O O
9 O O
% O O
and O O
the O O
renal O O
clearance O O
was O O
decreased O O
by O O
approximately O O
9 O O
% O O
. O O

Warfarin B-Drug B-Drug
- O O
Administration O O
of O O
9 O O
mg O O
/ O O
day O O
racemic O O
citalopram B-Drug B-Drug
for O O
9 O O
days O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
warfarin B-Drug B-Drug
a O O
CYP9A9 O O
substrate O O
. O O

There O O
are O O
case O O
reports O O
of O O
patients O O
who O O
developed O O
increased O O
BUN O O
serum O O
creatinine O O
and O O
serum O O
potassium O O
levels O O
and O O
weight O O
gain O O
when O O
furosemide B-Drug B-Drug
was O O
used O O
in O O
conjunction O O
with O O
NSAIDs B-Group B-Group
. O O

Patients O O
in O O
clinical O O
studies O O
were O O
prohibited O O
from O O
receiving O O
growth O O
factor O O
treatment O O
for O O
9 O O
weeks O O
prior O O
to O O
the O O
ZEVALIN B-Brand B-Brand
therapeutic O O
regimen O O
as O O
well O O
as O O
for O O
9 O O
weeks O O
following O O
completion O O
of O O
the O O
regimen O O
. O O

Because O O
prostaglandina O O
play O O
an O O
important O O
role O O
in O O
hemostasis O O
and O O
ketoprofen B-Drug B-Drug
has O O
an O O
effect O O
on O O
platelet O O
function O O
as O O
well O O
concurent O O
therapy O O
with O O
ketoprofen B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
requires O O
close O O
monitoring O O
of O O
patients O O
on O O
both O O
drugs O O
. O O

Phenytoin B-Drug B-Drug
/ O O
Phenobarbital B-Drug B-Drug
: O O
The O O
coadministration O O
of O O
phenytoin B-Drug B-Drug
or O O
phenobarbital B-Drug B-Drug
will O O
not O O
affect O O
plasma O O
concentrations O O
of O O
vitamin B-Group B-Group
D I-Group I-Group
but O O
may O O
reduce O O
endogenous O O
plasma O O
levels O O
of O O
calcitriol B-Drug B-Drug
/ O O
ergocalcitriol O O
by O O
accelerating O O
metabolism O O
. O O

The O O
possibility O O
of O O
reduced O O
statin B-Group O
efficacy O O
should O O
be O O
considered O O
. O O

Hydrocodone B-Drug B-Drug
: O O
Coadministration O O
of O O
Neurontin B-Brand B-Brand
( O O
9 O O
to O O
9 O O
mg O O
; O O

T9 O O
resin O O
uptake O O
is O O
decreased O O
reflecting O O
the O O
elevated O O
TBG O O
. O O

Serum O O
transaminase O O
levels O O
should O O
be O O
obtained O O
before O O
starting O O
treatment O O
with O O
Plenaxis B-Brand B-Brand
and O O
periodically O O
during O O
treatment O O
. O O

The O O
concomitant O O
use O O
of O O
oxybutynin B-Drug B-Drug
with O O
other O O
anticholinergic B-Group B-Group
drugs I-Group I-Group
or O O
with O O
other O O
agents O O
which O O
produce O O
dry O O
mouth O O
constipation O O
somnolence O O
( O O
drowsiness O O
) O O
and O O
/ O O
or O O
other O O
anticholinergic O O
- O O
like O O
effects O O
may O O
increase O O
the O O
frequency O O
and O O
/ O O
or O O
severity O O
of O O
such O O
effects O O
. O O

Concomitant O O
administration O O
of O O
an O O
aluminum B-Drug B-Drug
- O O
containing O O
antacid B-Group B-Group
had O O
no O O
significant O O
effect O O
in O O
the O O
bioavailability O O
of O O
9MNA B-Drug_n B-Drug_n
. O O

Although O O
it O O
has O O
not O O
been O O
definitively O O
demonstrated O O
that O O
fluvoxamine B-Drug B-Drug
is O O
a O O
potent O O
IIIA9 O O
inhibitor O O
it O O
is O O
likely O O
to O O
be O O
given O O
the O O
substantial O O
interaction O O
of O O
fluvoxamine B-Drug B-Drug
with O O
alprazolam B-Drug B-Drug
. O O

Human O O
pharmacokinetic O O
data O O
indicate O O
that O O
oral O O
ketoconazole B-Drug B-Drug
markedly O O
inhibits O O
the O O
metabolism O O
of O O
cisapride B-Drug B-Drug
resulting O O
in O O
a O O
mean O O
eight O O
- O O
fold O O
increase O O
in O O
AUC O O
of O O
cisapride B-Drug B-Drug
. O O

Therefore O O
when O O
using O O
these O O
blocking O B-Group
agents O I-Group
to O O
treat O O
hypertension O O
patients O O
should O O
be O O
observed O O
carefully O O
in O O
order O O
to O O
confirm O O
that O O
the O O
desired O O
therapeutic O O
effect O O
has O O
been O O
obtained O O
. O O

Effect O O
of O O
other O O
agents O O
on O O
the O O
pharmacokinefics O O
of O O
aprepitant B-Drug B-Drug

N=9 O O
) O O
administration O O
. O O

Diazoxide B-Drug B-Drug
Hypotension O O

Since O O
higher O O
doses O O
of O O
ketoconazole B-Drug B-Drug
( O O
9 O O
mg O O
daily O O
) O O
may O O
result O O
in O O
higher O O
increases O O
in O O
Cmax O O
and O O
AUC O O
a O O
single O O
9 O O
mg O O
dose O O
of O O
Vardenafil B-Drug B-Drug
should O O
not O O
be O O
exceeded O O
in O O
a O O
9 O O
- O O
hour O O
period O O
when O O
used O O
in O O
combination O O
with O O
ketoconazole B-Drug B-Drug
9 O O
mg O O
daily O O
. O O

Concomitant O O
administration O O
of O O
rifampin B-Drug B-Drug
with O O
ketoconazole B-Drug B-Drug
tablets O O
reduces O O
the O O
blood O O
levels O O
of O O
the O O
latter O O
. O O

Oral O O
anticoagulant B-Group B-Group
agents I-Group I-Group
: O O
Pharmacokinetic O O
drug O O
- O O
drug O O
interactions O O
between O O
Argatroban B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
( O O
9 O O
mg O O
single O O
oral O O
dose O O
) O O
have O O
not O O
been O O
demonstrated O O
. O O

Coadministration O O
of O O
CRIXIVAN B-Brand B-Brand
and O O
drugs O O
primarily O O
metabolized O O
by O O
CYP9A9 O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
the O O
other O O
drug O O
which O O
could O O
increase O O
or O O
prolong O O
its O O
therapeutic O O
and O O
adverse O O
effects O O
. O O

Lincomycin B-Drug B-Drug
has O O
been O O
shown O O
to O O
have O O
neuromuscular O O
blocking O O
properties O O
that O O
may O O
enhance O O
the O O
action O O
of O O
other O O
neuromuscular B-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
. O O

antacids B-Group B-Group
; O O

Adrenocorticoids O O
: O O
Metabolic O O
clearance O O
of O O
adrenocorticoids O O
is O O
decreased O O
in O O
hypothyroid O O
patients O O
and O O
increased O O
in O O
hyperthyroid O O
patients O O
and O O
may O O
therefore O O
change O O
with O O
changing O O
thyroid O O
status O O
. O O

Patients O O
response O O
to O O
oral O O
anticoagulants B-Group B-Group
may O O
be O O
affected O O
by O O
his O O
/ O O
her O O
thyroid O O
and O O
metabolic O O
status O O
. O O

Caffeine B-Drug B-Drug
: O O
Two O O
hundred O O
mg O O
of O O
caffeine B-Drug B-Drug
( O O
equivalent O O
to O O
9 O O
to O O
9 O O
cups O O
of O O
American O O
coffee O O
) O O
was O O
administered O O
to O O
9 O O
normal O O
healthy O O
volunteers O O
who O O
had O O
achieved O O
steady O O
- O O
state O O
blood O O
concentrations O O
of O O
lomefloxacin B-Drug B-Drug
after O O
being O O
dosed O O
at O O
9 O O
mg O O
qd O O
. O O

Labor O O
and O O
Delivery O O
The O O
effects O O
of O O
ZETIA B-Brand B-Brand
on O O
labor O O
and O O
delivery O O
in O O
pregnant O O
women O O
are O O
unknown O O
. O O

Although O O
the O O
clinical O O
significance O O
is O O
not O O
known O O
it O O
is O O
not O O
recommended O O
that O O
cefditoren B-Drug B-Drug
pivoxil I-Drug I-Drug
be O O
taken O O
concomitantly O O
with O O
antacids B-Group B-Group
. O O

increased O O
norepinephrine O B-Drug
- O O
induced O O
platelet O O
aggregability O O

A O O
chemically O O
similar O O
drug O O
in O O
this O O
class O O
produced O O
optic O O
nerve O O
degeneration O O
( O O
Wallerian O O
degeneration O O
of O O
retinogeniculate O O
fibers O O
) O O
in O O
clinically O O
normal O O
dogs O O
in O O
a O O
dose O O
- O O
dependent O O
fashion O O
at O O
a O O
dose O O
that O O
produced O O
plasma O O
drug O O
levels O O
about O O
9 O O
times O O
higher O O
than O O
the O O
mean O O
drug O O
level O O
in O O
humans O O
taking O O
the O O
highest O O
recommended O O
dose O O
. O O

Caution O O
should O O
be O O
exercised O O
if O O
an O O
HMG B-Group B-Group
- O O
CoA B-Group B-Group
reductase I-Group I-Group
inhibitor I-Group I-Group
is O O
administered O O
concomitantly O O
with O O
drugs O O
that O O
may O O
decrease O O
the O O
levels O O
or O O
activity O O
of O O
endogenous O O
steroid O O
hormones O O
such O O
as O O
ketoconazole B-Drug B-Drug
spironolactone B-Drug B-Drug
and O O
cimetidine B-Drug B-Drug
. O O

Some O O
quinolones B-Group B-Group
have O O
also O O
been O O
shown O O
to O O
interfere O O
with O O
the O O
metabolism O O
of O O
caffeine B-Drug B-Drug
. O O

Therefore O O
hormonal B-Group B-Group
contraceptives I-Group I-Group
including O O
oral O O
injectable O O
transdermal O O
and O O
implantable O O
forms O O
may O O
not O O
be O O
reliable O O
when O O
TRACLEER B-Brand B-Brand
is O O
co O O
- O O
administered O O
. O O

No O O
teratogenic O O
effects O O
were O O
seen O O
in O O
the O O
offspring O O
delivered O O
at O O
term O O
. O O

Combined O O
effects O O
may O O
induce O O
serious O O
cardiac O O
arrhythmias O O
. O O

This O O
is O O
especially O O
important O O
for O O
drugs O O
associated O O
with O O
serious O O
toxicity O O
such O O
as O O
other O O
antiarrhythmics B-Group B-Group
. O O

A O O
9 O O
( O O
9 O O
) O O
% O O
decrease O O
in O O
the O O
steady O O
- O O
state O O
AUC O O
of O O
ganciclovir B-Drug B-Drug
was O O
observed O O
when O O
VIDEX B-Brand B-Brand
was O O
administered O O
9 O O
hours O O
prior O O
to O O
ganciclovir B-Drug B-Drug
but O O
not O O
when O O
the O O
two O O
drugs O O
were O O
administered O O
simultaneously O O
( O O
n O O
= O O
9 O O
) O O
. O O

Diuretic B-Group B-Group
agents I-Group I-Group
reduce O O
the O O
renal O O
clearance O O
of O O
lithium B-Drug B-Drug
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-Drug O
toxicity O O
. O O

There O O
is O O
one O O
reported O O
case O O
of O O
a O O
patient O O
with O O
acute O O
delirium O O
associated O O
with O O
the O O
simultaneous O O
use O O
of O O
fluphenazine B-Drug B-Drug
and O O
oral O O
clonidine B-Drug B-Drug
. O O

Studies O O
to O O
evaluate O O
potential O O
interactions O O
of O O
terfenadine B-Drug B-Drug
with O O
azithromycin B-Drug B-Drug
are O O
in O O
progress O O
. O O

Testicular O O
atrophy O O
was O O
seen O O
with O O
dexrazoxane B-Drug B-Drug
administration O O
at O O
doses O O
as O O
low O O
as O O
9 O O
mg O O
/ O O
kg O O
weekly O O
for O O
9 O O
weeks O O
in O O
rats O O
( O O
9 O O
/ O O
9 O O
the O O
human O O
dose O O
on O O
a O O
mg O O
/ O O
m O O
9 O O
basis O O
) O O
and O O
as O O
low O O
as O O
9 O O
mg O O
/ O O
kg O O
weekly O O
for O O
9 O O
weeks O O
in O O
dogs O O
( O O
approximately O O
equal O O
to O O
the O O
human O O
dose O O
on O O
a O O
mg O O
/ O O
m O O
9 O O
basis O O
) O O
. O O

Drugs O O
Metabolized O O
by O O
P9 O O
9D9 O O
: O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P9 O O
9D9 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
Caucasian O O
population O O
( O O
about O O
9 O O
- O O
9 O O
% O O
of O O
Caucasians O O
are O O
so O O
- O O
called O O
poor O O
metabolizers O O
) O O
; O O

Drugs O O
which O O
may O O
enhance O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
TRACRIUM B-Brand B-Brand
include O O
: O O
enflurane B-Drug B-Drug
; O O
isoflurane B-Drug B-Drug
; O O
halothane B-Drug B-Drug
; O O
certain O O
antibiotics B-Group B-Group
especially O O
the O O
aminoglycosides B-Group B-Group
and O O
polymyxins B-Group B-Group
; O O
lithium B-Drug B-Drug
; O O
magnesium B-Drug B-Drug
salts O O
; O O
procainamide B-Drug B-Drug
; O O
and O O
quinidine B-Drug B-Drug
. O O

( O O
SGOT O O
) O O
ALT O O
( O O
SGPT O O
) O O

Examples O O
of O O
Drugs O O
in O O
Which O O
Plasma O O
Concentrations O O
May O O
Be O O
Decreased O O
By O O
Co O O
- O O
administration O O
With O O
Nevirapine B-Drug B-Drug

Dosages O O
of O O
concomitantly O O
administered O O
opioids B-Group B-Group
should O O
be O O
reduced O O
by O O
approximately O O
half O O
because O O
levomepromazine B-Drug B-Drug
amplifies O O
the O O
therapeutic O O
actions O O
and O O
side O O
- O O
effects O O
of O O
opioids B-Group B-Group
. O O

Certain O O
antibiotic B-Group B-Group
cisplatin B-Drug B-Drug
cyclosporine B-Drug B-Drug
diuretic B-Group B-Group
foscarnet B-Drug B-Drug
and O O
vaccines B-Group B-Group
. O O

Unfortunately O O
folic B-Drug B-Drug
acid I-Drug I-Drug
will O O
not O O
correct O O
changes O O
in O O
the O O
nervous O O
system O O
that O O
result O O
from O O
vitamin O O
B9 O O
deficiency O O
. O O

the O O
disulfiram B-Drug B-Drug
should O O
be O O
discontinued O O
if O O
such O O
signs O O
appear O O
. O O

Exert O O
particular O O
caution O O
in O O
combining O O
chlorprothixene B-Drug B-Drug
with O O
other O O
anticholinergic B-Group B-Group
drugs I-Group I-Group
( O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
and O O
antiparkinsonian B-Group B-Group
agents I-Group I-Group
) O O
: O O
Particularly O O
the O O
elderly O O
may O O
develop O O
delirium O O
high O O
fever O O
severe O O
obstipation O O
even O O
ileus O O
and O O
glaucoma O O
. O O

Read O O
circulars O O
for O O
lithium B-Drug B-Drug
preparations O O
before O O
use O O
of O O
such O O
concomitant O O
therapy O O
. O O

antacids B-Group B-Group
after O O
meals O O
. O O

Because O O
Nalfon B-Brand B-Brand
has O O
not O O
been O O
shown O O
to O O
produce O O
any O O
additional O O
effect O O
beyond O O
that O O
obtained O O
with O O
aspirin B-Brand B-Brand
alone O O
and O O
because O O
aspirin B-Brand B-Brand
increases O O
the O O
rate O O
of O O
excretion O O
of O O
Nalfon B-Brand B-Brand
the O O
concomitant O O
use O O
of O O
Nalfon B-Brand B-Brand
and O O
salicylates B-Group B-Group
is O O
not O O
recommended O O
. O O

Concomitant O O
administration O O
of O O
Norpace B-Brand B-Brand
and O O
quinidine B-Drug B-Drug
resulted O O
in O O
slight O O
increases O O
in O O
plasma O O
disopyramide B-Drug B-Drug
levels O O
and O O
slight O O
decreases O O
in O O
plasma O O
quinidine B-Drug B-Drug
levels O O
. O O

- O O
Increased O O
serum O O
triglyceride O O
and O O
phospholipid O O
concentration O O
. O O

9 O O
. O O

Nine O O
additional O O
patients O O
who O O
had O O
initial O O
positive O O
tests O O
were O O
negative O O
on O O
repeat O O
testing O O
. O O

Restoration O O
of O O
female O O
fertility O O
to O O
values O O
similar O O
to O O
controls O O
was O O
evident O O
following O O
a O O
9 O O
- O O
day O O
withdrawal O O
period O O
after O O
dosing O O
at O O
9 O O
mg O O
/ O O
kg O O
/ O O
day O O
( O O
twice O O
the O O
human O O
dose O O
based O O
on O O
BSA O O
) O O
. O O

however O O
as O O
with O O
other O O
NSAIDs B-Group B-Group
concomitant O O
administration O O
of O O
Lodine B-Brand B-Brand
and O O
aspirin B-Brand B-Brand
is O O
not O O
generally O O
recommended O O
because O O
of O O
the O O
potential O O
of O O
increased O O
adverse O O
effects O O
. O O

one O O
- O O
half O O
the O O
human O O
dose O O
on O O
BSA O O
) O O
when O O
administered O O
during O O
the O O
period O O
of O O
organogenesis O O
. O O

In O O
a O O
ten O O
- O O
subject O O
study O O
coadministration O O
of O O
diltiazem B-Drug B-Drug
( O O
9 O O
mg O O
bid O O
) O O
with O O
lovastatin B-Drug B-Drug
resulted O O
in O O
a O O
9 O O
- O O
9 O O
times O O
increase O O
in O O
mean O O
lovastatin B-Drug B-Drug
AUC O O
and O O
Cmax O O
vs. O O
lovastatin B-Drug B-Drug
alone O O
; O O

Both O O
digoxin B-Drug B-Drug
and O O
COREG B-Brand B-Brand
slow O O
AV O O
conduction O O
. O O

this O O
did O O
not O O
interfere O O
with O O
its O O
effect O O
. O O

Administration O O
of O O
ELLENCE B-Brand B-Brand
after O O
previous O O
radiation O O
therapy O O
may O O
induce O O
an O O
inflammatory O O
recall O O
reaction O O
at O O
the O O
site O O
of O O
the O O
irradiation O O
. O O

Itraconazole B-Drug B-Drug
: O O
Torsades O O
de O O
pointes O O
and O O
elevated O O
parent O O
terfenadine B-Drug B-Drug
levels O O
have O O
been O O
reported O O
during O O
concomitant O O
use O O
of O O
terfenadine B-Drug B-Drug
and O O
itraconazole B-Drug B-Drug
in O O
clinical O O
trials O O
of O O
itraconazole B-Drug B-Drug
and O O
from O O
foreign O O
post O O
- O O
marketing O O
sources O O
. O O

Fenofibrate B-Drug B-Drug
: O O
In O O
a O O
pharmacokinetic O O
study O O
concomitant O O
fenofibrate B-Drug B-Drug
administration O O
increased O O
total O O
ezetimibe B-Drug B-Drug
concentrations O O
approximately O O
9 O O
- O O
fold O O
. O O

Fluoxetine B-Drug B-Drug

The O O
effectiveness O O
of O O
progestin B-Group B-Group
- O O
only O O
pills O O
is O O
reduced O O
by O O
hepatic O O
enzyme O O
- O O
inducing O O
drugs O O
such O O
as O O
the O O
anticonvulsants B-Group B-Group
phenytoin B-Drug B-Drug
carbamazepine B-Drug B-Drug
and O O
barbiturates B-Group B-Group
and O O
the O O
antituberculosis B-Group O
drug I-Group O
rifampin B-Drug B-Drug
. O O

Laboratory O O
Tests O O
The O O
pathologist O O
should O O
be O O
advised O O
of O O
progestin O O
therapy O O
when O O
relevant O O
specimens O O
are O O
submitted O O
. O O

It O O
is O O
recommended O O
that O O
Myfortic B-Drug B-Brand
and O O
antacids B-Group B-Group
not O O
be O O
administered O O
simultaneously O O
. O O

Drugs O O
That O O
Induce O O
CYP9A9 O O
Rifampin B-Drug B-Drug
: O O
CYP9A9 O O
is O O
ordinarily O O
a O O
minor O O
metabolizing O O
enzyme O O
of O O
zaleplon B-Drug B-Drug
. O O

- O O
Androgens B-Group B-Group
( O O
male O O
hormones O O
) O O
or O O

Warfarin B-Drug B-Drug
Digoxin B-Drug B-Drug
Salicylate B-Group B-Group
and O O
Heparin B-Drug B-Drug
The O O
in O O
vitro O O
binding O O
of O O
warfarin B-Drug B-Drug
to O O
plasma O O
proteins O O
is O O
only O O
slightly O O
reduced O O
by O O
ketorolac B-Drug B-Drug
tromethamine I-Drug I-Drug
( O O
9 O O
% O O
control O O
vs O O
9 O O
% O O
) O O
when O O
ketorolac B-Drug B-Drug
plasma O O
concentrations O O
reach O O
9 O O
to9 O O
m O O
g O O
/ O O
mL O O
. O O

Clinically O O
significant O O
effects O O
have O O
been O O
reported O O
with O O
the O O
tricyclic B-Drug B-Group
antidepressants I-Drug I-Group
when O O
used O O
concomitantly O O
with O O
cimetidine B-Drug B-Drug
. O O

Rifampin B-Drug B-Drug
: O O
Rifampin B-Drug B-Drug
enhances O O
the O O
metabolism O O
of O O
concurrently O O
administered O O
DIFLUCAN B-Brand B-Brand
. O O

Phenobarbital B-Drug B-Drug
: O O
It O O
appears O O
that O O
phenobarbital B-Drug B-Drug
may O O
reduce O O
plasma O O
felbamate B-Drug B-Drug
concentrations O O
. O O

DEA O O
concentrations O O
were O O
not O O
affected O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
unknown O O
. O O

If O O
the O O
TARCEVA B-Brand B-Brand
dose O O
is O O
adjusted O O
upward O O
the O O
dose O O
will O O
need O O
to O O
be O O
reduced O O
upon O O
discontinuation O O
of O O
rifampicin B-Drug B-Drug
or O O
other O O
inducers O O
. O O

Carcinogenesis O O
Mutagenesis O O
Impairment O O
of O O
Fertility O O
A O O
9 O O
- O O
week O O
dietary O O
carcinogenicity O O
study O O
with O O
ezetimibe B-Drug B-Drug
was O O
conducted O O
in O O
rats O O
at O O
doses O O
up O O
to O O
9 O O
mg O O
/ O O
kg O O
/ O O
day O O
( O O
males O O
) O O
and O O
9 O O
mg O O
/ O O
kg O O
/ O O
day O O
( O O
females O O
) O O
( O O
~9 O O
times O O
the O O
human O O
exposure O O
at O O
9 O O
mg O O
daily O O
based O O
on O O
AUC9 O O
- O O
9hr O O
for O O
total O O
ezetimibe B-Drug B-Drug
) O O
. O O

It O O
is O O
recommended O O
that O O
serum O O
lithium B-Drug B-Drug
levels O O
be O O
monitored O O
frequently O O
if O O
PRINIVIL B-Brand B-Brand
is O O
administered O O
concomitantly O O
with O O
lithium B-Drug B-Drug
. O O

RESPIRATORY O O
DEPRESSION O O
HYPOTENSION O O
AND O O
PROFOUND O O
SEDATION O O
OR O O
COMA O O
MAY O O
RESULT O O
. O O

prolonged O O
hot O O
weather O O
; O O

The O O
appropriate O O
interval O O
between O O
administration O O
of O O
these O O
agents O O
and O O
dexfenfluramine B-Drug B-Drug
has O O
not O O
been O O
established O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
INDOCIN B-Brand B-Brand
and O O
anticoagulants B-Group B-Group
are O O
administered O O
concomitantly O O
. O O

Also O O
the O O
potential O O
for O O
hepatic O O
injury O O
should O O
be O O
considered O O
when O O
Rebif B-Brand B-Brand
is O O
used O O
in O O
combination O O
with O O
other O O
products O O
associated O O
with O O
hepatic O O
injury O O
or O O
when O O
new O O
agents O O
are O O
added O O
to O O
the O O
regimen O O
of O O
patients O O
already O O
on O O
Rebif B-Brand B-Brand
. O O

FORADIL B-Brand B-Brand
should O O
not O O
be O O
used O O
as O O
a O O
substitute O O
for O O
oral O O
or O O
inhaled O O
corticosteroids B-Group B-Group
. O O

. O O

metronidazole B-Drug B-Drug
; O O

Preliminary O O
animal O O
and O O
human O O
studies O O
have O O
shown O O
that O O
small O O
quantities O O
of O O
systemically O O
administered O O
leucovorin B-Drug B-Drug
enter O O
the O O
CSF O O
primarily O O
as O O
9 O O
- O O
methyltetrahydro O O
- O O
folate O O
and O O
in O O
humans O O
remain O O
9 O O
to O O
9 O O
orders O O
of O O
magnitude O O
lower O O
than O O
the O O
usual O O
methotrexate B-Drug B-Drug
concentrations O O
following O O
intrathecal O O
administration O O
. O O

These O O
individuals O O
may O O
have O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
when O O
given O O
usual O O
doses O O
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P9 O O
9D9 O O
isozyme O O
activity O O
among O O
Asian O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

Absorption O O
of O O
tetracyclines B-Group B-Group
is O O
impaired O O
by O O
antacids B-Group B-Group
containing O O
aluminum B-Drug B-Drug
calcium B-Drug B-Drug
or O O
magnesium B-Drug B-Drug
and O O
iron B-Drug B-Drug
- O O
containing O O
preparations O O
. O O

Aprepitant B-Drug B-Drug
is O O
unlikely O O
to O O
interact O O
with O O
drugs O O
that O O
are O O
substrates O O
for O O
the O O
P O O
- O O
glycoprotein O O
transporter O O
as O O
demonstrated O O
by O O
the O O
lack O O
of O O
interaction O O
of O O
Aprepitant B-Drug B-Drug
with O O
digoxin B-Drug B-Drug
in O O
a O O
clinical O O
drug O O
interaction O O
study O O
. O O

The O O
concurrent O O
use O O
of O O
TORADOL B-Brand B-Brand
with O O
muscle B-Group B-Group
relaxants I-Group I-Group
has O O
not O O
been O O
formally O O
studied O O
. O O

Other O O
short B-Group B-Group
- O O
acting B-Group B-Group
beta I-Group I-Group
adrenergic I-Group I-Group
aerosol I-Group I-Group
bronchodilators I-Group I-Group
should O O
not O O
be O O
used O O
concomitantly O O
with O O
MAXAIR B-Brand B-Brand
AUTOHALER I-Brand B-Brand
because O O
they O O
may O O
have O O
additive O O
effects O O
. O O

Concomitant O O
administration O O
of O O
itraconazole B-Drug B-Drug
and O O
terfenadine B-Drug B-Drug
is O O
contraindicated O O
. O O

These O O
drugs O O
should O O
not O O
be O O
given O O
concomitantly O O
. O O

NOTE O O
: O O
Do O O
not O O
use O O
the O O
injection O O
if O O
it O O
contains O O
precipitate O O
. O O

Theophylline B-Drug B-Drug
- O O
Combined O O
administration O O
of O O
racemic O O
citalopram B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
day O O
for O O
9 O O
days O O
) O O
and O O
the O O
CYP9A9 O O
substrate O O
theophylline B-Drug B-Drug
( O O
single O O
dose O O
of O O
9 O O
mg O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
theophylline B-Drug B-Drug
. O O

Although O O
erythromycin O B-Drug
measurably O O
decreases O O
the O O
clearance O O
of O O
the O O
terfenadine B-Drug B-Drug
acid O I-Drug
metabolite O O
its O O
influence O O
on O O
terfenadine O B-Drug
plasma O O
levels O O
is O O
still O O
under O O
investigation O O
. O O

The O O
clinical O O
significance O O
if O O
any O O
of O O
these O O
observations O O
is O O
unknown O O
. O O

Drugs O O
Metabolized O O
by O O
P9 O O
9D9 O O
: O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P9 O O
9D9 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
caucasian O O
population O O
( O O
about O O
9 O O
to O O
9 O O
% O O
of O O
caucasians O O
are O O
so O O
called O O
poor O O
metabolizers O O
) O O
; O O

Ibuprofen B-Drug B-Drug
- O O
L B-Drug B-Drug
- O O
arginine B-Drug B-Drug
may O O
increase O O
the O O
absorption O O
of O O
ibuprofen B-Drug B-Drug
if O O
taken O O
concomitantly O O
. O O

Other O O
binding O O
proteins O O
may O O
be O O
elevated O O
in O O
serum O O
( O O
i.e. O O
corticosteroid O O
binding O O
globulin O O
( O O
CBG O O
) O O
sex O O
hormone O O
binding O O
globulin O O
( O O
SHBG O O
) O O
) O O
leading O O
to O O
increased O O
total O O
circulating O O
corticosteroids B-Group B-Group
and O O
sex B-Group B-Group
steroids I-Group I-Group
respectively O O
. O O

Drugs O O
that O O
raise O O
the O O
gastrointestinal O O
pH O O
may O O
lead O O
to O O
an O O
earlier O O
release O O
of O O
duloxetine B-Drug B-Drug
. O O

Mixing O O
of O O
Insulins B-Group O

FLUOTHANE B-Brand B-Brand
may O O
augment O O
the O O
hypotension O O
caused O O
by O O
the O O
ganglionic O O
- O O
blocking O O
effect O O
of O O
tubocurarine B-Drug B-Drug
. O O

Therefore O O
precaution O O
should O O
be O O
taken O O
when O O
coadministration O O
is O O
necessary O O
. O O

Cimetidine B-Drug B-Drug
- O O
In O O
subjects O O
who O O
had O O
received O O
9 O O
days O O
of O O
9 O O
mg O O
/ O O
day O O
racemic O O
citalopram B-Drug B-Drug
combined O O
administration O O
of O O
9 O O
mg O O
/ O O
day O O
cimetidine B-Drug B-Drug
for O O
9 O O
days O O
resulted O O
in O O
an O O
increase O O
in O O
citalopram B-Drug B-Drug
AUC O O
and O O
Cmax O O
of O O
9 O O
% O O
and O O
9 O O
% O O
respectively O O
. O O

Each O O
month O O
of O O
therapy O O
the O O
patient O O
must O O
have O O
a O O
negative O O
result O O
from O O
a O O
urine O O
or O O
serum O O
pregnancy O O
test O O
. O O

Other O O
serious O O
reactions O O
( O O
including O O
severe O O
agitation O O
hallucinations O O
and O O
death O O
) O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
this O O
combination O O
. O O

This O O
may O O
adversely O O
affect O O
blood O O
pressure O O
control O O
in O O
patients O O
treated O O
with O O
methyldopa B-Drug B-Drug
. O O

Dasatinib B-Drug B-Drug
and O O
its O O
metabolites O O
are O O
minimally O O
excreted O O
via O O
the O O
kidney O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
unknown O O
; O O

No O O
inhibition O O
of O O
any O O
of O O
the O O
other O O
isoforms O O
tested O O
was O O
observed O O
at O O
gabapentin B-Drug B-Drug
concentrations O O
up O O
to O O
9 O O
mg O O
/ O O
mL O O
( O O
approximately O O
9 O O
times O O
the O O
Cmax O O
at O O
9 O O
mg O O
/ O O
day O O
) O O
. O O

ACE B-Group B-Group
- O O
inhibitors B-Group B-Group
: O O
Reports O O
suggest O O
that O O
NSAIDs B-Group B-Group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
ACE B-Group B-Group
- O O
inhibitors B-Group B-Group
. O O

In O O
clinical O O
trials O O
in O O
patients O O
undergoing O O
PTCA O O
/ O O
PCI O O
co O O
- O O
administration O O
of O O
Angiomax B-Brand B-Brand
with O O
heparin B-Drug B-Drug
warfarin B-Drug B-Drug
thrombolytics B-Group B-Group
or O O
glycoprotein O O
IIb O O
/ O O
IIIa O O
inhibitors O O
was O O
associated O O
with O O
increased O O
risks O O
of O O
major O O
bleeding O O
events O O
compared O O
to O O
patients O O
not O O
receiving O O
these O O
concomitant O O
medications O O
. O O

In O O
addition O O
there O O
was O O
no O O
evidence O O
of O O
genotoxicity O O
in O O
the O O
in O O
vivo O O
mouse O O
micronucleus O O
test O O
. O O

If O O
a O O
patient O O
has O O
been O O
treated O O
with O O
cyclophosphamide B-Drug B-Drug
within O O
9 O O
days O O
of O O
general O O
anesthesia O O
the O O
anesthesiologist O O
should O O
be O O
alerted O O
. O O

However O O
it O O
was O O
observed O O
that O O
the O O
pharmacokinetics O O
of O O
ENBREL B-Brand B-Brand
was O O
unaltered O O
by O O
concomitant O O
methotrexate B-Drug B-Drug
in O O
rheumatoid O O
arthritis O O
patients O O
. O O

In O O
addition O O
to O O
established O O
drug O O
interactions O O
there O O
may O O
be O O
potential O O
pharmacokinetic O O
interactions O O
between O O
nevirapine B-Drug B-Drug
and O O
other O O
drug O O
classes O O
that O O
are O O
metabolized O O
by O O
the O O
cytochrome O O
P9 O O
system O O
. O O

If O O
short B-Group B-Group
- O O
acting B-Group B-Group
benzodiazepines I-Group I-Group
which O O
are O O
metabolized O O
by O O
the O O
cytochrome O O
P9 O O
system O O
are O O
concomitantly O O
administered O O
with O O
fluconazole B-Drug B-Drug
consideration O O
should O O
be O O
given O O
to O O
decreasing O O
the O O
benzodiazepine B-Group B-Group
dosage O O
and O O
the O O
patients O O
should O O
be O O
appropriately O O
monitored O O
. O O

Ritonavir B-Drug B-Drug
( O O
9 O O
mg O O
b.i.d O O
. O O
) O O
co O O
- O O
administered O O
with O O
Vardenafil B-Drug B-Drug
9 O O
mg O O
resulted O O
in O O
a O O
9 O O
- O O
fold O O
increase O O
in O O
vardenafil B-Drug B-Drug
AUC O O
and O O
a O O
9 O O
- O O
fold O O
increase O O
in O O
vardenafil B-Drug B-Drug
Cmax O O
. O O

Beta B-Group B-Group
- O O
adrenergic B-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
: O O
concurrent O O
use O O
may O O
blunt O O
the O O
response O O
to O O
arbutamine B-Drug B-Drug
. O O

Concomitant O O
administration O O
of O O
Targretin B-Brand O
capsules O O
and O O
gemfibrozil B-Drug B-Drug
resulted O O
in O O
substantial O O
increases O O
in O O
plasma O O
concentrations O O
of O O
bexarotene B-Drug B-Drug
probably O O
at O O
least O O
partially O O
related O O
to O O
cytochrome O O
P9 O O
9A9 O O
inhibition O O
by O O
gemfibrozil B-Drug B-Drug
. O O

Histamine B-Group B-Group
H9 I-Group I-Group
- O O
receptor B-Group B-Group
antagonists I-Group I-Group
: O O
Histamine B-Group B-Group
H9 I-Group I-Group
- O O
receptor B-Group B-Group
antagonists I-Group I-Group
appear O O
to O O
have O O
no O O
significant O O
effect O O
on O O
the O O
bioavailability O O
of O O
ciprofloxacin B-Drug B-Drug
. O O

Patients O O
receiving O O
these O O
drugs O O
who O O
are O O
given O O
Lodine B-Brand B-Brand
or O O
any O O
other O O
NSAID B-Group B-Group
and O O
particularly O O
those O O
patients O O
with O O
altered O O
renal O O
function O O
should O O
be O O
observed O O
for O O
the O O
development O O
of O O
the O O
specific O O
toxicities O O
of O O
these O O
drugs O O
. O O

The O O
principal O O
drugs O O
given O O
( O O
number O O
of O O
patients O O
in O O
parentheses O O
) O O
were O O
: O O
cardiac B-Group B-Group
glycosides I-Group I-Group
( O O
9 O O
) O O
sedatives B-Group B-Group
and O O
hypnotics B-Group B-Group
( O O
9 O O
) O O
coronary B-Group O
vasodilators I-Group B-Group
( O O
9 O O
) O O
oral O O
hypoglycemics B-Group B-Group
( O O
9 O O
) O O
cough O O
and O O
cold O O
preparations O O
( O O
9 O O
) O O
NSAIDs B-Group B-Group
( O O
9 O O
) O O
antihyperlipidemics B-Group O
( O O
9 O O
) O O
antigout B-Group O
drugs I-Group O
( O O
9 O O
) O O
oral O O
contraceptives B-Group B-Group
( O O
9 O O
) O O
bronchodilators B-Group B-Group
( O O
9 O O
) O O
insulin B-Drug B-Drug
( O O
9 O O
) O O
and O O
beta B-Group B-Group
blockers I-Group I-Group
( O O
9 O O
) O O
. O O

Finasteride B-Drug B-Drug
does O O
not O O
appear O O
to O O
affect O O
the O O
cytochrome O O
P9 O O
- O O
linked O O
drug O O
- O O
metabolizing O O
enzyme O O
system O O
. O O

Coadministration O O
of O O
VIRACEPT B-Brand B-Brand
and O O
drugs O O
that O O
inhibit O O
CYP9A O O
may O O
increase O O
nelfinavir B-Drug B-Drug
plasma O O
concentrations O O
. O O

Influence O O
of O O
Trileptal B-Brand B-Brand
on O O
AED B-Group B-Group
Concentration O O
( O O
Mean O O
change O O
9 O O
% O O
Confidence O O
Interval O O
) O O

Other O O
binding O O
proteins O O
may O O
be O O
elevated O O
in O O
serum O O
i.e. O O
corticosteroid O O
binding O O
globulin O O
( O O
CBG O O
) O O
sex O O
hormone O O
- O O
binding O O
globulin O O
( O O
SHBG O O
) O O
leading O O
to O O
increased O O
total O O
circulating O O
corticosteroids B-Group B-Group
and O O
sex B-Group O
steroids I-Group O
respectively O O
. O O

Ketoconazole B-Drug B-Drug
( O O
9 O O
mg O O
once O O
daily O O
) O O

Patients O O
on O O
warfarin B-Group B-Drug
- O O
type B-Group B-Group
anticoagulant I-Group I-Group
therapy O O
may O O
require O O
dosage O O
adjustment O O
of O O
the O O
anticoagulant O B-Group
during O O
and O O
after O O
griseofulvin B-Drug B-Drug
therapy O O
. O O

cardiovascular O O
effects O O
can O O
be O O
potentiated O O
. O O

Ketoconazole B-Drug B-Drug
: O O
When O O
a O O
single O O
9 O O
- O O
mg O O
dose O O
of O O
Aprepitant B-Drug B-Drug
was O O
administered O O
on O O
Day9 O O
of O O
a O O
9 O O
- O O
day O O
regimen O O
of O O
9 O O
mg O O
/ O O
day O O
of O O
ketoconazole B-Drug B-Drug
a O O
strong O O
CYP9A9 O O
inhibitor O O
the O O
AUC O O
of O O
aprepitant B-Drug B-Drug
increased O O
approximately O O
9 O O
- O O
fold O O
and O O
the O O
mean O O
terminal O O
half O O
- O O
life O O
of O O
aprepitant B-Drug B-Drug
increased O O
approximately O O
9 O O
- O O
fold O O
. O O

Warfarin B-Drug B-Drug
: O O
The O O
effects O O
of O O
warfarin B-Drug B-Drug
and O O
NSAIDs B-Group B-Group
on O O
GI O O
bleeding O O
are O O
synergistic O O
such O O
that O O
users O O
of O O
both O O
drugs O O
together O O
have O O
a O O
risk O O
of O O
serious O O
GI O O
bleeding O O
higher O O
than O O
that O O
of O O
users O O
of O O
either O O
drug O O
alone O O
. O O

Furosemide B-Drug B-Drug
: O O
Clinical O O
studies O O
as O O
well O O
as O O
post O O
- O O
marketing O O
observations O O
have O O
shown O O
that O O
NSAIDs B-Group B-Group
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-Drug B-Drug
and O O
thiazides B-Group B-Group
in O O
some O O
patients O O
. O O

Similarly O O
patients O O
receiving O O
the O O
drug O O
and O O
a O O
hydantoin B-Group B-Group
sulfonamide B-Group I-Group
or O O
sulfonylurea B-Group B-Drug
should O O
be O O
observed O O
for O O
signs O O
of O O
toxicity O O
to O O
these O O
drugs O O
. O O

Drug O O
/ O O
Laboratory O O
Interactions O O
No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
with O O
Campath B-Brand B-Brand
. O O

Monitor O O
cardiovascular O O
status O O
. O O

Pimozide B-Drug B-Drug
and O O
Celexa B-Brand B-Brand
- O O
In O O
a O O
controlled O O
study O O
a O O
single O O
dose O O
of O O
pimozide B-Drug B-Drug
9 O O
mg O O
co O O
- O O
administered O O
with O O
racemic O O
citalopram B-Drug B-Drug
9 O O
mg O O
given O O
once O O
daily O O
for O O
9 O O
days O O
was O O
associated O O
with O O
a O O
mean O O
increase O O
in O O
QTc O O
values O O
of O O
approximately O O
9 O O
msec O O
compared O O
to O O
pimozide B-Drug B-Drug
given O O
alone O O
. O O

Epidural O O
clonidine B-Drug B-Drug
may O O
prolong O O
the O O
duration O O
of O O
pharmacologic O O
effects O O
of O O
epidural O O
local O O
anesthetics B-Group B-Group
including O O
both O O
sensory O O
and O O
motor O O
blockade O O
. O O

Short B-Group B-Group
- O O
acting B-Group B-Group
Benzodiazepines I-Group I-Group
: O O
Following O O
oral O O
administration O O
of O O
midazolam B-Drug B-Drug
fluconazole B-Drug B-Drug
resulted O O
in O O
substantial O O
increases O O
in O O
midazolam B-Drug B-Drug
concentrations O O
and O O
psychomotor O O
effects O O
. O O

increased O O
levels O O
of O O
fibrinogen B-Drug O
and O O
fibrinogen B-Drug O
activity O O
; O O

The O O
following O O
are O O
examples O O
of O O
substances O O
that O O
may O O
increase O O
the O O
blood O O
- O O
glucose O O
- O O
lowering O O
effect O O
and O O
susceptibility O O
to O O
hypoglycemia O O
: O O
oral O O
antidiabetes O O
products O O
ACE B-Group B-Group
inhibitors I-Group I-Group
disopyramide B-Drug B-Drug
fibrates B-Group B-Group
fluoxetine B-Drug B-Group
MAO B-Group I-Group
inhibitors I-Group I-Group
propoxyphene B-Drug B-Drug
salicylates B-Group B-Group
somatostatin B-Group B-Group
analog I-Group I-Group
( O O
e.g. O O
octreotide B-Drug B-Drug
) O O
sulfonamide B-Group B-Group
antibiotics I-Group I-Group
. O O

Extended O O
Release O O
Tablets O O
: O O
Administration O O
of O O
nifedipine B-Drug B-Drug
with O O
digoxin B-Drug B-Drug
increased O O
digoxin B-Drug B-Drug
levels O O
in O O
9 O O
of O O
9 O O
normal O O
volunteers O O
. O O

When O O
carbamazepine B-Drug B-Drug
is O O
withdrawn O O
from O O
the O O
combination O O
therapy O O
aripiprazole B-Drug B-Drug
dose O O
should O O
then O O
be O O
reduced O O
. O O

Nephrotoxic O B-Group
agents O I-Group
: O O
Concomitant O O
administration O O
of O O
VISTIDE B-Brand B-Brand
and O O
agents O O
with O O
nephrotoxic O O
potential O O
[ O O
e.g. O O
intravenous O O
aminoglycosides B-Group B-Group
( O O
e.g. O O
tobramycin B-Drug B-Drug
gentamicin B-Drug B-Drug
and O O
amikacin B-Drug B-Drug
) O O
amphotericin B-Drug B-Drug
B I-Drug I-Drug
foscarnet B-Drug B-Drug
intravenous O O
pentamidine B-Drug B-Drug
vancomycin B-Drug B-Drug
and O O
non B-Group B-Group
- O O
steroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
agents I-Group I-Group
] O O
is O O
contraindicated O O
. O O

propranolol B-Drug B-Drug
to O O
healthy O O
volunteers O O
under O O
steady O O
- O O
state O O
conditions O O
had O O
no O O
relevant O O
effect O O
on O O
either O O
drug O O
bioavailability O O
AUC O O
and O O
Cmax O O
differences O O
were O O
9 O O
% O O
between O O
isradipine B-Drug B-Drug
given O O
singly O O
and O O
in O O
combination O O
with O O
propranolol B-Drug B-Drug
and O O
between O O
propranolol B-Drug B-Drug
given O O
singly O O
and O O
in O O
combination O O
with O O
isradipine B-Drug B-Drug
. O O

Cross O O
- O O
reactions O O
with O O
non O O
- O O
Aspergillus O O
polysaccharides O O
and O O
polyfuranoses O O
with O O
the O O
Bio O O
- O O
Rad O O
Laboratories O O
Platelia O O
Aspergillus O O
EIA O O
test O O
have O O
been O O
reported O O
. O O

However O O
since O O
aspirin B-Brand B-Brand
NSAIDs B-Group B-Group
and O O
bisphosphonates B-Group B-Group
are O O
all O O
associated O O
with O O
gastrointestinal O O
irritation O O
caution O O
should O O
be O O
exercised O O
in O O
the O O
concomitant O O
use O O
of O O
aspirin B-Brand B-Brand
or O O
NSAIDs B-Group B-Group
with O O
Ibandronate B-Drug B-Drug
. O O

**No O O
significant O O
effect O O
. O O

Monitoring O O
of O O
cyclosporine B-Drug B-Drug
levels O O
and O O
possible O O
adjustment O O
of O O
cyclosporine B-Drug B-Drug
dosage O O
should O O
be O O
considered O O
when O O
these O O
drugs O O
are O O
co O O
- O O
administered O O
. O O

Dexamethasone O B-Drug
suppression O O
test O O
( O O
DST O O
) O O
: O O
False O O
- O O
negative O O
results O O
in O O
the O O
dexamethasone O O
suppression O O
test O O
( O O
DST O O
) O O
in O O
patients O O
being O O
treated O O
with O O
indomethacin B-Drug B-Drug
have O O
been O O
reported O O
. O O

Exert O O
particular O O
caution O O
in O O
combining O O
levomepromazine B-Drug B-Drug
with O O
other O O
anticholinergic B-Group B-Group
drugs I-Group I-Group
( O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
and O O
antiparkinsonian B-Group B-Group
- O O
agents B-Group O
) O O
: O O
Particularly O O
the O O
elderly O O
may O O
develop O O
delirium O O
high O O
fever O O
severe O O
obstipation O O
even O O
ileus O O
and O O
glaucoma O O
. O O

When O O
such O O
combined O O
therapy O O
is O O
contemplated O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

TAMBOCOR B-Brand B-Brand
has O O
been O O
used O O
in O O
a O O
large O O
number O O
of O O
patients O O
receiving O O
diuretics B-Group B-Group
without O O
apparent O O
interaction O O
. O O

Antacids B-Group B-Group
: O O
Nonclinical O O
data O O
demonstrate O O
that O O
the O O
solubility O O
of O O
dasatinib B-Drug B-Drug
is O O
pH O O
dependent O O
. O O

A O O
reduced O O
Clozapine B-Drug B-Drug
dose O O
should O O
be O O
considered O O
. O O

Due O O
to O O
the O O
frequent O O
occurrence O O
of O O
severe O O
and O O
prolonged O O
thrombocytopenia O O
the O O
potential O O
benefits O O
of O O
medications O O
which O O
interfere O O
with O O
platelet O O
function O O
and O O
/ O O
or O O
anticoagulation O O
should O O
be O O
weighed O O
against O O
the O O
potential O O
increased O O
risks O O
of O O
bleeding O O
and O O
hemorrhage O O
. O O

The O O
absorption O O
of O O
tetracycline B-Drug B-Drug
furosemide B-Drug B-Drug
penicillin B-Drug B-Drug
G I-Drug I-Drug
hydrochlorothiazide B-Drug B-Drug
and O O
gemfibrozil B-Drug B-Drug
was O O
significantly O O
decreased O O
when O O
given O O
simultaneously O O
with O O
colestipol B-Drug B-Drug
hydrochloride I-Drug I-Drug
; O O

Caution O O
should O O
be O O
exercised O O
when O O
administering O O
ETOPOPHOS B-Brand B-Brand
with O O
drugs O O
that O O
are O O
known O O
to O O
inhibit O O
phosphatase O O
activities O O
( O O
e.g. O O
levamisole B-Drug B-Drug
hydrochloride I-Drug I-Drug
) O O
. O O

A O O
false O O
- O O
positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
with O O
copper O O
reduction O O
tests O O
( O O
Benedicts O O
or O O
Fehlings O O
solution O O
or O O
with O O
CLINITEST O O
tablets O O
) O O
but O O
not O O
with O O
enzyme O O
- O O
based O O
tests O O
for O O
glycosuria O O
( O O
e.g. O O
CLINISTIX O O
TES O O
- O O
TAPE O O
) O O
. O O

An O O
initial O O
dose O O
of O O
9 O O
mg O O
should O O
be O O
given O O
to O O
patients O O
who O O
are O O
concomitantly O O
being O O
treated O O
with O O
cimetidine B-Drug B-Drug
. O O

Caution O O
however O O
is O O
advised O O
in O O
patients O O
taking O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
which O O
can O O
affect O O
the O O
metabolism O O
and O O
uptake O O
of O O
circulating O O
amines O O
. O O

Pretreatment O O
and O O
follow O O
- O O
up O O
measurements O O
should O O
be O O
obtained O O
under O O
fasting O O
conditions O O
. O O

Phenobarbital B-Drug B-Drug
: O O
Estimates O O
of O O
steady O O
- O O
state O O
pharmacokinetic O O
parameters O O
for O O
phenobarbital B-Drug B-Drug
or O O
gabapentin B-Drug B-Drug
( O O
9 O O
mg O O
TID O O
; O O

Coadministration O O
of O O
glyburide B-Drug B-Drug
with O O
doses O O
higher O O
than O O
9 O O
mg O O
valdecoxib B-Drug B-Drug
( O O
e.g. O O
9 O O
mg O O
BID O O
) O O
have O O
not O O
been O O
studied O O
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
DIABINESE B-Brand B-Brand
the O O
patient O O
should O O
be O O
closely O O
observed O O
for O O
loss O O
of O O
control O O
. O O

Potassium B-Group B-Group
- O O
sparing B-Group B-Group
diuretics I-Group I-Group
( O O
spironolactone B-Drug B-Drug
amiloride B-Drug B-Drug
triamterene B-Drug B-Drug
and O O
others O O
) O O
or O O
potassium B-Drug B-Drug
supplements O O
can O O
increase O O
the O O
risk O O
of O O
hyperkalemia O O
. O O

clarithromycin B-Drug B-Drug
concentration O O
indinavir B-Drug B-Drug
concentration O O

Coadministration O O
of O O
thioridazine B-Drug B-Drug
has O O
been O O
reported O O
to O O
worsen O O
the O O
tremor O O
in O O
elderly O O
patients O O
with O O
Parkinsons O O
disease O O
; O O

Labetalol B-Drug B-Drug
HCl I-Drug I-Drug
has O O
also O O
been O O
reported O O
to O O
produce O O
a O O
false O O
positive O O
test O O
for O O
amphetamine B-Drug B-Drug
when O O
screening O O
urine O O
for O O
the O O
presence O O
of O O
drugs O O
using O O
the O O
commercially O O
available O O
assay O O
methods O O
Toxi O O
- O O
Lab O O
A O O
( O O
thin O O
- O O
layer O O
chromatographic O O
assay O O
) O O
and O O
Emit O O
- O O
d.a.u O O
. O O
( O O
radioenzymatic O O
assay O O
) O O
. O O

Verapamil B-Drug B-Drug
produced O O
a O O
decrease O O
of O O
9 O O
% O O
[ O O
9 O O
% O O
CI O O
: O O
9 O O
- O O
9 O O
] O O
of O O
the O O
plasma O O
levels O O
of O O
MHD B-Drug_n B-Drug_n
. O O

It O O
is O O
not O O
known O O
if O O
REGRANEX B-Brand B-Brand
Gel O O
interacts O O
with O O
other O O
topical O O
medications O O
applied O O
to O O
the O O
ulcer O O
site O O
. O O

Because O O
the O O
small O O
magnitude O O
and O O
the O O
direction O O
of O O
the O O
effect O O
on O O
theophylline B-Drug B-Drug
clearance O O
this O O
interaction O O
is O O
unlikely O O
to O O
be O O
clinical O O
concern O O
. O O

The O O
following O O
drug O O
interactions O O
were O O
observed O O
in O O
some O O
patients O O
undergoing O O
treatment O O
with O O
oral O O
allopurinol B-Drug B-Drug
. O O

The O O
concurrent O O
use O O
of O O
intravenously O O
or O O
orally O O
administered O O
methylxanthines B-Group B-Group
( O O
e.g. O O
aminophylline B-Drug B-Drug
theophylline B-Drug B-Drug
) O O
by O O
patients O O
receiving O O
BROVANA B-Brand B-Brand
has O O
not O O
been O O
completely O O
evaluated O O
. O O

Plasma O O
valproate B-Drug B-Drug
concentration O O
should O O
be O O
monitored O O
when O O
isoniazid B-Drug B-Drug
and O O
valproate B-Drug B-Drug
are O O
co O O
administered O O
and O O
appropriate O O
dosage O O
adjustments O O
of O O
valproate B-Drug B-Drug
should O O
be O O
made O O
. O O

Aprepitant B-Drug B-Drug
is O O
a O O
substrate O O
a O O
moderate O O
inhibitor O O
and O O
an O O
inducer O O
of O O
CYP9A9 O O
. O O

Steroids B-Group O
enhance O O
the O O
renal O O
toxicity O O
of O O
edetate B-Drug O
calcium I-Drug O
disodium I-Drug O
in O O
animals O O
. O O
9 O O
Edetate B-Drug O
calcium I-Drug O
disodium I-Drug O
interferes O O
with O O
the O O
action O O
of O O
zinc B-Drug B-Drug
insulin I-Drug I-Drug
preparations O O
by O O
chelating O O
the O O
zinc B-Drug B-Drug
. O O
9 O O

When O O
methyldopa B-Drug B-Drug
is O O
used O O
with O O
other O O
antihypertensive B-Group B-Group
drugs I-Group I-Group
potentiation O O
of O O
antihypertensive O O
effect O O
may O O
occur O O
. O O

The O O
effect O O
of O O
digoxin B-Drug B-Drug
on O O
Exjade B-Brand B-Brand
pharmacokinetics O O
has O O
not O O
been O O
studied O O
. O O

Avoid O O
saw O O
palmetto O O
red O O
clover O O
ginseng O O
. O O

Thalidomide B-Drug B-Drug
: O O
Co O O
- O O
administration O O
with O O
thalidomide B-Drug B-Drug
should O O
be O O
employed O O
cautiously O O
as O O
toxic O O
epidermal O O
necrolysis O O
has O O
been O O
reported O O
with O O
concomitant O O
use O O
. O O

one O O
patient O O
died O O
with O O
severe O O
hypocalcemia O O
. O O

Prothrombin O O
time O O
was O O
increased O O
by O O
9 O O
% O O
the O O
clinical O O
significance O O
of O O
which O O
is O O
unknown O O
. O O

Interaction O O
with O O
Other O O
Central B-Group B-Group
Nervous I-Group I-Group
System I-Group I-Group
Depressants I-Group I-Group
: O O
MEPERIDINE B-Drug O
SHOULD O O
BE O O
USED O O
WITH O O
GREAT O O
CAUTION O O
AND O O
IN O O
REDUCED O O
DOSAGE O O
IN O O
PATIENTS O O
WHO O O
ARE O O
CONCURRENTLY O O
RECEIVING O O
OTHER O O
NARCOTIC B-Group B-Group
ANALGESICS I-Group I-Group
GENERAL O O
ANESTHETICS B-Group O
PHENOTHIAZINES B-Group O
OTHER O O
TRANQUILIZERS B-Group O
SEDATIVE B-Group O
- O O
HYPNOTICS B-Group O
( O O
INCLUDING O B-Group
BARBITURATES B-Group I-Group
) O O
TRICYCLIC B-Group B-Group
ANTIDEPRESSANTS I-Group I-Group
AND O O
OTHER O O
CNS B-Group B-Group
DEPRESSANTS I-Group I-Group
( O O
INCLUDING O B-Brand
ALCOHOL B-Drug B-Brand
) O O
. O O

Reduced O O
response O O
to O O
metyrapone O O
test O O
. O O

Methscopolamine B-Drug B-Drug
may O O
interact O O
with O O
antidepressants B-Group B-Group
( O O
tricyclic B-Group B-Group
type O I-Group
) O O
MAO B-Group B-Group
inhibitors I-Group I-Group
( O O
e.g. O O
phenelzine B-Drug B-Drug
linezolid B-Drug B-Drug
tranylcypromine B-Drug B-Drug
isocarboxazid B-Drug B-Drug
selegiline B-Drug B-Drug
furazolidone B-Drug B-Drug
) O O
quinidine B-Drug B-Drug
amantadine B-Drug B-Drug
antihistamines B-Group B-Group
( O O
e.g. O O
diphenhydramine B-Drug B-Drug
) O O
other O O
anticholinergics B-Group B-Group
potassium B-Drug B-Group
chloride I-Drug I-Group
supplements O O
antacids B-Group B-Group
absorbent B-Group O
- O O
type B-Group O
anti I-Group O
- O O
diarrhea B-Group O
medicines I-Group O
( O O
e.g. O O
kaolin B-Drug B-Drug
- O O
pectin B-Drug B-Drug
) O O
phenothiazines B-Group B-Group
( O O
e.g. O O
chlorpromazine B-Drug B-Drug
promethazine B-Drug B-Drug
) O O
. O O

The O O
elevation O O
of O O
prothrombin O O
time O O
induced O O
by O O
warfarin B-Drug B-Drug
is O O
not O O
affected O O
by O O
administration O O
of O O
Exelon B-Brand B-Brand
. O O

. O O

An O O
interval O O
of O O
at O O
least O O
two O O
hours O O
between O O
intake O O
of O O
this O O
agent O O
and O O
chloroquine B-Drug B-Drug
should O O
be O O
observed O O
. O O

The O O
effect O O
of O O
gabapentin B-Drug B-Drug
on O O
cimetidine B-Drug B-Drug
was O O
not O O
evaluated O O
. O O

*Increased O O
and O O
decreased O O
prothrombin O O
time O O
responses O O
have O O
been O O
reported O O
. O O

Marked O O
symptomatic O O
orthostatic O O
hypotension O O
has O O
been O O
reported O O
when O O
calcium B-Group B-Group
channel I-Group I-Group
blockers I-Group I-Group
and O O
organic B-Group O
nitrates I-Group B-Group
were O O
used O O
in O O
combination O O
. O O

Tissue O O
culture O O
and O O
animal O O
studies O O
indicate O O
that O O
ELSPAR B-Brand B-Brand
can O O
diminish O O
or O O
abolish O O
the O O
effect O O
of O O
methotrexate B-Drug B-Drug
on O O
malignant O O
cells.9 O O
This O O
effect O O
on O O
methotrexate B-Drug B-Drug
activity O O
persists O O
as O O
long O O
as O O
plasma O O
asparagine O O
levels O O
are O O
suppressed O O
. O O

Such O O
interactions O O
might O O
be O O
manifested O O
by O O
increased O O
susceptibility O O
to O O
bruising O O
nosebleeds O O
hemoptysis O O
hematemesis O O
hematuria O O
and O O
blood O O
in O O
the O O
stool O O
. O O

in O O
9 O O
out O O
of O O
9 O O
patients O O
methadone B-Drug B-Drug
AUC O O
doubled O O
. O O

There O O
have O O
been O O
reports O O
of O O
interactions O O
of O O
erythromycin B-Drug B-Drug
with O O
carbamazepine B-Drug B-Drug
cyclosporine B-Drug B-Drug
tacrolimus B-Drug B-Drug
hexobarbital B-Drug B-Drug
phenytoin B-Drug B-Drug
alfentanil B-Drug B-Drug
cisapride B-Drug B-Drug
disopyramide B-Drug B-Drug
lovastatin B-Drug B-Drug
bromocriptine B-Drug B-Drug
valproate B-Drug B-Drug
terfenadine B-Drug B-Drug
and O O
astemizole B-Drug B-Drug
. O O

Patients O O
receiving O O
both O O
drugs O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
diuretic O O
and O O
/ O O
or O O
antihypertensive O O
effect O O
of O O
furosemide B-Drug B-Drug
is O O
achieved O O
. O O

The O O
pharmacokinetics O O
of O O
ethanol B-Drug B-Drug
were O O
not O O
affected O O
by O O
multiple O O
- O O
dose O O
administration O O
of O O
tiagabine B-Drug B-Drug
. O O

Caution O O
should O O
also O O
be O O
applied O O
for O O
other O O
sympathomimetics B-Group B-Group
and O O
for O O
aminophylline B-Drug B-Drug
and O O
theophylline B-Drug B-Drug
and O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
which O O
may O O
also O O
precipitate O O
arrhythmias O O
. O O

Antacids B-Group B-Group
increase O O
the O O
rate O O
of O O
absorption O O
of O O
pseudoephedrine B-Drug B-Drug
while O O
kaolin B-Drug O
decreases O O
it O O
. O O

If O O
possible O O
anticholinesterase B-Group B-Group
agents I-Group I-Group
should O O
be O O
withdrawn O O
at O O
least O O
9 O O
hours O O
before O O
initiating O O
corticosteroid B-Group O
therapy O O
. O O

Fluconazole B-Drug B-Drug
and O O
Ketoconazole B-Drug B-Drug
: O O
Ketoconazole B-Drug B-Drug
and O O
fluconazole B-Drug B-Drug
are O O
predominantly O O
CYP O O
9A9 O O
and O O
9C9 O O
inhibitors O O
respectively O O
. O O

Potentiation O O
occurs O O
with O O
ganglionic B-Group B-Group
peripheral I-Group I-Group
adrenergic I-Group I-Group
blocking I-Group I-Group
drugs I-Group I-Group
. O O

( O O
Concurrent O O
use O O
with O O
thiazide B-Group B-Group
diuretics I-Group I-Group
is O O
not O O
recommended O O
as O O
they O O
may O O
provoke O O
lithium B-Drug B-Drug
toxicity O O
because O O
of O O
reduced O O
renal O O
clearance O O
. O O
) O O

Care O O
should O O
be O O
taken O O
if O O
labetalol B-Drug B-Drug
is O O
used O O
concomitantly O O
with O O
calcium B-Group B-Group
antagonists I-Group I-Group
of O O
the O O
verapamil B-Drug B-Drug
type O I-Drug
. O O

thyroid O O
function O O
and O O
basal O O
metabolism O O
are O O
unaffected O O
. O O

Digoxin B-Drug B-Drug
and O O
verapamil B-Drug B-Drug
use O O
may O O
be O O
rarely O O
associated O O
with O O
ventricular O O
fibrillation O O
when O O
combined O O
with O O
Adenocard B-Brand B-Brand
. O O

Additive O O
depressant O O
effect O O
when O O
used O O
with O O
general O O
anesthetics B-Group B-Group
sedatives B-Group B-Group
antianxiety B-Group B-Group
drugs I-Group I-Group
hypnotics B-Group B-Group
alcohol B-Drug B-Drug
and O O
other O O
opiate B-Group B-Group
analgesics I-Group I-Group
. O O

In O O
adjuvant O O
trials O O
of O O
epirubicin B-Drug B-Drug
- O O
containing O O
CEF O O
- O O
9 O O
or O O
FEC O O
- O O
9 O O
chemotherapies O O
breast O O
irradiation O O
was O O
delayed O O
until O O
after O O
chemotherapy O O
was O O
completed O O
. O O

9 O O
. O O

Although O O
not O O
studied O O
with O O
alosetron B-Drug B-Drug
inhibition O O
of O O
N O B-Drug_n
- O O
acetyltransferase O O
may O O
have O O
clinically O O
relevant O O
consequences O O
for O O
drugs O O
such O O
as O O
isoniazid B-Drug B-Drug
procainamide B-Drug B-Drug
and O O
hydralazine B-Drug B-Drug
. O O

CANCIDAS B-Brand B-Brand
reduced O O
the O O
blood O O
AUC9 O O
- O O
9 O O
of O O
tacrolimus B-Drug O
by O O
approximately O O
9 O O
% O O
peak O O
blood O O
concentration O O
( O O
Cmax O O
) O O
by O O
9 O O
% O O
and O O
9 O O
- O O
hour O O
blood O O
concentration O O
( O O
C9hr O O
) O O
by O O
9 O O
% O O
in O O
healthy O O
subjects O O
when O O
tacrolimus B-Drug O
( O O
9 O O
doses O O
of O O
9 O O
mg O O
/ O O
kg O O
9 O O
hours O O
apart O O
) O O
was O O
administered O O
on O O
the O O
9th O O
day O O
of O O
CANCIDAS B-Brand B-Brand
9 O O
mg O O
daily O O
as O O
compared O O
to O O
results O O
from O O
a O O
control O O
period O O
in O O
which O O
tacrolimus B-Drug B-Drug
was O O
administered O O
alone O O
. O O

Geriatric O O
Use O O
Of O O
the O O
patients O O
who O O
received O O
ZETIA B-Brand B-Brand
in O O
clinical O O
studies O O
9 O O
were O O
9 O O
and O O
older O O
( O O
this O O
included O O
9 O O
who O O
were O O
9 O O
and O O
older O O
) O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
: O O
Measurement O O
of O O
serum O O
creatinine O O
levels O O
should O O
be O O
determined O O
by O O
the O O
Jaffe O O
reaction O O
since O O
Ancobon B-Brand B-Brand
does O O
not O O
interfere O O
with O O
the O O
determination O O
of O O
creatinine O O
values O O
by O O
this O O
method O O
. O O

Gentamicin B-Drug B-Drug
- O O
Methionine B-Drug B-Drug
may O O
protect O O
against O O
the O O
ototoxic O O
effects O O
of O O
gentamicin B-Drug B-Drug
. O O

Due O O
to O O
high O O
inter O O
- O O
patient O O
variability O O
and O O
limited O O
sampling O O
the O O
extent O O
of O O
the O O
increase O O
in O O
SN9 B-Drug_n O
levels O O
in O O
patients O O
receiving O O
concurrent O O
irinotecan B-Drug B-Drug
and O O
AVASTIN B-Brand B-Brand
is O O
uncertain O O
. O O

Patients O O
taking O O
diuretics B-Group B-Group
are O O
at O O
a O O
greater O O
risk O O
of O O
developing O O
renal O O
failure O O
secondary O O
to O O
a O O
decrease O O
in O O
renal O O
blood O O
flow O O
caused O O
by O O
prostaglandin O O
inhibition O O
. O O

No O O
formal O O
clinical O O
studies O O
have O O
been O O
conducted O O
to O O
assess O O
if O O
there O O
is O O
an O O
interactive O O
effect O O
on O O
bone O O
loss O O
between O O
phenytoin B-Drug B-Drug
and O O
Accutane B-Brand B-Brand
. O O

The O O
therapeutic O O
efficacy O O
of O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
may O O
be O O
compromised O O
in O O
these O O
patients O O
when O O
cimetidine B-Drug B-Drug
is O O
discontinued O O
. O O

Rifabutin B-Drug B-Drug
: O O
Coadministration O O
of O O
rifabutin B-Drug B-Drug
and O O
VIRACEPT B-Brand B-Brand
resulted O O
in O O
a O O
9 O O
% O O
decrease O O
in O O
nelfinavir B-Drug B-Drug
plasma O O
AUC O O
and O O
a O O
9 O O
% O O
increase O O
in O O
rifabutin B-Drug B-Drug
plasma O O
A.C O O
. O O

Intravenous O O
infusion O O
of O O
iloprost B-Drug B-Drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-Drug B-Drug
. O O

In O O
a O O
study O O
of O O
schizophrenic O O
patients O O
who O O
received O O
clozapine B-Drug B-Drug
under O O
steady O O
state O O
conditions O O
fluvoxamine B-Drug B-Drug
or O O
paroxetine B-Drug B-Drug
was O O
added O O
in O O
9 O O
and O O
9 O O
patients O O
respectively O O
. O O

phophatase O O

The O O
effect O O
of O O
Keppra B-Brand B-Brand
on O O
probenecid B-Drug B-Drug
was O O
not O O
studied O O
. O O

This O O
allows O O
bitolterol B-Drug B-Drug
to O O
open O O
air O O
passages O O
increasing O O
the O O
effectiveness O O
of O O
the O O
steroid B-Group B-Group
. O O

Interations O O

* O O
No O O
longer O O
marketed O O
in O O
the O O
US O O
. O O

If O O
you O O
think O O
you O O
are O O
taking O O
an O O
MAO B-Group B-Group
inhibitor I-Group I-Group
talk O O
to O O
your O O
doctor O O
or O O
pharmacist O O
. O O

9 O O
. O O

pentoxifylline B-Drug B-Drug
; O O

Expected O O
to O O
substantially O O
decrease O O
plasma O O
levels O O
of O O
efavirenz B-Drug B-Drug
; O O
has O O
not O O
been O O
studied O O
in O O
combination O O
with O O
SUSTIVA B-Brand B-Brand
. O O

In O O
a O O
single O O
- O O
dose O O
crossover O O
study O O
examining O O
lansoprazole B-Drug B-Drug
9 O O
mg O O
and O O
omeprazole B-Drug B-Drug
9 O O
mg O O
each O O
administered O O
alone O O
and O O
concomitantly O O
with O O
sucralfate B-Drug B-Drug
9 O O
gram O O
absorption O O
of O O
the O O
proton B-Group B-Group
pump I-Group I-Group
inhibitors I-Group I-Group
was O O
delayed O O
and O O
their O O
bioavailability O O
was O O
reduced O O
by O O
9 O O
% O O
and O O
9 O O
% O O
respectively O O
when O O
administered O O
concomitantly O O
with O O
sucralfate B-Drug B-Drug
. O O

The O O
steady O O
- O O
state O O
Cmin O O
increased O O
to O O
9 O O
9 O O
micrograms O O
/ O O
mL O O
when O O
9 O O
mg O O
/ O O
day O O
of O O
felbamate B-Drug B-Drug
was O O
coadministered O O
. O O

This O O
may O O
be O O
avoided O O
by O O
using O O
the O O
lowest O O
dose O O
possible O O
with O O
the O O
substances O O
in O O
question O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interaction O O
Fosinopril B-Drug B-Drug
may O O
cause O O
a O O
false O O
low O O
measurement O O
of O O
serum O O
digoxin B-Drug B-Drug
levels O O
with O O
the O O
Digi O O
- O O
Tab O O
RIA O O
Kit O O
for O O
Digoxin B-Drug B-Drug
. O O

Patients O O
on O O
thyroid O O
replacement O O
therapy O O
may O O
require O O
higher O O
doses O O
of O O
thyroid B-Group B-Group
hormone I-Group I-Group
. O O

Dolasetron B-Drug B-Drug
has O O
been O O
safely O O
coadministered O O
with O O
drugs O O
used O O
in O O
chemotherapy O O
and O O
surgery O O
. O O

Use O O
cautiously O O
with O O
pressor O O
agents O O
. O O

Antimyasthenics O O
Concurrent O O
use O O
of O O
procaine B-Drug B-Drug
hydrochloride I-Drug I-Drug
and O O
antimyasthenics O B-Group
may O O
result O O
in O O
loss O O
of O O
control O O
of O O
symptoms O O
of O O
myasthenia O O
gravis O O
due O O
to O O
antagonism O O
of O O
the O O
effects O O
of O O
antimyasthenics O O
on O O
skeletal O B-Group
muscle O I-Group
. O O

Naproxen B-Drug B-Drug
had O O
no O O
effect O O
on O O
plasma O O
levels O O
of O O
diflunisal B-Drug B-Drug
. O O

There O O
is O O
no O O
evidence O O
that O O
EPA B-Drug B-Drug
supplements O O
have O O
detrimental O O
effects O O
on O O
glucose O O
tolerance O O
insulin O O
secretion O O
or O O
insulin O B-Drug
resistance O O
in O O
non O O
- O O
diabetic O O
subjects O O
. O O

Laboratory O O
Tests O O
Because O O
serious O O
GI O O
tract O O
ulceration O O
and O O
bleeding O O
can O O
occur O O
without O O
warning O O
symptoms O O
physicians O O
should O O
follow O O
chronically O O
treated O O
patients O O
for O O
the O O
signs O O
and O O
symptoms O O
of O O
ulceration O O
and O O
bleeding O O
and O O
should O O
inform O O
them O O
of O O
the O O
importance O O
of O O
this O O
follow O O
- O O
up O O
. O O

Therefore O O
a O O
starting O O
daily O O
dose O O
of O O
9 O O
mg O O
of O O
VIOXX B-Brand B-Brand
should O O
be O O
considered O O
for O O
the O O
treatment O O
of O O
osteoarthritis O O
when O O
VIOXX B-Brand B-Brand
is O O
co O O
- O O
administered O O
with O O
potent O O
inducers O O
of O O
hepatic O O
metabolism O O
. O O

These O O
drugs O O
include O O
the O O
thiazides B-Group B-Group
and O O
other O O
diuretics B-Group B-Group
corticosteroids B-Group B-Group
phe O O
- O O
nothiazines O O
thyroid B-Group O
products I-Group O
estrogens B-Group B-Group
oral O O
contraceptives B-Group B-Group
phenytoin B-Drug B-Drug
nicotinic B-Drug B-Drug
acid I-Drug I-Drug
sympathomimet O O
- O O
ics O O
calcium B-Group B-Group
channel I-Group I-Group
blocking I-Group I-Group
drugs I-Group I-Group
and O O
isoniazid B-Drug B-Drug
. O O

TABLE O O
9 O O
Effects O O
on O O
Plasma O O
Concentrations O O
( O O
AUC O O
9 O O
- O O
9 O O
hrs O O
) O O
of O O
Loratadine B-Drug B-Drug
and O O
Descarboethoxyloratadine B-Drug B-Drug
After O O
9 O O
Days O O
of O O
Coadministration O O
( O O
Loratadine B-Drug B-Drug
9 O O
mg O O
) O O
in O O
Normal O O
Volunteers O O

When O O
daily O O
doses O O
of O O
sulfasalazine B-Drug B-Drug
9 O O
g O O
and O O
weekly O O
doses O O
of O O
methotrexate B-Drug B-Drug
9 O O
mg O O
were O O
coadministered O O
to O O
9 O O
rheumatoid O O
arthritis O O
patients O O
in O O
a O O
drug O O
- O O
drug O O
interaction O O
study O O
the O O
pharmacokinetic O O
disposition O O
of O O
the O O
drugs O O
was O O
not O O
altered O O
. O O

Phenytoin B-Drug B-Drug
decreases O O
serum O O
amiodarone O B-Drug
levels O O
. O O

Ethosuximide B-Drug B-Drug
: O O
Amphetamines B-Group B-Group
may O O
delay O O
intestinal O O
absorption O O
of O O
ethosuximide B-Drug B-Drug
. O O

Aspirin B-Brand B-Brand
: O O
Concomitant O O
administration O O
of O O
aspirin B-Brand B-Brand
with O O
valdecoxib B-Drug B-Drug
may O O
result O O
in O O
an O O
increased O O
risk O O
of O O
GI O O
ulceration O O
and O O
complications O O
compared O O
to O O
valdecoxib B-Drug B-Drug
alone O O
. O O

. O O

Paroxetine B-Drug B-Drug
produced O O
only O O
minor O O
changes O O
in O O
the O O
levels O O
of O O
clozapine B-Drug B-Drug
and O O
its O O
metabolites O O
. O O

Coadministration O O
of O O
phenytoin B-Drug B-Drug
with O O
9 O O
mg O O
SULAR B-Brand B-Brand
tablets O O
in O O
epileptic O O
patients O O
lowered O O
the O O
nisoldipine B-Drug B-Drug
plasma O O
concentrations O O
to O O
undetectable O O
levels O O
. O O

While O O
only O O
a O O
limited O O
number O O
of O O
in O O
vivo O O
drug O O
- O O
drug O O
interactions O O
with O O
amiodarone B-Drug B-Drug
have O O
been O O
reported O O
chiefly O O
with O O
the O O
oral O O
formulation O O
the O O
potential O O
for O O
other O O
interactions O O
should O O
be O O
anticipated O O
. O O

Methyldopa B-Drug B-Drug
does O O
not O O
interfere O O
with O O
measurement O O
of O O
VMA B-Drug_n B-Brand
( O O
vanillylmandelic B-Drug_n O
acid I-Drug_n O
) O O
a O O
test O O
for O O
pheochromocytoma O O
by O O
those O O
methods O O
which O O
convert O O
VMA B-Drug_n O
to O O
vanillin B-Drug_n O
. O O

Anastrozole B-Drug B-Drug
did O O
not O O
inhibit O O
P9 O O
9A9 O O
or O O
the O O
polymorphic O O
P9 O O
9D9 O O
in O O
human O O
liver O O
microsomes O O
. O O

. O O

Antidiabetic B-Group B-Group
drugs I-Group I-Group
( O O
oral O O
agents O O
and O O
insulin B-Drug B-Drug
) O O
diminished O O
antidiabetic O O
effect O O
. O O

Gastrointestinal O B-Drug
: O O
Nausea O O
( O O
9 O O
- O O
9 O O
% O O
) O O
constipation O O
( O O
9 O O
- O O
9 O O
% O O
) O O
; O O

when O O
the O O
drugs O O
were O O
administered O O
together O O
the O O
effects O O
were O O
additive O O
. O O

Due O O
to O O
the O O
chemical O O
similarity O O
of O O
other O O
azole B-Group B-Group
- O O
type B-Group B-Group
antifungal I-Group I-Group
agents I-Group I-Group
( O O
including O O
fluconazole B-Drug B-Drug
metronidazole B-Drug B-Drug
and O O
miconazole B-Drug B-Drug
) O O
to O O
ketoconazole B-Drug B-Drug
and O O
itraconazole B-Drug B-Drug
concomitant O O
use O O
of O O
these O O
products O O
with O O
terfenadine B-Drug B-Drug
is O O
not O O
recommended O O
pending O O
full O O
examination O O
of O O
potential O O
interactions O O
. O O

tricyclic B-Group B-Group
antidepressants I-Group I-Group
. O O

This O O
has O O
been O O
observed O O
with O O
CLINITEST O O
reagent O O
tablets O O

Coadministration O O
of O O
single O O
oral O O
doses O O
of O O
zaleplon B-Drug B-Drug
with O O
erythromycin B-Drug B-Drug
( O O
9 O O
mg O O
and O O
9 O O
mg O O
respectively O O
) O O
a O O
strong O O
selective O O
CYP9A9 O O
inhibitor O O
produced O O
a O O
9 O O
% O O
increase O O
in O O
zaleplons B-Drug O
maximal O O
plasma O O
concentrations O O
and O O
a O O
9 O O
% O O
increase O O
in O O
the O O
area O O
under O O
the O O
plasma O O
concentration O O
- O O
time O O
curve O O
. O O

Exposure O O
from O O
the O O
proposed O O
topical O O
dose O O
is O O
about O O
9 O O
% O O
of O O
that O O
from O O
the O O
9 O O
mg O O
oral O O
dose O O
even O O
when O O
co O O
- O O
administered O O
with O O
TMP B-Drug B-Drug
/ O O
SMX B-Drug B-Drug
. O O

Therefore O O
the O O
potential O O
for O O
such O O
drug O O
interactions O O
should O O
be O O
considered O O
in O O
patients O O
receiving O O
dorzolamide B-Drug B-Drug
. O O

Co O O
- O O
administration O O
of O O
bosentan B-Drug B-Drug
decreased O O
the O O
plasma O O
concentrations O O
of O O
glyburide B-Drug B-Drug
by O O
approximately O O
9 O O
% O O
. O O

In O O
vivo O O
interaction O O
studies O O
in O O
humans O O
have O O
demonstrated O O
that O O
digoxin B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
do O O
not O O
affect O O
the O O
PK O O
properties O O
of O O
anagrelide B-Drug B-Drug
nor O O
does O O
anagrelide B-Drug B-Drug
affect O O
the O O
PK O O
properties O O
of O O
digoxin B-Drug B-Drug
or O O
warfarin B-Drug B-Drug
. O O

Inducers O O
of O O
CYP9A9 O O

Blood O O
glucose O O
concentrations O O
should O O
be O O
carefully O O
monitored O O
when O O
Itraconazole B-Drug B-Drug
and O O
oral O O
hypoglycemic B-Group B-Group
agents I-Group I-Group
are O O
coadministered O O
. O O

Quinidine B-Drug B-Drug
and O O
procainamide O B-Drug
doses O O
should O O
be O O
reduced O O
by O O
one O O
- O O
third O O
when O O
either O O
is O O
administered O O
with O O
amiodarone B-Drug B-Drug
. O O

The O O
amount O O
of O O
metformin B-Drug B-Drug
absorbed O O
while O O
taking O O
Acarbose B-Drug B-Drug
was O O
bioequivalent O O
to O O
the O O
amount O O
absorbed O O
when O O
taking O O
placebo O O
as O O
indicated O O
by O O
the O O
plasma O O
AUC O O
values O O
. O O

SYMLIN B-Brand B-Brand
has O O
the O O
potential O O
to O O
delay O O
the O O
absorption O O
of O O
concomitantly O O
administered O O
oral O O
medications O O
. O O

Permanent O O
nerve O O
damage O O
could O O
theoretically O O
occur O O
if O O
vitamin O O
B9 O O
deficiency O O
is O O
not O O
treated O O
. O O

Probenecid B-Drug B-Drug
: O O
As O O
with O O
other O O
b B-Group B-Group
- O O
lactam B-Group B-Group
antibiotics I-Group I-Group
renal O O
excretion O O
of O O
loracarbef B-Drug O
is O O
inhibited O O
by O O
probenecid B-Drug B-Drug
and O O
resulted O O
in O O
an O O
approximate O O
9 O O
% O O
increase O O
in O O
the O O
AUC O O
for O O
loracarbef B-Drug O
. O O

May O O
interact O O
with O O
the O O
following O O
: O O
beta B-Group B-Group
- O O
adrenergic B-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
( O O
these O O
medicines O O
may O O
make O O
your O O
condition O O
worse O O
and O O
prevent O O
the O O
adrenergic B-Group O
bronchodilators I-Group B-Group
from O O
working O O
properly O O
) O O
and O O
disopyramide B-Drug B-Drug
quinidine B-Drug B-Drug
phenothiazines B-Group B-Group
and O O
procainamide B-Drug B-Drug
( O O
these O O
medicines O O
may O O
increase O O
the O O
risk O O
of O O
heart O O
problems O O
) O O
. O O

sulfonamides B-Group B-Group
long O O
acting O O
; O O

Antacid B-Group B-Group
( O O
Maalox B-Brand B-Brand
) O O
: O O
Maalox B-Brand B-Brand
reduced O O
the O O
bioavailability O O
of O O
gabapentin B-Drug B-Drug
( O O
N=9 O O
) O O
by O O
about O O
9 O O
% O O
. O O

In O O
addition O O
certain O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
isoenzyme O O
including O O
many O O
antidepressants B-Group B-Group
( O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
selective B-Group B-Group
serotonin I-Group I-Group
reuptake I-Group I-Group
inhibitors I-Group I-Group
and O O
others O O
) O O
may O O
inhibit O O
the O O
activity O O
of O O
this O O
isoenzyme O O
and O O
thus O O
may O O
make O O
normal O O
metab O O
- O O
olizers O O
resemble O O
poor O O
metabolizers O O
with O O
regard O O
to O O
concomitant O O
therapy O O
with O O
other O O
drugs O O
metabolized O O
by O O
this O O
enzyme O O
system O O
leading O O
to O O
drug O O
interactions O O
. O O

This O O
oxidation O O
which O O
is O O
catalyzed O O
by O O
xanthine O O
oxidase O O
inactivates O O
mercaptopurine B-Drug B-Drug
. O O

Clonidine B-Drug B-Drug
: O O
Concomitant O O
administration O O
of O O
clonidine B-Drug B-Drug
with O O
agents B-Group O
with I-Group O
b I-Group B-Group
- O O
blocking B-Group B-Group
properties I-Group I-Group
may O O
potentiate O O
blood O O
- O O
pressure O O
- O O
and O O
heart O O
- O O
rate O O
- O O
lowering O O
effects O O
. O O

CANCIDAS B-Brand B-Brand
did O O
not O O
increase O O
the O O
plasma O O
levels O O
of O O
cyclosporine B-Drug B-Drug
. O O

antibiotics B-Group B-Group
; O O

CIMETlDINE B-Drug B-Drug
: O O
Cerivastatin B-Drug B-Drug
plasma O O
concentrations O O
were O O
not O O
affected O O
by O O
co O O
- O O
administration O O
of O O
cimetidine B-Drug B-Drug
. O O

Other O O
depressasnts O O
such O O
as O O
alcohol B-Drug B-Drug
barbiturates B-Group B-Group
and O O
MAOIs B-Group B-Group
may O O
enhance O O
CNS O O
depression O O
when O O
administered O O
with O O
ethchlorvynol B-Drug B-Drug
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
: O O
Amphetamines B-Group B-Group
can O O
cause O O
a O O
significant O O
elevation O O
in O O
plasma O O
corticosteroid B-Group O
levels O O
. O O

No O O
evaluation O O
of O O
EXTRANEALs B-Brand O
effects O O
on O O
the O O
cytochrome O O
P9 O O
system O O
was O O
conducted O O
. O O

The O O
elimination O O
half O O
life O O
of O O
midazolam B-Drug B-Drug
and O O
triazolam B-Drug B-Drug
also O O
increased O O
( O O
9 O O
- O O
9 O O
fold O O
) O O
during O O
coadministration O O
with O O
diltiazem B-Drug B-Drug
. O O

Ketoconazole B-Drug B-Drug
( O O
9 O O
mg O O
q9h O O
) O O
9 O O
% O O
9% O O

Coadministration O O
of O O
rifampin B-Drug B-Drug
with O O
diltiazem B-Drug B-Drug
lowered O O
the O O
diltiazem B-Drug B-Drug
plasma O O
concentrations O O
to O O
undetectable O O
levels O O
. O O

- O O
Mephenytoin B-Drug B-Drug
( O O
e.g. O O
Mesantoin B-Brand B-Brand
) O O
Use O O
of O O
sulfapyridine B-Drug B-Drug
with O O
these O O
medicines O O
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
of O O
these O O
medicines O O

If O O
additional O O
adrenergic B-Group O
drugs I-Group O
are O O
to O O
be O O
administered O O
by O O
any O O
route O O
they O O
should O O
be O O
used O O
with O O
caution O O
because O O
the O O
pharmacologically O O
predictable O O
sympathetic O O
effects O O
of O O
BROVANA B-Brand B-Brand
may O O
be O O
potentiated O O
. O O

Drugs O O
Prolonging O O
the O O
QT O O
/ O O
QTc O O
Interval O O
Caution O O
should O O
be O O
exercised O O
when O O
prescribing O O
apomorphine B-Drug B-Drug
concomitantly O O
with O O
drugs O O
that O O
prolong O O
the O O
QT O O
/ O O
QTc O O
interval O O
. O O

Each O O
volunteer O O
was O O
administered O O
one O O
9 O O
- O O
mg O O
ceftibuten B-Drug B-Drug
capsule O O
. O O

The O O
findings O O
of O O
these O O
studies O O
are O O
summarized O O
in O O
the O O
following O O
table O O
: O O
Effects O O
on O O
steady O O
- O O
state O O
fexofenadine B-Drug B-Drug
pharmacokinetics O O
after O O
9 O O
days O O
of O O
co O O
- O O
administration O O
with O O
fexofenadine B-Drug B-Drug
hydrochloride I-Drug I-Drug
9 O O
mg O O
every O O
9 O O
hours O O
( O O
two O O
times O O
the O O
recommended O O
twice O O
daily O O
dose O O
) O O
in O O
healthy O O
volunteers O O
( O O
n=9 O O
) O O

Probenecid B-Drug B-Drug
- O O
concurrent O O
use O O
decreases O O
gastrointestinal O O
absorption O O
of O O
riboflavin B-Drug B-Drug
; O O

Interconversion O O
between O O
caffeine B-Drug B-Drug
and O O
theophylline B-Drug B-Drug
has O O
been O O
reported O O
in O O
preterm O O
neonates O O
. O O

Anticholinergic B-Group B-Group
drugs I-Group I-Group
in O O
the O O
presence O O
of O O
increased O O
intraocular O O
pressure O O
may O O
be O O
hazardous O O
when O O
taken O O
concurrently O O
with O O
agents O O
such O O
as O O
corticosteroids B-Group B-Group
. O O

Alcohol B-Drug B-Drug
: O O
There O O
was O O
no O O
significant O O
difference O O
between O O
aripiprazole B-Drug B-Drug
coadministered O O
with O O
ethanol B-Drug B-Drug
and O O
placebo O O
coadministered O O
with O O
ethanol B-Drug B-Drug
on O O
performance O O
of O O
gross O O
motor O O
skills O O
or O O
stimulus O O
response O O
in O O
healthy O O
subjects O O
. O O

Careful O O
monitoring O O
of O O
serum O O
theophylline B-Drug B-Drug
concentrations O O
in O O
patients O O
receiving O O
DIFLUCAN B-Brand B-Brand
and O O
theophylline B-Drug B-Drug
is O O
recommended O O
. O O

Increased O O
anticoagulation O O
effects O O
due O O
to O O
interactions O O
of O O
erythromycin B-Drug B-Drug
with O O
various O O
oral O O
anticoagulents O O
may O O
be O O
more O O
pronounced O O
in O O
the O O
elderly O O
. O O

Diltiazem B-Drug B-Drug
plasma O O
levels O O
were O O
not O O
significantly O O
affected O O
by O O
lovastatin B-Drug B-Drug
or O O
pravastatin B-Drug B-Drug
. O O

Diuretic B-Group B-Group
: O O
Hydrochlorothiazide B-Drug B-Drug
given O O
concomitantly O O
with O O
ketoprofen B-Drug B-Drug
produces O O
a O O
reduction O O
in O O
urinary O O
potassium O O
and O O
chloride O O
excretion O O
compared O O
to O O
hydrochlorothiazide B-Drug B-Drug
alone O O
. O O

Tell O O
your O O
doctor O O
if O O
you O O
are O O
taking O O
any O O
of O O
the O O
following O O
drugs O O
: O O
blood B-Group O
thinners I-Group O
( O O
Coumadin B-Brand O
) O O
other O O
antidepressants B-Group B-Group
metoprolol B-Drug B-Drug
antihistamines B-Group B-Group
carbamazepine B-Drug B-Drug
( O O
Tegretol B-Brand B-Brand
) O O
cimetidine B-Drug B-Drug
( O O
Tagamet B-Brand B-Brand
) O O
estrogens B-Group B-Group
fluoxetine B-Drug B-Drug
( O O
Prozac B-Brand B-Brand
) O O
intraconazole O B-Drug
( O O
Sporanox B-Brand B-Brand
) O O
ketoconazole B-Drug B-Drug
( O O
Nizoral B-Brand B-Brand
) O O
levodopa B-Drug B-Drug
lithium B-Drug B-Drug
muscle B-Group B-Group
relaxants I-Group I-Group
birth O O
control O O
pills O O
sleeping O O
pills O O
thyroid O B-Group
medications O I-Group

in O O
vitro O O
Gleevec B-Brand B-Brand
inhibits O O
the O O
cytochrome O O
P9 O O
isoenzyme O O
CYP9D9 O O
activity O O
at O O
similar O O
concentrations O O
that O O
affect O O
CYP9A9 O O
activity O O
. O O

In O O
several O O
well O O
- O O
controlled O O
studies O O
guanfacine B-Drug B-Drug
was O O
administered O O
together O O
with O O
diuretics B-Group B-Group
with O O
no O O
drug O O
interactions O O
reported O O
. O O

. O O

Vecuronium B-Drug B-Drug
: O O
When O O
used O O
in O O
the O O
perioperative O O
period O O
piperacillin B-Drug B-Drug
has O O
been O O
implicated O O
in O O
the O O
prolongation O O
of O O
the O O
neuromuscular O O
blockade O O
of O O
vecuronium B-Drug B-Drug
. O O

These O O
doses O O
correspond O O
to O O
approximately O O
9 O O
- O O
9 O O
- O O
and O O
9 O O
- O O
fold O O
( O O
in O O
females O O
) O O
and O O
9 O O
- O O
9 O O
- O O
and O O
9 O O
- O O
fold O O
( O O
in O O
males O O
) O O
the O O
systemic O O
exposure O O
[ O O
AUC9 O O
- O O
9 O O
days O O
] O O
] O O
achieved O O
in O O
women O O
receiving O O
the O O
recommended O O
dose O O
of O O
9 O O
mg O O
/ O O
month O O
. O O

The O O
utilization O O
of O O
digitoxin B-Drug B-Drug
for O O
such O O
patients O O
may O O
be O O
considered O O
as O O
an O O
alternative O O
. O O

Potential O O
for O O
reduction O O
in O O
anticonvulsant B-Group B-Group
and O O
/ O O
or O O
efavirenz B-Drug B-Drug
plasma O O
levels O O
; O O

Since O O
bacteriostatic O O
drugs O O
may O O
interfere O O
with O O
the O O
bactericidal O O
action O O
of O O
penicillin B-Drug B-Drug
it O O
is O O
advisable O O
to O O
avoid O O
giving O O
tetracyclines B-Group B-Group
in O O
conjunction O O
with O O
penicillin B-Group B-Drug
. O O

Carbamazepine B-Drug B-Drug
- O O
Combined O O
administration O O
of O O
racemic O O
citalopram B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
day O O
for O O
9 O O
days O O
) O O
and O O
carbamazepine B-Drug B-Drug
( O O
titrated O O
to O O
9 O O
mg O O
/ O O
day O O
for O O
9 O O
days O O
) O O
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
carbamazepine B-Drug B-Drug
a O O
CYP9A9 O B-Drug
substrate O O
. O O

On O O
the O O
average O O
for O O
the O O
group O O
the O O
dose O O
of O O
cyclosporine B-Drug B-Drug
was O O
reduced O O
about O O
9 O O
% O O
in O O
these O O
patients O O
. O O

Other O O
inhibitors O O
of O O
the O O
cytochrome O O
P9 O O
9A9 O O
enzyme O O
system O O
such O O
as O O
antimycotic B-Group O
agents I-Group O
( O O
e.g. O O
itraconazole B-Drug B-Drug
and O O
miconazole B-Drug B-Drug
) O O
or O O
macrolide B-Group B-Group
antibiotics I-Group I-Group
( O O
e.g. O O
erythromycin B-Drug B-Drug
and O O
clarithromycin B-Drug B-Drug
) O O
may O O
alter O O
oxybutynin B-Drug B-Drug
mean O O
pharmacokinetic O O
parameters O O
( O O
i.e. O O
Cmax O O
and O O
AUC O O
) O O
. O O

There O O
was O O
no O O
evidence O O
of O O
drug O O
interactions O O
in O O
clinical O O
studies O O
in O O
which O O
dobutamine B-Drug B-Drug
was O O
administered O O
concurrently O O
with O O
other O O
drugs O O
including O O
digitalis B-Group B-Group
preparations I-Group I-Group
furosemide B-Drug B-Drug
spironolactone B-Drug B-Drug
lidocaine B-Drug B-Drug
glyceryl B-Drug O
trinitrate I-Drug O
isosorbide B-Drug B-Drug
dinitrate I-Drug I-Drug
morphine B-Drug B-Drug
atropine B-Drug B-Drug
heparin B-Drug B-Drug
protamine B-Drug O
potassium B-Drug O
chloride I-Drug O
folic B-Drug B-Drug
acid I-Drug I-Drug
and O O
acetaminophen B-Drug B-Drug
. O O

Effects O O
of O O
Erythromycin B-Drug B-Drug
on O O
Felbatol B-Brand B-Brand
The O O
coadministration O O
of O O
erythromycin B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
day O O
) O O
for O O
9 O O
days O O
did O O
not O O
alter O O
the O O
pharmacokinetic O O
parameters O O
of O O
Cmax O O
Cmin O O
AUC O O
CI O O
/ O O
kg O O
or O O
tmax O O
at O O
felbamate B-Drug B-Drug
daily O O
doses O O
of O O
9 O O
or O O
9 O O
mg O O
/ O O
day O O
in O O
9 O O
otherwise O O
healthy O O
subjects O O
with O O
epilepsy O O
. O O

May O O
interact O O
with O O
addictive O O
medications O O
especially O O
central B-Group B-Group
nervous I-Group I-Group
system I-Group I-Group
CNS I-Group I-Group
depressants I-Group I-Group
with O O
habituating O O
potential O O
( O O
prolonged O O
concurrent O O
use O O
may O O
increase O O
the O O
risk O O
of O O
habituation O O
) O O
alcohol B-Drug B-Drug
or O O
CNS O B-Group
depression O I-Group
producing O I-Group
medications O I-Group
( O O
concurrent O O
use O O
may O O
increase O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
ethinamate B-Drug O
) O O
. O O

Sildenafil B-Drug B-Drug
citrate I-Drug I-Drug
- O O
Theoretically O O
L B-Drug B-Drug
- O O
arginine B-Drug B-Drug
supplements O O
taken O O
concomitantly O O
with O O
sildenafil B-Drug B-Drug
citrate I-Drug I-Drug
may O O
potentiate O O
the O O
effects O O
of O O
the O O
drug O O
. O O

A O O
study O O
of O O
interaction O O
between O O
BREVIBLOC B-Brand B-Brand
and O O
warfarin B-Drug B-Drug
showed O O
that O O
concomitant O O
administration O O
of O O
BREVIBLOC B-Brand B-Brand
and O O
warfarin B-Drug B-Drug
does O O
not O O
alter O O
warfarin B-Drug B-Drug
plasma O O
levels O O
. O O

Among O O
9 O O
subjects O O
who O O
received O O
Angiomax B-Brand B-Brand
in O O
clinical O O
trials O O
and O O
were O O
tested O O
for O O
antibodies O B-Group
9 O O
subjects O O
had O O
treatment O O
- O O
emergent O O
positive O O
bivalirudin B-Drug O
antibody O O
tests O O
. O O

Steady O O
- O O
state O O
bosentan B-Drug B-Drug
plasma O O
concentrations O O
were O O
9 O O
- O O
to O O
9 O O
- O O
fold O O
higher O O
than O O
in O O
the O O
absence O O
of O O
cyclosporine B-Drug B-Drug
A I-Drug I-Drug
. O O

Patients O O
in O O
a O O
clinical O O
study O O
who O O
were O O
on O O
established O O
therapy O O
with O O
sulfasalazine B-Drug B-Drug
to O O
which O O
ENBREL B-Brand B-Brand
was O O
added O O
were O O
noted O O
to O O
develop O O
a O O
mild O O
decrease O O
in O O
mean O O
neutrophil O O
counts O O
in O O
comparison O O
to O O
groups O O
treated O O
with O O
either O O
ENBREL B-Brand B-Brand
CI O I-Brand
or O O
sulfasalazine B-Drug B-Drug
alone O O
. O O

Alternatives O O
to O O
clarithromycin B-Drug B-Drug
such O O
as O O
azithromycin B-Drug B-Drug
should O O
be O O
considered O O
. O O

Because O O
of O O
its O O
potential O O
for O O
inducing O O
orthostatic O O
hypotension O O
an O O
additive O O
effect O O
may O O
be O O
observed O O
when O O
INVEGA B-Brand B-Brand
is O O
administered O O
with O O
other O O
therapeutic O O
agents O O
that O O
have O O
this O O
potential O O
. O O

No O O
dose O O
adjustment O O
of O O
bosentan B-Drug B-Drug
is O O
necessary O O
but O O
increased O O
effects O O
of O O
bosentan B-Drug B-Drug
should O O
be O O
considered O O
. O O

Both O O
itraconazole B-Drug B-Drug
and O O
its O O
major O O
metabolite O O
hydroxyitraconazole B-Drug_n B-Drug_n
are O O
inhibitors O O
of O O
the O O
cytochrome O O
P9 O O
9A9 O O
enzyme O O
system O O
. O O

Further O O
in O O
rabbits O O
dosed O O
at O O
9 O O
mg O O
/ O O
kg O O
/ O O
day O O
( O O
about O O
one O O
- O O
half O O
the O O
human O O
dose O O
on O O
BSA O O
) O O
increases O O
in O O
placental O O
weight O O
and O O
post O O
- O O
implantation O O
loss O O
were O O
observed O O
but O O
there O O
were O O
no O O
observed O O
effects O O
on O O
fetal O O
development O O
. O O

Drug O O
and O O
Laboratory O O
Test O O
Interactions O O
9 O O
. O O

fenoprofen B-Drug B-Drug
; O O

Data O O
from O O
in O O
vitro O O
studies O O
of O O
benzodiazepines B-Group B-Group
other O O
than O O
alprazolam B-Drug B-Drug
suggest O O
a O O
possible O O
drug O O
interaction O O
for O O
the O O
following O O
: O O
ergotamine B-Drug B-Drug
cyclosporine B-Drug B-Drug
amiodarone B-Drug B-Drug
nicardipine B-Drug B-Drug
and O O
nifedipine B-Drug B-Drug
. O O

Nicotine B-Drug B-Drug
Transdermal O O
System O O
: O O
. O O

The O O
safety O O
of O O
such O O
concomitant O O
use O O
with O O
Activase B-Brand B-Brand
for O O
the O O
management O O
of O O
acute O O
ischemic O O
stroke O O
is O O
unknown O O
. O O

In O O
a O O
similar O O
study O O
with O O
tamsulosin B-Drug B-Drug
in O O
healthy O O
volunteers O O
9 O O
of O O
9 O O
subjects O O
dosed O O
with O O
Vardenafil B-Drug B-Drug
9 O O
mg O O
and O O
tamsulosin B-Drug B-Drug
9 O O
mg O O
separated O O
by O O
9 O O
hours O O
experienced O O
a O O
standing O O
systolic O O
blood O O
pressure O O
below O O
9 O O
mm O O
Hg O O
. O O

Other O O
strong O O
inhibitors O O
of O O
CYP9A9 O O
( O O
itraconazole B-Drug B-Drug
) O O
would O O
be O O
expected O O
to O O
have O O
similar O O
effects O O
and O O
need O O
similar O O
dose O O
reductions O O
; O O

Carbamazepine B-Drug B-Drug
( O O
CBZ B-Drug O
) O O

Since O O
colestipol B-Drug B-Drug
hydrochloride I-Drug I-Drug
is O O
an O O
anion B-Group B-Group
exchange I-Group I-Group
resin I-Group I-Group
it O O
may O O
have O O
a O O
strong O O
affinity O O
for O O
anions O O
other O O
than O O
the O O
bile O O
acids O O
. O O

Delavirdine B-Drug B-Drug

See O O

Ketoconazole B-Drug B-Drug
: O O
Potential O O
interaction O O
of O O
Ketoconazole B-Drug B-Drug
and O O
Isoniazid B-Drug B-Drug
may O O
exist O O
. O O

The O O
administration O O
of O O
epinephrine B-Drug B-Drug
should O O
be O O
avoided O O
in O O
the O O
treatment O O
of O O
drug O O
induced O O
hypotension O O
because O O
of O O
a O O
possible O O
reverse O O
epinephrine B-Drug O
effect O O
. O O

. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
with O O
Cetrotide B-Brand B-Brand
. O O

Drugs O O
such O O
as O O
troleandomycin B-Drug B-Drug
and O O
ketoconazole B-Drug B-Drug
may O O
inhibit O O
the O O
metabolism O O
of O O
corticosteroids B-Group B-Group
and O O
thus O O
decrease O O
their O O
clearance O O
. O O

In O O
vitro O O
perfusion O O
of O O
isolated O O
rat O O
liver O O
has O O
shown O O
that O O
cimetidine B-Drug B-Drug
caused O O
a O O
significant O O
reduction O O
in O O
trimetrexate B-Drug B-Drug
metabolism O O
and O O
that O O
acetaminophen B-Drug B-Drug
altered O O
the O O
relative O O
concentration O O
of O O
trimetrexate O O
metabolites O O
possibly O O
by O O
competing O O
for O O
sulfate O O
metabolites O O
. O O

There O O
have O O
been O O
no O O
formal O O
drug O O
interaction O O
studies O O
performed O O
with O O
HERCEPTIN B-Brand B-Brand
in O O
humans O O
. O O

Azathioprine B-Drug B-Drug
/ O O
Mycophenolate B-Drug O
Mofetil I-Drug O
: O O
Given O O
that O O
azathioprine B-Drug B-Drug
and O O
mycophenolate B-Drug B-Drug
mofetil I-Drug I-Drug
inhibit O O
purine O O
metabolism O O
it O O
is O O
recommended O O
that O O
Myfortic B-Brand B-Brand
not O O
be O O
administered O O
concomitantly O O
with O O
azathioprine B-Drug B-Drug
or O O
mycophenolate B-Drug B-Drug
mofetil I-Drug I-Drug
. O O

Pediatric O O
Use O O

In O O
vivo O O
the O O
plasma O O
clearance O O
of O O
ropivacaine B-Drug B-Drug
was O O
reduced O O
by O O
9 O O
% O O
during O O
coadministration O O
of O O
fluvoxamine B-Drug B-Drug
( O O
9 O O
mg O O
bid O O
for O O
9 O O
days O O
) O O
a O O
selective O O
and O O
potent O O
CYP9A9 O O
inhibitor O O
. O O

The O O
atorvastatin B-Drug B-Drug
Cmax O O
values O O
were O O
not O O
significantly O O
affected O O
by O O
fenofibrate B-Drug B-Drug
. O O

Concomitant O O
use O O
of O O
calcium B-Drug B-Drug
supplements O O
and O O
L B-Drug B-Drug
- O O
lysine B-Drug B-Brand
may O O
increase O O
calcium B-Drug B-Drug
absorption O O

Indomethacin B-Drug B-Drug
may O O
also O O
affect O O
plasma O O
renin O O
levels O O
aldosterone O O
excretion O O
and O O
renin O O
profile O O
evaluation O O
. O O

Clinically O O
significant O O
effects O O
have O O
been O O
reported O O
with O O
the O O
warfarin B-Group B-Group
anticoagulants I-Group I-Group
; O O

In O O
order O O
to O O
avoid O O
the O O
occurrence O O
of O O
severe O O
hypersensitivity O O
reactions O O
all O O
patients O O
treated O O
with O O
TAXOL B-Brand B-Brand
should O O
be O O
premedicated O O
with O O
corticosteroids B-Group B-Group
( O O
such O O
as O O
dexamethasone B-Drug B-Drug
) O O
diphen O B-Drug
- O O
hydramine O B-Drug
and O O
H9 B-Group B-Group
antagonists I-Group I-Group
( O O
such O O
as O O
cimetidine B-Drug B-Drug
or O O
ranitidine B-Drug B-Drug
) O O
. O O

In O O
vitro O O
data O O
indicate O O
that O O
the O O
phosphorylation O O
of O O
stavudine B-Drug B-Drug
is O O
also O O
inhibited O O
at O O
relevant O O
concentrations O O
by O O
doxorubicin B-Drug B-Drug
and O O
ribavirin B-Drug B-Drug
. O O

Some O O
quinolone B-Group B-Group
antibiotics I-Group I-Group
would O O
be O O
expected O O
to O O
have O O
similar O O
effects O O
and O O
these O O
combinations O O
should O O
be O O
avoided O O
. O O

. O O

A O O
further O O
phenomenon O O
of O O
toxicity O O
common O O
to O O
many O O
hydrazine B-Group O
derivatives I-Group O
is O O
hemolysis O O
and O O
the O O
appearance O O
of O O
Heinz O O
- O O
Ehrlich O O
inclusion O O
bodies O O
in O O
erythrocytes O O
. O O

Depending O O
on O O
the O O
fraction O O
of O O
drug O O
metabolized O O
by O O
P9 O O
9D9 O O
the O O
increase O O
in O O
plasma O O
concentration O O
may O O
be O O
small O O
or O O
quite O O
large O O
( O O
9 O O
- O O
fold O O
increase O O
in O O
plasma O O
AUC O O
of O O
the O O
TCA B-Group B-Group
) O O
. O O

The O O
possibility O O
of O O
worsened O O
glucose O O
control O O
in O O
patients O O
using O O
these O O
agents O O
should O O
be O O
considered O O
. O O

Ketoconazole B-Drug B-Drug

MAO B-Group B-Group
inhibitors I-Group I-Group
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
effects O O
of O O
antihistamines B-Group B-Group
. O O

Caution O O
is O O
advised O O
when O O
TRISENOX B-Brand B-Brand
is O O
coadministered O O
with O O
other O O
medications O O
that O O
can O O
prolong O O
the O O
QT O O
interval O O
( O O
e.g O O
. O O
certain O O
antiarrhythmics B-Group B-Group
or O O
thioridazine B-Drug B-Drug
) O O
or O O
lead O O
to O O
electrolyte O O
abnormalities O O
( O O
such O O
as O O
diuretics B-Group B-Group
or O O
amphotericin B-Drug B-Drug
B I-Drug I-Drug
) O O
. O O

H O B-Group
- O O
9 O O
Antagonists O O
: O O
In O O
studies O O
with O O
human O O
volunteers O O
co O O
- O O
administration O O
of O O
cimetidine B-Drug B-Drug
or O O
ranitidine B-Drug B-Drug
with O O
ibuprofen B-Drug B-Drug
had O O
no O O
substantive O O
effect O O
on O O
ibuprofen B-Drug B-Drug
serum O O
concentrations O O
. O O

therefore O O
administration O O
of O O
EQUETROTM B-Brand B-Brand
to O O
a O O
patient O O
taking O O
another O O
drug O O
that O O
is O O
highly O O
protein O O
bound O O
should O O
not O O
cause O O
increased O O
free O O
concentrations O O
of O O
the O O
other O O
drug O O
. O O

Videx B-Brand B-Brand
( O O
Didanosine B-Drug B-Drug
) O O
chewable O O
/ O O
buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
should O O
not O O
be O O
administered O O
concomitantly O O
with O O
or O O
within O O
9 O O
hours O O
of O O
the O O
administration O O
of O O
norfloxacin B-Drug B-Drug
because O O
these O O
products O O
may O O
interfere O O
with O O
absorption O O
resulting O O
in O O
lower O O
serum O O
and O O
urine O O
levels O O
of O O
norfloxacin B-Drug B-Drug
. O O

The O O
magnitude O O
and O O
relative O O
importance O O
of O O
the O O
effects O O
noted O O
below O O
are O O
likely O O
to O O
be O O
patient O O
specific O O
and O O
may O O
vary O O
by O O
such O O
factors O O
as O O
age O O
gender O O
race O O
intercurrent O O
illnesses O O
dose O O
of O O
either O O
agent O O
additional O O
concomitant O O
medications O O
and O O
timing O O
of O O
drug O O
administration O O
. O O

Among O O
aspirin B-Brand B-Brand
or O O
NSAID B-Group B-Group
users O O
the O O
incidence O O
of O O
upper O O
gastrointestinal O O
adverse O O
events O O
in O O
patients O O
treated O O
with O O
ibandronate B-Drug B-Drug
9 O O
mg O O
daily O O
( O O
9 O O
% O O
) O O
was O O
similar O O
to O O
that O O
in O O
placebo O O
- O O
treated O O
patients O O
( O O
9 O O
% O O
) O O
. O O

Netilmicin B-Drug B-Drug
should O O
not O O
be O O
administered O O
concomitantly O O
with O O
potent O O
loop B-Group B-Group
diuretics I-Group I-Group
such O O
as O O
furosemide B-Drug B-Drug
and O O
ethacrynic B-Drug B-Drug
acid I-Drug I-Drug
as O O
the O O
potential O O
for O O
ototoxicity O O
is O O
enhanced O O
by O O
the O O
combination O O
. O O

Elevated O O
serum O O
levels O O
of O O
cyclosporine B-Drug B-Drug
have O O
been O O
reported O O
with O O
the O O
concomitant O O
use O O
of O O
some O O
quinolones B-Group B-Group
and O O
cyclosporine B-Drug B-Drug
. O O

monitor O O
closely O O
for O O
evidence O O
of O O
hypotension O O
and O O
/ O O
or O O
excessive O O
bradycardia O O
( O O
e.g. O O
vertigo O O
syncope O O
postural O O
hypotension O O
) O O
. O O

Alternate O O
or O O
additional O O
contraceptive O B-Group
measures O I-Group
should O O
be O O
used O O
during O O
therapy O O
with O O
VIRACEPT B-Brand B-Brand

Compounds O O
that O O
have O O
been O O
tested O O
in O O
man O O
include O O
antipyrine B-Drug B-Drug
digoxin B-Drug B-Drug
propranolol B-Drug B-Drug
theophylline B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
and O O
no O O
clinically O O
meaningful O O
interactions O O
were O O
found O O
. O O

Because O O
of O O
the O O
small O O
effect O O
on O O
half O O
- O O
life O O
the O O
coadministration O O
with O O
probenecid B-Drug B-Drug
to O O
extend O O
the O O
half O O
- O O
life O O
of O O
ertapenem B-Drug B-Drug
is O O
not O O
recommended O O
. O O

certain O O
antipsychotic B-Group B-Group
medications I-Group I-Group
( O O
such O O
as O O
sertindole B-Drug B-Drug
) O O
; O O

Observations O O
from O O
drug O O
interaction O O
studies O O
with O O
FORTOVASE B-Brand B-Brand
may O O
not O O
be O O
predictive O O
for O O
INVIRASE B-Brand B-Brand
. O O

Pregnancy O O
Pregnancy O O
Category O O
: O O
C O O
There O O
are O O
no O O
adequate O O
and O O
well O O
- O O
controlled O O
studies O O
of O O
ezetimibe B-Drug B-Drug
in O O
pregnant O O
women O O
. O O

Therefore O O
the O O
dose O O
of O O
corticosteroid B-Group B-Group
should O O
be O O
titrated O O
to O O
avoid O O
steroid O O
toxicity O O
. O O

Dexbrompheniramine B-Drug B-Drug
can O O
interact O O
with O O
alcohol B-Drug B-Drug
or O O
other O O
CNS B-Group B-Group
depressants I-Group I-Group
( O O
may O O
potentiate O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
antihistamines B-Group B-Group
) O O
anticholinergics B-Group B-Group
or O O
other O O
medications O O
with O O
anticholinergic O O
activity O O
( O O
anticholinergic O O
effects O O
may O O
be O O
potentiated O O
when O O
these O O
medications O O
are O O
used O O
concurrently O O
with O O
antihistamines B-Group B-Group
) O O
and O O
monoamine B-Group B-Group
oxidase I-Group I-Group
MAO I-Group I-Group
inhibitors I-Group I-Group
( O O
concurrent O O
use O O
with O O
antihistamines B-Group B-Group
may O O
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
and O O
CNS O O
depressant O O
effects O O
of O O
antihistamines B-Group B-Group
) O O
. O O

No O O
effects O O
on O O
plasma O O
concentrations O O
of O O
cimetidine B-Drug B-Drug
or O O
ketoconazole B-Drug B-Drug
were O O
observed O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
patients O O
receiving O O
Acarbose B-Drug B-Drug
in O O
combination O O
with O O
sulfonylureas B-Group B-Group
or O O
insulin B-Drug B-Drug
patients O O
should O O
be O O
observed O O
closely O O
for O O
any O O
evidence O O
of O O
hypoglycemia O O
. O O

Pregnancy O O
( O O
Category O O
B O O
) O O

fluoxetine B-Drug B-Drug
fluvoxamine B-Drug B-Drug
paroxetine B-Drug B-Drug
sertraline B-Drug B-Drug
) O O
. O O

Drug O O
interactions O O
with O O
SUSTIVA B-Brand B-Brand
are O O
summarized O O
in O O
Table O O
9 O O
. O O

Patients O O
receiving O O
SUTENT B-Brand B-Brand
should O O
not O O
take O O
St O O
. O O

In O O
vitro O O
studies O O
have O O
shown O O
that O O
because O O
of O O
its O O
affinity O O
for O O
protein O O
9MNA B-Drug_n B-Drug_n
may O O
displace O O
other O O
protein O O
- O O
bound O O
drugs O O
from O O
their O O
binding O O
site O O
. O O

Medications O O
can O O
interfere O O
with O O
folate O O
utilization O O
including O O
: O O
anticonvulsant B-Group B-Group
medications I-Group I-Group
( O O
such O O
as O O
phenytoin B-Drug B-Drug
and O O
primidone B-Drug B-Drug
) O O
metformin B-Drug B-Drug
( O O
sometimes O O
prescribed O O
to O O
control O O
blood O O
sugar O O
in O O
type O O
9 O O
diabetes O O
) O O
sulfasalazine B-Drug B-Drug
( O O
used O O
to O O
control O O
inflammation O O
associated O O
with O O
Crohns O O
disease O O
and O O
ulcerative O O
colitis O O
) O O
triamterene B-Drug B-Drug
( O O
a O O
diuretic B-Group B-Group
) O O
Methotrexate B-Drug B-Drug
There O O
has O O
been O O
concern O O
about O O
the O O
interaction O O
between O O
vitamin B-Drug B-Drug
B9 I-Drug I-Drug
and O O
folic B-Drug B-Drug
acid I-Drug I-Drug
. O O

While O O
all O O
the O O
selective B-Group B-Group
serotonin I-Group I-Group
reuptake I-Group I-Group
inhibitors I-Group I-Group
( O O
SSRIs B-Group B-Group
) O O
e. O O
g. O O
fluoxetine B-Drug B-Drug
sertraline B-Drug B-Drug
and O O
paroxetine B-Drug B-Drug
inhibit O O
P9 O O
9D9 O O
they O O
may O O
vary O O
in O O
the O O
extent O O
of O O
inhibition O O
. O O

Reproductive O O
toxicology O O
studies O O
have O O
been O O
performed O O
in O O
cynomolgus O O
monkeys O O
at O O
doses O O
up O O
to O O
9 O O
mg O O
/ O O
kg O O
/ O O
week O O
( O O
about O O
9 O O
times O O
the O O
human O O
dose O O
based O O
on O O
body O O
weight O O
) O O
and O O
have O O
revealed O O
no O O
evidence O O
of O O
impaired O O
fertility O O
or O O
harm O O
to O O
the O O
fetus O O
due O O
to O O
AMEVIVE B-Brand B-Brand
. O O

e.g. O O
other O O
belladonna B-Group B-Group
alkaloids I-Group I-Group
antihistamines B-Group B-Group
( O O
including O O
meclizine B-Drug B-Drug
) O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
and O O
muscle B-Group B-Group
relaxants I-Group I-Group
. O O

Because O O
antacids B-Group B-Group
may O O
interfere O O
with O O
the O O
absorption O O
of O O
anticholinergic B-Group B-Group
agents I-Group I-Group
simultaneous O O
use O O
of O O
these O O
drugs O O
should O O
be O O
avoided O O
. O O

CNS O O
- O O
Active O O
Drugs O O
Ethanol B-Drug B-Drug
An O O
additive O O
effect O O
on O O
psychomotor O O
performance O O
was O O
seen O O
with O O
coadministration O O
of O O
eszopiclone B-Drug B-Drug
and O O
ethanol B-Drug B-Drug
9 O O
g O O
/ O O
kg O O
for O O
up O O
to O O
9 O O
hours O O
after O O
ethanol B-Drug B-Drug
administration O O
. O O

Because O O
warfarin B-Drug B-Drug
is O O
metabolized O O
by O O
CYP9C9 O O
and O O
CYP9A9 O O
patients O O
who O O
require O O
anticoagulation O O
should O O
receive O O
low O O
- O O
molecular O O
weight O O
or O O
standard O O
heparin B-Drug B-Drug
. O O

Laboratory O O
Tests O O
Response O O
to O O
Plenaxis B-Brand B-Brand
should O O
be O O
monitored O O
by O O
measuring O O
serum O O
total O O
testosterone B-Drug O
concentrations O O
just O O
prior O O
to O O
administration O O
on O O
Day O O
9 O O
and O O
every O O
9 O O
weeks O O
thereafter O O
. O O

Administration O O
of O O
phenytoin B-Drug B-Drug
to O O
patients O O
receiving O O
dopamine B-Drug B-Drug
HCl I-Drug I-Drug
has O O
been O O
reported O O
to O O
lead O O
to O O
hypotension O O
and O O
bradycardia O O
. O O

Drugs O O
That O O
Inhibit O O
Alprazolam B-Drug O
Metabolism O O
Via O O
Cytochrome O O
P9 O O
9A O O
: O O
The O O
initial O O
step O O
in O O
alprazolam B-Drug B-Drug
metabolism O O
is O O
hydroxylation O O
catalyzed O O
by O O
cytochrome O O
P9 O O
9A O O
( O O
CYP O O
9A O O
) O O
. O O

indinavir B-Drug B-Drug
concentration O O

The O O
drug O O
interaction O O
data O O
described O O
in O O
this O O
section O O
were O O
obtained O O
from O O
studies O O
involving O O
healthy O O
adults O O
and O O
adult O O
patients O O
with O O
epilepsy O O
. O O

The O O
pharmacodynamic O O
effects O O
can O O
be O O
explained O O
by O O
a O O
combination O O
of O O
the O O
increase O O
in O O
dofetilide B-Drug B-Drug
exposure O O
and O O
the O O
reductions O O
in O O
serum O O
potassium O O
. O O

During O O
co O O
- O O
administration O O
systemic O O
levels O O
of O O
TMP B-Drug B-Drug
and O O
SMX B-Drug B-Drug
were O O
essentially O O
unchanged O O
. O O

They O O
are O O
weak O O
inhibitors O O
of O O
CYP9C9 O O
and O O
CYP9A9 O O
and O O
mild O O
- O O
to O O
- O O
moderate O O
inhibitors O O
of O O
CYP9C9 O O
at O O
therapeutic O O
concentrations O O
. O O

Clinical O O
interaction O O
studies O O
with O O
cimetidine B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
indicated O O
that O O
the O O
coadministration O O
of O O
Femara B-Brand B-Brand
with O O
these O O
drugs O O
does O O
not O O
result O O
in O O
clinically O O
- O O
significant O O
drug O O
interactions O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
of O O
Aranesp B-Brand B-Brand
have O O
been O O
performed O O
. O O

Also O O
concomitant O O
administration O O
of O O
quinolones B-Group B-Group
with O O
products O O
containing O O
iron B-Drug B-Drug
multivitamins B-Group I-Drug
containing O O
zinc B-Drug B-Drug
or O O
Videx B-Brand B-Brand
( O O
didanosine B-Drug B-Drug
) O O
chewable O O
/ O O
buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
may O O
result O O
in O O
low O O
urine O O
levels O O
. O O

( O O
Indomethacin B-Drug B-Drug
) O O
diuretics B-Group B-Group
are O O
used O O
concomitantly O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-Group B-Group
is O O
obtained O O
. O O

There O O
is O O
no O O
information O O
available O O
from O O
adequate O O
drug O O
- O O
drug O O
interaction O O
studies O O
with O O
the O O
following O O
classes O O
of O O
drugs O O
: O O
oral O O
contraceptives B-Group B-Group
hormone O O
replacement O O
therapies O O
hypoglycemics B-Group B-Group
theophyllines B-Drug O
phenytoins B-Drug O
thiazide B-Group B-Group
diuretics I-Group I-Group
beta B-Group B-Group
blockers I-Group I-Group
and O O
calcium B-Group B-Group
channel I-Group I-Group
blockers I-Group I-Group
. O O

There O O
have O O
been O O
rare O O
reports O O
of O O
reddish O O
stools O O
in O O
patients O O
who O O
have O O
received O O
cefdinir B-Drug B-Drug
in O O
Japan O O
. O O

Antacids B-Group B-Group
: O O
Administration O O
of O O
flurbiprofen B-Drug B-Drug
to O O
volunteers O O
under O O
fasting O O
conditions O O
or O O
with O O
antacid B-Group B-Group
suspension O O
yielded O O
similar O O
serum O O
flurbiprofen B-Drug O
time O O
profiles O O
in O O
young O O
subjects O O
( O O
n=9 O O
) O O
. O O

Although O O
clinical O O
studies O O
have O O
not O O
been O O
performed O O
based O O
on O O
the O O
involvement O O
of O O
the O O
cytochrome O O
P O O
- O O
9 O O
9A O O
family O O
in O O
clonazepam B-Drug B-Drug
metabolism O O
inhibitors O O
of O O
this O O
enzyme O O
system O O
notably O O
oral O O
antifungal B-Group B-Group
agents I-Group I-Group
should O O
be O O
used O O
cautiously O O
in O O
patients O O
receiving O O
clonazepam B-Drug B-Drug
. O O

Indinavir B-Drug B-Drug
steady O O
- O O
state O O
Cmax O O
A.C. O O
and O O
Cmin O O
were O O
decreased O O
by O O
9 O O
% O O
9 O O
% O O
and O O
9 O O
% O O
respectively O O
by O O
concomitant O O
amprenavir B-Drug B-Drug
. O O

angioedema O O

Other O O
Antihypertensives B-Group B-Drug
: O O
When O O
MYKROX B-Brand B-Brand
Tablets O O
are O O
used O O
with O O
other O O
antihypertensive B-Group B-Group
drugs I-Group I-Group
care O O
must O O
be O O
taken O O
especially O O
during O O
initial O O
therapy O O
. O O

Grapefruit O O
may O O
also O O
increase O O
plasma O O
concentrations O O
of O O
SUTENT B-Brand B-Brand
. O O

Although O O
not O O
observed O O
in O O
this O O
study O O
adverse O O
effects O O
could O O
potentially O O
arise O O
from O O
co O O
- O O
administration O O
of O O
cephalexin B-Drug B-Drug
and O O
metformin B-Drug B-Drug
by O O
inhibition O O
of O O
tubular O O
secretion O O
via O O
organic O O
cationic O O
transporter O O
systems O O
. O O

Therefore O O
concurrent O O
use O O
of O O
aspirin B-Brand B-Brand
and O O
ketoprofen B-Drug B-Drug
is O O
not O O
recommended O O
. O O

increased O O
alkaline O O

Carbamazepine B-Drug B-Drug
: O O
Felbatol B-Brand B-Brand
causes O O
a O O
decrease O O
in O O
the O O
steady O O
- O O
state O O
carbamazepine B-Drug B-Drug
plasma O O
concentrations O O
and O O
an O O
increase O O
in O O
the O O
steady O O
- O O
state O O
carbamazepine B-Drug_n B-Drug_n
epoxide I-Drug_n I-Drug_n
plasma O O
concentration O O
. O O

Since O O
there O O
is O O
a O O
high O O
degree O O
of O O
variability O O
in O O
the O O
bioavailability O O
of O O
verapamil B-Drug B-Drug
the O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
unclear O O
. O O

In O O
addition O O
there O O
have O O
been O O
cases O O
reported O O
in O O
which O O
concomitant O O
use O O
of O O
amphotericin B-Drug B-Drug
B I-Drug I-Drug
and O O
hydrocortisone B-Drug B-Drug
was O O
followed O O
by O O
cardiac O O
enlargement O O
and O O
congestive O O
heart O O
failure O O
. O O

In O O
patients O O
receiving O O
coumarin B-Group B-Group
- O O
type B-Group B-Group
anticoagulants I-Group I-Group
the O O
addition O O
of O O
Nalfon B-Brand B-Brand
to O O
therapy O O
could O O
prolong O O
the O O
prothrombin O O
time O O
. O O

With O O
oral O O
dapsone B-Drug B-Drug
treatment O O
folic B-Group B-Group
acid I-Group I-Group
antagonists I-Group I-Group
such O O
as O O
pyrimethamine B-Drug B-Drug
have O O
been O O
noted O O
to O O
possibly O O
increase O O
the O O
likelihood O O
of O O
hematologic O O
reactions O O

Cardiac O O
effects O O
of O O
dopamine B-Drug B-Drug
are O O
antagonized O O
by O O
beta B-Group B-Group
- O O
adrenergic B-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
such O O
as O O
propranolol B-Drug B-Drug
and O O
metoprolol B-Drug B-Drug
. O O

Renal O O
Impairment O O
There O O
are O O
currently O O
no O O
clinical O O
studies O O
with O O
SPRYCEL B-Brand B-Brand
in O O
patients O O
with O O
impaired O O
renal O O
function O O
( O O
clinical O O
studies O O
have O O
excluded O O
patients O O
with O O
serum O O
creatinine O O
concentration O O
9 O O
times O O
the O O
upper O O
limit O O
of O O
the O O
normal O O
range O O
) O O
. O O

Therefore O O
the O O
dose O O
of O O
methylprednisolone B-Drug B-Drug
should O O
be O O
titrated O O
to O O
avoid O O
steroid O O
toxicity O O
. O O

Concomitant O O
use O O
of O O
these O O
substances O O
should O O
be O O
avoided O O
. O O

Thiabendazole B-Drug B-Drug
may O O
compete O O
with O O
other O O
drugs O O
such O O
as O O
theophylline B-Drug B-Drug
for O O
sites O O
of O O
metabolism O O
in O O
the O O
liver O O
thus O O
elevating O O
the O O
serum O O
levels O O
of O O
such O O
compounds O O
to O O
potentially O O
toxic O O
levels O O
. O O

Methadone B-Drug B-Drug
levels O O
may O O
be O O
decreased O O
; O O
increased O O
dosages O O
may O O
be O O
required O O
to O O
prevent O O
symptoms O O
of O O
opiate B-Group B-Group
withdrawal O O
. O O
Methadone B-Drug B-Drug
maintained O O
patients O O
beginning O O
nevirapine B-Drug B-Drug
therapy O O
should O O
be O O
monitored O O
forevidence O O
of O O
withdrawal O O
and O O
methadone B-Drug B-Drug
dose O O
should O O
be O O
adjusted O O
accordingly O O
. O O

Acetazolamide B-Drug B-Drug
and O O
sodium B-Drug B-Drug
bicarbonate I-Drug I-Drug
used O O
concurrently O O
increases O O
the O O
risk O O
of O O
renal O O
calculus O O
formation O O
. O O

However O O
this O O
sample O O
size O O
is O O
too O O
small O O
to O O
allow O O
for O O
any O O
conclusions O O
to O O
be O O
drawn O O
regarding O O
the O O
risk O O
of O O
rashes O O
with O O
concomitant O O
AUGMENTIN B-Brand B-Brand
XR I-Brand I-Brand
and O O
allopurinol B-Drug B-Drug
use O O
. O O

If O O
combination O O
therapy O O
is O O
needed O O
careful O O
consideration O O
should O O
be O O
given O O
to O O
the O O
pharmacology O O
of O O
all O O
agents O O
to O O
be O O
used O O
. O O

Compounds O O
tested O O
in O O
man O O
include O O
warfarin B-Drug B-Drug
theophylline B-Drug B-Drug
phenytoin B-Drug B-Drug
diazepam B-Drug B-Drug
aminopyrine B-Drug B-Drug
and O O
antipyrine B-Drug B-Drug
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
glipizide B-Drug B-Drug
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
loss O O
of O O
control O O
. O O

Approximately O O
9 O O
/ O O
9 O O
of O O
the O O
patients O O
in O O
the O O
Phase O O
9 O O
study O O
received O O
either O O
prophylactic O O
low O O
dose O O
heparin B-Drug B-Drug
( O O
unfractionated B-Drug O
heparin I-Drug B-Drug
up O O
to O O
9 O O
9 O O
units O O
/ O O
day O O
) O O
or O O
prophylactic O O
doses O O
of O O
low B-Group O
molecular I-Group O
weight I-Group O
heparins I-Group O
as O O
indicated O O
in O O
the O O
prescribing O O
information O O
for O O
the O O
specific O O
products O O
. O O

Although O O
there O O
is O O
little O O
risk O O
for O O
loss O O
of O O
contraceptive O O
efficacy O O
the O O
clinical O O
significance O O
of O O
these O O
increased O O
exposures O O
in O O
terms O O
of O O
safety O O
is O O
not O O
known O O
. O O

. O O

Concomitant O O
use O O
of O O
SPRYCEL B-Brand B-Brand
and O O
drugs O O
that O O
inhibit O O
CYP9A9 O O
( O O
eg O O
ketoconazole B-Drug B-Drug
itraconazole B-Drug B-Drug
erythromycin B-Drug B-Drug
clarithromycin B-Drug B-Drug
ritonavir B-Drug B-Drug
atazanavir B-Drug B-Drug
indinavir B-Drug B-Drug
nefazodone B-Drug B-Drug
nelfinavir B-Drug B-Drug
saquinavir B-Drug B-Drug
telithromycin B-Drug B-Drug
) O O
may O O
increase O O
exposure O O
to O O
dasatinib B-Drug B-Drug
and O O
should O O
be O O
avoided O O
. O O

The O O
concomitant O O
use O O
of O O
nitrofurantoin B-Drug B-Drug
is O O
not O O
recommended O O
since O O
nitrofurantoin B-Drug B-Drug
may O O
antagonize O O
the O O
antibacterial O O
effect O O
of O O
Norfloxacin B-Drug B-Drug
in O O
the O O
urinary O O
tract O O
. O O

Products O O
containing O O
calcium B-Drug B-Drug
and O O
other O O
multivalent B-Drug O
cations I-Drug O
likely O O
will O O
interfere O O
with O O
absorption O O
of O O
alendronate B-Drug B-Drug
. O O

Studies O O
showed O O
that O O
diltiazem B-Drug B-Drug
increased O O
the O O
AUC O O
of O O
midazolam B-Drug B-Drug
and O O
triazolam B-Drug B-Drug
by O O
9 O O
- O O
9 O O
fold O O
and O O
the O O
Cmax O O
by O O
9 O O
- O O
fold O O
compared O O
to O O
placebo O O
. O O

No O O
clinically O O
relevant O O
interactions O O
with O O
drugs O O
metabolized O O
by O O
these O O
CYP O O
enzymes O O
would O O
be O O
expected O O
. O O

The O O
pharmacokinetic O O
interactions O O
listed O O
below O O
are O O
potentially O O
clinically O O
important O O
. O O

Digoxin B-Drug B-Drug
: O O
In O O
controlled O O
studies O O
in O O
healthy O O
volunteers O O
bepridil B-Drug B-Drug
hydrochloride I-Drug I-Drug
either O O
had O O
no O O
effect O O
( O O
one O O
study O O
) O O
or O O
was O O
associated O O
with O O
modest O O
increases O O
about O O
9 O O
% O O
( O O
two O O
studies O O
) O O
in O O
steady O O
- O O
state O O
serum O O
digoxin B-Drug B-Drug
concentrations O O
. O O

Concomitant O O
treatment O O
with O O
NEXAVAR B-Brand B-Brand
resulted O O
in O O
a O O
9 O O
% O O
increase O O
in O O
the O O
AUC O O
of O O
doxorubicin B-Drug B-Drug
. O O

Although O O
a O O
dose O O
adjustment O O
of O O
azithromycin B-Drug B-Drug
is O O
not O O
recommended O O
when O O
administered O O
in O O
combination O O
with O O
nelfinavir B-Drug B-Drug
close O O
monitoring O O
for O O
known O O
side O O
effects O O
of O O
azithromycin B-Drug B-Drug
such O O
as O O
liver O O
enzyme O O
abnormalities O O
and O O
hearing O O
impairment O O
is O O
warranted O O
. O O

Concomitant O O
treatment O O
with O O
thrombolytics B-Group B-Drug
( O O
eg O O
rt O O
- O O
PA O O
or O O
streptokinase B-Drug O
) O O
may O O
: O O
- O O
increase O O
the O O
risk O O
of O O
bleeding O O
complications O O
- O O
considerably O O
enhance O O
the O O
effect O O
of O O
REFLUDAN B-Brand B-Brand
on O O
aPTT O O
prolongation O O

In O O
these O O
studies O O
no O O
interaction O O
that O O
altered O O
the O O
pharmacokinetics O O
of O O
micafungin B-Drug B-Drug
was O O
observed O O
. O O

Warfarin B-Drug B-Drug
: O O
No O O
significant O O
differences O O
were O O
observed O O
in O O
the O O
steady O O
- O O
state O O
pharmacokinetics O O
of O O
R B-Drug B-Drug
- O O
warfarin B-Drug B-Drug
or O O
S B-Drug B-Drug
- O O
warfarin B-Drug B-Drug
with O O
the O O
addition O O
of O O
tiagabine B-Drug B-Drug
given O O
as O O
a O O
single O O
dose O O
. O O

Concomitant O O
use O O
of O O
Isocarboxazid B-Drug B-Drug
and O O
other O O
psychotropic B-Group B-Group
agents I-Group I-Group
is O O
generally O O
not O O
recommended O O
because O O
of O O
possible O O
potentiating O O
effects O O
. O O

This O O
has O O
been O O
demonstrated O O
in O O
view O O
however O O
the O O
clinical O O
significance O O
of O O
this O O
interaction O O
is O O
not O O
well O O
documented O O
. O O

When O O
a O O
single O O
9 O O
mg O O
dose O O
of O O
rimantadine B-Drug B-Drug
HCl I-Drug I-Drug
was O O
administered O O
one O O
hour O O
after O O
the O O
initiation O O
of O O
Cimetidine B-Drug B-Drug
( O O
9 O O
mg O O
four O O
times O O
a O O
day O O
) O O
the O O
apparent O O
total O O
rimantadine B-Drug B-Drug
clearance O O
of O O
this O O
single O O
dose O O
in O O
normal O O
healthy O O
adults O O
was O O
reduced O O
by O O
9 O O
% O O
( O O
compared O O
to O O
the O O
apparent O O
total O O
rimantadine B-Drug B-Drug
clearance O O
in O O
the O O
same O O
subjects O O
in O O
the O O
absence O O
of O O
cimetidine B-Drug B-Drug
) O O
. O O

In O O
situations O O
when O O
concurrent O O
therapy O O
is O O
necessary O O
careful O O
patient O O
monitoring O O
is O O
essential O O
. O O

These O O
agents O O
may O O
also O O
prolong O O
the O O
clinically O O
effective O O
duration O O
of O O
action O O
by O O
up O O
to O O
9 O O
% O O
. O O

H9 B-Group B-Group
- O O
Receptor B-Group B-Group
Antagonists I-Group I-Group
: O O
Co O O
- O O
administration O O
of O O
a O O
single O O
dose O O
of O O
intravenously O O
administered O O
famotidine B-Drug B-Drug
( O O
9 O O
mg O O
) O O
reduced O O
the O O
oral O O
absorption O O
of O O
a O O
single O O
9 O O
mg O O
dose O O
of O O
cefditoren B-Drug B-Drug
pivoxil I-Drug I-Drug
administered O O
following O O
a O O
meal O O
as O O
evidenced O O
by O O
a O O
9 O O
% O O
decrease O O
in O O
mean O O
Cmax O O
and O O
a O O
9 O O
% O O
decrease O O
in O O
mean O O
AUC O O
. O O

A O O
possible O O
interaction O O
has O O
been O O
suggested O O
with O O
hormonal B-Group B-Group
contraceptives I-Group I-Group
and O O
the O O
herbal O O
supplement O O
St. O O
Johns O O
Wort O O
based O O
on O O
some O O
reports O O
of O O
oral O O
contraceptive B-Group O
users O O
experiencing O O
breakthrough O O
bleeding O O
shortly O O
after O O
starting O O
St. O O
Johns O O
Wort O O
. O O

Do O O
not O O
start O O
or O O
stop O O
any O O
medicine O O
without O O
doctor O O
or O O
pharmacist O O
approval O B-Drug
. O O

While O O
mean O O
INR O O
values O O
were O O
only O O
slightly O O
increased O O
with O O
coadministration O O
of O O
valdecoxib B-Drug B-Drug
the O O
day O O
- O O
to O O
- O O
day O O
variability O O
in O O
individual O O
INR O O
values O O
was O O
increased O O
. O O

Therefore O O
OMNICEF B-Brand B-Brand
for O O
Oral O O
Suspension O O
can O O
be O O
administered O O
with O O
iron B-Drug_n B-Drug_n
- O O
fortified O O
infant O O
formula O O
. O O

block O O
or O O
arrhythmia O O
. O O

The O O
effect O O
of O O
corticosteroids B-Group B-Group
on O O
oral O O
anticoagulants B-Group B-Group
is O O
variable O O
. O O

- O O
Anticoagulants B-Group B-Group
: O O
Interaction O O
studies O O
in O O
humans O O
have O O
shown O O
bumetanide B-Drug B-Drug
to O O
have O O
no O O
effect O O
on O O
warfarin B-Drug B-Drug
metabolism O O
or O O
on O O
plasma O O
prothrombin O O
activity O O
. O O

. O O

Nevertheless O O
the O O
effects O O
of O O
Mefloquine B-Drug B-Drug
on O O
travelers O O
receiving O O
comedication O O
particularly O O
diabetics O O
or O O
patients O O
using O O
anticoagulants B-Group B-Group
should O O
be O O
checked O O
before O O
departure O O
. O O

Since O O
entecavir B-Drug B-Drug
is O O
primarily O O
eliminated O O
by O O
the O O
kidneys O O
coadministration O O
of O O
BARACLUDE B-Brand B-Brand
with O O
drugs O O
that O O
reduce O O
renal O O
function O O
or O O
compete O O
for O O
active O O
tubular O O
secretion O O
may O O
increase O O
serum O O
concentrations O O
of O O
either O O
entecavir B-Drug B-Drug
or O O
the O O
coadministered O O
drug O O
. O O

If O O
concomitant O O
treatment O O
with O O
naratriptan B-Drug B-Drug
and O O
an O O
SSRI B-Group B-Group
is O O
clinically O O
warranted O O
appropriate O O
observation O O
of O O
the O O
patient O O
is O O
advised O O
. O O

Antihistamines B-Group B-Group
may O O
partially O O
counteract O O
the O O
anticoagulation O O
effects O O
of O O
heparin B-Drug B-Drug
or O O
warfarin B-Drug B-Drug
. O O

Limited O O
published O O
data O O
indicate O O
that O O
GH B-Drug B-Drug
treatment O O
increases O O
cytochrome O O
P9 O O
( O O
CP9 O O
) O O
mediated O O
antipyrine B-Drug B-Drug
clearance O O
in O O
man O O
. O O

therefore O O
the O O
disposition O O
of O O
eszopiclone B-Drug B-Drug
is O O
not O O
expected O O
to O O
be O O
sensitive O O
to O O
alterations O O
in O O
protein O O
binding O O
. O O

Drugs O O
such O O
as O O
troleandomycin B-Drug B-Drug
and O O
ketoconazole B-Drug B-Drug
may O O
inhibit O O
the O O
metabolism O O
of O O
methylprednisolone B-Drug B-Drug
and O O
thus O O
decrease O O
its O O
clearance O O
. O O

Of O O
particular O O
importance O O
sufficient O O
time O O
must O O
elapse O O
before O O
initiating O O
TCA O O
treatment O O
in O O
a O O
patient O O
being O O
withdrawn O O
from O O
fluoxetine B-Drug B-Drug
given O O
the O O
long O O
half O O
- O O
life O O
of O O
the O O
parent O O
and O O
active O O
metabolite O O
( O O
at O O
least O O
9 O O
weeks O O
may O O
be O O
necessary O O
) O O
. O O

Patients O O
medicated O O
with O O
these O O
drugs O O
and O O
trimetrexate B-Drug B-Drug
should O O
be O O
carefully O O
monitored O O
. O O

aBased O O
on O O
reports O O
of O O
narcotic O B-Group
withdrawal O O
syndrome O O
in O O
patients O O
treated O O
with O O
nevirapine B-Drug B-Drug
and O O
methadone B-Drug B-Drug
concurrently O O
and O O
evidence O O
of O O
decreased O O
plasma O O
concentrations O O
of O O
methadone B-Drug B-Drug
. O O

Other O O
interactions O O
: O O
Vardenafil B-Drug B-Drug
had O O
no O O
effect O O
on O O
the O O
pharmacodynamics O O
of O O
glyburide B-Drug B-Drug
( O O
glucose O O
and O O
insulin O B-Drug
concentrations O O
) O O
and O O
warfarin B-Drug B-Drug
( O O
prothrombin O O
time O O
or O O
other O O
pharmacodynamic O O
parameters O O
) O O
. O O

Special O O
consideration O O
should O O
be O O
given O O
to O O
the O O
administration O O
of O O
ETHYOL B-Brand B-Brand
in O O
patients O O
receiving O O
antihypertensive B-Group B-Group
medications I-Group I-Group
or O O
other O O
drugs O O
that O O
could O O
cause O O
or O O
potentiate O O
hypotension O O
. O O

Once O O
a O O
stable O O
prothrombin O O
time O O
has O O
been O O
documented O O
prothrombin O O
times O O
can O O
be O O
monitored O O
at O O
the O O
intervals O O
usually O O
recommended O O
for O O
patients O O
on O O
coumarin B-Group B-Group
anticoagulants I-Group I-Group
. O O

A O O
greater O O
potentiation O O
of O O
the O O
neuromuscular O O
blocking O O
effects O O
of O O
MIVACRON B-Brand B-Brand
may O O
be O O
expected O O
with O O
higher O O
concentrations O O
of O O
enflurane B-Drug B-Drug
or O O
isoflurane B-Drug B-Drug
. O O

Based O O
on O O
an O O
in O O
vitro O O
rat O O
liver O O
model O O
nitrogen O O
substituted O O
imidazole B-Group O
drugs I-Group O
( O O
clotrimazole B-Drug B-Drug
ketoconazole B-Drug B-Drug
miconazole B-Drug B-Drug
) O O
were O O
potent O O
non O O
- O O
competitive O O
inhibitors O O
of O O
trimetrexate B-Drug B-Drug
metabolism O O
. O O

. O O

Multivalent O O
Cation O O
- O O
Containing O O
Products O O
: O O
Concurrent O O
administration O O
of O O
a O O
quinolone B-Group B-Group
including O O
ciprofloxacin B-Drug B-Drug
with O O
multivalent O O
cation O O
- O O
containing O O
products O O
such O O
as O O
magnesium B-Drug B-Drug
or O O
aluminum B-Drug B-Group
antacids B-Group I-Group
sucralfate B-Drug B-Drug
VIDEX B-Brand B-Brand
chewable O O
/ O O
buffered O O
tablets O O
or O O
pediatric O O
powder O O
or O O
products O O
containing O O
calcium B-Drug B-Drug
iron B-Drug B-Drug
or O O
zinc B-Drug B-Drug
may O O
substantially O O
decrease O O
the O O
absorption O O
of O O
ciprofloxacin B-Drug B-Drug
resulting O O
in O O
serum O O
and O O
urine O O
levels O O
considerably O O
lower O O
than O O
desired O O
. O O

If O O
the O O
treatment O O
is O O
continued O O
these O O
patients O O
should O O
be O O
particularly O O
carefully O O
monitored O O
for O O
adverse O O
effects O O
especially O O
conduction O O
disturbances O O
and O O
exacerbation O O
of O O
tachyarrhythmias O O
as O O
amiodarone B-Drug B-Drug
is O O
continued O O
. O O

. O O

Neither O O
subject O O
demonstrated O O
clinical O O
evidence O O
of O O
allergic O O
or O O
anaphylactic O O
reactions O O
and O O
repeat O O
testing O O
was O O
not O O
performed O O
. O O

Oral O O
neomycin B-Drug B-Drug
sulfate I-Drug I-Drug
may O O
enhance O O
the O O
effect O O
of O O
coumarin B-Group B-Group
in O O
anticoagulants B-Group B-Group
by O O
decreasing O O
vitamin O O
K O O
availability O O
. O O

Thus O O
the O O
interaction O O
observed O O
between O O
erythromycin B-Drug B-Drug
and O O
terfenadine B-Drug B-Drug
is O O
not O O
expected O O
for O O
dirithromycin B-Drug B-Drug
. O O

For O O
patients O O
receiving O O
ketoconazole B-Drug B-Drug
or O O
other O O
potent O O
CYP9A9 O O
inhibitors O O
such O O
as O O
other O O
azole B-Group B-Group
antifungals I-Group I-Group
( O O
eg O O
itraconazole B-Drug B-Drug
miconazole B-Drug B-Drug
) O O
or O O
macrolide B-Group B-Group
antibiotics I-Group I-Group
( O O
eg O O
erythromycin B-Drug B-Drug
clarithromycin B-Drug B-Drug
) O O
or O O
cyclosporine B-Drug B-Drug
or O O
vinblastine B-Drug B-Drug
the O O
recommended O O
dose O O
of O O
DETROL B-Brand B-Brand
LA I-Brand I-Brand
is O O
9 O O
mg O O
daily O O
. O O

In O O
one O O
controlled O O
clinical O O
study O O
the O O
ureidopenicillins O O
including O O
piperacillin B-Drug B-Drug
were O O
reported O O
to O O
prolong O O
the O O
action O O
of O O
vecuronium B-Drug B-Drug
. O O

In O O
five O O
men O O
terfenadine B-Drug B-Drug
levels O O
were O O
undetectable O O
( O O
9 O O
ng O O
/ O O
mL O O
) O O
throughout O O
the O O
study O O
; O O

Avoid O O
the O O
use O O
of O O
preparations O O
such O O
as O O
decongestants B-Group B-Group
and O O
local O O
anesthetics B-Group B-Group
which O O
contain O O
any O O
sympathomimetic B-Group B-Group
amine I-Group O
( O O
e.g. O O
epinephrine B-Drug B-Drug
norepinephrine B-Drug B-Drug
) O O
since O O
it O O
has O O
been O O
reported O O
that O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
can O O
potentiate O O
the O O
effects O O
of O O
catecholamines O B-Group
. O O

Concurrent O O
use O O
of O O
phenothiazines B-Group B-Group
may O O
antagonize O O
the O O
anorectic O O
effect O O
of O O
diethylpropion B-Drug B-Drug
. O O

In O O
the O O
absence O O
of O O
definitive O O
information O O
caution O O
should O O
be O O
used O O
when O O
coadministering O O
fluconazole B-Drug B-Drug
. O O

Therefore O O
precaution O O
should O O
be O O
taken O O
when O O
coadministration O O
is O O
necessary O O
. O O

Leucovorin B-Drug B-Drug
: O O
The O O
concentration O O
of O O
9 B-Drug B-Drug
- O O
fluorouracil B-Drug B-Drug
is O O
increased O O
and O O
its O O
toxicity O O
may O O
be O O
enhanced O O
by O O
leucovorin B-Drug B-Drug
. O O

When O O
carbamazepine B-Drug B-Drug
is O O
added O O
to O O
aripiprazole B-Drug B-Drug
therapy O O
aripiprazole B-Drug B-Drug
dose O O
should O O
be O O
doubled O O
. O O

administration O O
9 O O
hour O O
before O O
or O O
9 O O
hours O O
after O O
colestipol B-Drug B-Drug
is O O
recommended O O
. O O
) O O

= O O
increase O O
; O O

Since O O
animal O O
studies O O
suggest O O
that O O
the O O
action O O
of O O
barbiturates B-Group B-Group
may O O
be O O
prolonged O O
by O O
therapy O O
with O O
chlorpropamide B-Drug B-Drug
barbiturates B-Group B-Group
should O O
be O O
employed O O
with O O
caution O O
. O O

The O O
potential O O
for O O
drug O O
- O O
drug O O
interaction O O
with O O
drugs O O
affected O O
by O O
cytochrome O O
P9 O O
enzymes O O
may O O
not O O
be O O
ruled O O
out O O
. O O

therefore O O
the O O
disposition O O
of O O
zaleplon B-Drug B-Drug
is O O
not O O
expected O O
to O O
be O O
sensitive O O
to O O
alterations O O
in O O
protein O O
binding O O
. O O

In O O
addition O O
based O O
on O O
the O O
population O O
pharmacokinetics O O
analysis O O
of O O
the O O
combined O O
data O O
from O O
grapefruit O O
and O O
orange O O
juices O O
studies O O
with O O
the O O
data O O
from O O
a O O
bioequivalence O O
study O O
the O O
bioavailability O O
of O O
fexofenadine B-Drug B-Drug
was O O
reduced O O
by O O
9 O O
% O O
. O O

Elevated O O
cyclosporine B-Drug B-Drug
serum O O
levels O O
have O O
been O O
reported O O
with O O
the O O
concomitant O O
use O O
of O O
quinolones B-Group B-Group
and O O
cyclosporine B-Drug B-Drug
. O O

However O O
there O O
were O O
9 O O
% O O
and O O
9 O O
% O O
increases O O
in O O
the O O
AUC O O
and O O
Cmax O O
respectively O O
of O O
the O O
combined O O
moieties O O
of O O
threohydrobupropion B-Drug_n B-Drug_n
and O O
erythrohydrobupropion B-Drug_n B-Drug_n
. O O

The O O
effect O O
of O O
clofarabine B-Drug B-Drug
on O O
the O O
metabolism O O
of O O
cytochrome O O
p9 O O
substrates O O
has O O
not O O
been O O
studied O O
. O O

Hypotension O O
Patients O O
on O O
Diuretic B-Group O
Therapy O O
: O O
Patients O O
on O O
diuretics B-Group B-Group
and O O
especially O O
those O O
in O O
whom O O
diuretic B-Group O
therapy O O
was O O
recently O O
instituted O O
as O O
well O O
as O O
those O O
on O O
severe O O
dietary O O
salt O O
restriction O O
or O O
dialysis O O
may O O
occasionally O O
experience O O
a O O
precipitous O O
reduction O O
of O O
blood O O
pressure O O
usually O O
within O O
the O O
first O O
hour O O
after O O
receiving O O
the O O
initial O O
dose O O
of O O
captopril B-Drug B-Drug
. O O

Therefore O O
the O O
potential O O
exists O O
for O O
a O O
drug O O
interaction O O
between O O
WELLBUTRIN B-Brand B-Brand
and O O
drugs O O
that O O
affect O O
the O O
CYP9B9 O O
isoenzyme O O
( O O
e.g. O O
orphenadrine B-Drug B-Drug
and O O
cyclophosphamide B-Drug B-Drug
) O O
. O O

The O O
concentrations O O
of O O
SN9 B-Drug_n O
the O O
active O O
metabolite O O
of O O
irinotecan B-Drug B-Drug
were O O
on O O
average O O
9 O O
% O O
higher O O
in O O
patients O O
receiving O O
bolus O O
- O O
IFL O O
in O O
combination O O
with O O
AVASTIN B-Brand B-Brand
when O O
compared O O
with O O
bolus O O
- O O
IFL O O
alone O O
. O O

Although O O
such O O
a O O
reaction O O
has O O
not O O
been O O
demonstrated O O
with O O
roxithromycin B-Drug B-Drug
concomitant O O
administration O O
of O O
roxithromycin B-Drug B-Drug
with O O
terfenadine B-Drug B-Drug
or O O
astemizole B-Drug B-Drug
is O O
not O O
recommended O O
. O O

9 O O
% O O

Rare O O
cases O O
of O O
a O O
disulfiram O B-Drug
- O O
like O O
reaction O O
to O O
alcohol B-Drug B-Drug
have O O
been O O
reported O O
. O O

plasma O O
levels O O
of O O
several O O
closely O O
related O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
have O O
been O O
reported O O
to O O
be O O
increased O O
by O O
the O O
concomitant O O
administration O O
of O O
methylphenidate B-Drug B-Drug
or O O
hepatic O O
enzyme O O
inhibitors O O
( O O
e.g. O O
cimetidine B-Drug B-Drug
fluoxetine B-Drug B-Drug
) O O
and O O
decreased O O
by O O
the O O
concomitant O O
administration O O
of O O
hepatic O O
enzyme O O
inducers O O
( O O
e.g. O O
barbiturates B-Group B-Group
phenytoin B-Drug B-Drug
) O O
and O O
such O O
an O O
effect O O
may O O
be O O
anticipated O O
with O O
CMI B-Drug B-Drug
as O O
well O O
. O O

Terfenadine B-Drug B-Drug
: O O
In O O
a O O
prospective O O
study O O
involving O O
six O O
- O O
healthy O O
- O O
male O O
volunteers O O
dirithromycin B-Drug B-Drug
did O O
not O O
affect O O
the O O
metabolism O O
of O O
terfenadine B-Drug B-Drug
. O O

The O O
AUC O O
of O O
ciprofloxacin B-Drug B-Drug
was O O
decreased O O
an O O
average O O
of O O
9 O O
- O O
fold O O
in O O
9 O O
healthy O O
subjects O O
given O O
ciprofloxacin B-Drug B-Drug
and O O
didanosine B-Drug B-Drug
- O O
placebo O O
tablets O O
concurrently O O
. O O

Antiarrhythmics B-Group B-Drug
: O O
amiodarone B-Drug B-Drug

Prednisone B-Drug B-Drug
/ O O
prednisolone B-Drug B-Drug
: O O
Rofecoxib B-Drug B-Drug
did O O
not O O
have O O
any O O
clinically O O
important O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
prednisolone B-Drug B-Drug
or O O
prednisone B-Drug B-Drug
. O O

In O O
addition O O
a O O
decrease O O
in O O
PBI O O
and O O
radioactive O O
iodine O O
uptake O O
may O O
occur O O
. O O

Hypersensitivity O O
reactions O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
combination O O
regimens O O
containing O O
sequential O O
high O O
dose O O
PROLEUKIN B-Brand B-Brand
and O O
antineoplastic B-Group B-Group
agents I-Group I-Group
specifically O O
dacarbazine B-Drug O
cis B-Drug O
- O O
platinum B-Drug O
tamoxifen B-Drug B-Drug
and O O
interferon B-Drug B-Drug
- O O
alfa B-Drug B-Drug
. O O

Anastrozole B-Drug B-Drug
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
antipyrine B-Drug B-Drug
. O O

Fluvoxamine B-Drug B-Drug
increased O O
mean O O
alosetron B-Drug B-Drug
plasma O O
concentrations O O
( O O
AUC O O
) O O
approximately O O
9 O O
- O O
fold O O
and O O
prolonged O O
the O O
half O O
- O O
life O O
by O O
approximately O O
9 O O
- O O
fold O O
. O O

Therefore O O
concurrent O O
use O O
of O O
Trileptal B-Brand B-Brand
with O O
hormonal B-Group B-Group
contraceptives I-Group I-Group
may O O
render O O
these O O
contraceptives B-Group B-Group
less O O
effective O O
. O O

Quinolone B-Group B-Group
Antibiotics I-Group I-Group
: O O
VIDEX B-Brand B-Brand
should O O
be O O
administered O O
at O O
least O O
9 O O
hours O O
after O O
or O O
9 O O
hours O O
before O O
dosing O O
with O O
ciprofloxacin B-Drug B-Drug
because O O
plasma O O
concentrations O O
of O O
ciprofloxacin B-Drug B-Drug
are O O
decreased O O
when O O
administered O O
with O O
antacids B-Group B-Group
containing O O
magnesium B-Drug B-Drug
calcium B-Drug B-Drug
or O O
aluminum B-Drug B-Drug
. O O

These O O
are O O
described O O
in O O
greater O O
detail O O
below O O
: O O
DIFLUCAN B-Brand B-Brand
and O O
the O O
following O O
agents O O
/ O O
classes O O
have O O
been O O
observed O O
. O O

Ritonavir B-Drug B-Drug
- O O
Combined O O
administration O O
of O O
a O O
single O O
dose O O
of O O
ritonavir B-Drug B-Drug
( O O
9 O O
mg O O
) O O
both O O
a O O
CYP9A9 O O
substrate O O
and O O
a O O
potent O O
inhibitor O O
of O O
CYP9A9 O O
and O O
escitalopram B-Drug B-Drug
( O O
9 O O
mg O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
either O O
ritonavir B-Drug B-Drug
or O O
escitalopram B-Drug B-Drug
. O O

Amprenavir B-Drug B-Drug

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
MICRONASE B-Brand B-Brand
the O O
patient O O
should O O
be O O
closely O O
observed O O
for O O
loss O O
of O O
control O O
. O O

The O O
second O O
pregnancy O O
test O O
( O O
a O O
confirmation O O
test O O
) O O
should O O
be O O
done O O
during O O
the O O
first O O
9 O O
days O O
of O O
the O O
menstrual O O
period O O
immediately O O
preceding O O
the O O
beginning O O
of O O
Accutane B-Brand B-Brand
therapy O O
. O O

Because O O
severe O O
hypoglycemia O O
has O O
been O O
reported O O
in O O
patients O O
concomitantly O O
receiving O O
oral O O
miconazole B-Drug B-Drug
( O O
an O O
imidazole B-Group B-Drug
) O O
and O O
oral O O
hypoglycemic B-Group B-Group
agents I-Group I-Group
such O O
a O O
potential O O
interaction O O
involving O O
the O O
latter O O
agents O O
when O O
used O O
concomitantly O O
with O O
ketoconazole B-Drug B-Drug
tablets O O
( O O
an O O
imidazole B-Group B-Drug
) O O
can O O
not O O
be O O
ruled O O
out O O
. O O

Itraconazole B-Drug B-Drug

Concomitant O O
Crohn O O
disease O O
medications O O
were O O
antibiotics B-Group B-Group
antivirals B-Group O
corticosteroids B-Group B-Group
9 B-Drug O
- O O
MP B-Drug O
/ O O
AZA B-Drug O
and O O
aminosalicylates O O
. O O

Fluvoxamine B-Drug B-Drug
has O O
also O O
been O O
shown O O
to O O
inhibit O O
P9 O O
9A9 O O
an O O
isoform O O
also O O
involved O O
in O O
TCA B-Group B-Group
metabolism O O
. O O

Acute O O
symptoms O O
should O O
be O O
treated O O
with O O
a O O
short O B-Group
- O O
acting O O
inhaled O O
beta9 B-Group B-Group
- O O
agonist B-Group O
such O O
as O O
salbutamol B-Drug B-Drug
( O O
the O O
physician O O
should O O
provide O O
the O O
patient O O
with O O
such O O
medication O O
and O O
instruct O O
the O O
patient O O
in O O
how O O
it O O
should O O
be O O
used O O
) O O
. O O

. O O

The O O
mean O O
minimum O O
lithium B-Drug B-Drug
concentration O O
increased O O
9 O O
% O O
and O O
the O O
renal O O
clearance O O
of O O
lithium B-Drug B-Drug
was O O
decreased O O
by O O
9 O O
% O O
during O O
this O O
period O O
of O O
concomitant O O
drug O O
administration O O
. O O

Erythromycin B-Drug B-Drug
has O O
been O O
reported O O
to O O
decrease O O
the O O
clearance O O
of O O
triazolam B-Drug B-Drug
and O O
midazolam B-Drug B-Drug
and O O
thus O O
may O O
increase O O
the O O
pharmacologic O O
effect O O
of O O
these O O
benzodiazepines B-Group B-Group
. O O

Usually O O
this O O
has O O
been O O
observed O O
in O O
patients O O
with O O
a O O
history O O
of O O
diabetes O O
mellitus O O
or O O
evidence O O
of O O
glucose O O
intolerance O O
prior O O
to O O
administration O O
of O O
CAMPTOSAR B-Brand B-Brand
. O O

Acetaminophen B-Drug B-Drug
and O O
methotrexate B-Drug B-Drug
- O O
L B-Drug B-Drug
- O O
methionine B-Drug B-Drug
may O O
decrease O O
hepatic O O
toxicity O O
in O O
those O O
with O O
acetaminophen B-Drug B-Drug
overdosage O O
or O O
in O O
those O O
taking O O
methotrexate B-Drug B-Drug
. O O

In O O
vitro O O
studies O O
have O O
shown O O
succimer B-Drug O
to O O
cause O O
false O O
positive O O
results O O
for O O
ketones O O
in O O
urine O O
using O O
nitroprusside O B-Drug
reagents O O
such O O
as O O
Ketostix O O
and O O
falsely O O
decreased O O
measurements O O
of O O
serum O O
uric O O
acid O O
and O O
CPK O O
. O O

Caution O O
is O O
advised O O
if O O
patients O O
receive O O
large O O
doses O O
of O O
ethchlorvynol B-Drug B-Drug
concurrently O O
. O O

The O O
plasma O O
concentration O O
of O O
imipramine B-Drug B-Drug
may O O
increase O O
when O O
the O O
drug O O
is O O
given O O
concomitantly O O
with O O
hepatic O O
enzyme O O
inhibitors O O
( O O
e.g. O O
cimetidine B-Drug B-Drug
fluoxetine B-Drug B-Drug
) O O
and O O
decrease O O
by O O
concomitant O O
administration O O
of O O
hepatic O O
enzyme O O
inducers O O
( O O
e.g. O O
barbiturates B-Group B-Group
phenytoin B-Drug B-Drug
) O O
and O O
adjustment O O
of O O
the O O
dosage O O
of O O
imipramine B-Drug B-Drug
may O O
therefore O O
be O O
necessary O O
. O O

The O O
clinical O O
significance O O
of O O
these O O
findings O O
is O O
unknown O O
. O O

In O O
some O O
patients O O
the O O
combined O O
use O O
of O O
indomethacin B-Drug B-Drug
and O O
diflunisal B-Drug B-Drug
has O O
been O O
associated O O
with O O
fatal O O
gastrointestinal O O
hemorrhage O O
. O O

Antimycobacterial B-Group B-Group
: O O
rifampin B-Drug B-Drug

In O O
a O O
pharmacokinetic O O
study O O
9 O O
healthy O O
female O O
subjects O O
received O O
ketoconazole B-Drug B-Drug
9 O O
mg O O
twice O O
daily O O
for O O
9 O O
days O O
with O O
coadministration O O
of O O
alosetron B-Drug B-Drug
9 O O
mg O O
on O O
the O O
last O O
day O O
. O O

The O O
magnitude O O
of O O
interaction O O
within O O
the O O
recommended O O
dose O O
ranges O O
of O O
either O O
drug O O
is O O
not O O
known O O
. O O

In O O
the O O
case O O
that O O
you O O
are O O
taking O O
digoxin B-Drug B-Drug
while O O
taking O O
aminosalicylic B-Drug B-Drug
acid I-Drug I-Drug
higher O O
doses O O
of O O
digoxin B-Drug B-Drug
may O O
be O O
needed O O
. O O

Anti B-Group B-Group
- O O
arrhythmics B-Group B-Group
and O O
tricyclic B-Group B-Group
anti I-Group I-Group
- O O
depressants B-Group B-Group
could O O
exaggerate O O
the O O
prolongation O O
of O O
the O O
QT O O
interval O O
observed O O
with O O
bepridil B-Drug B-Drug
hydrochloride I-Drug I-Drug
. O O

The O O
rate O O
and O O
extent O O
of O O
perindopril B-Drug B-Drug
absorption O O
and O O
elimination O O
are O O
not O O
affected O O
by O O
concomitant O O
diuretics B-Group B-Group
. O O

Caution O O
should O O
be O O
exercised O O
when O O
imipramine B-Drug B-Drug
hydrochloride I-Drug I-Drug
is O O
used O O
with O O
agents O O
that O O
lower O O
blood O O
pressure O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
Cephalosporins B-Group B-Group
are O O
known O O
to O O
occasionally O O
induce O O
a O O
positive O O
direct O O
Coombs O O
test O O
. O O

Cerubidine B-Brand B-Brand
should O O
not O O
be O O
used O O
in O O
patients O O
who O O
have O O
previously O O
received O O
the O O
recommended O O
maximum O O
cumulative O O
doses O O
of O O
doxorubicin B-Drug B-Drug
or O O
Cerubidine B-Brand B-Brand
. O O

Acetazolamide B-Drug B-Drug
: O O
Concurrent O O
use O O
of O O
acetazolamide B-Drug B-Drug
and O O
procaine B-Drug B-Drug
hydrochloride I-Drug I-Drug
may O O
extend O O
the O O
plasma O O
half O O
- O O
life O O
of O O
procaine B-Drug B-Drug
. O O

urticaria O O

Other O O
nephrotoxic O O
medications O O
: O O
agents O O
such O O
as O O
aminoglycosides B-Group B-Group
cyclosporine B-Drug B-Drug
and O O
pentamidine B-Drug B-Drug
may O O
enhance O O
the O O
potential O O
for O O
drug O O
- O O
induced O O
renal O O
toxicity O O
and O O
should O O
be O O
used O O
concomitantly O O
only O O
with O O
great O O
caution O O
. O O

In O O
vitro O O
studies O O
with O O
human O O
liver O O
microsomes O O
showed O O
that O O
terbinafine B-Drug B-Drug
does O O
not O O
inhibit O O
the O O
metabolism O O
of O O
tolbutamide B-Drug B-Drug
ethinylestradiol B-Drug B-Drug
ethoxycoumarin B-Drug_n B-Drug
and O O
cyclosporine B-Drug B-Drug
. O O

Patients O O
treated O O
with O O
Nalfon B-Brand B-Brand
may O O
be O O
resistant O O
to O O
the O O
effects O O
of O O
loop B-Group B-Group
diuretics I-Group I-Group
. O O

Inhibition O O
of O O
metabolism O O
may O O
produce O O
significant O O
increases O O
in O O
circulating O O
phenytoin B-Drug B-Drug
concentrations O O
and O O
enhance O O
the O O
risk O O
of O O
drug O O
toxicity O O
. O O

Systemic O O
clonidine B-Drug B-Drug
may O O
inhibit O O
the O O
production O O
of O O
catecholamines O B-Group
in O O
response O O
to O O
insulin O B-Drug
- O O
induced O O
hypoglycemia O O
and O O
mask O O
the O O
signs O O
and O O
symptoms O O
of O O
hypoglycemia O O
. O O

- O O
did O O
not O O
change O O
the O O
plasma O O
concentration O O
profile O O
of O O
terfenadine B-Drug B-Drug
( O O
a O O
substrate O O
of O O
cytochrome O O
P9 O O
9A9 O O
) O O
or O O
fexofenadine B-Drug B-Drug
its O O
carboxylated O O
metabolite O O
and O O
did O O
not O O
prolong O O
the O O
QTc O O
interval O O
following O O
co O O
- O O
administration O O
with O O
terfenadine B-Drug B-Drug
9 O O
mg O O
twice O O
daily O O
. O O

The O O
onset O O
of O O
neuromuscular O O
blockade O O
by O O
succinylcholine B-Drug B-Drug
was O O
unaffected O O
by O O
BREVIBLOC B-Brand B-Brand
but O O
the O O
duration O O
of O O
neuromuscular O O
blockade O O
was O O
prolonged O O
from O O
9 O O
minutes O O
to O O
9 O O
minutes O O
. O O

Drugs O O
that O O
induce O O
hepatic O O
enzymes O O
such O O
as O O
phenobarbital B-Drug B-Drug
phenytoin B-Drug B-Drug
and O O
rifampin B-Drug B-Drug
may O O
increase O O
the O O
clearance O O
of O O
corticosteroids B-Group B-Group
and O O
may O O
require O O
increases O O
in O O
corticosteroid B-Group B-Group
dose O O
to O O
achieve O O
the O O
desired O O
response O O
. O O

Agents O O
with O O
Increased O O
Levels O O
in O O
the O O
Presence O O
of O O
Carbamazepine B-Drug B-Drug
: O O
EQUETROTM B-Brand B-Brand
increases O O
the O O
plasma O O
levels O O
of O O
the O O
following O O
agents O O
: O O
Clomipramine B-Drug B-Drug
HCl I-Drug I-Drug
Phenytoin B-Drug B-Drug
( O O
9 O O
) O O
and O O
primidone B-Drug B-Drug
Thus O O
if O O
a O O
patient O O
has O O
been O O
titrated O O
to O O
a O O
stable O O
dosage O O
on O O
one O O
of O O
the O O
agents O O
in O O
this O O
category O O
and O O
then O O
begins O O
a O O
course O O
of O O
the O O
treatment O O
with O O
EQUETROTM B-Brand B-Brand
it O O
is O O
reasonable O O
to O O
expect O O
that O O
a O O
dose O O
decrease O O
for O O
the O O
concomitant O O
agent O O
may O O
be O O
necessary O O
. O O

Fenbufen B-Drug B-Drug
is O O
not O O
approved O O
in O O
the O O
United O O
States O O
at O O
this O O
time O O
. O O

Drugs O O
that O O
may O O
decrease O O
dasatinib B-Drug B-Drug
plasma O O
concentrations O O
CYP9A9 O O
Inducers O O
: O O
Drugs O O
that O O
induce O O
CYP9A9 O O
activity O O
may O O
decrease O O
dasatinib B-Drug B-Drug
plasma O O
concentrations O O
. O O

Therefore O O
it O O
is O O
recommended O O
that O O
oral O O
contraceptives B-Group B-Group
are O O
co O O
- O O
administered O O
with O O
Myfortic B-Brand B-Brand
with O O
caution O O
and O O
additional O O
birth O O
control O O
methods O O
be O O
considered O O
. O O

Disulfiram B-Drug B-Drug
appears O O
to O O
decrease O O
the O O
rate O O
at O O
which O O
certain O O
drugs O O
are O O
metabolized O O
and O O
therefore O O
may O O
increase O O
the O O
blood O O
levels O O
and O O
the O O
possibility O O
of O O
clinical O O
toxicity O O
of O O
drugs O O
given O O
concomitantly O O
. O O

As O O
with O O
other O O
drugs O O
that O O
block O O
angiotensin O O
II O O
or O O
its O O
effects O O
concomitant O O
use O O
of O O
potassium B-Group B-Group
- O O
sparing B-Group B-Group
diuretics I-Group I-Group
( O O
e.g. O O
spironolactone B-Drug B-Drug
triamterene B-Drug B-Drug
amiloride B-Drug B-Drug
) O O
potassium B-Drug B-Drug
supplements O O
or O O
salt O O
substitutes O O
containing O O
potassium O B-Drug
may O O
lead O O
to O O
increases O O
in O O
serum O O
potassium O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
DIABINESE B-Brand B-Brand
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Therefore O O
co O O
- O O
administration O O
of O O
clozapine B-Drug B-Drug
with O O
other O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
isozyme O O
including O O
antidepressants B-Group B-Group
phenothiazines B-Group B-Group
carbamazepine B-Drug B-Drug
and O O
Type B-Group B-Group
9C I-Group I-Group
antiarrhythmics I-Group I-Group
( O O
e.g. O O
propafenone B-Drug B-Drug
flecainide B-Drug B-Drug
and O O
encainide B-Drug B-Drug
) O O
or O O
that O O
inhibit O O
this O O
enzyme O O
( O O
e.g. O O
quinidine B-Drug B-Drug
) O O
should O O
be O O
approached O O
with O O
caution O O
. O O

ARAMINE B-Brand B-Brand
should O O
be O O
used O O
with O O
caution O O
in O O
digitalized O O
patients O O
since O O
the O O
combination O O
of O O
digitalis B-Group B-Group
and O O
sympathomimetic B-Group B-Group
amines I-Group I-Group
may O O
cause O O
ectopic O O
arrhythmias O O
. O O

Downward O O
dosage O O
adjustments O O
of O O
these O O
drugs O O
may O O
be O O
required O O
when O O
given O O
concomitantly O O
with O O
Ritalin B-Brand B-Brand
. O O

As O O
with O O
other O O
drugs O O
the O O
potential O O
for O O
interaction O O
by O O
a O O
variety O O
of O O
mechanisms O O
( O O
e.g. O O
pharmacodynamic O O
pharmacokinetic O O
inhibition O O
or O O
enhancement O O
etc O O
. O O
) O O

this O O
phenomenon O O
was O O
not O O
observed O O
in O O
North O O
American O O
clinical O O
trials O O
. O O

9HT9 B-Group O
Antagonists I-Group B-Group
: O O
Based O O
on O O
reports O O
of O O
profound O O
hypotension O O
and O O
loss O O
of O O
consciousness O O
when O O
apomorphine B-Drug B-Drug
was O O
administered O O
with O O
ondansetron B-Drug B-Drug
the O O
concomitant O O
use O O
of O O
apomorphine B-Drug B-Drug
with O O
drugs O O
of O O
the O O
9HT9 B-Group O
antagonist I-Group O
class I-Group O
( O O
including O O
for O O
example O O
ondansetron B-Drug B-Drug
granisetron B-Drug B-Drug
dolasetron B-Drug B-Drug
palonosetron B-Drug B-Drug
and O O
alosetron B-Drug B-Drug
) O O
is O O
contraindicated O O
. O O

The O O
effects O O
of O O
coadministration O O
of O O
BARACLUDE B-Brand B-Brand
with O O
other O O
drugs O O
that O O
are O O
renally O O
eliminated O O
or O O
are O O
known O O
to O O
affect O O
renal O O
function O O
have O O
not O O
been O O
evaluated O O
and O O
patients O O
should O O
be O O
monitored O O
closely O O
for O O
adverse O O
events O O
when O O
BARACLUDE B-Brand B-Brand
is O O
coadministered O O
with O O
such O O
drugs O O
. O O

However O O
current O O
evidence O O
suggests O O
that O O
isoniazid B-Drug B-Drug
does O O
induce O O
P O O
- O O
9IIE9 O O
a O O
mixed O O
- O O
function O O
oxidase O O
enzyme O O
that O O
appears O O
to O O
generate O O
the O O
toxic O O
metabolites O O
in O O
the O O
liver O O
. O O

Benzthiazide B-Drug B-Drug
may O O
interact O O
with O O
alcohol B-Drug B-Drug
blood B-Group O
thinners I-Group O
decongestant B-Group O
drugs I-Group O
( O O
allergy O O
cold O O
and O O
sinus O O
medicines O O
) O O
diabetic O O
drugs O O
lithium B-Drug B-Drug
norepinephrine B-Drug B-Drug
NSAIDs B-Group B-Group
like O O
Aleve B-Brand B-Brand
or O O
Ibuprofen B-Drug B-Drug
and O O
high O O
blood O O
pressure O O
medications O O
. O O

cimetidine B-Drug B-Drug
) O O
and O O
many O O
that O O
are O O
substrates O O
for O O
P9 O O
9D9 O O
( O O
many O O
other O O
antidepressants B-Group B-Group
phenothiazines B-Group B-Group
and O O
the O O
Type B-Group B-Group
9C I-Group I-Group
antiarrhythmics I-Group I-Group
propafenone B-Drug B-Drug
and O O
flecainide B-Drug B-Drug
) O O
. O O

Increases O O
in O O
plasma O O
levels O O
of O O
tricyclic B-Drug B-Group
antidepressants I-Drug I-Group
and O O
in O O
the O O
frequency O O
and O O
severity O O
of O O
side O O
effects O O
particularly O O
anticholinergic B-Drug B-Group
have O O
been O O
reported O O
when O O
cimetidine B-Drug B-Drug
was O O
added O O
to O O
the O O
drug B-Drug O
regimen O O
. O O

Phenytoin B-Drug B-Drug
phenobarbital B-Drug B-Drug
and O O
carbamazepine B-Drug B-Drug
are O O
ge O O
nerally O O
classified O O
as O O
enzyme O O
inducers O O
; O O

Tetracyclines B-Group B-Group
: O O
Since O O
both O O
acitretin B-Drug B-Drug
and O O
tetracyclines B-Group B-Group
can O O
cause O O
increased O O
intracranial O O
pressure O O
their O O
combined O O
use O O
is O O
contraindicated O O
. O O

When O O
DIFLUCAN B-Brand B-Brand
is O O
used O O
concomitantly O O
with O O
these O O
or O O
other O O
sulfonylurea B-Group B-Group
oral I-Group O
hypoglycemic I-Group O
agents I-Group O
blood O O
glucose O O
concentrations O O
should O O
be O O
carefully O O
monitored O O
and O O
the O O
dose O O
of O O
the O O
sulfonylurea B-Group B-Group
should O O
be O O
adjusted O O
as O O
necessary O O
. O O

ranitidine B-Drug B-Drug
* O O
; O O

Zidovudine B-Drug B-Drug
: O O
There O O
is O O
no O O
significant O O
pharmacokinetic O O
interaction O O
between O O
ZDV B-Drug B-Drug
and O O
zalcitabine B-Drug B-Drug
which O O
has O O
been O O
confirmed O O
clinically O O
. O O

In O O
a O O
pharmacokinetic O O
study O O
9 O O
healthy O O
female O O
subjects O O
received O O
fluvoxamine B-Drug B-Drug
in O O
escalating O O
doses O O
from O O
9 O O
to O O
9 O O
mg O O
per O O
day O O
for O O
9 O O
days O O
with O O
coadministration O O
of O O
alosetron B-Drug B-Drug
9 O O
mg O O
on O O
the O O
last O O
day O O
. O O

Beta B-Group B-Group
- O O
adrenergic B-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
may O O
also O O
interact O O
with O O
sympathomimetics B-Group B-Group
. O O

Results O O
demonstrate O O
that O O
oxcarbazepine B-Drug B-Drug
and O O
its O O
pharmacologically O O
active O O
9 O O
- O O
monohydroxy O O
metabolite O O
( O O
MHD B-Drug_n B-Drug_n
) O O
have O O
little O O
or O O
no O O
capacity O O
to O O
function O O
as O O
inhibitors O O
for O O
most O O
of O O
the O O
human O O
cytochrome O O
P9 O O
enzymes O O
evaluated O O
( O O
CYP9A9 O O
CYP9A9 O O
CYP9C9 O O
CYP9D9 O O
CYP9E9 O O
CYP9A9 O O
and O O
CYP9A9 O O
) O O
with O O
the O O
exception O O
of O O
CYP9C9 O O
and O O
CYP9A9 O O
/ O O
9 O O
. O O

9 O O
. O O

Both O O
groups O O
of O O
agents O O
increase O O
blood O O
levels O O
and O O
therefore O O
potentiate O O
the O O
actions O O
of O O
amphetamines B-Group B-Group
. O O

Fluconazole B-Drug B-Drug

( O O
See O O
CLINICAL O O
PHARMACOLOGY O O
) O O
Coadministration O O
of O O
Femara B-Brand B-Brand
and O O
tamoxifen B-Drug B-Drug
9 O O
mg O O
daily O O
resulted O O
in O O
a O O
reduction O O
of O O
letrozole B-Drug B-Drug
plasma O O
levels O O
by O O
9 O O
% O O
on O O
average O O
. O O

The O O
carcinogenic O O
potential O O
of O O
ribavirin B-Drug B-Drug
has O O
not O O
been O O
fully O O
determined O O
. O O

Anticoagulants B-Group B-Group
: O O
There O O
have O O
been O O
reports O O
of O O
increased O O
anticoagulant O O
effects O O
when O O
erythromycin B-Drug B-Drug
and O O
oral O O
anticoagulants B-Group B-Group
were O O
used O O
concomitantly O O
. O O

The O O
mean O O
minimum O O
lithium B-Drug B-Drug
concentration O O
increased O O
9 O O
% O O
and O O
the O O
renal O O
clearance O O
was O O
decreased O O
by O O
approximately O O
9 O O
% O O
. O O

Although O O
this O O
has O O
not O O
occurred O O
in O O
in O O
vitro O O
studies O O
with O O
coumarin B-Group B-Group
- O O
type B-Group B-Group
anticoagulants I-Group I-Group
interactions O O
with O O
coumarin B-Group B-Group
- O O
type B-Group B-Group
anticoagulants I-Group I-Group
have O O
been O O
reported O O
with O O
FELDENE B-Brand B-Brand
since O O
marketing O O
therefore O O
physicians O O
should O O
closely O O
monitor O O
patients O O
for O O
a O O
change O O
in O O
dosage O O
requirements O O
when O O
administering O O
FELDENE B-Brand B-Brand
to O O
patients O O
on O O
coumarin B-Group B-Group
- O O
type B-Group B-Group
anticoagulants I-Group I-Group
and O O
other O O
highly O O
protein O O
- O O
bound O O
drugs O O
. O O

The O O
risk O O
of O O
hypoglycemia O O
secondary O O
to O O
this O O
mechanism O O
may O O
be O O
increased O O
if O O
allopurinol B-Drug B-Drug
and O O
chlorpropamide B-Drug B-Drug
are O O
given O O
concomitantly O O
in O O
the O O
presence O O
of O O
renal O O
insufficiency O O
. O O

Amphetamines B-Group B-Group
may O O
enhance O O
the O O
effects O O
of O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
. O O

Drug O O
Name O O

Ingestion O O
of O O
diclofenac B-Drug B-Drug
may O O
increase O O
serum O O
concentrations O O
of O O
digoxin B-Drug B-Drug
and O O
methotrexate B-Drug B-Drug
and O O
increase O O
cyclosporine B-Drug B-Drug
nephrotoxicity O O
. O O

Such O O
agents O O
must O O
be O O
discontinued O O
at O O
least O O
seven O O
days O O
prior O O
to O O
starting O O
therapy O O
with O O
VISTIDE B-Brand B-Brand
. O O

In O O
addition O O
certain O O
drugs O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
and O O
make O O
normal O O
metabolizers O O
resemble O O
poor O O
metabolizers O O
. O O

- O O
Vitamin B-Group B-Group
K I-Group I-Group
( O O
e.g. O O
AquaMEPHYTON B-Brand B-Brand
Synkayvite B-Brand B-Brand
) O O
Use O O
of O O
sulfapyridine B-Drug B-Drug
with O O
these O O
medicines O O
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
blood O O

Streptozocin B-Drug B-Drug
has O O
been O O
reported O O
to O O
prolong O O
the O O
elimination O O
half O O
- O O
life O O
of O O
doxorubicin B-Drug B-Drug
and O O
may O O
lead O O
to O O
severe O O
bone O O
marrow O O
suppression O O
; O O

In O O
vitro O O
studies O O
in O O
human O O
liver O O
microsomes O O
suggest O O
that O O
decitabine B-Drug B-Drug
is O O
unlikely O O
to O O
inhibit O O
or O O
induce O O
cytochrome O O
P9 O O
enzymes O O
. O O

Lovastatin B-Drug B-Drug
therapy O O
has O O
not O O
been O O
associated O O
with O O
bleeding O O
or O O
with O O
changes O O
in O O
prothrombin O O
time O O
in O O
patients O O
not O O
taking O O
anticoagulants B-Group B-Group
. O O

- O O
The O O
action O O
of O O
sulphonylureas B-Group B-Group
and O O
insulin B-Drug B-Drug
may O O
be O O
enhanced O O
by O O
Bezalip B-Brand B-Brand
or O O
Bezalip B-Brand B-Brand
retard I-Brand I-Brand
. O O

Concurrent O O
administration O O
of O O
cimetidine B-Drug B-Drug
and O O
Mexitil B-Brand B-Brand
has O O
been O O
reported O O
to O O
increase O O
decrease O O
or O O
leave O O
unchanged O O
Mexitil B-Brand B-Brand
plasma O O
levels O O
; O O

When O O
indinavir B-Drug B-Drug
at O O
an O O
increased O O
dose O O
( O O
9 O O
mg O O
every O O
9 O O
hours O O
) O O
was O O
given O O
with O O
SUSTIVA B-Brand B-Brand
( O O
9 O O
mg O O
once O O
daily O O
) O O
the O O
indinavir B-Drug B-Drug
AUC O O
and O O
Cmin O O
were O O
decreased O O
on O O
average O O
by O O
9 O O
- O O
9 O O
% O O
and O O
9 O O
- O O
9 O O
% O O
respectively O O
compared O O
to O O
when O O
indinavir B-Drug B-Drug
( O O
9 O O
mg O O
every O O
9 O O
hours O O
) O O
was O O
given O O
alone O O
. O O

Concomitant O O
use O O
of O O
HIVID B-Drug B-Drug
with O O
didanosine B-Drug B-Drug
is O O
not O O
recommended O O
. O O

Other O O
quinolones B-Group B-Group
have O O
demonstrated O O
moderate O O
to O O
marked O O
interference O O
with O O
the O O
metabolism O O
of O O
caffeine B-Drug B-Drug
resulting O O
in O O
a O O
reduced O O
clearance O O
a O O
prolongation O O
of O O
plasma O O
half O O
- O O
life O O
and O O
an O O
increase O O
in O O
symptoms O O
that O O
accompany O O
high O O
levels O O
of O O
caffeine B-Drug B-Drug
. O O

Drug O O
- O O
Laboratory O O
- O O
Test O O
Interactions O O
Interactions O O
between O O
Sanctura B-Brand B-Brand
and O O
laboratory O O
tests O O
have O O
not O O
been O O
studied O O
. O O

Phospholine B-Drug B-Drug
Iodide I-Drug I-Drug
potentiates O O
other O O
cholinesterase B-Group B-Group
inhibitors I-Group I-Group
such O O
as O O
succinylcholine B-Drug B-Drug
or O O
organophosphate B-Drug_n O
and O O
carbamate B-Drug_n O
insecticide I-Drug_n O
. O O

Ketoconazole B-Drug B-Drug
: O O
Spontaneous O O
adverse O O
reaction O O
reports O O
of O O
patients O O
taking O O
concomitant O O
ketoconazole B-Drug B-Drug
with O O
recommended O O
doses O O
of O O
terfenadine B-Drug B-Drug
demonstrate O O
QT O O
interval O O
prolongation O O
and O O
rare O O
serious O O
cardiac O O
events O O
e.g O O
. O O

There O O
have O O
been O O
no O O
formal O O
studies O O
of O O
the O O
interaction O O
of O O
LEVULAN B-Brand B-Brand
KERASTICK I-Brand I-Brand
for O O
Topical O O
Solution O O
with O O
any O O
other O O
drugs O O
and O O
no O O
drug O O
- O O
specific O O
interactions O O
were O O
noted O O
during O O
any O O
of O O
the O O
controlled O O
clinical O O
trials O O
. O O

Corticosteroids B-Group B-Group
or O O
ACTH B-Drug B-Drug
: O O
May O O
increase O O
the O O
risk O O
of O O
hypokalemia O O
and O O
increase O O
salt O O
and O O
water O O
retention O O
. O O

- O O
Although O O
not O O
a O O
true O O
drug O O
interaction O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
may O O
precipitate O O
seizures O O
in O O
susceptible O O
patients O O
and O O
Cerebyx B-Brand B-Brand
dosage O O
may O O
need O O
to O O
be O O
adjusted O O

Certain O O
concomitant O O
medications O O
( O O
such O O
as O O
rifampin B-Drug B-Drug
anticonvulsants B-Group B-Group
St O O
. O O

Aminophylline B-Drug O
Etomidate B-Drug O
antagonism O O

In O O
uninfected O O
volunteers O O
9 O O
% O O
developed O O
rash O O
while O O
receiving O O
SUSTIVA B-Brand B-Brand
and O O
clarithromycin B-Drug B-Drug
. O O

Edema O O
has O O
been O O
reported O O
in O O
patients O O
concomitantly O O
receiving O O
Itraconazole B-Drug B-Drug
and O O
dihydropyridine B-Group B-Group
calcium I-Group I-Group
channel I-Group I-Group
blockers I-Group I-Group
. O O

Pharmacokinetic O O
- O O
related O O
Interactions O O
: O O
Clozapine B-Drug B-Drug
is O O
a O O
substrate O O
for O O
many O O
CYP O O
9 O O
isozymes O O
in O O
particular O O
9A9 O O
9D9 O O
and O O
9A9 O O
. O O

Cardiovascular O O
: O O
Hypotension O O
( O O
9 O O
- O O
9 O O
% O O
) O O
. O O

Concurrent O O
use O O
of O O
butorphanol B-Drug B-Drug
with O O
central B-Group B-Group
nervous I-Group I-Group
system I-Group I-Group
depressants I-Group I-Group
( O O
e.g. O O
alcohol B-Drug B-Drug
barbiturates B-Group B-Group
tranquilizers B-Group B-Group
and O O
antihistamines B-Group B-Group
) O O
may O O
result O O
in O O
increased O O
central B-Group O
nervous I-Group O
system I-Group O
depressant I-Group O
effects O O
. O O

Of O O
particular O O
importance O O
sufficient O O
time O O
must O O
elapse O O
before O O
initiating O O
TCA B-Group O
treatment O O
in O O
a O O
patient O O
being O O
withdrawn O O
from O O
fluoxetine B-Drug B-Drug
given O O
the O O
long O O
half O O
- O O
life O O
of O O
the O O
parent O O
and O O
active O O
metabolite O O
( O O
at O O
least O O
9 O O
weeks O O
may O O
be O O
necessary O O
) O O
. O O

Inhibition O O
of O O
the O O
other O O
isozymes O O
evaluated O O
( O O
CYPs O O
9A9 O O
9C9 O O
9C9 O O
9D9 O O
9A9 O O
and O O
9E9 O O
) O O
was O O
9 O O
- O O
9 O O
% O O
. O O

Warfarin B-Drug B-Drug
: O O
Co O O
- O O
administration O O
of O O
bosentan B-Drug B-Drug
9 O O
mg O O
b.i.d O O
. O O
for O O
9 O O
days O O
decreased O O
the O O
plasma O O
concentrations O O
of O O
both O O
S B-Drug B-Drug
- O O
warfarin B-Drug B-Drug
( O O
a O O
CYP9C9 O O
substrate O O
) O O
and O O
R B-Drug B-Drug
- O O
warfarin B-Drug B-Drug
( O O
a O O
CYP9A9 O O
substrate O O
) O O
by O O
9 O O
and O O
9 O O
% O O
respectively O O
. O O

Neither O O
racemic O O
warfarin B-Drug B-Drug
nor O O
isradipine B-Drug B-Drug
binding O O
to O O
plasma O O
proteins O O
in O O
vitro O O
was O O
altered O O
by O O
the O O
addition O O
of O O
the O O
other O O
drug O O
. O O

Concomitant O O
administration O O
of O O
ketoconazole B-Drug B-Drug
tablets O O
with O O
phenytoin B-Drug B-Drug
may O O
alter O O
the O O
metabolism O O
of O O
one O O
or O O
both O O
of O O
the O O
drugs O O
. O O

Concurrent O O
use O O
of O O
rifampin B-Drug B-Drug
increases O O
the O O
metabolic O O
clearance O O
of O O
ZEBETA B-Brand B-Brand
resulting O O
in O O
a O O
shortened O O
elimination O O
half O O
- O O
life O O
of O O
ZEBETA B-Brand B-Brand
. O O

Calcium B-Group B-Group
channel I-Group I-Group
blocking I-Group I-Group
agents I-Group I-Group
: O O
Coadministration O O
of O O
calcium B-Group B-Group
channel I-Group I-Group
blockers I-Group I-Group
did O O
not O O
have O O
any O O
effect O O
on O O
either O O
the O O
safety O O
or O O
efficacy O O
of O O
ibutilide B-Drug B-Drug
in O O
the O O
clinical O O
trials O O
. O O

Antacids B-Group B-Group
kaolin B-Drug B-Drug
- O O
pectin O B-Drug
sulfasalazine B-Drug B-Drug
neomycin B-Drug B-Drug
cholestyramine B-Drug B-Drug
certain O O
anticancer O B-Group
drugs O I-Group
and O O
metoclopramide B-Drug B-Drug
may O O
interfere O O
with O O
intestinal O O
digoxin B-Drug B-Drug
absorption O O
resulting O O
in O O
unexpectedly O O
low O O
serum O O
concentrations O O
. O O

A O O
study O O
in O O
eight O O
healthy O O
volunteers O O
has O O
shown O O
a O O
9 O O
% O O
increase O O
in O O
mean O O
peak O O
nimodipine B-Drug B-Drug
plasma O O
concentrations O O
and O O
a O O
9 O O
% O O
increase O O
in O O
mean O O
area O O
under O O
the O O
curve O O
after O O
a O O
one O O
week O O
course O O
of O O
cimetidine B-Drug B-Drug
at O O
9 O O
9 O O
mg O O
/ O O
day O O
and O O
nimodipine B-Drug B-Drug
at O O
9 O O
mg O O
/ O O
day O O
. O O

Amphetamines B-Group B-Group
may O O
interfere O O
with O O
urinary O O
steroid O O
determinations O O
. O O

The O O
anticoagulant O O
effect O O
of O O
heparin B-Drug B-Drug
is O O
enhanced O O
by O O
concurrent O O
treatment O O
with O O
antithrombin B-Drug B-Drug
III I-Drug I-Drug
( O O
human O O
) O O
in O O
patients O O
with O O
hereditary O O
antithrombin O O
III O O
deficiency O O
. O O

Hypokalemia O O
may O O
develop O O
during O O
concomitant O O
use O O
of O O
steroids B-Group B-Group
or O O
ACTH B-Drug B-Group
. O O

Vitamin B-Group B-Group
A I-Group I-Group
and O O
oral O O
retinoids B-Group B-Group
: O O
Concomitant O O
administration O O
of O O
vitamin B-Group B-Group
A I-Group I-Group
and O O
/ O O
or O O
other O O
oral O O
retinoids B-Group O
with O O
acitretin B-Drug B-Drug
must O O
be O O
avoided O O
because O O
of O O
the O O
risk O O
of O O
hypervitaminosis O O
A O O
. O O

Use O O
with O O
caution O O
and O O
be O O
prepared O O
to O O
treat O O
hypertension O O
if O O
necessary O O
. O O

It O O
is O O
not O O
clear O O
whether O O
this O O
was O O
due O O
to O O
the O O
combination O O
of O O
therapy O O
. O O

Neuromuscular B-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
( O O
such O O
as O O
suxamethonium B-Drug B-Drug
chloride I-Drug I-Drug
) O O
: O O
Concurrent O O
use O O
of O O
procaine B-Drug B-Drug
hydrochloride I-Drug I-Drug
and O O
neuromuscular B-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
may O O
result O O
in O O
prolongation O O
or O O
enhancement O O
of O O
the O O
neuromuscular O O
blockade O O
. O O

The O O
following O O
drug O O
interactions O O
were O O
studied O O
with O O
ketoprofen B-Drug B-Drug
doses O O
of O O
9 O O
mg O O
/ O O
day O O
. O O

When O O
concomitant O O
treatment O O
with O O
agents B-Group O
with I-Group O
b I-Group B-Group
- O O
blocking B-Group B-Group
properties I-Group I-Group
and O O
clonidine B-Drug B-Drug
is O O
to O O
be O O
terminated O O
the O O
b B-Group O
- O O
blocking B-Group B-Group
agent I-Group I-Group
should O O
be O O
discontinued O O
first O O
. O O

The O O
effect O O
of O O
orally O O
ingested O O
peginterferon B-Drug B-Drug
or O O
ribavirin B-Drug B-Drug
from O O
breast O O
milk O O
on O O
the O O
nursing O O
infant O O
has O O
not O O
been O O
evaluated O O
. O O

Nephrotoxicity O O
associated O O
with O O
cyclosporine B-Drug B-Drug
may O O
also O O
be O O
enhanced O O
. O O

It O O
is O O
reasonable O O
to O O
employ O O
appropriate O O
clinical O O
monitoring O O
when O O
potent O O
cytochrome O O
P9 O O
enzyme O O
inducers O O
such O O
as O O
phenobarbital B-Drug B-Drug
or O O
rifampin B-Drug B-Drug
are O O
co O O
- O O
administered O O
with O O
montelukast B-Drug B-Drug
. O O

Effects O O
of O O
GABITRIL B-Brand B-Brand
on O O
other O O
Antiepilepsy O O
Drugs O O
( O O
AEDs B-Group B-Group
) O O
: O O
Phenytoin B-Drug B-Drug
: O O
Tiagabine B-Drug B-Drug
had O O
no O O
effect O O
on O O
the O O
steady O O
- O O
state O O
plasma O O
concentrations O O
of O O
phenytoin B-Drug B-Drug
in O O
patients O O
with O O
epilepsy O O
. O O

Patients O O
with O O
Congenital O O
or O O
Acquired O O
QT O O
Prolongation O O
In O O
a O O
study O O
of O O
the O O
effect O O
of O O
solifenacin B-Drug B-Drug
on O O
the O O
QT O O
interval O O
in O O
9 O O
healthy O O
women O O
the O O
QT O O
prolonging O O
effect O O
appeared O O
less O O
with O O
solifenacin B-Drug B-Drug
9 O O
mg O O
than O O
with O O
9 O O
mg O O
( O O
three O O
times O O
the O O
maximum O O
recommended O O
dose O O
) O O
and O O
the O O
effect O O
of O O
solifenacin B-Drug B-Drug
9 O O
mg O O
did O O
not O O
appear O O
as O O
large O O
as O O
that O O
of O O
the O O
positive O O
control O O
moxifloxacin B-Drug O
at O O
its O O
therapeutic O O
dose O O
. O O

Do O O
not O O
take O O
this O O
medicine O O
with O O
thioridizine O B-Drug
or O O
within O O
9 O O
weeks O O
of O O
taking O O
fluoxetine B-Drug B-Drug
. O O

. O O

ondansetron B-Drug B-Drug
did O O
not O O
increase O O
blood O O
levels O O
of O O
high O O
- O O
dose O O
methotrexate B-Drug B-Drug
. O O

. O O

Insulin B-Drug B-Drug
or O O
Oral O O
Hypoglycemics B-Group B-Group
: O O
Initiating O O
thyroid O O
replacement O O
therapy O O
may O O
cause O O
increases O O
in O O
insulin B-Drug B-Drug
or O O
oral O O
hypoglycemic B-Group B-Group
requirements O O
. O O

CYP9A9 O O
inducers O O
: O O
CYP9A9 O O
inducers O O
may O O
decrease O O
the O O
levels O O
/ O O
effects O O
of O O
ethinyl B-Drug B-Drug
estradiol I-Drug I-Drug
. O O

Drug O O
- O O
Laboratory O O
Test O O
Interactions O O
There O O
are O O
no O O
known O O
interactions O O
between O O
CAMPTOSAR B-Brand B-Brand
and O O
laboratory O O
tests O O
. O O

Ergotamine B-Drug B-Drug
or O O
dihydroergotamine B-Drug B-Drug
acute O O
ergot O O
toxicity O O
characterized O O
by O O
severe O O
peripheral O O
vasospasm O O
and O O
dysesthesia O O
. O O

This O O
treatment O O
arm O O
was O O
discontinued O O
from O O
the O O
trial O O
. O O

Also O O
antimyasthenics O O
may O O
have O O
anticholinesterase O O
activity O O
. O O

Thus O O
when O O
NSAIDs B-Group B-Group
and O O
lithium B-Drug B-Drug
are O O
administered O O
concurrently O O
subjects O O
should O O
be O O
observed O O
carefully O O
for O O
signs O O
of O O
lithium B-Drug B-Drug
toxicity O O
. O O

No O O
pharmacokinetic O O
interactions O O
between O O
dexmedetomidine B-Drug B-Drug
and O O
isoflurane B-Drug B-Drug
propofol B-Drug B-Drug
alfentanil B-Drug B-Drug
and O O
midazolam B-Drug B-Drug
have O O
been O O
demonstrated O O
. O O

Warfarin B-Drug B-Drug
: O O
A O O
single O O
9 O O
- O O
mg O O
dose O O
of O O
Aprepitant B-Drug B-Drug
was O O
administered O O
on O O
Day O O
9 O O
and O O
9 O O
mg O O
/ O O
day O O
on O O
Days O O
9 O O
and O O
9 O O
to O O
healthy O O
subjects O O
who O O
were O O
stabilized O O
on O O
chronic O O
warfarin B-Drug B-Drug
therapy O O
. O O

9 O O
. O O

An O O
inhibitor O O
of O O
CYP9C9 O O
( O O
such O O
as O O
gemfibrozil B-Drug B-Drug
) O O
may O O
increase O O
the O O
AUC O O
of O O
rosiglitazone B-Drug B-Drug
and O O
an O O
inducer O O
of O O
CYP9C9 O O
( O O
such O O
as O O
rifampin B-Drug B-Drug
) O O
may O O
decrease O O
the O O
AUC O O
of O O
rosiglitazone B-Drug B-Drug
. O O

Vardenafil B-Drug B-Drug

Mean O O
oxybutynin B-Drug B-Drug
chloride I-Drug I-Drug
plasma O O
concentrations O O
were O O
approximately O O
9 O O
fold O O
higher O O
when O O
DITROPAN B-Brand B-Brand
XL I-Brand O
was O O
administered O O
with O O
ketoconazole B-Drug B-Drug
a O O
potent O O
CYP9A9 O O
inhibitor O O
. O O

Patients O O
may O O
require O O
reduced O O
doses O O
of O O
anesthetics B-Group B-Group
when O O
on O O
methyldopa B-Drug B-Drug
. O O

Beta B-Group B-Group
Blockers I-Group I-Group

Therefore O O
if O O
concomitant O O
use O O
of O O
such O O
agents O O
is O O
indicated O O
they O O
should O O
be O O
given O O
with O O
caution O O
and O O
the O O
patients O O
serum O O
potassium O O
should O O
be O O
monitored O O
frequently O O
. O O

Patients O O
taking O O
both O O
flurbiprofen B-Drug B-Drug
and O O
a O O
beta B-Group B-Group
- O O
blocker B-Group B-Group
should O O
be O O
monitored O O
to O O
ensure O O
that O O
a O O
satisfactory O O
hypotensive O O
effect O O
is O O
achieved O O
. O O

Antiacid O O
clarithromycin B-Drug B-Drug
Didanosine B-Drug B-Drug
Fluconazole B-Drug B-Drug
Fluoxetine B-Drug B-Drug
Indanavir O B-Drug
Ketoconazole B-Drug B-Drug
Phenytoin B-Drug B-Drug
Phenobarbitol O B-Drug
carbamazepine B-Drug B-Drug
Rifabutin B-Drug B-Drug
Rifampin B-Drug B-Drug
Ritanovir O B-Drug
Saquinavir B-Drug B-Drug
. O O

The O O
following O O
drugs O O
have O O
been O O
coadministered O O
with O O
Kerlone B-Brand B-Brand
and O O
have O O
not O O
altered O O
its O O
pharmacokinetics O O
: O O
cimetidine B-Drug B-Drug
nifedipine B-Drug B-Drug
chlorthalidone B-Drug B-Drug
and O O
hydrochlorothiazide B-Drug B-Drug
. O O

THE O O
DOSAGE O O
OF O O
THE O O
ANTICOAGULANTS B-Group O
SHOULD O O
BE O O
REDUCED O O
TO O O
MAINTAIN O O
THE O O
PROTHROMBIN O O
TIME O O
/ O O
INR O O
AT O O
THE O O
DESIRED O O
LEVEL O O
TO O O
PREVENT O O
BLEEDING O O
COMPLICATIONS O O
. O O

In O O
clinical O O
studies O O
propofol B-Drug B-Drug
had O O
no O O
effect O O
on O O
the O O
duration O O
of O O
action O O
or O O
dosing O O
requirements O O
for O O
NIMBEX B-Brand B-Brand
. O O

If O O
such O O
drugs O O
are O O
needed O O
their O O
dose O O
should O O
be O O
reassessed O O
and O O
where O O
appropriate O O
plasma O O
concentration O O
measured O O
. O O

Micafungin B-Drug B-Drug
is O O
not O O
an O O
inhibitor O O
of O O
P O O
- O O
glycoprotein O O
and O O
therefore O O
would O O
not O O
be O O
expected O O
to O O
alter O O
P O O
- O O
glycoprotein O O
- O O
mediated O O
drug O O
transport O O
activity O O
. O O

Refer O O
to O O
the O O
package O O
insert O O
for O O
lithium B-Drug B-Drug
preparations O O
before O O
use O O
of O O
such O O
preparations O O
with O O
Hydrochlorothiazide B-Drug B-Drug
. O O

PEGASYS B-Brand B-Brand
and O O
COPEGUS B-Brand B-Brand
are O O
excreted O O
by O O
the O O
kidney O O
and O O
the O O
risk O O
of O O
toxic O O
reactions O O
to O O
this O O
therapy O O
may O O
be O O
greater O O
in O O
patients O O
with O O
impaired O O
renal O O
function O O
. O O

Orthostatic O O
hypotension O O
in O O
patients O O
taking O O
clozapine B-Drug B-Drug
can O O
in O O
rare O O
cases O O
( O O
approximately O O
9 O O
case O O
per O O
9 O O
9 O O
patients O O
) O O
be O O
accompanied O O
by O O
profound O O
collapse O O
and O O
respiratory O O
and O O
/ O O
or O O
cardiac O O
arrest O O
. O O

There O O
have O O
been O O
spontaneous O O
reports O O
of O O
increase O O
or O O
decrease O O
in O O
prothrombin O O
times O O
in O O
patients O O
concomitantly O O
taking O O
oral O O
terbinafine B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
however O O
a O O
causal O O
relationship O O
between O O
LAMISIL B-Brand B-Brand
Tablets O O
and O O
these O O
changes O O
has O O
not O O
been O O
established O O
. O O

In O O
common O O
with O O
other O O
broad B-Group O
- O O
spectrum B-Group O
antibiotics I-Group B-Group
AUGMENTIN B-Brand B-Brand
XR I-Brand I-Brand
may O O
reduce O O
the O O
efficacy O O
of O O
oral O O
contraceptives B-Group B-Group

Ergotamine B-Drug B-Drug
: O O
Concurrent O O
use O O
of O O
erythromycin B-Drug B-Drug
and O O
ergotamine B-Drug B-Drug
or O O
dihydroergotamine B-Drug B-Drug
has O O
been O O
associated O O
in O O
some O O
patients O O
with O O
acute O O
ergot O O
toxicity O O
characterized O O
by O O
severe O O
peripheral O O
vasospasm O O
and O O
dysesthesia O O
. O O

and O O
rarely O O
enuresis O O
urinary O O
retention O O
dysuria O O
impotence O O
inability O O
to O O
ejaculate O O
nocturia O O
hematuria O O
. O O

Ampicillin B-Drug B-Drug
: O O
In O O
a O O
study O O
of O O
healthy O O
volunteers O O
chloroquine B-Drug B-Drug
significantly O O
reduced O O
the O O
bioavailability O O
of O O
ampicillin B-Drug B-Drug
. O O

Lamivudine B-Drug B-Drug
is O O
predominantly O O
eliminated O O
in O O
the O O
urine O O
by O O
active O O
organic O O
cationic O O
secretion O O
. O O

Coadministration O O
of O O
terfenadine B-Drug B-Drug
with O O
Itraconazole B-Drug B-Drug
has O O
led O O
to O O
elevated O O
plasma O O
concentrations O O
of O O
terfenadine B-Drug B-Drug
resulting O O
in O O
rare O O
instances O O
of O O
life O O
- O O
threatening O O
cardiac O O
dysrhythmias O O
and O O
one O O
death O O
. O O

No O O
volunteer O O
showed O O
hormonal O O
evidence O O
of O O
ovulation O O
but O O
one O O
volunteer O O
reported O O
intermenstrual O O
bleeding O O
during O O
felbamate B-Drug B-Drug
treatment O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
: O O
Amphetamines B-Group B-Group
can O O
cause O O
a O O
significant O O
elevation O O
in O O
plasma O O
corticosteroid O O
levels O O
. O O

Dosage O O
adjustment O O
of O O
STRATTERA B-Brand B-Brand
may O O
be O O
necessary O O
when O O
coadministered O O
with O O
CYP9D9 O O
inhibitors O O
e.g. O O
paroxetine B-Drug B-Drug
fluoxetine B-Drug B-Drug
and O O
quinidine B-Drug B-Drug
. O O

diflunisal B-Drug B-Drug
; O O

Other O O
common O O
adverse O O
reactions O O
are O O
dizziness O O
( O O
9 O O
- O O
9 O O
% O O
) O O
weakness O O
( O O
9 O O
- O O
9 O O
% O O
) O O
and O O
fatigue O O
( O O
9 O O
- O O
9 O O
% O O
) O O
. O O

In O O
a O O
9 O O
- O O
month O O
controlled O O
trial O O
that O O
included O O
a O O
9 O O
mcg O O
once O O
daily O O
BROVANA B-Brand B-Brand
dose O O
9 O O
of O O
the O O
9 O O
BROVANA B-Brand B-Brand
- O O
treated O O
subjects O O
received O O
concomitant O O
theophylline B-Drug B-Drug
at O O
study O O
entry O O
. O O

. O O

Potential O O
for O O
Other O O
Drugs O O
to O O
Affect O O
ABILIFY B-Brand O
Aripiprazole B-Brand B-Drug
is O O
not O O
a O O
substrate O O
of O O
CYP9A9 O O
CYP9A9 O O
CYP9A9 O O
CYP9B9 O O
CYP9C9 O O
CYP9C9 O O
CYP9C9 O O
or O O
CYP9E9 O O
enzymes O O
. O O

Heparin B-Drug B-Drug
: O O
Since O O
heparin B-Drug B-Drug
is O O
contraindicated O O
in O O
patients O O
with O O
heparin B-Drug B-Drug
- O O
induced O O
thrombocytopenia O O
the O O
co O O
- O O
administration O O
of O O
Argatroban B-Drug B-Drug
and O O
heparin B-Drug B-Drug
is O O
unlikely O O
for O O
this O O
indication O O
. O O

Caution O O
is O O
warranted O O
and O O
clinical O O
monitoring O O
of O O
patients O O
is O O
recommended O O
. O O

Similarly O O
in O O
the O O
9 O O
- O O
year O O
monthly O O
comparison O O
study O O
aspirin B-Brand B-Brand
and O O
nonsteroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
drugs I-Group I-Group
were O O
taken O O
by O O
9 O O
% O O
of O O
the O O
9 O O
patients O O
. O O

- O O
Quinine B-Drug O
( O O
e.g. O O
Quinamm B-Brand B-Brand
) O O
or O O

Cholestyramine B-Drug B-Drug
- O O
Concomitant O O
intake O O
of O O
cholestyramine B-Drug B-Drug
and O O
vitamin B-Group B-Group
K I-Group I-Group
may O O
reduce O O
the O O
absorption O O
of O O
vitamin B-Group B-Group
K I-Group I-Group
. O O

Drugs O O
Metabolized O O
by O O
P9 O O
9D9 O O
- O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P9 O O
9D9 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
caucasian O O
population O O
( O O
about O O
9 O O
- O O
9 O O
% O O
of O O
caucasians O O
are O O
so O O
called O O
poor O O
metabolizers O O
) O O
; O O

Hepatotoxic O O
medications O O
such O O
as O O
high O O
- O O
dose O O
methotrexate B-Drug B-Drug
may O O
impair O O
liver O O
function O O
and O O
increase O O
the O O
risk O O
of O O
toxicity O O
. O O

When O O
these O O
products O O
are O O
administered O O
concomitantly O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
test O O
should O O
be O O
closely O O
monitored O O
. O O

Nevertheless O O
the O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
test O O
should O O
be O O
monitored O O
when O O
warfarin B-Drug B-Drug
or O O
its O O
derivatives O O
and O O
enoxacin B-Drug B-Drug
are O O
given O O
concomitantly O O
. O O

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
reactions O O
be O O
used O O
. O O

Fluoxetine B-Drug B-Drug
and O O
its O O
active O O
metabolite O O
norfluoxe O B-Drug_n
- O O
tine O O
have O O
long O O
half O O
- O O
lives O O
( O O
9 O O
to O O
9 O O
days O O
for O O
norfluoxetine B-Drug_n O
) O O
that O O
may O O
affect O O
strategies O O
during O O
conversion O O
from O O
one O O
drug O O
to O O
the O O
other O O
. O O

Patients O O
taking O O
these O O
drugs O O
with O O
LODOSYN B-Brand B-Brand
and O O
levodopa B-Drug B-Drug
or O O
carbidopa B-Drug B-Drug
- O O
levodopa B-Drug B-Drug
combination O O
products O O
should O O
be O O
carefully O O
observed O O
for O O
loss O O
of O O
therapeutic O O
response O O
. O O

However O O
the O O
plasma O O
clearance O O
of O O
methotrexate B-Drug B-Drug
was O O
slightly O O
increased O O
. O O

The O O
addition O O
of O O
aspirin B-Brand B-Brand
to O O
Streptokinase B-Drug B-Drug
causes O O
a O O
minimal O O
increase O O
in O O
the O O
risk O O
of O O
minor O O
bleeding O O
( O O
9 O O
% O O
vs. O O
9 O O
% O O
) O O
but O O
does O O
not O O
appear O O
to O O
increase O O
the O O
incidence O O
of O O
major O O
bleeding O O
( O O
see O O

Potential O O
interactions O O
between O O
TAXOL B-Brand B-Brand
a O O
substrate O O
of O O
CYP9A9 O O
and O O
protease B-Group B-Group
inhibitors I-Group I-Group
( O O
ritonavir B-Drug B-Drug
saquinavir B-Drug B-Drug
indinavir B-Drug B-Drug
and O O
nelfinavir B-Drug B-Drug
) O O
which O O
are O O
substrates O O
and O O
/ O O
or O O
inhibitors O O
of O O
CYP9A9 O O
have O O
not O O
been O O
evaluated O O
in O O
clinical O O
trials O O
. O O

Salicylates B-Group B-Group
given O O
concomitantly O O
with O O
anticoagulant B-Group B-Group
drugs I-Group I-Group
may O O
predispose O O
to O O
systemic O O
bleeding O O
. O O

Nursing O O
Mothers O O

indinavir B-Drug B-Drug
concentration O O

isoflurane B-Drug B-Drug
; O O

Warfarin B-Drug B-Drug
: O O
When O O
healthy O O
subjects O O
were O O
administered O O
Starlix B-Brand B-Brand
9 O O
mg O O
three O O
times O O
daily O O
before O O
meals O O
for O O
four O O
days O O
in O O
combination O O
with O O
a O O
single O O
dose O O
of O O
warfarin B-Drug B-Drug
9 O O
mg O O
on O O
day O O
9 O O
there O O
were O O
no O O
alterations O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

This O O
is O O
also O O
to O O
be O O
considered O O
when O O
leflunomide B-Drug B-Drug
treatment O O
is O O
followed O O
by O O
such O O
drugs O O
without O O
a O O
drug O O
elimination O O
procedure O O
. O O

Bosentan B-Drug B-Drug
is O O
also O O
expected O O
to O O
reduce O O
plasma O O
concentrations O O
of O O
other O O
oral O O
hypoglycemic B-Group O
agents I-Group O
that O O
are O O
predominantly O O
metabolized O O
by O O
CYP9C9 O O
or O O
CYP9A9 O O
. O O

However O O
LDL O O
- O O
C O O
reduction O O
was O O
greater O O
when O O
atorvastatin B-Drug B-Drug
and O O
colestipol B-Drug B-Drug
were O O
coadministered O O
than O O
when O O
either O O
drug O O
was O O
given O O
alone O O
. O O

In O O
vitro O O
studies O O
: O O
Vardenafil B-Drug B-Drug
and O O
its O O
metabolites O O
had O O
no O O
effect O O
on O O
CYP9A9 O O
9A9 O O
and O O
9E9 O O
( O O
Ki O O
9uM O O
) O O
. O O

Ketoconazole B-Drug B-Drug
: O O
Ketoconazole B-Drug B-Drug
may O O
inhibit O O
both O O
synthetic O O
and O O
catabolic O O
enzymes O O
of O O
vitamin B-Group B-Group
D I-Group I-Group
. O O

If O O
midazolam B-Drug B-Drug
is O O
administered O O
parenterally O O
special O O
precaution O O
is O O
required O O
since O O
the O O
sedative O O
effect O O
may O O
be O O
prolonged O O
. O O

Other O O
beta B-Group B-Group
adrenergic I-Group I-Group
aerosol I-Group I-Group
bronchodilators I-Group I-Group
should O O
not O O
be O O
used O O
concomitantly O O
with O O
Alupent B-Brand B-Brand
( O O
metaproterenol B-Drug O
sulfate I-Drug O
USP O O
) O O
because O O
they O O
may O O
have O O
additive O O
effects O O
. O O

These O O
facts O O
should O O
be O O
considered O O
when O O
evaluating O O
plasma O O
renin O O
activity O O
in O O
hypertensive O O
patients O O
. O O

( O O
d O B-Drug
) O O
T9 O O
- O O
uptake O O
values O O
may O O
decrease O O
. O O

T9 O O
resin O O
uptake O O
is O O
decreased O O
reflecting O O
the O O
elevated O O
TBG O O
. O O

Concurrent O O
administration O O
of O O
vasopressor B-Group B-Group
drugs I-Group I-Group
and O O
of O O
ergot B-Group B-Group
- O O
type B-Group B-Group
oxytocic I-Group I-Group
drugs I-Group I-Group
may O O
cause O O
severe O O
persistent O O
hypertension O O
or O O
cerebrovascular O O
accidents O O
. O O

9% O O
9% O O
9% O O
9% O O

Laboratory O O
Tests O O
: O O
The O O
combination O O
of O O
Amprenavir B-Drug B-Drug
and O O
low O O
- O O
dose O O
ritonavir B-Drug B-Drug
has O O
been O O
associated O O
with O O
elevations O O
of O O
cholesterol O O
and O O
triglycerides O O
SGOT O O
( O O
AST O O
) O O
and O O
SGPT O O
( O O
ALT O O
) O O
in O O
some O O
patients O O
. O O

If O O
they O O
do O O
occur O O
the O O
EPA B-Drug O
dose O O
should O O
be O O
lowered O O
or O O
discontinued O O
. O O

Tricyclic B-Group B-Group
antidepressants I-Group I-Group
have O O
been O O
reported O O
to O O
blunt O O
the O O
hypotensive O O
effect O O
of O O
systemic O O
clonidine B-Drug B-Drug
. O O

Use O O
With O O
Ribavirin B-Drug B-Drug
Ribavirin B-Drug B-Drug
is O O
genotoxic O O
and O O
mutagenic O O
. O O

There O O
is O O
little O O
if O O
any O O
clinically O O
significant O O
interaction O O
between O O
Acarbose B-Drug B-Drug
and O O
metformin B-Drug B-Drug
. O O

. O O

zaleplon B-Drug B-Drug
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
ethanol B-Drug B-Drug
. O O

The O O
use O O
of O O
drugs O O
that O O
stimulate O B-Group
alpha O I-Group
- O O
adrenergic O O
receptors O O
( O O
e.g. O O
phenylephrine B-Drug B-Drug
pseudoephedrine B-Drug B-Drug
ephedrine B-Drug B-Drug
phenylpropanolamine B-Drug B-Drug
or O O
dihydroergotamine B-Drug B-Drug
) O O
may O O
enhance O O
or O O
potentiate O O
the O O
pressor O O
effects O O
of O O
ProAmatine B-Brand B-Brand
. O O
Therefore O O
caution O O
should O O
be O O
used O O
when O O
ProAmatine B-Brand B-Brand
is O O
administered O O
concomitantly O O
with O O
agents O O
that O O
cause O O
vasoconstriction O O
. O O

Sinus O O
bradycardia O O
has O O
been O O
reported O O
with O O
oral O O
amiodarone B-Drug B-Drug
in O O
combination O O
with O O
lidocaine B-Drug B-Drug
( O O
CYP9A9 B-Drug O
substrate O O
) O O
given O O
for O O
local O O
anesthesia B-Drug O
. O O

If O O
indicated O O
dosage O O
of O O
the O O
antihypertensive B-Group B-Group
agents I-Group I-Group
should O O
be O O
reduced O O
. O O

Acarbose B-Drug B-Drug
may O O
affect O O
digoxin B-Drug B-Drug
bioavailabillty O O
and O O
may O O
require O O
dose O O
adjustment O O
of O O
digoxin B-Drug B-Drug
by O O
9 O O
% O O
( O O
9 O O
% O O
confidence O O
interval O O
: O O
9 O O
- O O
9 O O
% O O
) O O
decrease O O
mean O O
C O O
max O O
digoxin B-Drug B-Drug
by O O
9 O O
% O O
( O O
9 O O
% O O
confidence O O
interval O O
: O O
9 O O
- O O
9 O O
% O O
) O O
and O O
decrease O O
mean O O
trough O O
concentrations O O
of O O
digoxin B-Drug B-Drug
by O O
9 O O
% O O
( O O
9 O O
% O O
confidence O O
limit O O
: O O
9 O O
% O O
decrease O O
to O O
9 O O
% O O
increase O O
) O O
. O O

Antidepressants B-Group B-Group
( O O
tricyclic B-Group B-Drug
) O O
atropine B-Drug B-Drug
or O O
other O O
anticholinergic B-Group B-Group
agents I-Group I-Group
or O O
digitalis B-Group B-Group
glycosides I-Group I-Group
: O O
concurrent O O
use O O
with O O
arbutamine B-Drug B-Drug
may O O
produce O O
additive O O
inotropic O O
and O O
/ O O
or O O
chronotropic O O
effects O O
. O O

Plasma O O
levels O O
of O O
flecainide B-Drug B-Drug
have O O
been O O
reported O O
to O O
increase O O
in O O
the O O
presence O O
of O O
oral O O
amiodarone B-Drug B-Drug
; O O

Concomitant O O
use O O
of O O
bromocriptine B-Drug B-Drug
mesylate I-Drug I-Drug
with O O
other O O
ergot B-Group B-Group
alkaloids I-Group I-Group
is O O
not O O
recommended O O
. O O

Careful O O
supervision O O
of O O
diabetic O O
patients O O
under O O
treatment O O
with O O
Soriatane B-Brand B-Brand
is O O
recommended O O
. O O

Tablets O O
Injection O O
and O O
Oral O O
Solution O O
One O O
study O O
in O O
six O O
subjects O O
demonstrated O O
that O O
the O O
combination O O
of O O
furosemide B-Drug B-Drug
and O O
acetylsalicylic B-Drug B-Drug
acid I-Drug I-Drug
temporarily O O
reduced O O
creatinine O O
clearance O O
in O O
patients O O
with O O
chronic O O
renal O O
insufficiency O O
. O O

The O O
pharmacokinetics O O
of O O
a O O
9 O O
- O O
mg O O
dose O O
of O O
butorphanol B-Drug B-Drug
administered O O
as O O
STADOL B-Brand B-Brand
NS I-Brand I-Brand
were O O
not O O
affected O O
by O O
the O O
coadministration O O
of O O
cimetidine B-Drug B-Drug
( O O
9 O O
mg O O
QID O O
) O O
. O O

The O O
adverse O O
effects O O
of O O
CAMPTOSAR B-Brand B-Brand
such O O
as O O
myelosuppression O O
and O O
diarrhea O O
would O O
be O O
expected O O
to O O
be O O
exacerbated O O
by O O
other O O
antineoplastic B-Group B-Group
agents I-Group I-Group
having O O
similar O O
adverse O O
effects O O
. O O

In O O
clinical O O
studies O O
of O O
TOBI B-Brand B-Brand
patients O O
taking O O
TOBI B-Brand B-Brand
concomitantly O O
with O O
dornase B-Drug O
alfa I-Drug O
( O O
PULMOZYME B-Brand B-Brand
Genentech O O
) O O
beta B-Group B-Group
- O O
agonists B-Group B-Group
inhaled O O
corticosteroids B-Group B-Group
other O O
anti B-Group B-Group
- O O
pseudomonal B-Group B-Group
antibiotics I-Group I-Group
or O O
parenteral O O
aminoglycosides B-Group B-Group
demonstrated O O
adverse O O
experience O O
profiles O O
similar O O
to O O
the O O
study O O
population O O
as O O
a O O
whole O O
. O O

The O O
syndrome O O
requires O O
immediate O O
medical O O
attention O O
and O O
may O O
include O O
one O O
or O O
more O O
of O O
the O O
following O O
symptoms O O
: O O
excitement O O
hypomania O O
restlessness O O
loss O O
of O O
consciousness O O
confusion O O
disorientation O O
anxiety O O
agitation O O
motor O O
weakness O O
myoclonus O O
tremor O O
hemiballismus O O
hyperreflexia O O
ataxia O O
dysarthria O O
incoordination O O
hyperthermia O O
shivering O O
pupillary O O
dilation O O
diaphoresis O O
emesis O O
and O O
tachycardia O O
. O O

The O O
in O O
vitro O O
interaction O O
between O O
nevirapine B-Drug B-Drug
and O O
the O O
antithrombotic B-Group B-Group
agent I-Group I-Group
warfarin B-Drug B-Drug
is O O
complex O O
. O O

This O O
will O O
interfere O O
with O O
the O O
diagnosis O O
of O O
pheochromocytoma O O
. O O

The O O
elevated O O
plasma O O
alprazolam B-Drug B-Drug
concentrations O O
resulted O O
in O O
decreased O O
psychomotor O O
performance O O
and O O
memory O O
. O O

There O O
is O O
a O O
single O O
case O O
report O O
which O O
suggests O O
that O O
sucralfate B-Drug B-Drug
may O O
interfere O O
with O O
anagrelide B-Drug B-Drug
absorption O O
. O O

Salicylate B-Group O
levels O O
have O O
been O O
found O O
to O O
be O O
falsely O O
elevated O O
with O O
some O O
assay O O
methods O O
. O O

No O O
information O O
provided O O

In O O
addition O O
to O O
bleeding O O
associated O O
with O O
heparin B-Drug B-Drug
and O O
vitamin B-Group B-Group
K I-Group I-Group
antagonists I-Group I-Group
drugs O O
that O O
alter O O
platelet O O
function O O
( O O
such O O
as O O
aspirin B-Brand B-Brand
dipyridamole B-Drug B-Drug
and O O
abciximab B-Drug B-Drug
) O O
may O O
increase O O
the O O
risk O O
of O O
bleeding O O
if O O
administered O O
prior O O
to O O
or O O
after O O
Retavase B-Brand B-Brand
therapy O O
. O O

. O O

When O O
digoxin B-Drug B-Drug
and O O
BREVIBLOC B-Brand B-Brand
were O O
concomitantly O O
administered O O
intravenously O O
to O O
normal O O
volunteers O O
there O O
was O O
a O O
9 O O
- O O
9 O O
% O O
increase O O
in O O
digoxin B-Drug B-Drug
blood O O
levels O O
at O O
some O O
time O O
points O O
. O O

Although O O
there O O
was O O
no O O
clinical O O
evidence O O
in O O
the O O
vehicle O O
- O O
controlled O O
studies O O
of O O
drug O O
interactions O O
with O O
systemic O O
antiretroviral B-Group B-Group
agents I-Group I-Group
including O O
protease B-Group B-Group
inhibitors I-Group I-Group
macrolide B-Group B-Group
antibiotics I-Group I-Group
and O O
azole B-Group B-Group
antifungals I-Group I-Group
the O O
effect O O
of O O
Panretin B-Brand B-Brand
gel O O
on O O
the O O
steady O O
- O O
state O O
concentrations O O
of O O
these O O
drugs O O
is O O
not O O
known O O
. O O

Theoretically O O
fenoprofen B-Drug B-Drug
could O O
likewise O O
be O O
displaced O O
. O O

No O O
information O O
available O O
. O O

Drugs O O
that O O
inhibit O O
cytochrome O O
P9IID9 O O
such O O
as O O
quinidine B-Drug B-Drug
might O O
increase O O
the O O
plasma O O
concentrations O O
of O O
flecainide B-Drug B-Drug
in O O
patients O O
that O O
are O O
on O O
chronic O O
flecainide B-Drug B-Drug
therapy O O
; O O

Calcium B-Group B-Group
Channel I-Group I-Group
Blockers I-Group I-Group
: O O
Isolated O O
cases O O
of O O
conduction O O
disturbance O O
( O O
rarely O O
with O O
hemodynamic O O
compromise O O
) O O
have O O
been O O
observed O O
when O O
COREG B-Brand B-Brand
is O O
co O O
- O O
administered O O
with O O
diltiazem B-Drug B-Drug
. O O

MAO B-Group B-Group
inhibitors I-Group I-Group
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
( O O
drying O O
) O O
effects O O
of O O
antihistamines B-Group B-Group
. O O

Tinnitus O O
and O O
decreased O O
hearing O O
have O O
been O O
reported O O
in O O
patients O O
concomitantly O O
receiving O O
Itraconazole B-Drug B-Drug
and O O
quinidine B-Drug B-Drug
. O O

a O O
reduction O O
of O O
the O O
doxorubicin B-Drug B-Drug
dosage O O
should O O
be O O
considered O O
in O O
patients O O
receiving O O
ZANOSAR B-Brand B-Brand
concurrently O O
. O O

PEGASYS B-Brand B-Brand
is O O
recommended O O
for O O
use O O
in O O
women O O
of O O
childbearing O O
potential O O
only O O
when O O
they O O
are O O
using O O
effective O O
contraception O O
during O O
therapy O O
. O O

Antacids B-Group B-Group
and O O
kaolin B-Drug B-Drug
: O O
Antacids B-Group B-Group
and O O
kaolin B-Drug B-Drug
can O O
reduce O O
absorption O O
of O O
chloroquine B-Drug B-Drug
; O O

When O O
other O O
potent O O
parental O O
antihypertensive B-Group B-Group
drugs I-Group I-Group
such O O
as O O
diazoxide B-Drug B-Drug
are O O
used O O
in O O
combination O O
with O O
hydralazine B-Drug B-Drug
patients O O
should O O
be O O
continuously O O
observed O O
for O O
several O O
hours O O
for O O
any O O
excessive O O
fall O O
in O O
blood O O
pressure O O
. O O

A O O
dose O O
increase O O
of O O
lopinavir B-Drug B-Drug
/ O O
ritonavir B-Drug B-Drug
to O O
9 O O
/ O O
9 O O
mg O O
twice O O
daily O O
with O O
food O O
isrecommended O O
in O O
combination O O
with O O
nevirapine B-Drug B-Drug
. O O

Posicor B-Brand O
inhibits O O
some O O
of O O
the O O
liver O O
's O O
ability O O
to O O
metabolize O O
some O O
other O O
drugs O O
- O O
terfenadine B-Drug B-Drug
astemizole B-Drug B-Drug
cisapride B-Drug B-Drug
cyclosporine B-Drug B-Drug
and O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
. O O

Therefore O O
when O O
INDOCIN B-Brand B-Brand
and O O
digoxin B-Drug B-Drug
are O O
used O O
concomitantly O O
serum O O
digoxin B-Drug B-Drug
levels O O
should O O
be O O
closely O O
monitored O O
. O O

Erythromycin B-Drug B-Drug
( O O
9 O O
mg O O
q9h O O
) O O
+ O O
9 O O
% O O
9% O O

There O O
is O O
limited O O
experience O O
with O O
concomitant O O
antihypertensive B-Group B-Group
agents I-Group I-Group
such O O
as O O
alpha B-Group B-Group
- O O
blockers B-Group B-Group
calcium B-Group B-Group
channel I-Group I-Group
- O O
blockers B-Group B-Group
ACE B-Group B-Group
inhibitors I-Group I-Group
and O O
diuretics B-Group B-Group
( O O
both O O
thiazide B-Group B-Group
- O O
like O O
and O O
loop O B-Group
) O O
. O O

If O O
used O O
concomitantly O O
closely O O
monitor O O
serum O O
electrolytes O O
and O O
cardiac O O
function O O
. O O

Acetazolamide B-Drug B-Drug
may O O
prevent O O
the O O
urinary O O
antiseptic O O
effect O O
of O O
methenamine B-Drug B-Drug
. O O

Bentiromide B-Drug B-Drug
may O O
interact O O
with O O
acetaminophen B-Drug B-Drug
( O O
e.g. O O
Tylenol B-Brand B-Brand
) O O
chloramphenicol B-Drug B-Drug
( O O
e.g. O O
Chloromycetin B-Brand B-Brand
) O O
local O O
anesthetics B-Group B-Group
( O O
e.g. O O
benzocaine B-Drug B-Drug
and O O
lidocaine B-Drug B-Drug
) O O
para B-Drug_n B-Drug
- O O
aminobenzoic B-Drug_n B-Drug_n
acid I-Drug_n I-Drug_n
( O O
PABA B-Drug_n O
) O O
- O O
containing O O
preparations O O
( O O
e.g. O O
sunscreens O O
and O O
some O O
multivitamins B-Group B-Group
) O O
procainamide B-Drug B-Drug
( O O
e.g. O O
Pronestyl B-Brand B-Brand
) O O
sulfonamides B-Group B-Group
( O O
sulfa O B-Group
medicines O I-Group
) O O
thiazide B-Group B-Group
diuretics I-Group I-Group
( O O
use O O
of O O
these O O
medicines O O
during O O
the O O
test O O
period O O
will O O
affect O O
the O O
test O O
results O O
) O O
and O O
pancreatic O O
supplements O O
( O O
use O O
of O O
pancreatic O B-Drug
supplements O O
may O O
give O O
false O O
test O O
results O O
) O O
. O O

Valdecoxib B-Drug B-Drug
did O O
not O O
have O O
a O O
statistically O O
significant O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
phenytoin B-Drug B-Drug
( O O
a O O
CYP O O
9C9 O O
and O O
CYP O O
9C9 O O
substrate O O
) O O
. O O

Aspirin B-Brand B-Brand
: O O
As O O
with O O
other O O
NSAIDs B-Group B-Group
concomitant O O
administration O O
of O O
Ponstel B-Brand B-Brand
and O O
aspirin B-Brand B-Brand
is O O
not O O
generally O O
recommended O O
because O O
of O O
the O O
potential O O
of O O
increased O O
adverse O O
effects O O
. O O

Drugs O O
that O O
may O O
have O O
their O O
plasma O O
concentration O O
altered O O
by O O
dasatinib B-Drug B-Drug
CYP9A9 O O
Substrates O O
: O O
Dasatinib B-Drug B-Drug
is O O
a O O
time O O
- O O
dependent O O
inhibitor O O
of O O
CYP9A9 O O
. O O

There O O
are O O
no O O
significant O O
effects O O
on O O
cefdinir B-Drug B-Drug
pharmacokinetics O O
if O O
the O O
antacid B-Group B-Group
is O O
administered O O
9 O O
hours O O
before O O
or O O
9 O O
hours O O
after O O
cefdinir B-Drug B-Drug
. O O

Nonsteroidal B-Group B-Group
Anti I-Group I-Group
- O O
Inflammatory B-Group B-Group
Drugs I-Group I-Group
: O O
The O O
administration O O
of O O
diflunisal B-Drug B-Drug
to O O
normal O O
volunteers O O
receiving O O
indomethacin B-Drug B-Drug
decreased O O
the O O
renal O O
clearance O O
and O O
significantly O O
increased O O
the O O
plasma O O
levels O O
of O O
indomethacin B-Drug B-Drug
. O O

The O O
clinical O O
effects O O
of O O
this O O
combination O O
have O O
not O O
been O O
studied O O
. O O

Drugs O O
Highly O O
Bound O O
To O O
Plasma O O
Protein O O
Eszopiclone B-Drug B-Drug
is O O
not O O
highly O O
bound O O
to O O
plasma O O
proteins O O
( O O
9 O O
- O O
9 O O
% O O
bound O O
) O O
; O O

When O O
methyldopa B-Drug B-Drug
and O O
lithium B-Drug B-Drug
are O O
given O O
concomitantly O O
the O O
patient O O
should O O
be O O
carefully O O
monitored O O
for O O
symptoms O O
of O O
lithium B-Drug B-Drug
toxicity O O
. O O

In O O
separate O O
studies O O
of O O
patients O O
receiving O O
maintenance O O
doses O O
of O O
warfarin B-Drug B-Drug
hydrochlorothiazide B-Drug B-Drug
or O O
digoxin B-Drug B-Drug
irbesartan B-Drug B-Drug
administration O O
for O O
9 O O
days O O
had O O
no O O
effect O O
on O O
the O O
pharmacodynamics O O
of O O
warfarin B-Drug B-Drug
( O O
prothrombin O O
time O O
) O O
or O O
pharmacokinetics O O
of O O
digoxin B-Drug B-Drug
. O O

However O O
prudent O O
evaluation O O
of O O
individual O O
cases O O
is O O
warranted O O
in O O
the O O
clinical O O
setting O O
. O O

The O O
magnitude O O
of O O
interaction O O
with O O
multiple O O
doses O O
of O O
erythromycin B-Drug B-Drug
is O O
unknown O O
. O O

Cimetidine B-Drug B-Drug
( O O
9 O O
mg O O
qid O O
) O O
9 O O
% O O
+ O O
9 O O
% O O

This O O
may O O
be O O
of O O
clinical O O
relevance O O
for O O
compounds O O
predominantly O O
metabolized O O
by O O
this O O
enzyme O O
such O O
as O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
- O O
blockers O B-Group
selective B-Group B-Group
serotonin I-Group I-Group
reuptake I-Group I-Group
inhibitors I-Group I-Group
( O O
SSRIs B-Group B-Group
) O O
and O O
monoamine B-Group B-Group
oxidase I-Group I-Group
inhibitors I-Group I-Group
MAO I-Group B-Group
- O O
Is B-Group O
Type I-Group O
B I-Group O
if O O
they O O
have O O
a O O
narrow O O
therapeutic O O
window O O
. O O

CNS O O
depression O O
producing O B-Group
medications O I-Group
- O O
concurrent O O
use O O
may O O
potentiate O O
the O O
effects O O
of O O
either O O
these O O
medications O O
or O O
diphenidol B-Drug B-Drug
; O O

The O O
vasodilating O O
effects O O
of O O
isosorbide B-Drug B-Drug
mononitrate I-Drug I-Drug
may O O
be O O
additive O O
with O O
those O O
of O O
other O O
vasodilators B-Group B-Group
. O O

Patients O O
receiving O O
antibiotics B-Group B-Group
and O O
sulfonamides B-Group B-Group
generally O O
should O O
not O O
be O O
treated O O
with O O
ganglion B-Group B-Group
blockers I-Group I-Group
. O O

Anagrelide B-Drug B-Drug
demonstrates O O
some O O
limited O O
inhibitory O O
activity O O
towards O O
CYP9A9 O O
which O O
may O O
present O O
a O O
theoretical O O
potential O O
for O O
interaction O O
with O O
other O O
coadministered O O
medicinal O O
products O O
sharing O O
that O O
clearance O O
mechanism O O
e.g O O
. O O
theophylline B-Drug B-Drug
. O O

In O O
some O O
patients O O
the O O
administration O O
of O O
INDOCIN B-Brand B-Brand
can O O
reduce O O
the O O
diuretic O O
natriuretic O O
and O O
antihypertensive O O
effects O O
of O O
loop B-Group B-Group
potassium B-Group B-Group
- O O
sparing B-Group B-Group
and O O
thiazide B-Group B-Group
diuretics I-Group I-Group
. O O

Prior O O
administration O O
of O O
succinylcholine B-Drug B-Drug
had O O
no O O
effect O O
on O O
the O O
duration O O
of O O
neuromuscular O O
block O O
following O O
initial O O
or O O
maintenance O O
bolus O O
doses O O
of O O
NIMBEX B-Brand B-Brand
. O O

Pharmacokinetics O O
of O O
levetiracetam B-Drug B-Drug
were O O
also O O
not O O
affected O O
by O O
phenytoin B-Drug B-Drug
. O O

Phenytoin B-Drug B-Drug
nicotine B-Drug B-Drug
and O O
rifampin B-Drug B-Drug
may O O
decrease O O
Clozapine B-Drug B-Drug
plasma O O
levels O O
resulting O O
in O O
a O O
decrease O O
in O O
effectiveness O O
of O O
a O O
previously O O
effective O O
Clozapine B-Drug B-Drug
dose O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
The O O
following O O
drugs O O
or O O
moieties O O
are O O
known O O
to O O
interfere O O
with O O
laboratory O O
tests O O
performed O O
in O O
patients O O
on O O
thyroid B-Group O
hormone I-Group O
therapy O O
: O O
androgens B-Group B-Group
corticosteroids B-Group B-Group
estrogens B-Group B-Group
oral O O
contraceptives B-Group B-Group
containing O O
estrogens B-Group B-Group
iodine B-Group B-Group
- O O
containing O O
preparations O O
and O O
the O O
numerous O O
preparations O O
containing O O
salicylates B-Group B-Group
. O O

Less O O
potent O O
inhibitors O O
include O O
saquinavir B-Drug B-Drug
nefazodone B-Drug B-Drug
fluconazole B-Drug B-Drug
grapefruit O O
juice O O
fluoxetine B-Drug B-Drug
fluvoxamine B-Drug B-Drug
zileuton B-Drug B-Drug
and O O
clotrimazole B-Drug B-Drug
. O O

Based O O
on O O
known O O
metabolic O O
profiles O O
clinically O O
significant O O
drug O O
interactions O O
are O O
not O O
expected O O
between O O
VIRACEPT B-Brand B-Brand
and O O
dapsone B-Drug B-Drug
trimethoprim B-Drug B-Drug
/ O O
sulfamethoxazole B-Drug B-Drug
clarithromycin B-Drug B-Drug
erythromycin B-Drug B-Drug
itraconazole B-Drug B-Drug
or O O
fluconazole B-Drug B-Drug
. O O

- O O
Methyldopa B-Drug B-Drug
( O O
e.g. O O
Aldomet B-Brand B-Brand
) O O
Use O O
of O O
methyldopa B-Drug B-Drug
with O O
sulfapyridine B-Drug B-Drug
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
liver O O
and O O
/ O O
or O O
the O O
blood O O

reduced O O
serum O O
folate O O
concentration O O
; O O

Concurrent O O
administration O O
of O O
bacteriostatic B-Group B-Group
antibiotics I-Group I-Group
( O O
e.g. O O
erythromycin B-Drug B-Drug
tetracycline B-Drug B-Drug
) O O
may O O
diminish O O
the O O
bactericidal O O
effects O O
of O O
penicillins B-Group B-Drug
by O O
slowing O O
the O O
rate O O
of O O
bacterial O O
growth O O
. O O

Alteration O O
of O O
pH O O
may O O
affect O O
absorption O O
of O O
certain O O
drugs O O
( O O
e.g. O O
ketoconazole B-Drug B-Drug
) O O
. O O

Peak O O
plasma O O
concentrations O O
and O O
AUC O O
of O O
rimantadine B-Drug B-Drug
were O O
reduced O O
approximately O O
9 O O
% O O
in O O
the O O
presence O O
of O O
aspirin B-Brand B-Brand
. O O

Carbidopa B-Drug B-Drug
/ O O
Levodopa B-Drug B-Drug
: O O
Carbidopa B-Drug B-Drug
/ O O
Levodopa B-Drug B-Drug
does O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
pramipexole B-Drug B-Drug
in O O
healthy O O
volunteers O O
( O O
N= O O
9 O O
) O O
. O O

Antacids B-Group B-Group
: O O
Concomitant O O
administration O O
of O O
aluminum B-Drug B-Drug
and O O
magnesium B-Drug B-Drug
hydroxides I-Drug I-Drug
does O O
not O O
interfere O O
with O O
absorption O O
of O O
meclofenamate B-Drug B-Drug
sodium I-Drug I-Drug
. O O

Concomitant O O
administration O O
of O O
substances O O
that O O
are O O
also O O
tubularly O O
secreted O O
( O O
e.g. O O
probenecid B-Drug B-Drug
) O O
could O O
potentially O O
result O O
in O O
delayed O O
clearance O O
of O O
ALIMTA B-Brand B-Brand
. O O

. O O

Antihypertensives B-Group B-Group
: O O
Amphetamines B-Group B-Group
may O O
antagonize O O
the O O
hypotensive O O
effects O O
of O O
antihypertensives B-Group B-Group
. O O

In O O
vitro O O
buspirone B-Drug B-Drug
does O O
not O O
displace O O
tightly O O
bound O O
drugs O O
like O O
phenytoin B-Drug B-Drug
propranolol B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
from O O
serum O O
proteins O O
. O O

Prescribers O O
are O O
advised O O
to O O
consult O O
the O O
package O O
insert O O
of O O
medication O O
administered O O
concomitantly O O
with O O
hormonal B-Group B-Group
contraceptives I-Group I-Group
since O O
some O O
medications O O
may O O
decrease O O
the O O
effectiveness O O
of O O
these O O
birth O O
control O O
products O O
. O O

Aspirin B-Brand B-Brand
/ O O
Acetaminophen B-Drug B-Drug
: O O
Pharmacokinetic O O
or O O
pharmacodynamic O O
drug O O
- O O
drug O O
interactions O O
have O O
not O O
been O O
demonstrated O O
between O O
Argatroban B-Drug B-Drug
and O O
concomitantly O O
administered O O
aspirin B-Brand B-Brand
( O O
9 O O
mg O O
orally O O
given O O
9 O O
and O O
9 O O
hours O O
prior O O
to O O
initiation O O
of O O
Argatroban B-Drug B-Drug
9 O O
g O O
/ O O
kg O O
/ O O
min O O
. O O
over O O
9 O O
hours O O
) O O
or O O
acetaminophen B-Drug B-Drug
( O O
9 O O
mg O O
orally O O
given O O
9 O O
9 O O
and O O
9 O O
hours O O
prior O O
to O O
and O O
9 O O
and O O
9 O O
hours O O
subsequent O O
to O O
initiation O O
of O O
Argatroban B-Drug B-Drug
9 O O
g O O
/ O O
kg O O
/ O O
min O O
. O O
over O O
9 O O
hours O O
) O O
. O O

Oral O O
Contraceptives B-Group B-Group
: O O
Valdecoxib B-Drug B-Drug
( O O
9 O O
mg O O
BID O O
) O O
did O O
not O O
induce O O
the O O
metabolism O O
of O O
the O O
combination O O
oral O O
contraceptive B-Group B-Group
norethindrone B-Drug B-Drug
/ O O
ethinyl B-Drug B-Drug
estradiol I-Drug I-Drug
( O O
9 O O
mg O O
/ O O
9 O O
mcg O O
combination O O
Ortho B-Brand B-Brand
- O O
Novum B-Brand B-Brand
9 O O
/ O O
9 O O
) O O
. O O

Serum O O
theophylline B-Drug B-Drug
concentrations O O
increase O O
when O O
grepafloxacin B-Drug B-Drug
is O O
initiated O O
in O O
a O O
patient O O
maintained O O
on O O
theophylline B-Drug B-Drug
. O O

These O O
effects O O
are O O
usually O O
reversible O O
. O O

The O O
effect O O
of O O
BREVIBLOC B-Drug B-Brand
on O O
the O O
duration O O
of O O
succinylcholine B-Drug B-Drug
- O O
induced O O
neuromuscular O O
blockade O O
was O O
studied O O
in O O
patients O O
undergoing O O
surgery O O
. O O

These O O
drugs O O
should O O
be O O
coadministered O O
with O O
caution O O
and O O
frequent O O
monitoring O O
of O O
serum O O
lithium B-Drug B-Drug
levels O O
is O O
recommended O O
. O O

therefore O O
patients O O
should O O
be O O
followed O O
carefully O O
during O O
concurrent O O
therapy O O
. O O

No O O
formal O O
drug O O
- O O
interaction O O
studies O O
have O O
been O O
performed O O
and O O
a O O
clinically O O
significant O O
interaction O O
with O O
other O O
medications O O
used O O
in O O
the O O
treatment O O
of O O
hypoxic O O
respiratory O O
failure O O
can O O
not O O
be O O
excluded O O
based O O
on O O
the O O
available O O
data O O
. O O

Warfarin B-Drug B-Drug
: O O
Meclofenamate B-Drug B-Drug
sodium I-Drug I-Drug
enhances O O
the O O
effect O O
of O O
warfarin B-Drug B-Drug
. O O

in O O
vitro O O
data O O
on O O
metabolic O O
interactions O O
indicate O O
that O O
Keppra B-Brand B-Brand
is O O
unlikely O O
to O O
produce O O
or O O
be O O
subject O O
to O O
pharmacokinetic O O
interactions O O
. O O

There O O
are O O
other O O
agents O O
that O O
may O O
result O O
in O O
serious O O
and O O
/ O O
or O O
life O O
- O O
threatening O O
drug O O
interactions O O
. O O

No O O
drug O O
interactions O O
of O O
clinical O O
importance O O
have O O
been O O
identified O O
. O O

Lithium B-Drug B-Drug
: O O
Diclofenac B-Drug B-Drug
decreases O O
lithium B-Drug B-Drug
renal O O
clearance O O
and O O
increases O O
lithium B-Drug B-Drug
plasma O O
levels O O
. O O

Anticoagulants B-Group B-Group
: O O
Ten O O
patients O O
who O O
were O O
stabilized O O
on O O
oral O O
anticoagulants B-Group B-Group
were O O
given O O
guanfacine B-Drug B-Drug
9 O O
- O O
9 O O
mg O O
/ O O
day O O
for O O
9 O O
weeks O O
. O O

Particular O O
caution O O
should O O
be O O
observed O O
with O O
digitalis B-Group B-Group
preparations I-Group O
since O O
there O O
are O O
conflicting O O
results O O
for O O
the O O
effect O O
of O O
colestipol B-Drug B-Drug
hydrochloride I-Drug I-Drug
on O O
the O O
availability O O
of O O
digoxin B-Drug B-Drug
and O O
digitoxin B-Drug B-Drug
. O O

May O O
interact O O
with O O
thyroid O B-Group
medication O I-Group
( O O
e.g. O O
levothyroxine B-Drug B-Drug
) O O
iodine B-Drug B-Group
- O O
containing O O
products O O
antacids B-Group B-Group
H9 B-Group B-Group
- O O
antagonists B-Group B-Group
( O O
e.g. O O
famotidine B-Drug B-Drug
ranitidine B-Drug B-Drug
) O O
and O O
proton B-Group B-Group
pump I-Group I-Group
inhibitors I-Group I-Group
( O O
e.g. O O
lansoprazole B-Drug B-Drug
omeprazole B-Drug B-Drug
) O O
. O O

As O O
with O O
some O O
other O O
nondepolarizing B-Group B-Group
neuromuscular I-Group I-Group
blocking I-Group I-Group
agents I-Group I-Group
the O O
time O O
of O O
onset O O
of O O
neuromuscular O O
block O O
induced O O
by O O
NUROMAX B-Brand B-Brand
is O O
lengthened O O
and O O
the O O
duration O O
of O O
block O O
is O O
shortened O O
in O O
patients O O
receiving O O
phenytoin B-Drug B-Drug
or O O
carbamazepine B-Drug B-Drug
. O O

Care O O
should O O
be O O
taken O O
when O O
using O O
immunoanalytical O O
methods O O
to O O
measure O O
plasma O O
phenytoin B-Drug B-Drug
concentrations O O
following O O
Cerebyx B-Brand B-Brand
administration O O
. O O

Anesthetics B-Group B-Group

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
During O O
TNKase B-Brand B-Brand
therapy O O
results O O
of O O
coagulation O O
tests O O
and O O
/ O O
or O O
measures O O
of O O
fibrinolytic O O
activity O O
may O O
be O O
unreliable O O
unless O O
specific O O
precautions O O
are O O
taken O O
to O O
prevent O O
in O O
vitro O O
artifacts O O
. O O

Drug O O
Interaction O O
with O O
Fluoxetine B-Drug B-Drug
: O O
A O O
multiple O O
- O O
dose O O
study O O
was O O
conducted O O
to O O
assess O O
the O O
effect O O
of O O
fluoxetine B-Drug B-Drug
9 O O
mg O O
BID O O
on O O
the O O
pharmacokinetics O O
of O O
estazolam B-Drug B-Drug
9 O O
mg O O
QHS O O
after O O
seven O O
days O O
. O O

Concomitant O O
oral O O
administration O O
of O O
ketoconazole B-Drug B-Drug
( O O
a O O
known O O
inhibitor O O
of O O
CYP9A9 O O
activity O O
in O O
the O O
liver O O
and O O
in O O
the O O
intestinal O O
mucosa O O
) O O
caused O O
an O O
eight O O
- O O
fold O O
increase O O
of O O
the O O
systemic O O
exposure O O
to O O
oral O O
budesonide B-Drug B-Drug
. O O

Although O O
bupropion B-Drug B-Drug
is O O
not O O
metabolized O O
by O O
this O O
isoenzyme O O
bupropion B-Drug B-Drug
and O O
hydroxybupropion B-Drug_n B-Drug_n
are O O
inhibitors O O
of O O
the O O
CYP9D9 O O
isoenzyme O O
in O O
vitro O O
. O O

DIFLUCAN B-Brand B-Brand
reduces O O
the O O
metabolism O O
of O O
tolbutamide B-Drug B-Drug
glyburide B-Drug B-Drug
and O O
glipizide B-Drug B-Drug
and O O
increases O O
the O O
plasma O O
concentration O O
of O O
these O O
agents O O
. O O

Periodic O O
measurement O O
of O O
serum O O
PSA O O
levels O O
may O O
also O O
be O O
considered O O
. O O

Concomitant O O
administration O O
of O O
CHEMET B-Brand B-Brand
with O O
other O O
chelation O O
therapy O O
such O O
as O O
CaNa B-Drug O
9 I-Drug O
EDTA I-Drug O
is O O
not O O
recommended O O
. O O

These O O
medications O O
have O O
included O O
heparin B-Drug B-Drug
warfarin B-Drug B-Group
beta B-Group I-Group
- O O
adrenergic B-Group B-Group
receptor I-Group I-Group
blockers I-Group I-Group
calcium B-Group B-Group
channel I-Group I-Group
antagonists I-Group I-Group
angiotensin B-Group B-Group
converting I-Group I-Group
enzyme I-Group I-Group
inhibitors I-Group I-Group
intravenous O O
and O O
oral O O
nitrates B-Group B-Group
ticlopidine B-Drug B-Drug
and O O
aspirin B-Brand B-Brand
. O O

Coadministration O O
of O O
NIZORAL B-Brand B-Brand
Tablets O O
with O O
midazolam B-Drug B-Drug
or O O
triazolam B-Drug B-Drug
has O O
resulted O O
in O O
elevated O O
plasma O O
concentrations O O
of O O
the O O
latter O O
two O O
drugs O O
. O O

A O O
drug O O
- O O
drug O O
interaction O O
study O O
with O O
rifampin B-Drug B-Drug
in O O
healthy O O
volunteers O O
has O O
shown O O
a O O
9 O O
% O O
decrease O O
in O O
caspofungin B-Drug B-Drug
trough O O
concentrations O O
. O O

9 O O
. O O

Haloperidol B-Drug B-Drug
: O O
Haloperidol B-Drug B-Drug
blocks O O
dopamine O B-Drug
receptors O O
thus O O
inhibiting O O
the O O
central O O
stimulant O O
effects O O
of O O
amphetamines B-Group B-Group
. O O

Indinavir B-Drug B-Drug
and O O
didanosine B-Drug B-Drug
formulations O O
containing O O
buffer O O
should O O
be O O
administered O O
at O O
least O O
one O O
hour O O
apart O O
on O O
an O O
empty O O
stomach O O
. O O

The O O
benzodiazepines B-Group B-Group
including O O
alprazolam B-Drug B-Drug
produce O O
additive O O
CNS O O
depressant O O
effects O O
when O O
co O O
- O O
administered O O
with O O
other O O
psychotropic B-Group B-Group
medications I-Group I-Group
anticonvulsants B-Group B-Group
antihistaminics B-Group O
ethanol B-Drug B-Drug
and O O
other O O
drugs O O
which O O
themselves O O
produce O O
CNS O O
depression O O
. O O

The O O
effect O O
of O O
these O O
interactions O O
on O O
mean O O
AUCs O O
and O O
Cmin O O
are O O
summarized O O
in O O
Table O O
9 O O
: O O
Table O O
9 O O
: O O
Summary O O
of O O
AED O B-Group
interactions O O
with O O
Trileptal B-Brand B-Brand

Reported O O
examples O O
of O O
this O O
interaction O O
include O O
the O O
following O O
: O O
Immunosuppressives B-Drug O
: O O
Cyclosporine B-Drug B-Drug
( O O
CYP9A9 B-Drug O
substrate O O
) O O
administered O O
in O O
combination O O
with O O
oral O O
amiodarone B-Drug B-Drug
has O O
been O O
reported O O
to O O
produce O O
persistently O O
elevated O O
plasma O O
concentrations O O
of O O
cyclosporine B-Drug B-Drug
resulting O O
in O O
elevated O O
creatinine O O
despite O O
reduction O O
in O O
dose O O
of O O
cyclosporine B-Drug B-Drug
. O O

In O O
a O O
study O O
in O O
which O O
patients O O
with O O
active O O
RA O O
were O O
treated O O
for O O
up O O
to O O
9 O O
weeks O O
with O O
concurrent O O
ENBREL B-Brand B-Brand
and O O
anakinra B-Drug B-Drug
therapy O O
a O O
9 O O
% O O
rate O O
of O O
serious O O
infections O O
was O O
observed O O
which O O
was O O
higher O O
than O O
that O O
observed O O
with O O
ENBREL B-Brand B-Brand
alone O O
( O O
9 O O
% O O
) O O
. O O

Hypokalemia O O
may O O
increase O O
susceptibility O O
to O O
cardiac O O
arrhythmias O O
in O O
patients O O
treated O O
with O O
digitalis B-Group B-Group
. O O

however O O
patients O O
should O O
be O O
monitored O O
for O O
the O O
signs O O
and O O
symptoms O O
of O O
increased O O
narcotic O O
effect O O
. O O

Because O O
many O O
drugs O O
are O O
excreted O O
in O O
human O O
milk O O
and O O
because O O
there O O
exists O O
the O O
potential O O
for O O
serious O O
adverse O O
reactions O O
in O O
nursing O O
infants O O
from O O
AMEVIVE B-Brand B-Brand
a O O
decision O O
should O O
be O O
made O O
whether O O
to O O
discontinue O O
nursing O O
while O O
taking O O
the O O
drug O O
or O O
to O O
discontinue O O
the O O
use O O
of O O
the O O
drug O O
taking O O
into O O
account O O
the O O
importance O O
of O O
the O O
drug O O
to O O
the O O
mother O O
. O O

Examples O O
of O O
some O O
of O O
the O O
more O O
potent O O
CYP O O
9A9 O O
inhibitors O O
include O O
macrolide B-Group B-Group
antibiotics I-Group I-Group
( O O
e.g. O O
erythromycin B-Drug B-Drug
troleandomycin B-Drug B-Drug
clarithromycin B-Drug B-Drug
) O O
HIV B-Group B-Group
protease I-Group I-Group
or O O
reverse B-Group O
transcriptase I-Group O
inhibitors I-Group O
( O O
e.g. O O
ritonavir B-Drug B-Drug
indinavir B-Drug B-Drug
nelfinavir B-Drug B-Drug
delavirdine B-Drug B-Drug
) O O
or O O
azole B-Group B-Group
antifungals I-Group I-Group
( O O
e.g. O O
ketoconazole B-Drug B-Drug
itraconazole B-Drug B-Drug
voriconazole B-Drug B-Drug
) O O
. O O

Upon O O
administration O O
of O O
9 O O
mg O O
of O O
Vardenafil B-Drug B-Drug
with O O
9 O O
mg O O
TID O O
indinavir B-Drug B-Drug
the O O
Cmax O O
and O O
AUC O O
of O O
indinavir B-Drug B-Drug
were O O
reduced O O
by O O
9 O O
% O O
and O O
9 O O
% O O
respectively O O
. O O

Higher O O
dosage O O
of O O
oral O O
hypoglycemic B-Group B-Group
agents I-Group I-Group
may O O
be O O
required O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interferences O O
: O O
Dicumarol B-Drug B-Drug
and O O
indanedione B-Group B-Group
anticoagulants I-Group I-Group
including O O
anisindione B-Drug B-Drug
or O O
their O O
metabolites O O
may O O
color O O
alkaline O O
urine O O
red O O
- O O
orange O O
which O O
may O O
interfere O O
with O O
spectrophotometrically O O
determined O O
urinary O O
laboratory O O
tests O O
. O O

Warfarin B-Drug B-Drug
: O O
Quinolones B-Group B-Group
including O O
enoxacin B-Drug B-Drug
decrease O O
the O O
clearance O O
of O O
R B-Drug B-Drug
- O O
warfarin B-Drug B-Drug
the O O
less O O
active O O
isomer O O
of O O
racemic O O
warfarin B-Drug B-Drug
. O O

Insulin B-Drug B-Drug
or O O
Oral O O
Hypoglycemics B-Group B-Group
: O O
Agents B-Group B-Group
with I-Group O
b I-Group O
- O O
blocking B-Group B-Group
properties I-Group I-Group
may O O
enhance O O
the O O
blood O O
- O O
sugar O O
- O O
reducing O O
effect O O
of O O
insulin B-Drug B-Drug
and O O
oral O O
hypoglycemics B-Group B-Group
. O O

Pyrazolone B-Group B-Group
Derivatives I-Group I-Group
( O O
phenylbutazone B-Drug B-Drug
oxyphenbutazone B-Drug B-Drug
and O O
possibly O O
dipyrone B-Drug B-Drug
) O O
: O O
Concomitant O O
administration O O
with O O
aspirin B-Drug B-Brand
may O O
increase O O
the O O
risk O O
of O O
gastrointestinal O O
ulceration O O
. O O

Based O O
on O O
the O O
chemical O O
resemblance O O
of O O
itraconazole B-Drug B-Drug
and O O
ketoconazole B-Drug B-Drug
coadministration O O
of O O
astemizole B-Drug B-Drug
with O O
itraconazole B-Drug B-Drug
is O O
contraindicated O O
. O O

Tizoxanide B-Drug B-Drug
is O O
highly O O
bound O O
to O O
plasma O O
protein O O
( O O
9 O O
% O O
) O O
. O O

clinical O O
implications O O
are O O
unclear O O
. O O

In O O
some O O
patients O O
the O O
administration O O
of O O
a O O
non B-Group B-Group
- O O
steroidal B-Group B-Group
antiinflammatory I-Group I-Group
agent I-Group I-Group
can O O
reduce O O
the O O
diuretic O O
natriuretic O O
and O O
antihypertensive O O
effects O O
of O O
loop B-Group B-Group
potassium B-Group B-Group
- O O
sparing B-Group B-Group
and O O
thiazide B-Group B-Group
diuretics I-Group I-Group
. O O

Both O O
CRIXIVAN B-Brand B-Brand
and O O
atazanavir B-Drug B-Drug
are O O
associated O O
with O O
indirect O O
( O O
unconjugated O O
) O O
hyperbilirubinemia O O
. O O

These O O
reactions O O
have O O
also O O
been O O
reported O O
in O O
patients O O
who O O
have O O
discontinued O O
that O O
drug O O
and O O
have O O
been O O
started O O
on O O
a O O
MAOI B-Group B-Group
. O O

vii O O
. O O

Administer O O
LEVSIN B-Brand B-Brand
before O O
meals O O
; O O

Drugs O O
With O O
A O O
Narrow O O
Therapeutic O O
Index O O
Digoxin B-Drug B-Drug
A O O
single O O
dose O O
of O O
eszopiclone B-Drug B-Drug
9 O O
mg O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
digoxin B-Drug B-Drug
measured O O
at O O
steady O O
state O O
following O O
dosing O O
of O O
9 O O
mg O O
twice O O
daily O O
for O O
one O O
day O O
and O O
9 O O
mg O O
daily O O
for O O
the O O
next O O
9 O O
days O O
. O O

General O O
: O O
Significant O O
interactions O O
may O O
occur O O
when O O
celecoxib B-Drug B-Drug
is O O
administered O O
together O O
with O O
drugs O O
that O O
inhibit O O
P9 O O
9C9 O O
. O O

Cholestyramine B-Drug B-Drug
: O O
Pretreatment O O
for O O
four O O
days O O
with O O
cholestyramine B-Drug B-Drug
significantly O O
increased O O
the O O
clearance O O
of O O
meloxicam B-Drug B-Drug
by O O
9 O O
% O O
. O O

Although O O
undercarboxylated O O
osteocalcin O O
a O O
marker O O
of O O
vitamin O B-Group
K O I-Group
nutritional O O
status O O
was O O
unaltered O O
with O O
XENICAL B-Brand B-Brand
administration O O
vitamin O B-Group
K O I-Group
levels O O
tended O O
to O O
decline O O
in O O
subjects O O
taking O O
XENICAL B-Brand B-Brand
. O O

Ritonavir B-Drug B-Drug
and O O
indinavir B-Drug B-Drug
: O O
Upon O O
concomitant O O
administration O O
of O O
9 O O
mg O O
of O O
Vardenafil B-Drug B-Drug
with O O
9 O O
mg O O
BID O O
ritonavir B-Drug B-Drug
the O O
Cmax O O
and O O
AUC O O
of O O
ritonavir B-Drug B-Drug
were O O
reduced O O
by O O
approximately O O
9 O O
% O O
. O O

Sucralfate B-Drug B-Drug
should O O
not O O
be O O
taken O O
within O O
9 O O
hours O O
of O O
FACTIVE B-Brand B-Brand
. O O

Trough O O
plasma O O
enoxacin B-Drug B-Drug
levels O O
were O O
also O O
9 O O
% O O
higher O O
when O O
caffeine B-Drug B-Drug
and O O
enoxacin B-Drug B-Drug
were O O
administered O O
concomitantly O O
. O O

ANTACID B-Group B-Brand
( O O
Magnesium B-Drug B-Drug
- O O
Aluminum B-Drug B-Drug
Hydroxide I-Drug I-Drug
) O O
: O O
Cerivastatin B-Drug B-Drug
plasma O O
concentrations O O
were O O
not O O
affected O O
by O O
co O O
- O O
administration O O
of O O
antacid B-Group B-Group
. O O

Drugs O O
that O O
impair O O
intestinal O O
absorption O O
of O O
fat B-Group B-Group
- O O
soluble B-Group B-Group
vitamins I-Group I-Group
such O O
as O O
cholestyramine B-Drug B-Drug
may O O
interfere O O
with O O
the O O
absorption O O
of O O
Zemplar B-Brand B-Brand
Capsules O O
. O O

Carbamazepine B-Drug B-Drug
: O O
In O O
healthy O O
subjects O O
receiving O O
the O O
CYP9A9 O O
inducer O O
carbamazepine B-Drug B-Drug
at O O
9 O O
mg O O
twice O O
daily O O
for O O
9 O O
days O O
and O O
9 O O
mg O O
twice O O
daily O O
for O O
9 O O
days O O
systemic O O
exposure O O
( O O
AUC O O
) O O
to O O
lapatinib B-Drug B-Drug
was O O
decreased O O
approximately O O
9 O O
% O O
. O O

Although O O
the O O
specific O O
drug O O
interaction O O
was O O
not O O
studied O O
in O O
a O O
clinical O O
trial O O
there O O
have O O
been O O
more O O
than O O
9 O O
episodes O O
of O O
concomitant O O
use O O
of O O
antifibrinolytic O O
therapies O O
( O O
i.e. O O
tranexamic B-Drug O
acid I-Drug O
aminocaproic B-Drug O
acid I-Drug O
) O O
and O O
NovoSeven B-Brand B-Drug
. O O

The O O
drug O O
interaction O O
studies O O
with O O
valdecoxib B-Drug B-Drug
were O O
performed O O
both O O
with O O
valdecoxib B-Drug B-Drug
and O O
a O O
rapidly O O
hydrolyzed O O
intravenous O O
prodrug O O
form O O
. O O

9 O O
. O O

The O O
effect O O
of O O
cyclosporine B-Drug B-Drug
on O O
diltiazem B-Drug B-Drug
plasma O O
concentrations O O
has O O
not O O
been O O
evaluated O O
. O O

Serious O O
adverse O O
events O O
have O O
been O O
reported O O
in O O
concomitant O O
use O O
with O O
clonidine B-Drug B-Drug
although O O
no O O
causality O O
for O O
the O O
combination O O
has O O
been O O
established O O
. O O

The O O
concomitant O O
use O O
of O O
alcohol B-Drug B-Drug
or O O
other O O
central B-Group B-Group
nervous I-Group I-Group
system I-Group I-Group
depressants I-Group I-Group
may O O
have O O
an O O
additive O O
effect O O
. O O

Although O O
MIVACRON B-Brand B-Brand
( O O
a O O
mixture O O
of O O
three O O
stereoisomers O O
) O O
has O O
been O O
administered O O
safely O O
following O O
succinylcholine O B-Drug
- O O
facilitated O O
tracheal O O
intubation O O
the O O
interaction O O
between O O
MIVACRON B-Brand B-Brand
and O O
succinylcholine B-Drug B-Drug
has O O
not O O
been O O
systematically O O
studied O O
. O O

as O O
well O O
as O O
atropine B-Drug B-Drug
and O O
phosphorous B-Drug_n O
insecticides I-Drug_n O
. O O

Norepinephrine B-Drug B-Drug

It O O
is O O
recommended O O
that O O
in O O
patients O O
taking O O
anticoagulants B-Group B-Group
prothrombin O O
time O O
be O O
determined O O
before O O
starting O O
lovastatin B-Drug B-Drug
and O O
frequently O O
enough O O
during O O
early O O
therapy O O
to O O
insure O O
that O O
no O O
significant O O
alteration O O
of O O
prothrombin O O
time O O
occurs O O
. O O

When O O
amiloride B-Drug B-Drug
HCl O I-Drug
is O O
administered O O
concomitantly O O
with O O
an O O
angiotensin B-Group B-Group
- O O
converting B-Group B-Group
enzyme I-Group I-Group
inhibitor I-Group I-Group
the O O
risk O O
of O O
hyperkalemia O O
may O O
be O O
increased O O
. O O

If O O
these O O
drugs O O
are O O
to O O
be O O
used O O
in O O
the O O
initial O O
treatment O O
of O O
severe O O
malaria O O
Mefloquine B-Drug B-Drug
administration O O
should O O
be O O
delayed O O
at O O
least O O
9 O O
hours O O
after O O
the O O
last O O
dose O O
. O O

Alcohol B-Drug B-Drug
in O O
particular O O
has O O
been O O
found O O
to O O
exhibit O O
additive O O
effects O O
of O O
this O O
variety O O
. O O

Tetracyclines B-Group B-Group
: O O
Concomitant O O
treatment O O
with O O
Accutane B-Brand B-Brand
and O O
tetracyclines B-Group B-Group
should O O
be O O
avoided O O
because O O
Accutane B-Brand B-Brand
use O O
has O O
been O O
associated O O
with O O
a O O
number O O
of O O
cases O O
of O O
pseudotumor O O
cerebri O O
( O O
benign O O
intracranial O O
hypertension O O
) O O
some O O
of O O
which O O
involved O O
concomitant O O
use O O
of O O
tetracyclines B-Group B-Group

Valdecoxib B-Drug B-Drug
caused O O
a O O
statistically O O
significant O O
increase O O
in O O
plasma O O
exposures O O
of O O
R B-Drug B-Drug
- O O
warfarin B-Drug B-Drug
and O O
S B-Drug B-Drug_n
- O O
warfarin B-Drug B-Drug
( O O
9 O O
% O O
and O O
9 O O
% O O
respectively O O
) O O
and O O
in O O
the O O
pharmacodynamic O O
effects O O
( O O
prothrombin O O
time O O
measured O O
as O O
INR O O
) O O
of O O
warfarin B-Drug B-Drug
. O O

Coadministration O O
of O O
Itraconazole B-Drug B-Drug
and O O
drugs O O
primarily O O
metabolized O O
by O O
the O O
cytochrome O O
P9 O O
9A9 O O
enzyme O O
system O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
the O O
drugs O O
that O O
could O O
increase O O
or O O
prolong O O
both O O
therapeutic O O
and O O
adverse O O
effects O O
. O O

Population O O
pharmacokinetic O O
studies O O
showed O O
higher O O
concentrations O O
of O O
cilostazol B-Drug B-Drug
among O O
patients O O
concurrently O O
treated O O
with O O
diltiazem B-Drug B-Drug
an O O
inhibitor O O
of O O
C.P.A.. O B-Brand

Cholestyramine B-Drug B-Drug
: O O
Cholestyramine B-Drug B-Drug
binds O O
both O O
T9 B-Drug O
and O O
T9 B-Drug O
in O O
the O O
intestine O O
thus O O
impairing O O
absorption O O
of O O
these O O
thyroid B-Group B-Group
hormones I-Group I-Group
. O O

Cyclosporine B-Drug B-Drug
tacrolimus B-Drug B-Drug
and O O
digoxin B-Drug B-Drug
concentrations O O
should O O
be O O
monitored O O
at O O
the O O
initiation O O
of O O
Itraconazole B-Drug B-Drug
therapy O O
and O O
frequently O O
thereafter O O
and O O
the O O
dose O O
of O O
these O O
three O O
drug O O
products O O
adjusted O O
appropriately O O
. O O

Preliminary O O
clinical O O
data O O
suggest O O
that O O
the O O
incidence O O
of O O
nephrolithiasis O O
is O O
higher O O
in O O
patients O O
receiving O O
indinavir B-Drug B-Drug
in O O
combination O O
with O O
ritonavir B-Drug B-Drug
than O O
those O O
receiving O O
CRIXIVAN B-Brand B-Brand
9 O O
mg O O
q9h O O
. O O

The O O
interaction O O
between O O
lomefloxacin B-Drug B-Drug
and O O
cimetidine B-Drug B-Drug
has O O
not O O
been O O
studied O O
. O O

The O O
physician O O
is O O
advised O O
to O O
monitor O O
the O O
plasma O O
concentrations O O
of O O
itraconazole B-Drug B-Drug
when O O
any O O
of O O
these O O
drugs O O
is O O
taken O O
concurrently O O
and O O
to O O
increase O O
the O O
dose O O
of O O
Itraconazole B-Drug B-Drug
if O O
necessary O O
. O O

Proquin B-Brand B-Brand
XR I-Brand I-Brand
should O O
be O O
administered O O
at O O
least O O
9 O O
hours O O
before O O
or O O
9 O O
hours O O
after O O
these O O
products O O
. O O

Dose O O
adjustments O O
of O O
either O O
class O O
of O O
agents O O
may O O
be O O
necessary O O
. O O

A O O
multiple O O
dose O O
drug O O
- O O
drug O O
interaction O O
study O O
demonstrated O O
that O O
ketoconazole B-Drug B-Drug
approximately O O
doubled O O
paricalcitol B-Drug O
AUC9 O O
- O O
. O O
Since O O
paricalcitol B-Drug B-Drug
is O O
partially O O
metabolized O O
by O O
CYP9A O O
and O O
ketoconazole B-Drug B-Drug
le O O
is O O
known O O
to O O
be O O
a O O
strong O O
inhibitor O O
of O O
cytochrome O O
P9 O O
9A O O
enzyme O O
care O O
should O O
be O O
taken O O
while O O
dosing O O
paricalcitol B-Drug O
with O O
ketoconazole B-Drug B-Drug
and O O
other O O
strong O O
P9 O O
9A O O
inhibitors O O
including O O
atazanavir B-Drug B-Drug
clarithromycin B-Drug B-Drug
indinavir B-Drug B-Drug
itraconazole B-Drug B-Drug
nefazodone B-Drug B-Drug
nelfinavir B-Drug B-Drug
ritonavir B-Drug B-Drug
saquinavir B-Drug B-Drug
telithromycin B-Drug B-Drug
or O O
voriconazole B-Drug B-Drug
. O O

However O O
reports O O
suggest O O
that O O
NSAIDs B-Group B-Group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
ACE B-Group B-Group
inhibitors I-Group I-Group
. O O

Concomitant O O
administration O O
of O O
other O O
sympathomimetic B-Group B-Group
agents I-Group I-Group
may O O
potentiate O O
the O O
undesirable O O
effects O O
of O O
FORADIL B-Brand B-Brand
. O O

CRIXIVAN B-Brand B-Brand
may O O
not O O
be O O
effective O O
due O O
to O O
decreased O O
indinavir B-Drug B-Drug
concentrations O O
in O O
patients O O
taking O O
these O O
agents O O
concomitantly O O
. O O

Thus O O
it O O
is O O
recommended O O
not O O
to O O
use O O
such O O
methods O O
for O O
9 O O
- O O
9 O O
hours O O
after O O
administration O O
of O O
Omniscan B-Brand B-Brand
. O O

Ketoconazole B-Drug B-Drug

Cimetidine B-Drug B-Drug
treatment O O
should O O
be O O
stopped O O
during O O
treatment O O
with O O
ELLENCE B-Brand B-Brand
. O O

astemizole B-Drug B-Drug
bepridil B-Drug B-Drug
sparfloxacin B-Drug B-Drug
and O O
terodiline B-Drug B-Drug
. O O

Tricyclic B-Group B-Group
Antidepressants I-Group I-Group
: O O
Use O O
of O O
thyroid B-Group O
products I-Group O
with O O
imipramine B-Drug B-Drug
and O O
other O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
may O O
increase O O
receptor O B-Drug
sensitivity O O
and O O
enhance O O
antidepressant O O
activity O O
transient O O
cardiac O O
arrhythmias O O
have O O
been O O
observed O O
. O O

Lovastatin B-Drug B-Drug

These O O
cephalosporins B-Group B-Group
are O O
inhibitors O O
of O O
hepatic O O
vitamin O O
K O O
epoxide O O
reductase O O
. O O

This O O
diminution O O
is O O
not O O
sufficient O O
to O O
preclude O O
effectiveness O O
of O O
the O O
pressor O O
agent O O
for O O
therapeutic O O
use O O
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
DIABINESE B-Brand B-Brand
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Therefore O O
if O O
concomitant O O
use O O
of O O
such O O
agents O O
is O O
indicated O O
they O O
should O O
be O O
given O O
with O O
caution O O
and O O
the O O
patient O O
's O O
serum O O
potassium O O
should O O
be O O
monitored O O
. O O

( O O
May O O
inhibit O O
gastrointestinal O O
absorption O O
of O O
the O O
thiazide B-Group B-Group
diuretics I-Group I-Group
; O O

INH B-Drug O
( O O
Isoniazid B-Drug B-Drug
) O O
is O O
also O O
reported O O
to O O
affect O O
ketoconazole B-Drug B-Drug
concentrations O O
adversely O O
. O O

Caution O O
should O O
be O O
used O O
when O O
EVISTA B-Brand B-Brand
is O O
coadministered O O
with O O
other O O
highly O O
protein O O
- O O
bound O O
drugs O O
such O O
as O O
clofibrate B-Drug B-Drug
indomethacin B-Drug B-Drug
naproxen B-Drug B-Drug
ibuprofen B-Drug B-Drug
diazepam B-Drug B-Drug
and O O
diazoxide B-Drug B-Drug
. O O

The O O
ratios O O
of O O
the O O
AUCs O O
of O O
unbound O O
valproate B-Drug B-Drug
to O O
the O O
AUCs O O
of O O
the O O
total O O
valproate B-Drug B-Drug
were O O
9 O O
% O O
9 O O
% O O
and O O
9 O O
% O O
with O O
coadministration O O
of O O
9 O O
9 O O
and O O
9 O O
mg O O
/ O O
day O O
of O O
Felbatol B-Brand B-Brand
respectively O O
. O O

Cyclosporine B-Drug B-Drug
: O O
Administration O O
of O O
nonsteroial B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
drugs I-Group I-Group
concomitantly O O
with O O
cyclosporine B-Drug B-Drug
has O O
been O O
associated O O
with O O
an O O
increase O O
in O O
cyclosporine B-Drug B-Drug
- O O
induced O O
toxicity O O
possibly O O
due O O
to O O
decreased O O
synthesis O O
of O O
renal O O
prostacyclin O O
. O O

CELEBREX B-Brand B-Brand
should O O
be O O
introduced O O
at O O
the O O
lowest O O
recommended O O
dose O O
in O O
patients O O
receiving O O
fluconazole B-Drug B-Drug
. O O

A O O
9 O O
to O O
9 O O
% O O
increase O O
in O O
AUC O O
and O O
Cmax O O
of O O
nisoldipine B-Drug B-Drug
was O O
observed O O
with O O
concomitant O O
administration O O
of O O
cimetidine B-Drug B-Drug
9 I-Drug O
mg I-Drug O
twice O O
daily O O
. O O

These O O
increases O O
in O O
concentration O O
may O O
lead O O
to O O
increased O O
effects O O
( O O
lower O O
blood O O
pressure O O
and O O
increased O O
heart O O
rate O O
) O O
. O O

However O O
antacids B-Group B-Group
can O O
decrease O O
the O O
peak O O
concentration O O
reached O O
by O O
9 O O
% O O
to O O
9 O O
% O O
but O O
have O O
no O O
detectable O O
effect O O
on O O
the O O
time O O
- O O
to O O
- O O
peak O O
. O O

In O O
the O O
long O O
- O O
term O O
safety O O
studies O O
guanfacine B-Drug B-Drug
was O O
given O O
concomitantly O O
with O O
many O O
drugs O O
without O O
evidence O O
of O O
any O O
interactions O O
. O O

Because O O
of O O
the O O
potential O O
for O O
adverse O O
reactions O O
from O O
the O O
drugs O O
in O O
nursing O O
infants O O
a O O
decision O O
must O O
be O O
made O O
whether O O
to O O
discontinue O O
nursing O O
or O O
discontinue O O
PEGASYS B-Brand B-Brand
and O O
COPEGUS B-Brand B-Brand
treatment O O
. O O

Because O O
the O O
potential O O
interaction O O
of O O
efavirenz B-Drug B-Drug
with O O
oral O O
contraceptives B-Group B-Group
has O O
not O O
been O O
fully O O
characterized O O
a O O
reliable O O
method O O
of O O
barrier O O
contraception O O
should O O
be O O
used O O
in O O
addition O O
to O O
oral O O
contraceptives B-Group B-Group
. O O

Some O O
drug O O
interactions O O
are O O
: O O
- O O
birth O O
control O O
pills O O
- O O
corticosteroids B-Group B-Group
- O O
medicines O O
for O O
angina O O
or O O
high O O
blood O O
pressure O O
- O O
medicines O O
for O O
pain O O
- O O
medicines O O
to O O
control O O
seizures O O
such O O
as O O
phenytoin B-Drug B-Drug
or O O
carbamazepine B-Drug B-Drug
- O O
certain O O
antibiotics B-Group B-Group
given O O
by O O
injection O O
- O O
cisplatin B-Drug B-Drug
- O O
edrophonium B-Drug B-Drug_n
- O O
neostigmine B-Drug B-Drug_n
- O O
polymyxin B-Drug B-Drug
B I-Drug I-Drug
or O O
bacitracin B-Drug B-Group
- O O
local O O
anesthetics B-Group B-Group
such O O
as O O
procaine B-Drug B-Drug
- O O
general O O
anesthetics B-Group B-Group
- O O
succinylcholine B-Drug B-Drug
or O O
other O O
muscle B-Group B-Group
relaxants I-Group I-Group

Quinidine B-Drug B-Drug
at O O
9 O O
mg O O
bid O O
decreased O O
the O O
bioavailability O O
( O O
AUC O O
) O O
of O O
nisoldipine B-Drug B-Drug
by O O
9 O O
% O O
but O O
not O O
the O O
peak O O
concentration O O
. O O

INDOCIN B-Brand B-Brand
and O O
triamterene B-Drug B-Drug
should O O
not O O
be O O
administered O O
together O O
. O O

therefore O O
patients O O
who O O
may O O
be O O
adversely O O
affected O O
by O O
such O O
an O O
action O O
should O O
be O O
carefully O O
observed O O
. O O

Caution O O
should O O
be O O
used O O
when O O
alosetron B-Drug B-Drug
and O O
ketoconazole B-Drug B-Drug
are O O
administered O O
concomitantly O O
. O O

CNS O O
Toxicity O O
Brain O O
hemorrhage O O
was O O
seen O O
in O O
a O O
female O O
dog O O
treated O O
for O O
9 O O
months O O
at O O
9 O O
mg O O
/ O O
kg O O
/ O O
day O O
. O O

Also O O
in O O
vitro O O
experiments O O
demonstrated O O
a O O
lack O O
of O O
interaction O O
between O O
dirithromycin B-Drug B-Drug
and O O
terfenadine B-Drug B-Drug
. O O

Both O O
the O O
sedative O O
and O O
anticholinergic O O
effects O O
of O O
the O O
major B-Group O
tranquilizers I-Group B-Group
are O O
also O O
additive O O
to O O
those O O
of O O
desipramine B-Drug B-Drug
. O O

Caution O O
should O O
be O O
exercised O O
when O O
CYP9A9 O O
inhibitors O O
are O O
coadministered O O
. O O

Other O O
than O O
with O O
probenecid B-Drug B-Drug
no O O
specific O O
clinical O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O

Sulfamethoxazole B-Drug B-Drug
may O O
inhibit O O
the O O
hepatic O O
metabolism O O
of O O
phenytoin B-Drug B-Drug
. O O

Serum O O
potassium O O
levels O O
and O O
cardiac O O
function O O
should O O
be O O
closely O O
monitored O O
and O O
any O O
deficit O O
promptly O O
corrected O O
. O O

Read O O
the O O
circular O O
for O O
lithium B-Drug B-Drug
preparations O O
. O O

monitor O O
cyclosporine B-Drug B-Drug
levels O O
. O O

Concurrent O O
use O O
with O O
vasoconstrictor B-Group B-Group
agents I-Group I-Group
including O O
ergot B-Group B-Group
alkaloids I-Group I-Group
sumatriptan B-Drug B-Drug
and O O
nicotine B-Drug B-Drug
( O O
e.g O O
. O O
smoking O O
) O O
may O O
result O O
in O O
enhanced O O
vasoconstriction O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
The O O
administration O O
of O O
ceftazidime B-Drug B-Drug
may O O
result O O
in O O
a O O
false O O
- O O
positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
when O O
using O O
CLINITEST O O
tablets O O
Benedicts O O
solution O O
or O O
Fehlings O O
solution O O
. O O

Johns O B-Drug_n
Wort O I-Drug_n
may O O
decrease O O
SUTENT B-Brand B-Brand
plasma O O
concentrations O O
unpredictably O O
. O O

as O O
such O O
it O O
may O O
impair O O
intestinal O O
absorption O O
of O O
any O O
of O O
vitamin B-Group B-Group
D I-Group I-Group
. O O

it O O
is O O
possible O O
that O O
larger O O
theophylline B-Drug B-Drug
doses O O
could O O
have O O
a O O
greater O O
effect O O
. O O

The O O
concomitant O O
use O O
of O O
Sanctura B-Brand B-Brand
with O O
other O O
anticholinergic B-Group B-Group
agents I-Group I-Group
that O O
produce O O
dry O O
mouth O O
constipation O O
and O O
other O O
anticholinergic O O
pharmacological O O
effects O O
may O O
increase O O
the O O
frequency O O
and O O
/ O O
or O O
severity O O
of O O
such O O
effects O O
. O O

Few O O
systemic O O
data O O
have O O
been O O
collected O O
on O O
the O O
metabolism O O
of O O
WELLBUTRIN B-Brand B-Brand
following O O
concomitant O O
administration O O
with O O
other O O
drugs O O
or O O
alternatively O O
the O O
effect O O
of O O
concomitant O O
administration O O
of O O
WELLBUTRIN B-Brand B-Brand
on O O
the O O
metabolism O O
of O O
other O O
drugs O O
. O O

No O O
differences O O
in O O
safety O O
or O O
efficacy O O
were O O
observed O O
between O O
older O O
and O O
younger O O
patients O O
but O O
there O O
were O O
not O O
sufficient O O
data O O
to O O
exclude O O
important O O
differences O O
. O O

monitor O O
and O O
adjust O O
anticoagulant B-Group B-Group
dosage O O
accordingly O O
. O O

Additives O O
may O O
be O O
incompatible O O
. O O

Potential O O
Terfenadine B-Drug B-Drug
Astemizole B-Drug B-Drug
and O O
Cisapride B-Drug B-Drug
Interactions O O

Pharmacokinetic O O
properties O O
of O O
abacavir B-Drug B-Drug
were O O
not O O
altered O O
by O O
the O O
addition O O
of O O
either O O
lamivudine B-Drug B-Drug
or O O
zidovudine B-Drug B-Drug
or O O
the O O
combination O O
of O O
lamivudine B-Drug B-Drug
and O O
zidovudine B-Drug B-Drug
. O O

Medication O O
such O O
as O O
digitalis B-Group B-Group
may O O
also O O
influence O O
serum O O
electrolytes O O
. O O

Symptoms O O
resolved O O
when O O
clonidine B-Drug B-Drug
was O O
withdrawn O O
and O O
recurred O O
when O O
the O O
patient O O
was O O
rechallenged O O
with O O
clonidine B-Drug B-Drug
. O O

Tolbutamide B-Drug B-Drug
: O O
In O O
in O O
vitro O O
studies O O
M9 O O
was O O
shown O O
to O O
cause O O
increases O O
ranging O O
from O O
9 O O
- O O
9 O O
% O O
in O O
the O O
free O O
fraction O O
of O O
tolbutamide B-Drug B-Drug
at O O
concentrations O O
in O O
the O O
clinical O O
range O O
. O O

It O O
is O O
recommended O O
that O O
if O O
CASODEX B-Brand B-Brand
is O O
started O O
in O O
patients O O
already O O
receiving O O
coumarin B-Group B-Group
anticoagulants I-Group I-Group
prothrombin O O
times O O
should O O
be O O
closely O O
monitored O O
and O O
adjustment O O
of O O
the O O
anticoagulant B-Group B-Group
dose O O
may O O
be O O
necessary O O
. O O

Preliminary O O
evidence O O
suggests O O
that O O
cimetidine B-Drug B-Drug
inhibits O O
mebendazole B-Drug B-Drug
metabolism O O
and O O
may O O
result O O
in O O
an O O
increase O O
in O O
plasma O O
concentrations O O
of O O
mebendazole B-Drug B-Drug
. O O

Notably O O
systemic O O
exposure O O
( O O
AUC9 O O
- O O
9 O O
) O O
of O O
dapsone B-Drug_n B-Drug_n
hydroxylamine I-Drug_n I-Drug_n
( O O
DHA B-Drug_n O
) O O
was O O
more O O
than O O
doubled O O
in O O
the O O
presence O O
of O O
TMP B-Drug B-Drug
/ O O
SMX B-Drug B-Drug
. O O

In O O
vivo O O
studies O O
: O O
Nitrates B-Group B-Group
: O O
The O O
blood O O
pressure O O
lowering O O
effects O O
of O O
sublingual O O
nitrates B-Group B-Group
( O O
9 O O
mg O O
) O O
taken O O
9 O O
and O O
9 O O
hours O O
after O O
vardenafil B-Drug B-Drug
and O O
increases O O
in O O
heart O O
rate O O
when O O
taken O O
at O O
9 O O
9 O O
and O O
9 O O
hours O O
were O O
potentiated O O
by O O
a O O
9 O O
mg O O
dose O O
of O O
Vardenafil B-Drug B-Drug
in O O
healthy O O
middle O O
- O O
aged O O
subjects O O
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
glipizide B-Drug B-Drug
the O O
patient O O
should O O
be O O
closely O O
observed O O
for O O
loss O O
of O O
control O O
. O O

There O O
have O O
been O O
reports O O
of O O
QTc O O
prolongation O O
with O O
or O O
without O O
TdP O O
in O O
patients O O
taking O O
amiodarone B-Drug B-Drug
when O O
fluoroquinolones B-Drug O
macrolide B-Drug B-Group
antibiotics I-Drug I-Group
or O O
azoles O B-Group
were O O
administered O O
concomitantly O O
. O O

There O O
is O O
no O O
information O O
on O O
the O O
effect O O
of O O
other O O
highly O O
plasma O O
protein O O
bound O O
drugs O O
on O O
doxazosin B-Drug B-Drug
binding O O
. O O

9% O O
9% O O
9% O O
9% O O

- O O
Medicinal O B-Drug
or O O
dietary O O
iodine B-Group B-Drug
interferes O O
with O O
all O O
in O O
vivo O O
tests O O
of O O
radio O O
- O O
iodine O O
uptake O O
producing O O
low O O
uptakes O O
which O O
may O O
not O O
be O O
reflective O O
of O O
a O O
true O O
decrease O O
in O O
hormone O O
synthesis O O

There O O
have O O
been O O
postmarketing O O
reports O O
of O O
drug O O
interactions O O
when O O
erythromycin B-Drug B-Drug
is O O
coadministered O O
with O O
cisapride B-Drug B-Drug
resulting O O
in O O
QT O O
prolongation O O
cardiac O O
arrythmias O O
ventricular O O
tachycardia O O
ventricular O O
fibrulation O O
and O O
torsades O O
de O O
pointes O O
most O O
like O O
due O O
to O O
inhibition O O
of O O
hepatic O O
metabolism O O
of O O
cisapride B-Drug B-Drug
by O O
erythromycin B-Drug B-Drug
. O O

One O O
case O O
of O O
hypertensive O O
crisis O O
has O O
been O O
reported O O
in O O
a O O
patient O O
taking O O
the O O
recommended O O
doses O O
of O O
selegiline B-Drug B-Drug
and O O
a O O
sympathomimetic B-Group B-Group
medication I-Group I-Group
( O O
ephedrine B-Drug B-Drug
) O O
. O O

Chlorotrianisene B-Drug B-Drug
may O O
interact O O
with O O
antidepressants B-Group B-Group
aspirin B-Brand B-Brand
barbiturates B-Group B-Group
bromocriptine B-Drug B-Drug
calcium B-Drug B-Group
supplements O I-Group
corticosteroids B-Group B-Group
corticotropin B-Drug B-Drug
cyclosporine B-Drug B-Drug
dantrolene B-Drug B-Drug
nicotine B-Drug B-Drug
somatropin B-Drug B-Drug
tamoxifen B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
. O O

False O O
- O O
positive O O
direct O O
Coombs O O
tests O O
have O O
been O O
reported O O
during O O
treatment O O
with O O
other O O
cephalosporins B-Group B-Group
. O O

The O O
concomitant O O
use O O
of O O
diflunisal B-Drug B-Drug
tablets O O
and O O
other O O
NSAIDs B-Group B-Group
is O O
not O O
recommended O O
due O O
to O O
the O O
increased O O
possibility O O
of O O
gastrointestinal O O
toxicity O O
with O O
little O O
or O O
no O O
increase O O
in O O
efficacy O O
. O O

However O O
this O O
has O O
not O O
been O O
investigated O O
in O O
human O O
studies O O
. O O

The O O
effect O O
of O O
theophylline B-Drug B-Drug
on O O
the O O
pharmacokinetics O O
of O O
citalopram B-Drug B-Drug
was O O
not O O
evaluated O O
. O O

This O O
observation O O
should O O
be O O
considered O O
in O O
clinical O O
decisions O O
to O O
prescribe O O
VESIcare B-Brand B-Brand
for O O
patients O O
with O O
a O O
known O O
history O O
of O O
QT O O
prolongation O O
or O O
patients O O
who O O
are O O
taking O O
medications O O
known O O
to O O
prolong O O
the O O
QT O O
interval O O
. O O

Effect O O
of O O
other O O
drugs O O
on O O
Vardenafil B-Drug B-Drug

Concomitant O O
use O O
with O O
other O O
calcium B-Drug B-Group
- O O
containing O O
medicines O O
( O O
including O O
antacids B-Group B-Group
) O O
may O O
cause O O
too O O
much O O
calcium B-Drug B-Drug
in O O
the O O
blood O O
or O O
urine O O
which O O
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
. O O

A O O
9 O O
- O O
fold O O
increase O O
was O O
seen O O
in O O
another O O
9 O O
patients O O
. O O

BREVIBLOC B-Brand B-Brand
concentrations O O
were O O
equivocally O O
higher O O
when O O
given O O
with O O
warfarin B-Drug B-Drug
but O O
this O O
is O O
not O O
likely O O
to O O
be O O
clinically O O
important O O
. O O

Caution O O
however O O
is O O
advised O O
in O O
patients O O
taking O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
which O O
can O O
affect O O
the O O
metabolism O O
and O O
uptake O O
of O O
circulating O O
amines O O
. O O

Conversely O O
the O O
administration O O
of O O
STADOL B-Brand B-Brand
NS I-Brand I-Brand
( O O
9 O O
mg O O
butorphanol B-Drug B-Drug
QID O O
) O O
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
a O O
9 O O
- O O
mg O O
dose O O
of O O
cimetidine B-Drug B-Drug
. O O

Thus O O
cimetidine B-Drug B-Drug
appeared O O
to O O
alter O O
the O O
renal O O
excretion O O
of O O
both O O
gabapentin B-Drug B-Drug
and O O
creatinine O O
an O O
endogenous O O
marker O O
of O O
renal O O
function O O
. O O

Significant O O
increases O O
In O O
AUC O O
( O O
9 O O
% O O
) O O
and O O
Cmax O O
( O O
9 O O
% O O
) O O
and O O
decreases O O
in O O
tmax O O
( O O
9 O O
% O O
) O O
of O O
propranolol B-Drug B-Drug
were O O
noted O O
in O O
this O O
study O O
. O O

Probenecid B-Drug B-Drug
: O O
Probenecid B-Drug B-Drug
a O O
renal O O
tubular O O
secretion O O
blocking O O
agent O O
administered O O
at O O
a O O
dose O O
of O O
9 O O
mg O O
four O O
times O O
a O O
day O O
did O O
not O O
change O O
the O O
pharmacokinetics O O
of O O
levetiracetam B-Drug B-Drug
9 O O
mg O O
twice O O
daily O O
. O O

Antifungals B-Group B-Group

Drugs O O
such O O
as O O
erythromycin B-Drug B-Drug
diltiazem B-Drug B-Drug
verapamil B-Drug B-Drug
ketoconazole B-Drug B-Drug
fluconazole B-Drug B-Drug
and O O
itraconazole B-Drug B-Drug
were O O
shown O O
to O O
significantly O O
increase O O
the O O
C O O
max O O
and O O
AUC O O
of O O
orally O O
administered O O
midazolam B-Drug B-Drug
. O O

carbamazepine B-Drug B-Drug
; O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
: O O
None O O
known O O
. O O

Some O O
cases O O
presented O O
with O O
features O O
resembling O O
neuroleptic O O
malignant O O
syndrome O O
. O O

Dosage O O
adjustments O O
of O O
BROVANA B-Brand B-Brand
are O O
not O O
necessary O O
when O O
the O O
drug O O
is O O
given O O
concomitantly O O
with O O
potent O O
CYP9D9 O O
inhibitors O O
. O O

Thus O O
careful O O
monitoring O O
of O O
clinical O O
status O O
is O O
warranted O O
when O O
rifampin B-Drug B-Drug
is O O
administered O O
or O O
discontinued O O
in O O
haloperidol B-Drug B-Drug
- O O
treated O O
patients O O
. O O

The O O
magnitude O O
of O O
interaction O O
at O O
other O O
doses O O
is O O
not O O
known O O
. O O

DIDREX B-Brand B-Brand
should O O
not O O
be O O
used O O
concomitantly O O
with O O
other O O
CNS B-Group B-Group
stimulants I-Group I-Group
. O O

Starlix B-Brand B-Brand
is O O
a O O
potential O O
inhibitor O O
of O O
the O O
CYP9C9 O O
isoenzyme O O
in O O
vivo O O
as O O
indicated O O
by O O
its O O
ability O O
to O O
inhibit O O
the O O
in O O
vitro O O
metabolism O O
of O O
tolbutamide B-Drug B-Drug
. O O

Coadministration O O
of O O
CRIXIVAN B-Brand B-Brand
and O O
other O O
drugs O O
that O O
inhibit O O
CYP9A9 O O
may O O
decrease O O
the O O
clearance O O
of O O
indinavir B-Drug B-Drug
and O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
indinavir B-Drug B-Drug
. O O

Volatile O O
Anesthetic B-Drug O
Agents O O
: O O
. O O

Fulvestrant B-Drug B-Drug
is O O
metabolized O O
by O O
CYP O O
9A9 O O
in O O
vitro O O
. O O

Theophylline B-Drug B-Drug
: O O
A O O
single O O
9 O O
mg O O
dose O O
of O O
tiagabine B-Drug B-Drug
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
theophylline B-Drug B-Drug
at O O
steady O O
state O O
. O O

Fat B-Group B-Group
- O O
soluble B-Group B-Group
Vitamin I-Group I-Group
Supplements I-Group I-Group
and O O
Analogues O B-Group
: O O
A O O
pharmacokinetic O O
interaction O O
study O O
showed O O
a O O
9 O O
% O O
reduction O O
in O O
beta B-Drug O
- O O
carotene B-Drug O
supplement O O
absorption O O
when O O
concomitantly O O
administered O O
with O O
XENICAL B-Brand B-Brand
. O O

Tubocurarine B-Drug B-Drug

The O O
effect O O
of O O
alosetron B-Drug B-Drug
on O O
monoamine O B-Group
oxidases O I-Group
and O O
on O O
intestinal O O
first O O
pass O O
secondary O O
to O O
high O O
intraluminal O O
concentrations O O
have O O
not O O
been O O
examined O O
. O O

Another O O
oral O O
azole B-Group B-Group
antifungal I-Group I-Group
ketoconazole B-Drug B-Drug
inhibits O O
the O O
metabolism O O
of O O
astemizole B-Drug B-Drug
resulting O O
in O O
elevated O O
plasma O O
concentrations O O
of O O
astemizole B-Drug B-Drug
and O O
its O O
active O O
metabolite O O
desmethylastermizole B-Drug_n B-Drug_n
which O O
may O O
prolong O O
QT O O
intervals O O
. O O

Methotrexate B-Drug B-Drug
: O O
Ketoprofen B-Drug B-Drug
like O O
other O O
NSAIDs B-Group B-Group
may O O
cause O O
changes O O
in O O
the O O
elimination O O
of O O
methotrexate B-Drug B-Drug
leading O O
to O O
elevated O O
serum O O
levels O O
of O O
the O O
drug O O
and O O
increased O O
toxicity O O
. O O

Therefore O O
patients O O
with O O
COPD O O
should O O
not O O
normally O O
be O O
treated O O
with O O
beta B-Group B-Group
- O O
blockers B-Group B-Group
. O O

It O O
is O O
possible O O
that O O
the O O
cardiovascular O O
action O O
of O O
other O O
calcium B-Group B-Group
channel I-Group I-Group
blockers I-Group I-Group
could O O
be O O
enhanced O O
by O O
the O O
addition O O
of O O
Nimotop B-Brand B-Brand
. O O

Plasma O O
concentrations O O
of O O
azole B-Group B-Group
antifungal I-Group I-Group
agents I-Group I-Group
are O O
reduced O O
when O O
given O O
concurrently O O
with O O
isoniazid B-Drug B-Drug
. O O

In O O
an O O
uncontrolled O O
study O O
of O O
over O O
9 O O
patients O O
with O O
congestive O O
heart O O
failure O O
during O O
which O O
digoxin B-Drug B-Drug
blood O O
levels O O
were O O
not O O
measured O O
digitalis O B-Group
toxicity O O
was O O
not O O
observed O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
MICRONASE B-Brand B-Brand
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
loss O O
of O O
control O O
. O O

Bosentan B-Drug B-Drug
is O O
an O O
inducer O O
of O O
CYP9A9 O O
and O O
CYP9C9 O O
. O O

The O O
pharmacokinetics O O
of O O
praziquantel B-Drug B-Drug
were O O
unchanged O O
following O O
coadministration O O
with O O
albendazole B-Drug B-Drug
( O O
9 O O
mg O O
) O O
. O O

. O O

The O O
pharmacokinetic O O
interaction O O
between O O
cimetidine B-Drug B-Drug
and O O
FLOMAX B-Brand B-Brand
capsules O O
was O O
investigated O O
. O O

. O O

Acetaminophen B-Drug B-Drug
: O O
Rimantadine B-Drug B-Drug
HCl I-Drug I-Drug
9 O O
mg O O
was O O
given O O
twice O O
daily O O
for O O
9 O O
days O O
to O O
9 O O
healthy O O
volunteers O O
. O O

Fluconazole B-Drug B-Drug
an O O
inhibitor O O
of O O
P9 O O
9C9 O O
decreased O O
active O O
metabolite O O
concentration O O
and O O
increased O O
losartan B-Drug B-Drug
concentration O O
. O O

chymotrypsin B-Drug B-Drug
; O O

When O O
administering O O
other O O
drugs O O
for O O
which O O
alterations O O
in O O
blood O O
levels O O
could O O
have O O
a O O
clinically O O
significant O O
effect O O
on O O
safety O O
or O O
efficacy O O
physicians O O
should O O
consider O O
monitoring O O
drug O O
levels O O
or O O
effects O O
. O O

( O O
g O O
) O O
There O O
may O O
be O O
small O O
changes O O
in O O
lipid O O
profiles O O
. O O

In O O
vitro O O
studies O O
suggest O O
that O O
coadministration O O
of O O
cytochrome O O
P9 O O
inhibitors O O
to O O
PMs O O
will O O
not O O
increase O O
the O O
plasma O O
concentrations O O
of O O
atomoxetine B-Drug B-Drug
. O O

Indinavir B-Drug B-Drug

In O O
patients O O
in O O
whom O O
CYP9A9 O O
inducers O O
( O O
eg O O
dexamethasone B-Drug B-Drug
phenytoin B-Drug B-Drug
carbamazepine B-Drug B-Drug
rifampicin B-Drug B-Drug
phenobarbital B-Drug B-Drug
) O O
are O O
indicated O O
alternative O O
agents O O
with O O
less O O
enzyme O O
induction O O
potential O O
should O O
be O O
used O O
. O O

An O O
evaluation O O
of O O
prothrombin O O
time O O
and O O
an O O
adjustment O O
of O O
anticoagulant B-Group B-Group
dosage O O
are O O
recommended O O

In O O
another O O
drug O O
interaction O O
study O O
co O O
- O O
administration O O
of O O
orally O O
inhaled O O
ciclesonide B-Drug B-Drug
and O O
oral O O
ketoconazole B-Drug B-Drug
a O O
potent O O
inhibitor O O
of O O
cytochrome O O
P9 O O
9A9 O O
increased O O
the O O
exposure O O
( O O
AUC O O
) O O
of O O
des B-Drug B-Drug
- O O
ciclesonide B-Drug B-Drug
by O O
approximately O O
9 O O
- O O
fold O O
at O O
steady O O
state O O
while O O
levels O O
of O O
ciclesonide B-Drug B-Drug
remained O O
unchanged O O
. O O

Patients O O
treated O O
concurrently O O
with O O
BREVIBLOC B-Brand B-Brand
( O O
esmolol B-Drug B-Drug_n
HCl I-Drug I-Drug_n
) O O
and O O
a O O
catecholamine O O
depletor O O
should O O
therefore O O
be O O
closely O O
observed O O
for O O
evidence O O
of O O
hypotension O O
or O O
marked O O
bradycardia O O
which O O
may O O
result O O
in O O
vertigo O O
syncope O O
or O O
postural O O
hypotension O O
. O O

If O O
glucocorticoid B-Group B-Group
replacement O O
is O O
required O O
the O O
glucocorticoid B-Group O
dose O O
should O O
be O O
carefully O O
adjusted O O
. O O

however O O
during O O
the O O
period O O
of O O
treatment O O
physicians O O
should O O
monitor O O
blood O O
cell O O
counts O O
. O O

Dose O O
adjustment O O
of O O
Sensipar B-Brand B-Brand
may O O
be O O
required O O
and O O
PTH O O
and O O
serum O O
calcium O O
concentrations O O
should O O
be O O
closely O O
monitored O O
if O O
a O O
patient O O
initiates O O
or O O
discontinues O O
therapy O O
with O O
a O O
strong O O
CYP9A9 O O
inhibitor O O
( O O
e.g. O O
ketoconazole B-Drug B-Drug
erythromycin B-Drug B-Drug
itraconazole B-Drug B-Drug
; O O

Information O O
on O O
concurrent O O
usage O O
of O O
atenolol B-Drug B-Drug
and O O
aspirin B-Brand B-Brand
is O O
limited O O
. O O

The O O
risk O O
of O O
using O O
bromocriptine B-Drug B-Drug
mesylate I-Drug I-Drug
in O O
combination O O
with O O
other O O
drugs O O
has O O
not O O
been O O
systematically O O
evaluated O O
but O O
alcohol B-Drug B-Drug
may O O
potentiate O O
the O O
side O O
effects O O
of O O
bromocriptine B-Drug B-Drug
mesylate I-Drug I-Drug
. O O

Loratadine B-Drug B-Drug
Descarboethoxyloratadine B-Drug B-Drug

- O O
a O O
steroid B-Group O
medicine I-Group O
such O O
as O O
prednisone B-Drug B-Drug
( O O
Deltasone B-Brand B-Brand
Orasone B-Brand B-Brand
others O O
) O O
methylprednisolone B-Drug B-Drug
( O O
Medrol B-Brand B-Brand
others O O
) O O
prednisolone B-Drug B-Drug
( O O
Prelone B-Brand B-Brand
Pediapred B-Brand O
others O O
) O O
and O O
others O O
; O O

For O B-Group
example O I-Group
diuretics B-Group I-Group
( O O
e.g. O O
thiazides B-Group B-Group
) O O
may O O
activate O O
the O O
renin O O
- O O
angiotensin O O
- O O
aldosterone O O
system O O
. O O

In O O
patients O O
where O O
rifampin B-Drug B-Drug
or O O
other O O
CYP9A9 O O
inducers O O
are O O
indicated O O
alternative O O
therapeutic O O
agents O O
with O O
less O O
enzyme O O
induction O O
potential O O
should O O
be O O
considered O O
. O O

Potential O O
for O O
serious O O
reactions O O
such O O
as O O
risk O O
of O O
myopathy O O
including O O
rhabdomyolysis O O
. O O

Oral O O
Hypoglycemics B-Group B-Group
: O O
Diclofenac B-Drug B-Drug
does O O
not O O
alter O O
glucose O O
metabolism O O
in O O
normal O O
subjects O O
nor O O
does O O
it O O
alter O O
the O O
effects O O
of O O
oral O O
hypoglycemic B-Group B-Group
agents I-Group I-Group
. O O

The O O
mechanism O O
of O O
this O O
pharmacodynamic O O
interaction O O
is O O
not O O
known O O
. O O

- O O
Antidiabetic B-Group B-Group
drugs I-Group I-Group
: O O
( O O
Oral O O
agents O O
and O O
insulin B-Drug B-Drug
) O O
Dosage O O
adjustment O O
of O O
the O O
antidiabetic B-Group B-Group
drug I-Group I-Group
may O O
be O O
required O O

Antihypertensives B-Group B-Group
: O O
Amphetamines B-Group B-Group
may O O
antagonize O O
the O O
hypotensive O O
effects O O
of O O
antihypertensives B-Drug B-Group
. O O

Diltiazem B-Drug B-Drug
is O O
both O O
a O O
substrate O O
and O O
an O O
inhibitor O O
of O O
the O O
cytochrome O O
P O O
- O O
9 O O
9A9 O O
enzyme O O
system O O
. O O

No O O
drug O O
- O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
depo B-Brand O
- O O
subQ B-Brand O
provera I-Brand O
9 I-Brand O
. O O

- O O
Gold B-Drug B-Group
salts O O
( O O
medicine O O
for O O
arthritis O O
) O O
or O O

free O O
T9 O O
concentration O O
is O O
unaltered O O

Lithium B-Drug B-Drug
: O O
Increased O O
serum O O
lithium B-Drug B-Drug
and O O
symptoms O O
of O O
lithium B-Drug B-Drug
toxicity O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
concomitant O O
lithium B-Drug B-Drug
and O O
ACE O B-Group
inhibitor O I-Group
therapy O O
. O O

In O O
vitro O O
human O O
liver O O
microsome O O
studies O O
and O O
an O O
in O O
vivo O O
metabolic O O
probe O O
study O O
demonstrated O O
that O O
alosetron B-Drug B-Drug
did O O
not O O
inhibit O O
CYP O O
enzymes O O
9D9 O O
9A9 O O
9C9 O O
or O O
9C9 O O
. O O

If O O
these O O
products O O
are O O
needed O O
they O O
should O O
be O O
given O O
at O O
least O O
9 O O
hours O O
before O O
cimetidine B-Drug B-Drug
administration O O
. O O

Amprenavir B-Drug B-Drug
does O O
not O O
inhibit O O
CYP9D9 O O
CYP9A9 O O
CYP9C9 O O
CYP9C9 O O
CYP9E9 O O
or O O
uridine O O
glucuronosyltransferase O O
( O O
UDPGT O O
) O O
. O O

Additionally O O
paroxetine B-Drug B-Drug
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
Sonata B-Brand B-Brand
reflecting O O
the O O
absence O O
of O O
a O O
role O O
of O O
CYP9D9 O O
in O O
zaleplon B-Drug B-Drug
metabolism O O
. O O

Antacids B-Group B-Group
containing O O
magnesium B-Drug B-Drug
trisilicate I-Drug I-Drug
when O O
administered O O
concomitantly O O
with O O
nitrofurantoin B-Drug B-Drug
reduce O O
both O O
the O O
rate O O
and O O
extent O O
of O O
absorption O O
. O O

Similar O O
decreases O O
in O O
Cmax O O
and O O
AUC O O
were O O
seen O O
after O O
the O O
first O O
dose O O
. O O

Because O O
oral O O
anticoagulants B-Group B-Group
may O O
interfere O O
with O O
the O O
hepatic O O
metabolism O O
of O O
phenytoin B-Drug B-Drug
toxic O O
levels O O
of O O
the O O
anticonvulsant B-Group B-Group
may O O
occur O O
when O O
an O O
oral O O
anticoagulant B-Group B-Group
and O O
phenytoin B-Drug B-Drug
are O O
administered O O
concurrently O O
. O O

Pediatric O O
Use O O
The O O
safety O O
and O O
effectiveness O O
of O O
PEGASYS B-Brand B-Brand
alone O O
or O O
in O O
combination O O
with O O
COPEGUS B-Brand B-Brand
in O O
patients O O
below O O
the O O
age O O
of O O
9 O O
years O O
have O O
not O O
been O O
established O O
. O O

iv O O
. O O

In O O
some O O
cases O O
where O O
serious O O
ventricular O O
arrhythmias O O
QT O O
prolongation O O
and O O
torsades O O
de O O
pointes O O
have O O
occurred O O
when O O
cisapride B-Drug B-Drug
was O O
taken O O
in O O
conjunction O O
with O O
one O O
of O O
the O O
cytochrome O O
P9 O O
9A9 O O
inhibitors O O
elevated O O
blood O O
cisapride B-Drug B-Drug
levels O O
were O O
noted O O
at O O
the O O
time O O
of O O
the O O
QT O O
prolongation O O
. O O

In O O
a O O
study O O
involving O O
healthy O O
subjects O O
receiving O O
TAMBOCOR B-Brand B-Brand
and O O
propranolol B-Drug B-Drug
concurrently O O
plasma O O
flecainide B-Drug B-Drug
levels O O
were O O
increased O O
about O O
9 O O
% O O
and O O
propranolol B-Drug B-Drug
levels O O
were O O
increased O O
about O O
9 O O
% O O
compared O O
to O O
control O O
values O O
. O O

There O O
is O O
usually O O
complete O O
cross O O
- O O
resistance O O
between O O
PURINETHOL B-Brand B-Brand
( O O
mercaptopurine B-Drug B-Drug
) O O
and O O
TABLOID B-Brand B-Brand
brand O O
Thioguanine B-Drug B-Drug
. O O

No O O
dosage O O
adjustment O O
of O O
either O O
drug O O
is O O
recommended O O
when O O
azithromycin B-Drug B-Drug
is O O
co O O
administered O O
with O O
any O O
of O O
the O O
above O O
agents O O
. O O

unreliable O O
prothrombin O O
time O O
determinations O O
; O O

Cyclosporine B-Drug B-Drug
: O O
Increased O O
activity O O
of O O
both O O
cyclosporine B-Drug B-Drug
and O O
corticosteroids B-Group B-Group
may O O
occur O O
when O O
the O O
two O O
are O O
used O O
concurrently O O
. O O

Studies O O
have O O
demonstrated O O
that O O
pretreatment O O
with O O
isoniazid B-Drug B-Drug
potentiates O O
a O O
cetaminophen O O
hepatoxicity O O
in O O
rats O O
. O O

The O O
use O O
of O O
MIVACRON B-Brand B-Brand
before O O
succinylcholine B-Drug B-Drug
to O O
attenuate O O
some O O
of O O
the O O
side O O
effects O O
of O O
succinylcholine B-Drug B-Drug
has O O
not O O
been O O
studied O O
. O O

Pilocarpine B-Drug B-Drug
should O O
be O O
administered O O
with O O
caution O O
to O O
patients O O
taking O O
beta B-Group B-Group
adrenergic I-Group I-Group
antagonists I-Group I-Group
because O O
of O O
the O O
possibility O O
of O O
conduction O O
disturbances O O
. O O

In O O
vitro O O
studies O O
show O O
that O O
tiludronate B-Drug B-Drug
does O O
not O O
displace O O
warfarin B-Drug B-Drug
from O O
its O O
binding O O
site O O
on O O
protein O O
. O O

It O O
is O O
recommended O O
that O O
these O O
tests O O
be O O
performed O O
prior O O
to O O
initiation O O
of O O
Soriatane B-Brand B-Brand
therapy O O
at O O
9 O O
- O O
to O O
9 O O
- O O
week O O
intervals O O
until O O
stable O O
and O O
thereafter O O
at O O
intervals O O
as O O
clinically O O
indicated O O
. O O

Concurrent O O
administration O O
of O O
dyphylline B-Drug B-Drug
and O O
probenecid B-Drug B-Drug
which O O
competes O O
for O O
tubular O O
secretion O O
has O O
been O O
shown O O
to O O
increase O O
the O O
plasma O O
half O O
- O O
life O O
of O O
dyphylline B-Drug B-Drug
. O O

Patients O O
should O O
be O O
cautioned O O
against O O
engaging O O
in O O
hazardous O O
activities O O
requiring O O
complete O O
mental O O
alertness O O
such O O
as O O
operating O O
machinery O O
or O O
driving O O
a O O
motor O O
vehicle O O
. O O

this O O
can O O
cause O O
headaches O O
and O O
other O O
signs O O
of O O
hypertensive O O
crisis O O
. O O

Interactions O O
may O O
occur O O
between O O
EPA B-Drug B-Drug
supplements O O
and O O
aspirin B-Brand B-Brand
and O O
other O O
non B-Group B-Group
- O O
steroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
drugs I-Group I-Group
and O O
herbs O O
such O O
as O O
garlic O O
( O O
Allium O O
sativum O O
) O O
and O O
ginkgo B-Drug O
( O O
Ginkgo B-Drug O
biloba I-Drug O
) O O
. O O

indinavir B-Drug B-Drug
concentration O O

Clinical O O
studies O O
with O O
celecoxib B-Drug B-Drug
have O O
identified O O
potentially O O
significant O O
interactions O O
with O O
fluconazole B-Drug B-Drug
and O O
lithium B-Drug B-Drug
. O O

Barbiturates B-Group B-Group
phenytoin B-Drug B-Drug
or O O
rifampin B-Drug B-Drug
increased O O
metabolic O O
clearance O O
of O O
fludrocortisone B-Drug B-Drug
acetate I-Drug I-Drug
because O O
of O O
the O O
induction O O
of O O
hepatic O O
enzymes O O
. O O

These O O
agents O O
may O O
increase O O
the O O
anesthetic O O
or O O
sedative O O
effects O O
of O O
DIPRIVAN B-Brand B-Brand
Injectable O O
Emulsion O O
and O O
may O O
also O O
result O O
in O O
more O O
pronounced O O
decreases O O
in O O
systolic O O
diastolic O O
and O O
mean O O
arterial O O
pressures O O
and O O
cardiac O O
output O O
. O O

Corresponding O O
values O O
for O O
free O O
valproate B-Drug B-Drug
Cmin O O
concentrations O O
were O O
9 O O
9 O O
9 O O
9 O O
and O O
9 O O
9 O O
micrograms O O
/ O O
mL O O
for O O
9 O O
9 O O
and O O
9 O O
mg O O
/ O O
day O O
Felbatol B-Brand B-Brand
respectively O O
. O O

In O O
studies O O
in O O
female O O
rats O O
at O O
doses O O
9 O O
mg O O
/ O O
kg O O
/ O O
day O O
( O O
IM O O
; O O

Oral O O
Contraceptives B-Group B-Group
Rofecoxib B-Drug B-Drug
did O O
not O O
have O O
any O O
clinically O O
important O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
ethinyl B-Drug B-Drug
estradiol I-Drug I-Drug
and O O
norethindrone B-Drug B-Drug
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
anticoagulants B-Group B-Group
are O O
given O O
in O O
conjunction O O
with O O
Atromid B-Brand B-Brand
- O O
S B-Brand B-Brand
. O O

A O O
pharmacokinetic O O
interaction O O
between O O
diltiazem B-Drug B-Drug
and O O
cyclosporine B-Drug B-Drug
has O O
been O O
observed O O
during O O
studies O O
involving O O
renal O O
and O O
cardiac O O
transplant O O
patients O O
. O O

Phosphate O O
- O O
Binding O O
Agents O O
: O O
Since O O
vitamin B-Group B-Group
D I-Group I-Group
also O O
has O O
an O O
effect O O
on O O
phosphate O O
transport O O
in O O
the O O
intestine O O
kidneys O O
and O O
bones O O
the O O
dosage O O
of O O
phosphate O O
- O O
binding O O
agents O O
must O O
be O O
adjusted O O
in O O
accordance O O
with O O
the O O
serum O O
phosphate O O
concentration O O
. O O

Aminosalicylic B-Drug B-Drug
acid I-Drug I-Drug
may O O
also O O
decrease O O
the O O
absorption O O
of O O
vitamin B-Drug B-Drug
B9 I-Drug I-Drug
which O O
can O O
lead O O
to O O
a O O
deficiency O O
. O O

adjust O O
dosage O O
of O O
antidiabetic B-Group B-Group
drug I-Group I-Group
accordingly O O
. O O

Based O O
on O O
in O O
vitro O O
inhibition O O
information O O
coadministration O O
of O O
mifepristone B-Drug B-Drug
may O O
lead O O
to O O
an O O
increase O O
in O O
serum O O
levels O O
of O O
drugs O O
that O O
are O O
CYP O O
9A9 O O
substrates O O
. O O

Drugs O O
that O O
induce O O
hepatic O O
enzymes O O
such O O
as O O
phenobarbital B-Drug B-Drug
phenytoin B-Drug B-Drug
and O O
rifampin B-Drug B-Drug
may O O
increase O O
the O O
clearance O O
of O O
corticosteroids B-Group B-Group
and O O
may O O
require O O
increases O O
in O O
corticosteroid B-Group B-Group
dose O O
to O O
achieve O O
the O O
desired O O
response O O
. O O

Patients O O
receiving O O
these O O
drugs O O
concurrently O O
should O O
be O O
monitored O O
for O O
a O O
potential O O
drug O O
interaction O O
. O O

When O O
used O O
concurrently O O
with O O
such O O
drugs O O
the O O
dose O O
of O O
butorphanol B-Drug B-Drug
should O O
be O O
the O O
smallest O O
effective O O
dose O O
and O O
the O O
frequency O O
of O O
dosing O O
reduced O O
as O O
much O O
as O O
possible O O
when O O
administered O O
concomitantly O O
with O O
drugs O O
that O O
potentiate O O
the O O
action O O
of O O
opioids B-Group B-Group
. O O

The O O
concurrent O O
use O O
of O O
anticholinergics B-Group B-Group
with O O
hydrocodone B-Drug B-Drug
may O O
produce O O
paralytic O O
ileus O O
. O O

A O O
single O O
dose O O
of O O
pravastatin B-Drug B-Drug
had O O
no O O
clinically O O
important O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
fenofibric B-Drug_n B-Drug_n
acid I-Drug_n I-Drug_n
. O O

In O O
patients O O
receiving O O
treatment O O
with O O
SPRYCEL B-Brand B-Brand
close O O
monitoring O O
for O O
toxicity O O
and O O
a O O
SPRYCEL B-Brand B-Brand
dose O O
reduction O O
should O O
be O O
considered O O
if O O
systemic O O
administration O O
of O O
a O O
potent O O
CYP9A9 O O
inhibitor O O
can O O
not O O
be O O
avoided O O
. O O

Cholestyramine B-Drug B-Drug
and O O
Charcoal B-Drug O
Administration O O
of O O
cholestyramine B-Drug B-Drug
or O O
activated B-Drug B-Drug
charcoal I-Drug I-Drug
in O O
patients O O
( O O
n=9 O O
) O O
and O O
volunteers O O
( O O
n=9 O O
) O O
resulted O O
in O O
a O O
rapid O O
and O O
significant O O
decrease O O
in O O
plasma O O
M9 O O
( O O
the O O
active O O
metabolite O O
of O O
leflunomide B-Drug B-Drug
) O O
concentration O O
. O O

vitamin B-Drug B-Drug
C I-Drug I-Drug
; O O

The O O
hypotensive O O
effect O O
of O O
sodium B-Drug B-Drug
nitroprusside I-Drug I-Drug
is O O
augmented O O
by O O
that O O
of O O
most O O
other O O
hypotensive B-Group O
drugs I-Group O
including O O
ganglionic B-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
negative O O
inotropic O O
agents O O
and O O
inhaled O O
anesthetics B-Group B-Group
. O O

Interaction O O
of O O
GABITRIL B-Brand B-Brand
with O O
Highly O O
Protein O O
Bound O O
Drugs O O
: O O
In O O
vitro O O
data O O
showed O O
that O O
tiagabine B-Drug B-Drug
is O O
9 O O
% O O
bound O O
to O O
human O O
plasma O O
protein O O
and O O
therefore O O
has O O
the O O
potential O O
to O O
interact O O
with O O
other O O
highly O O
protein O O
bound O O
compounds O O
. O O

Potassium B-Group B-Group
- O O
depleting B-Group B-Group
diuretics I-Group I-Group
are O O
a O O
major O O
contributing O O
factor O O
to O O
digitalis B-Group B-Group
toxicity O O
. O O

However O O
because O O
nafarelin B-Drug B-Drug
acetate I-Drug I-Drug
is O O
a O O
peptide O O
that O O
is O O
primarily O O
degraded O O
by O O
peptidase O O
and O O
not O O
by O O
cytochrome O O
P O O
- O O
9 O O
enzymes O O
and O O
the O O
drug O O
is O O
only O O
about O O
9 O O
% O O
bound O O
to O O
plasma O O
proteins O O
at O O
9 O O
C O O
drug O O
interactions O O
would O O
not O O
be O O
expected O O
to O O
occur O O
. O O

Concomitant O O
administration O O
of O O
gemfibrozil B-Drug B-Drug
with O O
Targretin B-Brand O
capsules O O
is O O
not O O
recommended O O
. O O

A O O
9 O O
- O O
week O O
dietary O O
carcinogenicity O O
study O O
with O O
ezetimibe B-Drug B-Drug
was O O
also O O
conducted O O
in O O
mice O O
at O O
doses O O
up O O
to O O
9 O O
mg O O
/ O O
kg O O
/ O O
day O O
( O O
> O O
9 O O
times O O
the O O
human O O
exposure O O
at O O
9 O O
mg O O
daily O O
based O O
on O O
AUC9 O O
- O O
9hr O O
for O O
total O O
ezetimibe B-Drug B-Drug
) O O
. O O

Antibiotics B-Group B-Group
( O O
ampicillin B-Drug B-Drug
tetracycline B-Drug B-Drug
) O O
: O O
Pregnancy O O
has O O
been O O
reported O O
following O O
concomitant O O
use O O
however O O
pharmacokinetic O O
studies O O
have O O
not O O
shown O O
consistent O O
effects O O
with O O
these O O
antibiotics B-Group B-Group
on O O
plasma O O
concentrations O O
of O O
synthetic B-Group B-Group
steroids I-Group I-Group
. O O

This O O
may O O
lead O O
to O O
reduced O O
clearance O O
of O O
caffeine B-Drug B-Drug
and O O
the O O
prolongation O O
of O O
its O O
plasma O O
half O O
- O O
life O O
. O O

Pharmacokinetic O O
studies O O
have O O
demonstrated O O
that O O
omeprazole B-Drug B-Drug
and O O
erythromycin B-Drug B-Drug
significantly O O
increased O O
the O O
systemic O O
exposure O O
of O O
cilostazol B-Drug B-Drug
and O O
/ O O
or O O
its O O
major O O
metabolites O O
. O O

Use O O
of O O
Anticoagulants B-Group B-Group
and O O
Antiplatelet B-Group O
Agents I-Group O
- O O
- O O
Streptase B-Brand O
Streptokinase B-Drug B-Drug
alone O O
or O O
in O O
combination O O
with O O
antiplatelet B-Group B-Group
agents I-Group I-Group
and O O
anticoagulants B-Group B-Group
may O O
cause O O
bleeding O O
complications O O
. O O

Imidazoles B-Group O
( O O
e. O O
g. O O
ketoconazole B-Drug B-Drug
miconazole B-Drug B-Drug
clotrimazole B-Drug B-Drug
fluconazole B-Drug B-Drug
etc O O
. O O
) O O
: O O
in O O
vitro O O
and O O
animal O O
studies O O
with O O
the O O
combination O O
of O O
amphotericin B-Drug B-Drug
B I-Drug I-Drug
and O O
imidazoles B-Group O
suggest O O
that O O
imidazoles B-Group O
may O O
induce O O
fungal O O
resistance O O
to O O
amphotericin B-Drug B-Drug
B I-Drug I-Drug
. O O

9 O O
. O O

Inhibitors O O
of O O
CYP9A9 O B-Drug
: O O
Concomitant O O
use O O
of O O
duloxetine B-Drug B-Drug
with O O
fluvoxamine B-Drug B-Drug
an O O
inhibitor O O
of O O
CYP9A9 O O
results O O
in O O
approximately O O
a O O
9 O O
- O O
fold O O
increase O O
in O O
AUC O O
and O O
about O O
a O O
9 O O
- O O
fold O O
increase O O
in O O
Cmax O O
of O O
duloxetine B-Drug B-Drug
. O O

Skin O O
tests O O
: O O
Corticosteroids B-Group B-Group
may O O
suppress O O
reactions O O
to O O
skin O O
tests O O
. O O

Because O O
tetracyclines B-Group B-Group
have O O
been O O
shown O O
to O O
depress O O
plasma O O
prothrombin O O
activity O O
patients O O
who O O
are O O
on O O
anticoagulant B-Group B-Group
therapy O O
may O O
require O O
downward O O
adjustment O O
of O O
their O O
anticoagulant B-Group B-Group
dosage O O
. O O

If O O
co O O
- O O
administration O O
is O O
essential O O
close O O
monitoring O O
may O O
be O O
appropriate O O
. O O

If O O
iron B-Group B-Drug
supplements I-Group O
are O O
required O O
during O O
OMNICEF B-Brand B-Brand
therapy O O
OMNICEF B-Brand B-Brand
should O O
be O O
taken O O
at O O
least O O
9 O O
hours O O
before O O
or O O
after O O
the O O
supplement O O
. O O

Colestipol B-Drug B-Drug

. O O

In O O
a O O
pharmacokinetic O O
interaction O O
study O O
with O O
warfarin B-Drug B-Drug
bioavailability O O
parameters O O
the O O
degree O O
of O O
protein O O
binding O O
and O O
the O O
anticoagulant O O
effect O O
( O O
measured O O
by O O
prothrombin O O
time O O
) O O
of O O
warfarin B-Drug B-Drug
were O O
not O O
significantly O O
changed O O
. O O

Agents O O
Causing O O
Renin O O
Release O O
Captopril B-Drug O
's O O
effect O O
will O O
be O O
augmented O O
by O O
antihypertensive B-Group B-Group
agents I-Group I-Group
that O O
cause O O
renin O O
release O O
. O O

Doxazosin B-Drug B-Drug
mesylate I-Drug I-Drug
has O O
been O O
administered O O
without O O
any O O
evidence O O
of O O
an O O
adverse O O
drug O O
interaction O O
to O O
patients O O
receiving O O
thiazide B-Group B-Group
diuretics I-Group I-Group
beta B-Group B-Group
- O O
blocking B-Group B-Group
agents I-Group I-Group
and O O
nonsteroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
drugs I-Group I-Group
. O O

therefore O O
coadministration O O
of O O
Aprepitant B-Drug B-Drug
with O O
drugs O O
that O O
inhibit O O
CYP9A9 O O
activity O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
aprepitant B-Drug B-Drug
. O O

Methotrexate B-Drug B-Drug
: O O
HUMIRA B-Brand B-Brand
has O O
been O O
studied O O
in O O
rheumatoid O O
arthritis O O
patients O O
taking O O
concomitant O O
MTX B-Drug B-Drug
. O O

It O O
is O O
likely O O
that O O
experience O O
significantly O O
underestimates O O
the O O
degree O O
of O O
accumulation O O
that O O
might O O
occur O O
with O O
repealed O O
diazepam B-Drug B-Drug
administration O O
. O O

Drugs O O
that O O
are O O
contraindicated O O
specifically O O
due O O
to O O
the O O
expected O O
magnitude O O
of O O
interaction O O
and O O
potential O O
for O O
serious O O
adverse O O
events O O
are O O
listed O O
CONTRAINDICATIONS O O
. O O

Routine O O
administration O O
of O O
vaccines B-Group B-Group
or O O
toxoids O O
should O O
be O O
deferred O O
until O O
corticosteroid B-Group O
therapy O O
is O O
discontinued O O
if O O
possible O O
. O O

Serum O O
concentrations O O
of O O
drugs O O
metabolized O O
by O O
the O O
cytochrome O O
P9 O O
system O O
should O O
be O O
monitored O O
closely O O
in O O
patients O O
concurrently O O
receiving O O
erythromycin B-Drug B-Drug
. O O

Appropriate O O
doses O O
for O O
this O O
combination O O
arenot O O
established O O
but O O
an O O
increase O O
in O O
thedosage O O
of O O
saquinavir B-Drug B-Drug
may O O
be O O
required O O
. O O

Thalidomide B-Drug B-Drug
has O O
been O O
reported O O
to O O
enhance O O
the O O
sedative O O
activity O O
of O O
barbiturates B-Group B-Group
alcohol B-Drug B-Drug
chlorpromazine B-Drug B-Drug
and O O
reserpine B-Drug B-Drug
. O O

Cyclosporin B-Drug B-Drug
: O O
After O O
introduction O O
of O O
chloroquine B-Drug B-Drug
( O O
oral O O
form O O
) O O
a O O
sudden O O
increase O O
in O O
serum O O
cyclosporin B-Drug B-Drug
level O O
has O O
been O O
reported O O
. O O

Dofetilide B-Drug B-Drug
is O O
not O O
an O O
inhibitor O O
of O O
CYP9A9 O O
nor O O
of O O
other O O
cytochrome O O
P9 O O
isoenzymes O O
( O O
e.g. O O
CYP9C9 O O
CYP9D9 O O
) O O
and O O
is O O
not O O
expected O O
to O O
increase O O
levels O O
of O O
drugs O O
metabolized O O
by O O
CYP9A9 O O
. O O

Effects O O
of O O
sympathomimetics B-Group B-Group
are O O
increased O O
with O O
MAO B-Group B-Group
inhibitors I-Group I-Group
and O O
beta B-Group B-Group
adrenergic I-Group I-Group
blockers I-Group I-Group
. O O

However O O
if O O
the O O
patients O O
thyroid O O
gland O O
has O O
sufficient O O
function O O
the O O
decreased O O
free O O
thyroxine B-Drug O
will O O
result O O
in O O
a O O
compensatory O O
increase O O
in O O
thyroxin O O
output O O
by O O
the O O
thyroid O O
. O O

Aspirin B-Brand B-Brand
: O O
Rimantadine B-Drug B-Drug
HCl I-Drug I-Drug
9 O O
mg O O
was O O
given O O
twice O O
daily O O
fro O O
9 O O
days O O
to O O
9 O O
healthy O O
volunteers O O
. O O

Danazol B-Drug B-Drug
: O O
The O O
risk O O
of O O
myopathy O O
/ O O
rhabdomyolysis O O
is O O
increased O O
by O O
concomitant O O
administration O O
of O O
danazol B-Drug B-Drug
particularly O O
with O O
higher O O
doses O O
of O O
lovastatin B-Drug B-Drug
( O O
see O O
WARNINGS O O
Myopathy O O
/ O O
Rhabdomyolysis O O
) O O
. O O

This O O
medicine O O
should O O
not O O
be O O
taken O O
with O O
MAO B-Group B-Group
inhibitors I-Group I-Group
. O O

Drugs O O
Affecting O O
Hepatic O O
Metabolism O O
The O O
metabolism O O
and O O
pharmacokinetics O O
of O O
REMERON B-Brand B-Brand
SolTab I-Brand I-Brand
( O O
mirtazapine B-Drug B-Drug
) O O
Orally O O
Disintegrating O O
Tablets O O
may O O
be O O
affected O O
by O O
the O O
induction O O
or O O
inhibition O O
of O O
drug O O
- O O
metab O O
- O O
olizing O O
enzymes O O
. O O

Monoamine B-Drug B-Group
Oxidase I-Drug I-Group
Inhibitors I-Drug I-Group
: O O
Guanethidine B-Drug B-Drug
or O O
similarly O O
acting O O
compounds O O
; O O

The O O
peripheral O O
vasoconstriction O O
caused O O
by O O
high O O
doses O O
of O O
dopamine B-Drug B-Drug
HCl I-Drug I-Drug
is O O
antagonized O O
by O O
alpha B-Group B-Group
- O O
adrenergic B-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
. O O

Prospective O O
studies O O
on O O
the O O
potential O O
for O O
hydroxyurea B-Drug B-Drug
to O O
interact O O
with O O
other O O
drugs O O
have O O
not O O
been O O
performed O O
. O O

Agents O O
Affecting O O
Cytochrome O O
P9 O O
9A9 O O
Isoenzyme O O
System O O
Fentanyl B-Drug B-Drug
is O O
metabolized O O
mainly O O
via O O
the O O
human O O
cytochrome O O
P9 O O
9A9 O O
isoenzyme O O
system O O
( O O
CYP9A9 O O
) O O
therefore O O
potential O O
interactions O O
may O O
occur O O
when O O
DURAGESIC B-Brand B-Brand
is O O
given O O
concurrently O O
with O O
agents O O
that O O
affect O O
CYP9A9 O O
activity O O
. O O

Cimetidine B-Drug B-Drug
Ranitidine B-Drug B-Drug
: O O
In O O
normal O O
volunteers O O
( O O
n=9 O O
) O O
pretreatment O O
with O O
cimetidine B-Drug B-Drug
or O O
ranitidine B-Drug B-Drug
did O O
not O O
affect O O
flurbiprofen B-Drug B-Drug
pharmacokinetics O O
except O O
that O O
a O O
small O O
( O O
9 O O
% O O
) O O
but O O
statistically O O
significant O O
increase O O
in O O
the O O
area O O
under O O
the O O
serum O O
concentration O O
curve O O
of O O
flurbiprofen B-Drug B-Drug
resulted O O
with O O
cimetidine B-Drug B-Drug
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
DOXIL B-Brand B-Brand
. O O

multivitamins B-Group B-Group
containing O O
zinc B-Drug B-Drug
; O O

Consequently O O
estazolam B-Drug B-Drug
should O O
be O O
avoided O O
in O O
patients O O
receiving O O
ketoconazole B-Drug B-Drug
and O O
itraconazole B-Drug B-Drug
which O O
are O O
very O O
potent O O
inhibitors O O
of O O
CYP9A O O
. O O

While O O
in O O
vitro O O
studies O O
indicate O O
that O O
CYP9D9 O O
and O O
CYP9A9 O O
may O O
be O O
minimally O O
involved O O
in O O
paliperidone B-Drug B-Drug
metabolism O O
in O O
vivo O O
studies O O
do O O
not O O
show O O
decreased O O
elimination O O
by O O
these O O
isozymes O O
and O O
they O O
contribute O O
to O O
only O O
a O O
small O O
fraction O O
of O O
total O O
body O O
clearance O O
. O O

Additionally O O
saquinavir B-Drug B-Drug
is O O
a O O
substrate O O
for O O
P O O
- O O
Glycoprotein O O
( O O
Pgp O O
) O O
. O O

In O O
clinical O O
trials O O
FLOLAN B-Brand B-Brand
was O O
used O O
with O O
digoxin B-Drug B-Drug
diuretics B-Group B-Group
anticoagulants B-Group B-Group
oral O O
vasodilators B-Group B-Group
and O O
supplemental O O
oxygen B-Drug B-Drug
. O O
In O O
a O O
pharmacokinetic O O
substudy O O
in O O
patients O O
with O O
congestive O O
heart O O
failure O O
receiving O O
furosemide B-Drug B-Drug
or O O
digoxin B-Drug B-Drug
in O O
whom O O
therapy O O
with O O
FLOLAN B-Brand B-Brand
was O O
initiated O O
apparent O O
oral O O
clearance O O
values O O
for O O
furosemide B-Drug B-Drug
( O O
n O O
= O O
9 O O
) O O
and O O
digoxin B-Drug B-Drug
( O O
n O O
= O O
9 O O
) O O
were O O
decreased O O
by O O
9 O O
% O O
and O O
9 O O
% O O
respectively O O
on O O
the O O
second O O
day O O
of O O
therapy O O
and O O
had O O
returned O O
to O O
baseline O O
values O O
by O O
day O O
9 O O
. O O

Because O O
of O O
its O O
primary O O
CNS O O
effect O O
caution O O
should O O
be O O
used O O
when O O
EQUETROTM B-Brand B-Brand
is O O
taken O O
with O O
other O O
centrally B-Group B-Group
acting I-Group I-Group
drugs I-Group I-Group
and O O
alcohol B-Drug B-Drug
. O O

Greater O O
sensitivity O O
of O O
some O O
older O O
individuals O O
can O O
not O O
be O O
ruled O O
out O O
. O O

Fluvoxamine B-Drug B-Drug
is O O
a O O
known O O
strong O O
inhibitor O O
of O O
CYP9A9 O O
and O O
also O O
inhibits O O
CYP9A9 O O
CYP9C9 O O
and O O
CYP9C9 O O
. O O

Cyclosporine B-Drug B-Drug
: O O
Combination O O
hormonal B-Group B-Group
contraceptives I-Group I-Group
may O O
inhibit O O
the O O
metabolism O O
of O O
cyclosporine B-Drug B-Drug
leading O O
to O O
increased O O
plasma O O
concentrations O O
; O O

Valproate B-Drug B-Drug
: O O
Tiagabine B-Drug B-Drug
causes O O
a O O
slight O O
decrease O O
( O O
about O O
9 O O
% O O
) O O
in O O
steady O O
- O O
state O O
valproate B-Drug B-Drug
concentrations O O
. O O

inhalation O O
anesthetics B-Group B-Group
; O O

Though O O
individual O O
theophylline B-Drug B-Drug
levels O O
fluctuated O O
there O O
were O O
no O O
clinically O O
significant O O
symptoms O O
of O O
drug O O
inter O O
- O O
action O O
. O O

This O O
could O O
lead O O
to O O
decreased O O
salicylate B-Group B-Group
serum O O
levels O O
or O O
increase O O
the O O
risk O O
of O O
salicylate B-Group B-Group
toxicity O O
when O O
methylprednisolone B-Drug B-Drug
is O O
withdrawn O O
. O O

Ergot B-Group B-Group
- O O
containing O O
drugs O O
have O O
been O O
reported O O
to O O
cause O O
prolonged O O
vasospastic O O
reactions O O
. O O

Coumarin B-Group B-Group
- O O
Type B-Group B-Group
Anticoagulants I-Group I-Group
: O O
Several O O
short O O
- O O
term O O
controlled O O
studies O O
failed O O
to O O
wshow O O
that O O
ibuprofen B-Drug B-Drug
significantly O O
affected O O
prothrombin O O
times O O
or O O
a O O
variety O O
of O O
other O O
clotting O O
factors O O
when O O
administered O O
to O O
individuals O O
on O O
coumarin B-Group B-Group
- O O
type B-Group B-Group
anticoagulants I-Group I-Group
. O O

When O O
such O O
combined O O
therapy O O
is O O
contemplated O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
significantly O O
reduced O O
. O O

All O O
HMG B-Group B-Group
- O O
CoA B-Group B-Group
reductase I-Group I-Group
inhibitors I-Group I-Group
are O O
contraindicated O O
in O O
pregnant O O
and O O
nursing O O
women O O
. O O

. O O

indinavir B-Drug B-Drug
concentration O O

Norepinephrine B-Drug B-Drug
: O O
Amphetamines B-Group B-Group
enhance O O
the O O
adrenergic O O
effect O O
of O O
norepinephrine B-Drug B-Drug
. O O

There O O
was O O
no O O
evidence O O
of O O
clinically O O
important O O
adverse O O
interactions O O
. O O

Use O O
of O O
barrier O O
form O O
of O O
contraception O O
is O O
suggested O O
while O O
on O O
griseofulvin B-Drug B-Drug
therapy O O
. O O

Clinical O O
Comment O O

The O O
effects O O
of O O
PEGASYS B-Brand B-Brand
on O O
male O O
fertility O O
have O O
not O O
been O O
studied O O
. O O

This O O
increase O O
was O O
observed O O
at O O
the O O
first O O
test O O
point O O
which O O
was O O
the O O
second O O
day O O
after O O
starting O O
Mexitil B-Brand B-Brand
. O O
Theophylline B-Drug B-Drug
plasma O O
levels O O
returned O O
to O O
pre O O
- O O
Mexitil B-Brand B-Brand
values O O
within O O
9 O O
hours O O
after O O
discontinuing O O
Mexitil B-Brand B-Brand
. O O
If O O
Mexitil B-Brand B-Brand
and O O
theophylline B-Drug B-Drug
are O O
to O O
be O O
used O O
concurrently O O
theophylline B-Drug B-Drug
blood O O
levels O O
should O O
be O O
monitored O O
particularly O O
when O O
the O O
Mexitil B-Brand B-Brand
dose O O
is O O
changed O O
. O O

Mutagenesis O O
PEGASYS B-Brand B-Brand
did O O
not O O
cause O O
DNA O O
damage O O
when O O
tested O O
in O O
the O O
Ames O O
bacterial O O
mutagenicity O O
assay O O
and O O
in O O
the O O
in O O
vitro O O
chromosomal O O
aberration O O
assay O O
in O O
human O O
lymphocytes O O
either O O
in O O
the O O
presence O O
or O O
absence O O
of O O
metabolic O O
activation O O
. O O

Antidepressants B-Group B-Group
: O O
In O O
vitro O O
data O O
indicate O O
that O O
nefazodone B-Drug B-Drug
inhibits O O
the O O
metabolism O O
of O O
cisapride B-Drug B-Drug
which O O
can O O
result O O
in O O
an O O
increase O O
in O O
plasma O O
cisapride B-Drug B-Drug
levels O O
and O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

Theophylline B-Drug B-Drug
: O O
Twelve O O
healthy O O
male O O
volunteers O O
were O O
administered O O
one O O
9 O O
- O O
mg O O
ceftibuten B-Drug B-Drug
capsule O O
twice O O
daily O O
for O O
9 O O
days O O
. O O

Erythromycin B-Drug B-Drug
: O O
In O O
healthy O O
individuals O O
plasma O O
concentrations O O
of O O
atorvastatin B-Drug B-Drug
increased O O
approximately O O
9 O O
% O O
with O O
coadministration O O
of O O
atorvastatin B-Drug B-Drug
and O O
erythromycin B-Drug B-Drug
a O O
known O O
inhibitor O O
of O O
cytochrome O O
P9 O O
9A9 O O
. O O

Interactions O O
with O O
Fruit O O
Juices O O
Fruit O O
juices O O
such O O
as O O
grapefruit O O
orange O O
and O O
apple O O
may O O
reduce O O
the O O
bioavailability O O
and O O
exposure O O
of O O
fexofenadine B-Drug B-Drug
. O O

Cytokines B-Group O
( O O
interferon B-Group B-Drug
interleukin B-Group B-Drug
) O O
: O O
Cytokines B-Group B-Group
have O O
been O O
reported O O
to O O
induce O O
both O O
hyperthyroidism O O
and O O
hypothyroidism O O
. O O

Human O O
pharmacokinetics O O
data O O
indicate O O
that O O
oral O O
ketoconazole B-Drug B-Drug
potently O O
inhibits O O
the O O
metabolism O O
of O O
cisapride B-Drug B-Drug
resulting O O
in O O
an O O
eight O O
- O O
fold O O
increase O O
in O O
the O O
mean O O
AUC O O
of O O
cisapride B-Drug B-Drug
. O O

Theophylline B-Drug B-Drug
- O O
related O O
adverse O O
effects O O
have O O
occurred O O
in O O
patients O O
when O O
theophylline B-Drug B-Drug
and O O
enoxacin B-Drug B-Drug
were O O
coadministered O O
. O O

Meclofenamate B-Drug B-Drug
sodium I-Drug I-Drug
does O O
not O O
affect O O
serum O O
salicylate B-Group O
levels O O
. O O

In O O
addition O O
the O O
beneficial O O
effects O O
of O O
levodopa B-Drug B-Drug
in O O
Parkinsons O O
disease O O
have O O
been O O
reported O O
to O O
be O O
reversed O O
by O O
phenytoin B-Drug B-Drug
and O O
papaverine B-Drug B-Drug
. O O

or O O
- O O
over O O
- O O
the O O
- O O
counter O O
cough O O
cold O O
allergy O O
or O O
weight O O
loss O O
medications O O
. O O

However O O
due O O
to O O
possible O O
pharmacodynamic O O
interactions O O
when O O
co O O
- O O
administered O O
with O O
PRECEDEX B-Brand B-Brand
a O O
reduction O O
in O O
dosage O O
of O O
PRECEDEX B-Brand B-Brand
on O O
the O O
concomitant O O
anesthetic B-Group B-Group
sedative B-Group I-Group
hypnotic B-Group I-Group
or O O
opioid B-Group B-Group
may O O
be O O
required O O
. O O

Interactions O O
attributed O O
to O O
the O O
combined O O
use O O
of O O
baclofen B-Drug B-Drug
injection O O
and O O
epidural O O
morphine B-Drug B-Drug
include O O
hypotension O O
and O O
dyspnea O O
. O O

Co O O
- O O
administration O O
of O O
probenecid B-Drug B-Drug
with O O
acyclovir B-Drug B-Drug
has O O
been O O
shown O O
to O O
increase O O
the O O
mean O O
half O O
- O O
life O O
and O O
the O O
area O O
under O O
the O O
concentration O O
- O O
time O O
curve O O
. O O

Anticoagulants B-Group B-Group
: O O
Flurbiprofen B-Drug B-Drug
like O O
other O O
nonsteroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
drugs I-Group I-Group
has O O
been O O
shown O O
to O O
affect O O
bleeding O O
parameters O O
in O O
patients O O
receiving O O
anti B-Group O
- O O
coagulants B-Group O
and O O
serious O O
clinical O O
bleeding O O
has O O
been O O
reported O O
. O O

No O O
interactions O O
have O O
been O O
observed O O
between O O
nizatidine B-Drug B-Drug
and O O
theophylline B-Drug B-Drug
chlordiazepoxide B-Drug B-Drug
lorazepam B-Drug B-Drug
lidocaine B-Drug B-Drug
phenytoin B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
. O O

Mutagenesis O O
Impairment O O
of O O
Fertility O O
PEGASYS B-Brand B-Brand
may O O
impair O O
fertility O O
in O O
women O O
. O O

Physicians O O
should O O
be O O
aware O O
that O O
interaction O O
studies O O
with O O
medications O O
other O O
than O O
those O O
listed O O
in O O
the O O
< O O
a O O
href= O O
`` O O
flucon_cp.htm O O
# O O
CP O O
'' O O
> O O
CLINICAL O O
PHARMACOLOGY O O
section O O
have O O
not O O
been O O
conducted O O
but O O
such O O
interactions O O
may O O
occur O O
. O O

A O O
study O O
in O O
9 O O
normal O O
male O O
and O O
female O O
volunteers O O
suggests O O
that O O
coadministration O O
of O O
cisapride B-Drug B-Drug
and O O
ketoconazole B-Drug B-Drug
can O O
result O O
in O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

Check O O
serum O O
potassium O O
levels O O
at O O
frequent O O
intervals O O
; O O

In O O
such O O
cases O O
of O O
combined O O
treatment O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

Therefore O O
it O O
is O O
recommended O O
that O O
Fluvoxamine B-Drug B-Drug
Tablets O O
not O O
be O O
used O O
in O O
combination O O
with O O
MAOIs B-Group B-Group
or O O
within O O
9 O O
days O O
of O O
discontinuing O O
treatment O O
with O O
a O O
MAOI B-Group B-Group
. O O

Anticholinergics B-Group B-Group
: O O
Concurrent O O
administration O O
of O O
certain O O
anticholinergic B-Group B-Group
compounds I-Group I-Group
such O O
as O O
belladonna B-Group B-Group
alkaloids I-Group I-Group
and O O
dicyclomine B-Drug B-Drug
would O O
be O O
expected O O
to O O
compromise O O
the O O
beneficial O O
effects O O
of O O
cisapride B-Drug B-Drug
. O O

Anticoagulants B-Group B-Group
oral O O
: O O
Co O O
- O O
administration O O
of O O
corticosteroids B-Group B-Group
and O O
warfarin B-Drug B-Drug
usually O O
results O O
in O O
inhibition O O
of O O
response O O
to O O
warfarin B-Drug B-Drug
although O O
there O O
have O O
been O O
some O O
conflicting O O
reports O O
. O O

Therefore O O
erlotinib B-Drug B-Drug
exposure O O
may O O
be O O
increased O O
in O O
patients O O
with O O
hepatic O O
dysfunction O O
. O O

Pyrantel B-Drug O
( O O
e.g. O O
Antiminth B-Drug B-Brand
) O O
- O O
Taking O O
piperazine B-Drug B-Drug
and O O
pyrantel B-Drug O
together O O
may O O
decrease O O
the O O
effects O O
of O O
piperazine B-Drug B-Drug
. O O

In O O
some O O
patients O O
combined O O
use O O
of O O
INDOCIN B-Brand B-Brand
and O O
diflunisal B-Drug B-Drug
has O O
been O O
associated O O
with O O
fatal O O
gastrointestinal O O
hemorrhage O O
. O O

Plasma O O
concentrations O O
decreased O O
by O O
SUSTIVA B-Brand B-Brand
; O O

Although O O
specific O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
ALPHAGAN B-Brand B-Brand
P I-Brand I-Brand
the O O
possibility O O
of O O
an O O
additive O O
or O O
potentiating O O
effect O O
with O O
CNS B-Group B-Group
depressants I-Group I-Group
( O O
alcohol B-Drug B-Drug
barbiturates B-Group B-Group
opiates B-Group B-Group
sedatives B-Group B-Group
or O O
anesthetics B-Group B-Group
) O O
should O O
be O O
considered O O
. O O

When O O
patients O O
have O O
received O O
such O O
drugs O O
the O O
dose O O
of O O
INAPSINE B-Brand B-Brand
required O O
will O O
be O O
less O O
than O O
usual O O
. O O

Fluoroquinolones B-Drug O
macrolide B-Drug B-Group
antibiotics I-Drug I-Group
and O O
azoles O B-Group
are O O
known O O
to O O
cause O O
QTc O O
prolongation O O
. O O

d B-Drug B-Drug
- O O
amphetamine B-Drug B-Drug
with O O
desipramine B-Drug B-Drug
or O O
protriptyline B-Drug B-Drug
and O O
possibly O O
other O O
tricyclics B-Group B-Group
cause O O
striking O O
and O O
sustained O O
increases O O
in O O
the O O
concentration O O
of O O
d B-Drug B-Drug
- O O
amphetamine B-Drug B-Drug
in O O
the O O
brain O O
; O O

Sulfacetamide B-Drug B-Drug
preparations O O
are O O
incompatible O O
with O O
silver B-Drug O
preparations O O
. O O

Digoxin O B-Drug
When O O
given O O
concomitantly O O
with O O
PLENDIL B-Drug B-Drug
the O O
pharmacokinetics O O
of O O
digoxin B-Drug B-Drug
in O O
patients O O
with O O
heart O O
failure O O
were O O
not O O
significantly O O
altered O O
. O O

These O O
agents O O
include O O
medications O O
such O O
as O O
: O O
anticoagulants B-Group B-Group
platelet B-Group B-Group
inhibitors I-Group I-Group
including O O
acetylsalicylic B-Drug B-Drug
acid I-Drug I-Drug
sali O O
- O O
cylates O O
NSAIDs B-Group B-Group
( O O
including O O
ketorolac B-Drug B-Drug
tromethamine I-Drug B-Drug
) O O
dipyridamole B-Drug B-Drug
or O O
sulfinpyrazone B-Drug B-Drug
. O O

Furosemide B-Drug B-Drug
: O O
When O O
aliskiren B-Drug B-Drug
was O O
co O O
- O O
administered O O
with O O
furosemide B-Drug B-Drug
the O O
AUC O O
and O O
Cmax O O
of O O
furosemide B-Drug B-Drug
were O O
reduced O O
by O O
about O O
9 O O
% O O
and O O
9 O O
% O O
respectively O O
. O O

The O O
net O O
effect O O
of O O
these O O
interactions O O
is O O
summarized O O
in O O
the O O
following O O
table O O
: O O
AED B-Group B-Group
AED B-Group B-Group
Felbatol B-Brand B-Drug_n

substrates O O
in O O
vitro O O
data O O
suggest O O
similar O O
effects O O
of O O
grepafloxacin B-Drug B-Drug
in O O
CYP9A9 O O
mediated O O
metabolism O O
and O O
theophylline B-Drug B-Drug
metabolism O O
. O O

No O O
formal O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

When O O
INDOCIN B-Brand B-Brand
is O O
given O O
to O O
patients O O
receiving O O
probenecid B-Drug B-Drug
the O O
plasma O O
levels O O
of O O
indomethacin B-Drug B-Drug
are O O
likely O O
to O O
be O O
increased O O
. O O

This O O
could O O
lead O O
to O O
an O O
increase O O
in O O
blood O O
pressure O O
. O O

Paliperidone B-Drug B-Drug
is O O
therefore O O
not O O
expected O O
to O O
inhibit O O
P O O
- O O
glycoprotein O O
- O O
mediated O O
transport O O
of O O
other O O
drugs O O
in O O
a O O
clinically O O
relevant O O
manner O O
. O O

quinine B-Drug B-Drug
; O O

Alcohol B-Drug B-Drug
- O O
Although O O
LEXAPRO B-Brand B-Brand
did O O
not O O
potentiate O O
the O O
cognitive O O
and O O
motor O O
effects O O
of O O
alcohol B-Drug B-Drug
in O O
a O O
clinical O O
trial O O
as O O
with O O
other O O
psychotropic B-Group B-Group
medications I-Group I-Group
the O O
use O O
of O O
alcohol B-Drug B-Drug
by O O
patients O O
taking O O
LEXAPRO B-Brand B-Brand
is O O
not O O
recommended O O
. O O

In O O
vitro O O
methotrexate B-Drug B-Drug
did O O
not O O
displace O O
meloxicam B-Drug B-Drug
from O O
its O O
human O O
serum O O
binding O O
sites O O
. O O

ZEBETA B-Brand B-Brand
should O O
not O O
be O O
combined O O
with O O
other O O
beta B-Group B-Group
- O O
blocking B-Group B-Group
agents I-Group I-Group
. O O

Exacerbation O O
or O O
the O O
initial O O
presentation O O
of O O
a O O
number O O
of O O
autoimmune O O
and O O
inflammatory O O
disorders O O
has O O
been O O
observed O O
following O O
concurrent O O
use O O
of O O
interferon B-Drug B-Drug
- O O
alfa B-Drug B-Drug
and O O
PROLEUKIN B-Brand B-Brand
including O O
crescentic O O
IgA O O
glomerulonephritis O O
oculo O O
- O O
bulbar O O
myasthenia O O
gravis O O
inflammatory O O
arthritis O O
thyroiditis O O
bullous O O
pemphigoid O O
and O O
Stevens O O
- O O
Johnson O O
syndrome O O
. O O

CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and O O
/ O O
or O O
life O O
- O O
threatening O O
reactions O O
such O O
as O O
cardiac O O
arrhythmias O O
. O O

SINCE O O
THE O O
CONCOMITANT O O
ADMINISTRATION O O
OF O O
THESE O O
TWO O O
DRUGS O O
CAN O O
LEAD O O
TO O O
PHENYTOIN B-Drug B-Drug
INTOXICATION O O
PRIOR O O
TO O O
ADMINISTERING O O
DISULFIRAM B-Drug B-Drug
TO O O
A O O
PATIENT O O
ON O O
PHENYTOIN B-Drug B-Drug
THERAPY O O
A O O
BASELINE O O
PHENYTOIN B-Drug B-Drug
SERUM O O
LEVEL O O
SHOULD O O
BE O O
OBTAINED O O
. O O

In O O
many O O
of O O
these O O
cases O O
buprenorphine B-Drug B-Drug
was O O
misused O O
by O O
self O O
- O O
injection O O
of O O
crushed O O
SUBUTEX B-Brand B-Brand
tablets O O
. O O

Patients O O
receiving O O
the O O
two O O
drugs O O
concomitantly O O
should O O
be O O
carefully O O
monitored O O
. O O

MAO B-Group B-Group
inhibitors I-Group I-Group
and O O
beta B-Group B-Group
adrenergic I-Group I-Group
blockers I-Group I-Group
increase O O
the O O
effects O O
of O O
pseudoephedrine B-Drug B-Drug
. O O

antibody O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

Potassium B-Drug B-Drug
Supplements O O
and O O
Potassium B-Group B-Group
- O O
Sparing B-Group B-Group
Diuretics I-Group I-Group
Lotensin O B-Brand
can O O
attenuate O O
potassium O O
loss O O
caused O O
by O O
thiazide B-Group B-Group
diuretics I-Group I-Group
. O O

Positive O O
direct O O
and O O
indirect O O
antiglobulin O O
( O O
Coombs O O
) O O
tests O O
have O O
occurred O O
; O O

No O O
studies O O
have O O
been O O
conducted O O
at O O
intermediate O O
doses O O
of O O
cimetidine B-Drug B-Drug
. O O

There O O
is O O
no O O
pharmacokinetic O O
interaction O O
between O O
zaleplon B-Drug B-Drug
and O O
diphenhydramine B-Drug B-Drug
following O O
the O O
administration O O
of O O
a O O
single O O
dose O O
( O O
9 O O
mg O O
and O O
9 O O
mg O O
respectively O O
) O O
of O O
each O O
drug O O
. O O

Amitriptyline B-Drug B-Drug
: O O
Concurrent O O
administration O O
of O O
9 O O
mg O O
or O O
9 O O
mg O O
cinacalcet B-Drug B-Drug
with O O
9 O O
mg O O
amitriptyline B-Drug B-Drug
increased O O
amitriptyline B-Drug B-Drug
exposure O O
and O O
nortriptyline B-Drug_n B-Drug
( O O
active O O
metabolite O O
) O O
exposure O O
by O O
approximately O O
9 O O
% O O
in O O
CYP9D9 O O
extensive O O
metabolizers O O
. O O

Depending O O
on O O
clinical O O
circumstances O O
consideration O O
should O O
be O O
given O O
to O O
increasing O O
the O O
dose O O
of O O
DIFLUCAN B-Brand B-Brand
when O O
it O O
is O O
administered O O
with O O
rifampin B-Drug B-Drug
. O O

Theoretically O O
the O O
naproxen B-Drug B-Drug
anion O O
itself O O
could O O
likewise O O
be O O
displaced O O
. O O

MAO B-Group B-Group
inhibitors I-Group I-Group
narcotic B-Group B-Group
analgesics I-Group I-Group
( O O
e.g. O O
meperidine B-Drug B-Drug
) O O
nitrates B-Group B-Group
and O O
nitrites B-Group B-Group
sympathomimetic B-Group B-Group
agents I-Group I-Group
tricyclic B-Group B-Group
antidepressants I-Group I-Group
and O O
other O O
drugs O O
having O O
anticholinergic O O
activity O O
. O O

Maalox B-Brand B-Brand
* O O
Coadministration O O
of O O
Maalox B-Brand B-Brand
TC I-Brand I-Brand
had O O
no O O
effect O O
on O O
nicardipine B-Drug B-Drug
HCl I-Drug I-Drug
absorption O O
. O O

The O O
absorption O O
of O O
lymecycline B-Drug B-Drug
may O O
be O O
affected O O
by O O
the O O
simultaneous O O
administration O O
of O O
indigestion O O
remedies O O
iron B-Drug B-Drug
or O O
zinc B-Drug B-Drug
supplements O O
. O O

A O O
few O O
spontaneous O O
accounts O O
of O O
QT O O
interval O O
prolongation O O
with O O
ventricular O O
arrhythmia O O
including O O
torsades O O
de O O
pointes O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
erythromycin B-Drug B-Drug
or O O
troleandomycin B-Drug B-Drug
. O O

In O O
situations O O
when O O
concurrent O O
therapy O O
is O O
necessary O O
careful O O
patient O O
monitoring O O
is O O
essential O O
. O O

Insulin B-Drug B-Drug
requirements O O
in O O
diabetic O O
patients O O
may O O
be O O
increased O O
decreased O O
or O O
unchanged O O
. O O

In O O
the O O
first O O
study O O
concomitant O O
administration O O
of O O
9 O O
mg O O
cerivastatin B-Drug B-Drug
sodium I-Drug I-Drug
and O O
9 O O
g O O
cholestyramine B-Drug B-Drug
resulted O O
in O O
decreases O O
of O O
more O O
than O O
9 O O
% O O
for O O
AUC O O
and O O
9 O O
% O O
for O O
Cmax O O
when O O
compared O O
to O O
dosing O O
cerivastatin B-Drug B-Drug
sodium I-Drug I-Drug
alone O O
. O O

The O O
absorption O O
of O O
oral O O
gemifloxacin B-Drug B-Drug
is O O
significantly O O
reduced O O
by O O
the O O
concomitant O O
administration O O
of O O
an O O
antacid B-Group B-Group
containing O O
aluminum B-Drug B-Drug
and O O
magnesium B-Drug B-Drug
. O O

If O O
the O O
two O O
drugs O O
are O O
coadministered O O
the O O
beta B-Group O
blocker I-Group O
should O O
be O O
withdrawn O O
several O O
days O O
before O O
the O O
gradual O O
withdrawal O O
of O O
clonidine B-Drug B-Drug
. O O

Warfarin B-Drug B-Drug
: O O
Eszopiclone B-Drug B-Drug
9 O O
mg O O
administered O O
daily O O
for O O
9 O O
days O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
R B-Drug O
- O O
or O O
S B-Drug B-Drug
- O O
warfarin B-Drug B-Drug
nor O O
were O O
there O O
any O O
changes O O
in O O
the O O
pharmacodynamic O O
profile O O
( O O
prothrombin O O
time O O
) O O
following O O
a O O
single O O
9 O O
mg O O
oral O O
dose O O
of O O
warfarin B-Drug B-Drug

The O O
clinical O O
significance O O
of O O
these O O
in O O
vitro O O
interactions O O
is O O
unknown O O
; O O

Dose O O
reduction O O
of O O
rifabutin B-Drug B-Drug
to O O
half O O
the O O
standard O O
dose O O
and O O
a O O
dose O O
increase O O
of O O
CRIXIVAN B-Brand B-Brand
to O O
9 O O
mg O O
( O O
three O O
9 O O
- O O
mg O O
capsules O O
) O O
every O O
9 O O
hours O O
are O O
recommended O O
when O O
rifabutin B-Drug B-Drug
and O O
CRIXIVAN B-Brand B-Brand
are O O
coadministered O O
. O O

Warfarin B-Drug B-Drug
: O O
When O O
fluvoxamine B-Drug B-Drug
maleate I-Drug I-Drug
( O O
9 O O
mg O O
tid O O
) O O
was O O
administered O O
concomitantly O O
with O O
warfarin B-Drug B-Drug
for O O
two O O
weeks O O
warfarin B-Drug B-Drug
plasma O O
concentrations O O
increased O O
by O O
9 O O
% O O
and O O
prothrombin O O
times O O
were O O
prolonged O O
. O O

Dose O O
adjustment O O
of O O
lapatinib B-Drug B-Drug
should O O
be O O
considered O O
for O O
patients O O
who O O
must O O
receive O O
concomitant O O
strong O O
inhibitors O O
or O O
concomitant O O
strong O O
inducers O O
of O O
CYP9A9 O O
enzymes O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
None O O
known O O
. O O

Food O O
: O O
Isoniazid B-Drug B-Drug
should O O
not O O
be O O
administered O O
with O O
food O O
. O O

However O O
it O O
should O O
be O O
noted O O
that O O
both O O
products O O
are O O
capable O O
of O O
producing O O
transient O O
increases O O
in O O
blood O O
pressure O O
. O O

Patients O O
taking O O
Acamprosate B-Drug B-Drug
concomitantly O O
with O O
antidepressants B-Group B-Group
more O O
commonly O O
reported O O
both O O
weight O O
gain O O
and O O
weight O O
loss O O
compared O O
with O O
patients O O
taking O O
either O O
medication O O
alone O O
. O O

These O O
six O O
volunteers O O
received O O
terfenadine B-Drug B-Drug
alone O O
( O O
9 O O
mg O O
twice O O
daily O O
) O O
for O O
9 O O
days O O
followed O O
by O O
terfenadine B-Drug B-Drug
in O O
combination O O
with O O
dirithromycin B-Drug B-Drug
( O O
9 O O
mg O O
once O O
daily O O
) O O
for O O
9 O O
days O O
. O O

Catecholamine O O
- O O
depleting O O
drugs O O
( O O
e.g. O O
reserpine B-Drug B-Drug
) O O
: O O
additive O O
effect O O
; O O

9 O O
. O O

9 O O
. O O

Clinical O O
studies O O
of O O
PEGASYS B-Brand B-Brand
alone O O
or O O
in O O
combination O O
with O O
COPEGUS B-Brand B-Brand
did O O
not O O
include O O
sufficient O O
numbers O O
of O O
subjects O O
aged O O
9 O O
or O O
over O O
to O O
determine O O
whether O O
they O O
respond O O
differently O O
from O O
younger O O
subjects O O
. O O

The O O
concomitant O O
use O O
of O O
alcohol B-Drug B-Drug
or O O
other O O
central B-Group B-Group
nervous I-Group I-Group
system I-Group I-Group
depressants I-Group I-Group
may O O
have O O
an O O
additive O O
effect O O
. O O

Antigout B-Group O
medications I-Group O

Amiodarone B-Drug B-Drug
is O O
metabolized O O
to O O
desethylamiodarone B-Drug B-Drug
by O O
the O O
cytochrome O O
P9 O O
( O O
CYP9 O O
) O O
enzyme O O
group O O
specifically O O
cytochromes O O
P9 O O
9A9 O O
( O O
CYP9A9 O O
) O O
and O O
CYP9C9 O O
. O O

MOBIC B-Brand B-Brand
is O O
not O O
a O O
substitute O O
for O O
aspirin B-Brand B-Brand
for O O
cardiovascular O O
prophylaxis O O
. O O

Concurrent O O
administration O O
of O O
a O O
TNF B-Group B-Group
antagonist I-Group I-Group
with O O
ORENCIA B-Brand B-Brand
has O O
been O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
serious O O
infections O O
and O O
no O O
significant O O
additional O O
efficacy O O
over O O
use O O
of O O
the O O
TNF B-Group O
antagonists I-Group O
alone O O
. O O

In O O
separate O O
single O O
or O O
multiple O O
dose O O
pharmacokinetic O O
interaction O O
studies O O
with O O
chlorthalidone B-Drug B-Drug
nifedipine B-Drug B-Drug
propanolol B-Drug B-Drug
hydrochlorothiazide B-Drug B-Drug
cimetidine B-Drug B-Drug
metoclopramide B-Drug B-Drug
propantheline B-Drug B-Drug
digoxin B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
the O O
bioavailability O O
of O O
fosinoprilat B-Drug_n B-Drug_n
was O O
not O O
altered O O
by O O
coadministration O O
of O O
fosinopril B-Drug B-Drug
with O O
any O O
one O O
of O O
these O O
drugs O O
. O O

increased O O
serum O O
digoxin B-Drug B-Drug
concentrations O O
may O O
result O O
. O O

Non B-Group B-Group
- O O
selective B-Group B-Group
MAO I-Group I-Group
inhibitors I-Group I-Group
including O O
tranylcypromine B-Drug B-Drug
sulfate I-Drug I-Drug
phenelzine B-Drug B-Drug
sulfate I-Drug I-Drug
and O O
pargyline B-Drug B-Drug
HC9 O O
: O O
Concomitant O O
use O O
of O O
L B-Drug B-Drug
- O O
tyrosine B-Drug B-Drug
and O O
non O B-Group
- O O
selective O B-Group
MAO B-Group I-Group
inhibitors I-Group I-Group
may O O
cause O O
hypertension O O
. O O

Lithium B-Drug B-Drug
: O O
generally O O
should O O
not O O
be O O
given O O
with O O
diuretics B-Group B-Group
. O O

Co O O
- O O
administration O O
of O O
oral O O
ketoconazole B-Drug B-Drug
9 O O
mg O O
twice O O
daily O O
increased O O
retapamulin B-Drug B-Drug
geometric O O
mean O O
AUC O O
( O O
9 O O
- O O
9 O O
) O O
and O O
Cmax O O
by O O
9 O O
% O O
after O O
topical O O
application O O
of O O
retapamulin B-Drug B-Drug
ointment O O
9 O O
% O O
on O O
the O O
abraded O O
skin O O
of O O
healthy O O
adult O O
males O O
. O O

Cholestyramine B-Drug B-Drug
increases O O
enterohepatic O O
elimination O O
of O O
amiodarone B-Drug B-Drug
and O O
may O O
reduce O O
its O O
serum O O
levels O O
and O O
t9 B-Drug O
/ O O
9 O O
. O O

CYP O O
9A9 O O
Inhibitors O O
( O O
e.g O O
. O O
Macrolide B-Group B-Group
Antibiotics I-Group I-Group
and O O
Protease B-Group B-Group
Inhibitors I-Group I-Group
) O O
There O O
have O O
been O O
rare O O
reports O O
of O O
serious O O
adverse O O
events O O
in O O
connection O O
with O O
the O O
coadministration O O
of O O
certain O O
ergot B-Group B-Group
alkaloid I-Group I-Group
drugs I-Group I-Group
( O O
e.g O O
. O O
dihydroergotamine B-Drug B-Drug
and O O
ergotamine B-Drug B-Drug
) O O
and O O
potent O O
CYP O O
9A9 O O
inhibitors O O
resulting O O
in O O
vasospasm O O
leading O O
to O O
cerebral O O
ischemia O O
and O O
/ O O
or O O
ischemia O O
of O O
the O O
extremities O O
. O O

Blunting O O
of O O
the O O
antihypertensive O O
effect O O
of O O
beta B-Group B-Group
- O O
adrenoceptor B-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
by O O
nonsteroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
drugs I-Group I-Group
has O O
been O O
reported O O
. O O

Itraconazole B-Drug B-Drug
decreases O O
busulfan B-Drug B-Drug
clearance O O
by O O
up O O
to O O
9 O O
% O O
and O O
may O O
produce O O
AUCs O O
9 O O
M O O
min O O
in O O
some O O
patients O O
. O O

Studies O O
with O O
famotidine B-Drug B-Drug
in O O
man O O
in O O
animal O O
models O O
and O O
in O O
vitro O O
have O O
shown O O
no O O
significant O O
interference O O
with O O
the O O
disposition O O
of O O
compounds O O
metabolized O O
by O O
the O O
hepatic O O
microsomal O O
enzymes O O
e.g. O O
cytochrome O O
P9 O O
system O O
. O O

Salicylic B-Drug B-Drug
acid I-Drug I-Drug
: O O
Combination O O
hormonal B-Group B-Group
contraceptives I-Group I-Group
may O O
increase O O
the O O
clearance O O
of O O
salicylic B-Drug B-Drug
acid I-Drug I-Drug
. O O

Since O O
FOSCAVIR B-Brand B-Brand
decreases O O
serum O O
concentrations O O
of O O
ionized O O
calcium O O
concurrent O O
treatment O O
with O O
other O O
drugs O O
known O O
to O O
influence O O
serum O O
calcium O O
concentrations O O
should O O
be O O
used O O
with O O
particular O O
caution O O
. O O

Antidepressants B-Group B-Group
tricyclic B-Group B-Group
: O O
Amphetamines B-Group B-Group
may O O
enhance O O
the O O
activity O O
of O O
tricyclic B-Group B-Drug
or O O
sympathomimetic B-Group B-Group
agents I-Group I-Group
; O O

Glyburide B-Drug B-Drug
: O O
In O O
9 O O
normal O O
- O O
weight O O
subjects O O
receiving O O
orlistat B-Drug B-Drug
9 O O
mg O O
three O O
times O O
a O O
day O O
for O O
9 O O
days O O
orlistat B-Drug B-Drug
did O O
not O O
alter O O
the O O
pharmacokinetics O O
or O O
pharmacodynamics O O
( O O
blood O O
glucose O O
- O O
lowering O O
) O O
of O O
glyburide B-Drug B-Drug
. O O

Diclofenac B-Drug B-Drug
: O O
Administration O O
of O O
morning O O
and O O
lunch O O
doses O O
of O O
Starlix B-Brand B-Brand
9 O O
mg O O
in O O
combination O O
with O O
a O O
single O O
9 O O
- O O
mg O O
dose O O
of O O
diclofenac B-Drug B-Drug
in O O
healthy O O
volunteers O O
resulted O O
in O O
no O O
significant O O
changes O O
to O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

Therefore O O
when O O
chlorothiazide B-Drug B-Drug
and O O
non B-Group B-Group
- O O
steroidal B-Group B-Group
anti I-Group I-Group
- O O
inflammatory B-Group B-Group
agents I-Group I-Group
are O O
used O O
concomitantly O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-Group B-Group
is O O
obtained O O

Paroxetine B-Drug B-Drug
: O O
Coadministration O O
of O O
once O O
daily O O
doses O O
of O O
aprepitant B-Drug B-Drug
as O O
a O O
tablet O O
formulation O O
comparable O O
to O O
9 O O
mg O O
or O O
9 O O
mg O O
of O O
the O O
capsule O O
formulation O O
with O O
paroxetine B-Drug B-Drug
9 O O
mg O O
once O O
daily O O
resulted O O
in O O
a O O
decrease O O
in O O
AUC O O
by O O
approximately O O
9 O O
% O O
and O O
Cmax O O
by O O
approximately O O
9 O O
% O O
of O O
both O O
aprepitant B-Drug B-Drug
and O O
paroxetine B-Drug B-Drug
. O O

Because O O
CYP O O
9A9 O O
inhibitors O O
may O O
increase O O
plasma O O
concentrations O O
of O O
buprenorphine B-Drug B-Drug
patients O O
already O O
on O O
CYP O O
9A9 O O
inhibitors O O
such O O
as O O
azole B-Group B-Group
antifungals I-Group I-Group
( O O
e.g O O
. O O

When O O
administered O O
concurrently O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
adrenal B-Group O
corticosteroids I-Group B-Group
. O O

However O O
appropriate O O
monitoring O O
of O O
blood O O
glucose O O
should O O
be O O
performed O O
when O O
initiating O O
EXTRANEAL B-Brand B-Brand
in O O
diabetic O O
patients O O
and O O
insulin B-Drug B-Drug
dosage O O
should O O
be O O
adjusted O O
if O O
needed O O
. O O

thyroid B-Drug B-Group
medication O I-Group
; O O

Co O O
- O O
administration O O
of O O
anastrozole B-Drug B-Drug
and O O
tamoxifen B-Drug B-Drug
resulted O O
in O O
a O O
reduction O O
of O O
anastrozole B-Drug B-Drug
plasma O O
levels O O
by O O
9 O O
% O O
compared O O
with O O
those O O
achieved O O
with O O
anastrozole B-Drug B-Drug
alone O O
. O O

Doxazosin B-Drug B-Drug
mesylate I-Drug I-Drug
tablets O O
have O O
been O O
used O O
with O O
the O O
following O O
drugs O O
or O O
drug O O
classes O O
: O O
9 O O
. O O

There O O
was O O
no O O
significant O O
difference O O
in O O
the O O
pharmacodynamic O O
effect O O
of O O
warfarin B-Drug B-Drug
administered O O
alone O O
and O O
warfarin B-Drug B-Drug
administered O O
with O O
Lodine B-Brand B-Brand
as O O
measured O O
by O O
prothrombin O O
time O O
. O O

Because O O
of O O
the O O
potential O O
for O O
additive O O
or O O
synergistic O O
depressant O O
effects O O
on O O
the O O
SA O O
and O O
AV O O
nodes O O
however O O
Adenocard B-Brand B-Brand
should O O
be O O
used O O
with O O
caution O O
in O O
the O O
presence O O
of O O
these O O
agents O O
. O O

On O O
the O O
basis O O
of O O
the O O
metabolism O O
of O O
bexarotene B-Drug B-Drug
by O O
cytochrome O O
P9 O O
9A9 O O
ketoconazole B-Drug B-Drug
itraconazole B-Drug B-Drug
erythromycin B-Drug B-Drug
gemfibrozil B-Drug B-Drug
grapefruit O O
juice O O
and O O
other O O
inhibitors O O
of O O
cytochrome O O
P9 O O
9A9 O O
would O O
be O O
expected O O
to O O
lead O O
to O O
an O O
increase O O
in O O
plasma O O
bexarotene B-Drug B-Drug
concentrations O O
. O O

Therefore O O
simultaneous O O
use O O
of O O
creams O O
ointments O O
or O O
oils O O
should O O
be O O
avoided O O
. O O

No O O
separate O O
information O O
available O O

In O O
order O O
to O O
monitor O O
the O O
occurrence O O
of O O
myelotoxicity O O
it O O
is O O
recommended O O
that O O
frequent O O
peripheral O O
blood O O
cell O O
counts O O
be O O
performed O O
on O O
all O O
patients O O
receiving O O
TAXOL B-Brand B-Brand
. O O

Propantheline B-Drug B-Drug
and O O
diphenoxylate B-Drug B-Drug
by O O
decreasing O O
gut O O
motility O O
may O O
increase O O
digoxin B-Drug B-Drug
absorption O O
. O O

A O O
dose O O
adjustment O O
may O O
be O O
required O O
. O O

The O O
pharmacokinetics O O
of O O
fenofibric B-Drug_n B-Drug_n
acid I-Drug_n I-Drug_n
were O O
not O O
significantly O O
affected O O
by O O
atorvastatin B-Drug B-Drug

certain O O
antibiotics B-Group B-Group
especially O O
the O O
aminoglycosides B-Group B-Group
and O O
polymyxins B-Group B-Group
; O O

In O O
a O O
placebo O O
- O O
controlled O O
trial O O
in O O
normal O O
volunteers O O
the O O
administration O O
of O O
a O O
single O O
9 O O
mg O O
dose O O
of O O
doxazosin B-Drug B-Drug
on O O
day O O
9 O O
of O O
a O O
four O O
- O O
day O O
regimen O O
of O O
oral O O
cimetidine B-Drug B-Drug
( O O
9 O O
mg O O
twice O O
daily O O
) O O
resulted O O
in O O
a O O
9 O O
% O O
increase O O
in O O
mean O O
AUC O O
of O O
doxazosin B-Drug B-Drug
( O O
p=9 O O
) O O
and O O
a O O
slight O O
but O O
not O O
statistically O O
significant O O
increase O O
in O O
mean O O
Cmax O O
and O O
mean O O
half O O
- O O
life O O
of O O
doxazosin B-Drug B-Drug
. O O

Other O O
Agents O O
: O O
No O O
clinically O O
important O O
pharmacokinetic O O
interactions O O
occurred O O
when O O
UNIVASC B-Brand B-Brand
was O O
administered O O
concomitantly O O
with O O
hydrochlorothiazide B-Drug B-Drug
digoxin B-Drug B-Drug
or O O
cimetidine B-Drug B-Drug
. O O

It O O
is O O
recommended O O
to O O
avoid O O
concurrent O O
administration O O
of O O
ethambutol B-Drug B-Drug
with O O
aluminum B-Drug B-Drug
hydroxide I-Drug I-Drug
containing O O
antacids B-Group B-Group
for O O
at O O
least O O
9 O O
hours O O
following O O
ethambutol B-Drug B-Drug
administration O O
. O O

During O O
administration O O
of O O
multiple O O
oral O O
doses O O
of O O
TAMBOCOR B-Brand B-Brand
to O O
healthy O O
subjects O O
stabilized O O
on O O
a O O
maintenance O O
dose O O
of O O
digoxin B-Drug B-Drug
a O O
9 O O
% O O
- O O
9 O O
% O O
increase O O
in O O
plasma O O
digoxin B-Drug B-Drug
levels O O
occurred O O
at O O
six O O
hours O O
postdose O O
. O O

Patients O O
should O O
take O O
other O O
drugs O O
at O O
least O O
one O O
hour O O
before O O
or O O
four O O
hours O O
after O O
COLESTID B-Brand B-Brand
Tablets O O
to O O
avoid O O
impeding O O
their O O
absorption O O
. O O

In O O
diabetic O O
patients O O
the O O
metabolic O O
effects O O
of O O
androgens B-Group B-Group
may O O
decrease O O
blood O O
glucose O O
and O O
therefore O O
insulin B-Drug B-Drug
requirements O O
. O O

Similarly O O
nateglinide B-Drug B-Drug
had O O
no O O
influence O O
on O O
the O O
serum O O
protein O O
binding O O
of O O
propranolol B-Drug B-Drug
glyburide B-Drug B-Drug
nicardipine B-Drug B-Drug
warfarin B-Drug B-Drug
phenytoin B-Drug B-Drug
acetylsalicylic B-Drug B-Drug
acid I-Drug I-Drug
and O O
tolbutamide B-Drug B-Drug
in O O
vitro O O
. O O

Monoamine B-Group B-Group
Oxidase I-Group I-Group
Inhibitors I-Group I-Group
( O O
MAOIs B-Group B-Group
) O O

TAMBOCOR B-Brand B-Brand
has O O
been O O
administered O O
to O O
patients O O
receiving O O
digitalis B-Group B-Group
preparations I-Group I-Group
or O O
beta B-Group B-Group
- O O
adrenergic B-Group B-Group
blocking I-Group I-Group
agents I-Group I-Group
without O O
adverse O O
effects O O
. O O

Co O O
- O O
administration O O
of O O
lovastatin B-Drug B-Drug
atenolol B-Drug B-Drug
warfarin B-Drug B-Drug
furosemide B-Drug B-Drug
digoxin B-Drug B-Drug
celecoxib B-Drug B-Drug
hydrochlorothiazide B-Drug B-Drug
ramipril B-Drug B-Drug
valsartan B-Drug B-Drug
metformin B-Drug B-Drug
and O O
amlodipine B-Drug B-Drug
did O O
not O O
result O O
in O O
clinically O O
significant O O
increases O O
in O O
aliskiren B-Drug B-Drug
exposure O O
. O O

However O O
neuromuscular O O
paralysis O O
may O O
be O O
potentiated O O
by O O
co O O
- O O
administration O O
or O O
overlapping O O
administration O O
of O O
different O O
botulinum B-Group B-Group
toxin I-Group I-Group
serotypes O O
. O O

Patients O O
receiving O O
concurrent O O
administration O O
of O O
substrates O O
of O O
C.P.A O O
. O O
were O O
not O O
excluded O O
from O O
clinical O O
trials O O
of O O
grepafloxacin B-Drug B-Drug
. O O

Diazepam B-Drug B-Drug
: O O
Diazepam B-Drug B-Drug
( O O
Valium B-Brand B-Brand
) O O
is O O
a O O
CYP O O
9A9 O O
and O O
CYP O O
9C9 O O
substrate O O
. O O

Single O O
doses O O
of O O
either O O
cholestyramine B-Drug B-Drug
or O O
colestipol B-Drug B-Drug
resins B-Group B-Group
bind O O
the O O
hydrochlorothiazide B-Drug B-Drug
and O O
reduce O O
its O O
absorption O O
from O O
the O O
gastrointestinal O O
tract O O
by O O
up O O
to O O
9 O O
and O O
9 O O
percent O O
respectively O O
. O O

The O O
physician O O
should O O
be O O
notified O O
immediately O O
if O O
any O O
of O O
the O O
following O O
situations O O
occur O O
which O O
may O O
be O O
a O O
sign O O
of O O
seriously O O
worsening O O
asthma O O
: O O
Decreased O O
effectiveness O O
of O O
short B-Group B-Group
- O O
acting B-Group O
inhaled I-Group O
beta9 I-Group B-Group
- O O
agonists B-Group B-Group
; O O

These O O
drugs O O
should O O
be O O
coadministered O O
with O O
caution O O
and O O
frequent O O
monitoring O O
of O O
serum O O
lithium B-Drug B-Drug
levels O O
is O O
recommended O O
. O O

Probenecid B-Drug B-Drug
competes O O
with O O
meropenem B-Drug B-Drug
for O O
active O O
tubular O O
secretion O O
and O O
thus O O
inhibits O O
the O O
renal O O
excretion O O
of O O
meropenem B-Drug B-Drug
. O O

Vasopressors B-Group O
particularly O O
metaraminol B-Drug B-Drug
may O O
cause O O
serious O O
cardiac O O
arrhythmias O O
during O O
halothane B-Drug B-Drug
anesthesia O O
and O O
therefore O O
should O O
be O O
used O O
only O O
with O O
great O O
caution O O
or O O
not O O
at O O
all O O
. O O

Coadministration O O
of O O
SULAR B-Brand B-Brand
with O O
phenytoin B-Drug B-Drug
or O O
any O O
known O O
CYP9A9 O O
inducer O O
should O O
be O O
avoided O O
and O O
alternative O O
antihypertensive B-Group O
therapy O O
should O O
be O O
considered O O
. O O

for O O
adult O O
- O O
onset O O
diabetics O O
dosage O O
adjustment O O
of O O
hypoglycemic B-Group B-Group
medications I-Group I-Group
may O O
be O O
necessary O O
during O O
and O O
after O O
thiazide B-Group B-Group
diuretic I-Group I-Group
therapy O O
; O O

Propoxyphene B-Drug B-Drug
: O O
In O O
cases O O
of O O
propoxyphene B-Drug B-Drug
overdosage O O
amphetamine B-Drug B-Drug
CNS O O
stimulation O O
is O O
potentiated O O
and O O
fatal O O
convulsions O O
can O O
occur O O
. O O

clofibrate B-Drug B-Drug
; O O

lithium B-Drug B-Drug
; O O

However O O
the O O
impairment O O
of O O
motor O O
skills O O
produced O O
by O O
REMERON B-Brand B-Brand
has O O
been O O
shown O O
to O O
be O O
additive O O
with O O
those O O
caused O O
by O O
diazepam B-Drug B-Drug
. O O

Specific O O
Effects O O
of O O
Felbatol B-Brand B-Brand
on O O
Other O O
Antiepileptic B-Group B-Group
Drugs I-Group I-Group
Phenytoin B-Drug B-Drug
: O O
Felbatol B-Brand B-Brand
causes O O
an O O
increase O O
in O O
steady O O
- O O
state O O
phenytoin B-Drug B-Drug
plasma O O
concentrations O O
. O O

This O O
is O O
based O O
on O O
the O O
results O O
from O O
9 O O
clinical O O
studies O O
using O O
histamine B-Drug O
induced O O
skin O O
wheals O O
and O O
flares O O
coupled O O
with O O
population O O
pharmacokinetic O O
analysis O O
. O O

no O O
other O O
specific O O
drug O O
interaction O O
studies O O
were O O
performed O O
. O O

Patients O O
receiving O O
sirolimus B-Drug B-Drug
or O O
nifedipine B-Drug B-Drug
in O O
combination O O
with O O
MYCAMINE B-Brand B-Brand
should O O
be O O
monitored O O
for O O
sirolimus B-Drug B-Drug
or O O
nifedipine B-Drug B-Drug
toxicity O O
and O O
sirolimus B-Drug B-Drug
or O O
nifedipine B-Drug B-Drug
dosage O O
should O O
be O O
reduced O O
if O O
necessary O O
. O O

Alternate O O
treatments O O
lacking O O
CYP9A9 O O
inducing O O
activity O O
should O O
be O O
considered O O
. O O
